INTERFACE INC Form 8-K February 21, 2008

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 20, 2008

INTERFACE, INC. (Exact name of Registrant as Specified in its Charter)

Georgia (State or other Jurisdiction of Incorporation or Organization) 000-12016 (Commission File Number) 58-1451243 (IRS Employer Identification No.)

2859 Paces Ferry Road, Suite 2000 Atlanta, Georgia (Address of principal executive offices)

30339 (Zip code)

Registrant's telephone number, including area code: (770) 437-6800

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01 REGULATION FD DISCLOSURE.

On February 20, 2008, the Board of Directors of Interface, Inc. (the "Company") determined to adopt a new shareholder rights agreement to succeed its existing Rights Agreement dated March 4, 1998 and effective as of March 16, 1998, which expires on March 17, 2008. The Company anticipates that the new rights agreement will be substantially similar to the existing agreement, and that it will enter into the new rights agreement prior to the expiration of the existing agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERFACE, INC.

By:/s/ Raymond S. Willoch Raymond S. Willoch Senior Vice President

Date: February 21, 2008

Narrow" SIZE="1">9/16/16 USD 45.00 428 (100,580)

Sherwin-Williams Co.

Call 9/16/16 USD 300.00 35 (28,175)

Total

\$(4,517,340)

OTC Options Written

			Strike								
	Put/		Expiration								
Description	Call	Counterparty	Date	Price		Contracts		Value			
Kennedy-Wilson Holdings, Inc.	Call	Barclays Bank PLC	7/01/16	USD	21.63	32,000	\$				
Crown Holdings, Inc.	Call	Bank of America N.A.	7/05/16	USD	55.05	7,000					

Anheuser-Busch InBev SA	Call	Morgan Stanley & Co. International PLC	7/06/16	EUR	114.74	10,200	(52,787)
Delhaize Group	Call	UBS AG	7/06/16	EUR	94.19	9,400	(20,386)
Eni SpA	Call	UBS AG	7/06/16	EUR	13.75	121,000	(107,536)
Galp Energia SGPS SA	Call	UBS AG	7/06/16	EUR	12.10	85,000	(45,645)
Macquarie Infrastructure Corp.	Call	Bank of America N.A.	7/06/16	USD	72.53	21,500	(37,123)
Nestle SA	Call	Bank of America N.A.	7/06/16	CHF	73.63	32,300	(72,058)
Public Service Enterprise Group,							
Inc.	Call	Goldman Sachs International	7/06/16	USD	44.69	42,800	(82,413)
Roche Holding AG	Call	UBS AG	7/06/16	CHF	247.75	8,700	(90,782)
Samsonite International SA	Call	JPMorgan Chase Bank N.A.	7/06/16	HKD	23.20	128,000	(154)
SoftBank Group Corp.	Call	Morgan Stanley & Co. International PLC	7/06/16	JPY	6,130.20	33,200	(8,969)
Taiwan Semiconductor		<i>c .</i>					
Manufacturing Co. Ltd.	Call	Deutsche Bank AG	7/06/16	TWD	147.21	393,000	(186,663)
UBS Group AG	Call	Bank of America N.A.	7/06/16	CHF	15.45	70,500	(23)
Unibail-Rodamco SE REIT	Call	Bank of America N.A.	7/06/16	EUR	234.85	11,400	(17,589)
AIA Group Ltd.	Call	Bank of America N.A.	7/07/16	HKD	45.29	138,000	(26,827)
Aramark	Call	Morgan Stanley & Co. International PLC	7/07/16	USD	33.84	47,000	(7,401)
Delphi Automotive PLC	Call	Deutsche Bank AG	7/07/16	USD	67.64	25,400	(1,625)
Eastman Chemical Co.	Call	Credit Suisse International	7/07/16	USD	76.75	24,000	(1)
FirstEnergy Corp.	Call	UBS AG	7/07/16	USD	32.45	2,300	(5,695)
Fomento Economico Mexicano							
SAB de CV ADR	Call	Morgan Stanley & Co. International PLC	7/07/16	USD	97.56	9,700	(830)
GlaxoSmithKline PLC	Call	Bank of America N.A.	7/07/16	GBP	14.59	35,000	(71,883)
Hortonworks, Inc.	Call	Deutsche Bank AG	7/07/16	USD	12.43	86,000	(754)
Koninklijke Philips NV	Call	Morgan Stanley & Co. International PLC	7/07/16	EUR	23.79	43,000	(1,662)
Lloyds Banking Group PLC	Call	Morgan Stanley & Co. International PLC	7/07/16	GBP	0.67	731,000	(29)
Nintendo Co. Ltd.	Call	Goldman Sachs International	7/07/16	JPY	15,620.25	12,000	(14,098)
Panasonic Corp.	Call	Bank of America N.A.	7/07/16	JPY	971.65	95,000	(1,026)
Boston Scientific Corp.	Call	Goldman Sachs International	7/08/16	USD	21.78	84,000	(135,304)
Kennedy-Wilson Holdings, Inc.	Call	Morgan Stanley & Co. International PLC	7/08/16	USD	21.12	38,200	(183)
Lam Research Corp.	Call	Deutsche Bank AG	7/11/16	USD	75.01	18,400	(166,709)
WestRock Co.	Call	Citibank N.A.	7/11/16	USD	37.25	41,600	(83,131)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Global Opportunities Equity Trust (BOE)

				5	Strike		
	Put/		Expiration				
Description	Call	Counterparty	Date]	Price	Contracts	Value
ASML Holding NV	Call	Morgan Stanley & Co. International PLC	7/12/16	EUR	89.38	26,800	\$ (44,470)
BankUnited, Inc.	Call	Citibank N.A.	7/12/16	USD	89.38 34.23	20,800 47,000	\$ (44,470) (980)
Cellnex Telecom SAU	Call	Credit Suisse International	7/12/16	EUR	14.52	47,000 64,000	(10,678)
Crown Holdings, Inc.	Call	Bank of America N.A.	7/12/16	USD	52.56	48,200	(6,821)
Koninklijke Philips NV	Call	Bank of America N.A.	7/12/16	EUR	23.09	158,000	(41,694)
Largan Precision Co. Ltd.	Call	JPMorgan Chase Bank N.A.	7/12/16	TWD	3,036.17	40,000	(65,583)
Naspers Ltd., N Shares	Call	UBS AG	7/12/16	ZAR	2,238.08	18,200	(72,227)
Statoil ASA	Call	Credit Suisse International	7/12/16	NOK	138.83	66,000	(59,504)
Unilever PLC	Call	UBS AG	7/12/16	GBP	31.51	48,100	(287,357)
Worldpay Group PLC		Morgan Stanley & Co. International				-,	(
I S I I	Call	PLC	7/12/16	GBP	2.71	186,000	(18,890)
AIA Group Ltd.		Morgan Stanley & Co. International				,	
1	Call	PLC	7/13/16	HKD	44.64	247,000	(68,521)
Diageo PLC	Call	UBS AG	7/13/16	GBP	18.77	109,000	(323,982)
Eni SpA	Call	Goldman Sachs International	7/13/16	EUR	13.95	43,800	(33,634)
Lloyds Banking Group PLC		Morgan Stanley & Co. International					
	Call	PLC	7/13/16	GBP	0.75	1,099,000	(44)
Mondelez International, Inc., Class A	Call	UBS AG	7/13/16	USD	44.75	23,700	(34,974)
Nestle SA		Morgan Stanley & Co. International					
	Call	PLC	7/13/16	CHF	74.18	42,500	(78,421)
Nordea Bank AB	Call	Credit Suisse International	7/13/16	SEK	81.46	72,000	(418)
Nordea Bank AB	Call	Credit Suisse International	7/13/16	SEK	81.56	115,000	(635)
Samsonite International SA	Call	UBS AG	7/13/16	HKD	23.56	240,000	(611)
Aramark	Call	Wells Fargo Bank, National Association	7/14/16	USD	32.81	48,000	(39,653)
BAE Systems PLC	Call	UBS AG	7/14/16	GBP	4.99	256,000	(99,084)
Delhaize Group	Call	Bank of America N.A.	7/14/16	EUR	98.01	10,000	(10,014)
Kennedy-Wilson Holdings, Inc.	Call	Barclays Bank PLC	7/19/16	USD	21.00	32,000	(1,921)
Lloyds Banking Group PLC	Call	Goldman Sachs International	7/19/16	GBP	0.73	1,134,000	(218)
Unibail-Rodamco SE REIT	Call	UBS AG	7/19/16	EUR	243.39	10,000	(14,241)
Unilever PLC	Call	Goldman Sachs International	7/19/16	GBP	31.96	48,100	(260,237)
AstraZeneca PLC	Call	Credit Suisse International	7/20/16	GBP	40.54	10,100	(60,362)
Cellnex Telecom SAU		Morgan Stanley & Co. International					
	Call	PLC	7/20/16	EUR	14.33	27,000	(8,635)
Comcast Corp., Class A	Call	Barclays Bank PLC	7/20/16	USD	63.00	16,400	(38,624)
Galp Energia SGPS SA	Call	Goldman Sachs International	7/20/16	EUR	12.00	140,000	(104,163)
Lam Research Corp.	Call	Deutsche Bank AG	7/20/16	USD	75.65	19,000	(161,163)
Snam SpA	Call	Credit Suisse International	7/20/16	EUR	5.08	342,000	(126,487)
Xero Ltd.	Call	UBS AG	7/20/16	NZD	19.37	51,800	(11,024)
Intercontinental Exchange, Inc.	Call	Deutsche Bank AG	7/21/16	USD	261.50	10,000	(20,676)
PPL Corp.	0.11	Morgan Stanley & Co. International	7/01/17	LICD	20.75	20,000	(0.011)
	Call	PLC	7/21/16	USD	38.75	38,000	(8,011)
WisdomTree Investments, Inc.	Call	Goldman Sachs International	7/21/16	USD	11.50	65,000	(6,772)
Fairfax Financial Holdings Ltd.	C-11	Morgan Stanley & Co. International	7/22/16	CAD	(70.29	4 800	(0.1, 1.90)
A star Zana a DLC	Call	PLC Condit Suize Internetional	7/22/16	CAD	679.38	4,800	(94,180)
AstraZeneca PLC	Call	Credit Suisse International	7/26/16	GBP	40.50	23,500	(144,073)
China Construction Bank Corp., Class H	Call	Bank of America N.A.	7/26/16	HKD	5.28	4,020,000	(47,457)
Diageo PLC Clave Smith Kline PLC	Call	UBS AG Managan Stanlay, & Co. International	7/26/16	GBP	19.07	47,000	(123,865)
GlaxoSmithKline PLC	C-11	Morgan Stanley & Co. International	7/20/110	CDD	14.04	(2,000	(112.025)
Imperial Brands PLC	Call Call	PLC Citibank N.A.	7/26/16 7/26/16	GBP GBP	14.84 38.90	63,000 37,300	(112,935) (108,263)
Nordea Bank AB	Call	Bank of America N.A.	7/26/16	SEK	38.90 80.91	37,300 74,300	(108,263) (2,578)
	Call	Deutsche Bank AG	7/26/16	USD	80.91 45.44	10,000	(2,578) (14,036)
Public Service Enterprise Group, Inc. Samsonite International SA	Call	UBS AG	7/26/16	HKD	45.44 24.12	156,000	(14,036) (907)
UBS Group AG	Call	Morgan Stanley & Co. International	1120/10	IIND	24.12	150,000	(907)
	Call	PLC	7/26/16	CHF	15.80	46,786	(352)
Worldpay Group PLC	Call	Morgan Stanley & Co. International	1120/10	CIII	15.00	+0,700	(332)
Wonopay Oroup I LC	Call	PLC	7/26/16	GBP	2.84	146,400	(9,706)
Worldpay Group PLC	Call	Morgan Stanley & Co. International	1120/10	ODI	2.04	140,400	(9,700)
	Call	PLC	7/26/16	GBP	2.88	145,000	(7,282)
	Can		,,20,10	CDI	2.00	145,000	(7,202)

BAE Systems PLC	Call	Bank of America N.A.	7/27/16	GBP	5.21	139,000	(29,958)
Alps Electric Co. Ltd.	Call	UBS AG	7/28/16	JPY	2,316.23	76,400	(19,551)
Kennedy-Wilson Holdings, Inc.	Call	Barclays Bank PLC	7/28/16	USD	20.99	32,000	(3,825)
Adobe Systems, Inc.	Call	UBS AG	7/29/16	USD	98.47	42,000	(43,779)
Assured Guaranty Ltd.	Call	Barclays Bank PLC	7/29/16	USD	26.26	23,100	(6,440)
Intercontinental Exchange, Inc.	Call	Goldman Sachs International	7/29/16	USD	268.65	6,300	(12,607)
ServiceMaster Global Holdings, Inc.	Call	Deutsche Bank AG	7/29/16	USD	39.01	52,500	(76,915)
WestRock Co.	Call	Citibank N.A.	8/01/16	USD	37.25	41,700	(107,708)
Anheuser-Busch InBev SA	Call	HSBC Bank PLC	8/02/16	EUR	116.71	67,000	(370,963)
AstraZeneca PLC		Morgan Stanley & Co. International					
	Call	PLC	8/02/16	GBP	41.13	23,500	(125,712)
Atlantia SpA	Call	Credit Suisse International	8/02/16	EUR	24.13	41,000	(7,121)
Atlantia SpA	Call	UBS AG	8/02/16	EUR	22.22	43,000	(25,831)

See Notes to Financial Statements.

58

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Global Opportunities Equity Trust (BOE)

					Strike		
	Put/		Expiration		D •	a	¥7. ¥
Description BAE Systems PLC	Call	Counterparty Morgan Stanley & Co. International	Date		Price	Contracts	Value
DAE Systems I LC	Call	PLC	8/02/16	GBP	5.02	100,000	\$ (40,029)
Cellnex Telecom SAU	Call	Credit Suisse International	8/02/16	EUR	14.43	80,000	(30,845)
Diageo PLC		Morgan Stanley & Co. International					(20,012)
C	Call	PLC	8/02/16	GBP	19.09	47,000	(122,028)
Eni SpA	Call	Bank of America N.A.	8/02/16	EUR	14.51	18,000	(9,471)
GlaxoSmithKline PLC		Morgan Stanley & Co. International					
	Call	PLC	8/02/16	GBP	14.77	63,000	(117,747)
Lloyds Banking Group PLC		Morgan Stanley & Co. International	0.000.00.0	app	0.50	=======	(1.0.17)
Mater Darila DI C	Call	PLC	8/02/16	GBP	0.72	730,000	(1,247)
Metro Bank PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	21.15	37 200	(8.041)
Statoil ASA	Call	Credit Suisse International	8/02/16 8/02/16	NOK	142.08	37,200 56,000	(8,941) (53,760)
UBS Group AG	Call	Morgan Stanley & Co. International	8/02/10	NOK	142.08	50,000	(55,700)
ebb cloup no	Call	PLC	8/02/16	CHF	14.99	159,000	(6,263)
Unilever PLC	Call	Credit Suisse International	8/02/16	GBP	34.01	74,000	(214,251)
Worldpay Group PLC		Morgan Stanley & Co. International				,	
	Call	PLC	8/02/16	GBP	2.86	175,000	(12,627)
Galp Energia SGPS SA	Call	Goldman Sachs International	8/03/16	EUR	11.87	55,000	(51,982)
Nintendo Co. Ltd.	Call	Goldman Sachs International	8/03/16	JPY	16,704.47	7,000	(10,441)
SoftBank Group Corp.	Call	Bank of America N.A.	8/03/16	JPY	6,271.23	46,000	(43,711)
Sony Corp.	Call	Goldman Sachs International	8/03/16	JPY	3,192.58	59,000	(56,426)
Xero Ltd.		Morgan Stanley & Co. International					
	Call	PLC	8/03/16	NZD	19.75	17,355	(4,581)
Xero Ltd.	Call	UBS AG	8/03/16	NZD	19.04	28,700	(11,893)
Panasonic Corp.	Call	Goldman Sachs International	8/04/16	JPY	928.14	94,700	(25,243)
Worldpay Group PLC	Call	Morgan Stanley & Co. International	9/04/16	CDD	2 80	08 000	(6 174)
Public Service Enterprise Group, Inc.	Call Call	PLC UBS AG	8/04/16 8/05/16	GBP USD	2.89 45.49	98,000 4,900	(6,174) (8,506)
Roche Holding AG	Call	Goldman Sachs International	8/05/16	CHF	250.92	4,900	(81,833)
Worldpay Group PLC	Call	Morgan Stanley & Co. International	0/05/10	CIII	250.72	8,000	(01,055)
Wondpuy Group The	Call	PLC	8/05/16	GBP	2.73	184,000	(26,445)
BankUnited, Inc.	Call	Barclays Bank PLC	8/08/16	USD	33.88	50,000	(14,072)
Boston Scientific Corp.	Call	Deutsche Bank AG	8/08/16	USD	23.02	67,300	(65,632)
Anheuser-Busch InBev SA	Call	Credit Suisse International	8/09/16	EUR	111.80	11,700	(115,190)
Atlantia SpA		Morgan Stanley & Co. International					
	Call	PLC	8/09/16	EUR	22.61	41,000	(33,123)
Cellnex Telecom SAU	Call	Bank of America N.A.	8/09/16	EUR	14.40	67,500	(26,194)
China Construction Bank Corp., Class H	Call	UBS AG	8/09/16	HKD	5.23	3,320,000	(56,260)
Eni SpA	Call	Credit Suisse International	8/09/16	EUR	13.72	44,000	(50,636)
FirstEnergy Corp.	Call	Morgan Stanley & Co. International	9/00/16	UCD	2466	65 000	(61, 626)
Nordea Bank AB	Call Call	PLC Credit Suisse International	8/09/16 8/09/16	USD SEK	34.66 75.80	65,000 72,500	(61,636) (11,232)
Samsonite International SA	Call	UBS AG	8/09/16	HKD	23.08	72,000	(11,232) (2,312)
Snam SpA	Call	Credit Suisse International	8/09/16	EUR	5.01	342,000	(153,758)
Sony Corp.	Call	JPMorgan Chase Bank N.A.	8/09/16	JPY	3,043.94	59,000	(98,126)
Statoil ASA	Call	Credit Suisse International	8/09/16	NOK	146.36	65,000	(48,960)
Worldpay Group PLC		Morgan Stanley & Co. International				,	
	Call	PLC	8/09/16	GBP	2.87	175,000	(13,978)
AstraZeneca PLC	Call	Citibank N.A.	8/10/16	GBP	41.35	23,500	(122,931)
Naspers Ltd., N Shares	Call	UBS AG	8/10/16	ZAR	2,256.73	18,200	(115,835)
Imperial Brands PLC	Call	Citibank N.A.	8/11/16	GBP	38.20	37,000	(142,261)
AIA Group Ltd.	Call	UBS AG	8/12/16	HKD	46.25	247,000	(29,274)
Panasonic Corp.	Call	JPMorgan Chase Bank N.A.	8/12/16	JPY	909.95	31,000	(9,780)
Samsonite International SA	Call	UBS AG	8/12/16	HKD	21.97	301,800	(22,826)
Worldpay Group PLC	C 11	Morgan Stanley & Co. International	0/10/17	CDP	2.76	00.000	(0.77.0)
Vara I td	Call	PLC Managen Stanlay, & Co. International	8/12/16	GBP	2.76	80,000	(9,776)
Xero Ltd.	Call	Morgan Stanley & Co. International PLC	8/12/16	NZD	10 50	14 400	(8 166)
Aramark	Call	Morgan Stanley & Co. International	0/12/10	NLD	18.58	14,400	(8,466)
/ Humurk	Call	PLC	8/15/16	USD	33.69	62,000	(41,244)
		- 20	2. 10, 10		22.07	,000	(,=)

InterXion Holding NV	Call	Barclays Bank PLC	8/15/16	USD	37.25	59,800	(67,712)
Lowe s Cos., Inc.		Morgan Stanley & Co. International					
	Call	PLC	8/15/16	USD	80.35	49,100	(80,916)
BAE Systems PLC	Call	HSBC Bank PLC	8/16/16	GBP	4.83	138,000	(86,378)
Cellnex Telecom SAU	Call	UBS AG	8/16/16	EUR	14.15	24,000	(14,851)
Anheuser-Busch InBev SA	Call	Goldman Sachs International	8/17/16	EUR	117.26	29,000	(134,043)
Imperial Brands PLC		Morgan Stanley & Co. International					
	Call	PLC	8/17/16	GBP	40.45	40,000	(68,414)
Lloyds Banking Group PLC	Call	Goldman Sachs International	8/17/16	GBP	0.65	888,000	(11,415)
Taiwan Semiconductor Manufacturing Co.							
Ltd.	Call	UBS AG	8/17/16	TWD	160.93	386,000	(63,285)
Xero Ltd.		Morgan Stanley & Co. International					
	Call	PLC	8/17/16	NZD	17.64	37,000	(37,389)
PPL Corp.	Call	Citibank N.A.	8/18/16	USD	38.10	51,000	(37,123)
BankUnited, Inc.	Call	Barclays Bank PLC	8/23/16	USD	33.30	45,000	(10,139)
Cellnex Telecom SAU		Morgan Stanley & Co. International					
	Call	PLC	8/23/16	EUR	14.46	40,000	(20,626)
Eni SpA	Call	Goldman Sachs International	8/23/16	EUR	14.77	18,000	(9,545)
Fairfax Financial Holdings Ltd.	Call	Deutsche Bank AG	8/23/16	CAD	659.32	8,000	(288,033)
Galp Energia SGPS SA		Morgan Stanley & Co. International					
	Call	PLC	8/23/16	EUR	12.37	90,000	(65,059)
Statoil ASA	Call	Deutsche Bank AG	8/25/16	NOK	135.78	55,000	(83,991)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Global Opportunities Equity Trust (BOE)

		Strike						
	Put/		Expiration					
Description	Call	Counterparty	Date		Price	Contracts		Value
Boston Scientific Corp.	Call	Deutsche Bank AG	8/29/16	USD	23.02	67,300	\$	(78,337)
PPL Corp.	Call	Citibank N.A.	9/01/16	USD	39.68	17,000		(6,095)
BankUnited, Inc.	Call	Deutsche Bank AG	9/08/16	USD	32.21	23,000		(13,241)
	Ν	Iorgan Stanley & Co. International						
Nintendo Co. Ltd.	Call	PLC	9/08/16	JPY	14,327.71	6,700		(77,508)
Total							\$ (8,308,105)

Transactions in Options Written for the Period Ended June 30, 2016

	Calls		Puts	
	Contracts	Premiums Received	Contracts	Premiums Received
Outstanding options at beginning of period Options written Options exercised Options expired Options closed	26,290,347 81,542,754 (62,923) (42,956,977) (42,552,306)	\$ 11,916,657 44,739,889 (198,769) (19,514,351) (26,240,850)		
Outstanding options at end of period	22,260,895	\$ 10,702,576		

As of period end, the value of portfolio securities subject to covered call options written was \$433,191,150.

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		Commodity			Foreign Currency	0		
		Contracts	Credit Contracts	Equity Contracts	Exchange Contracts	Rate Contracts	Total	
Assets Derivative Financi Forward foreign currency exchange contracts	al Instruments Unrealized appreciation on forward foreign currency exchange contracts				\$109,407		\$ 109,40)7
Liabilities Derivative Fina Forward foreign currency exchange contracts Options written	ancial Instruments Unrealized depreciation on forward foreign currency exchange contracts Options written, at value			\$ 12,825,445	\$ 45,617		\$ 45,61 12,825,44	
Total				\$ 12,825,445	\$ 45,617		\$ 12,871,06	52

For the six months ended June 30, 2016, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss) from: Options purchased ¹ Options written Total	Commodity Contracts	Credit Contracts	Equity Contracts \$ (36,189) 10,629,203 \$ 10,593,014	Foreign Currency Exchange Contracts	Interest Rate Contracts	Total \$ (36,189) 10,629,203 \$ 10,593,014
Net Change in Unrealized Appreciation (Depreciation) on: Foreign currency translations Options purchased ² Options written			\$ 29,255 (5,915,951)	\$63,790		\$ 63,790 29,255 (5,915,951)
Total			\$ (5,886,696)	\$63,790		\$ (5,822,906)

¹ Options purchased are included in net realized gain (loss) from investments.

² Options purchased are included in net change in unrealized appreciation (depreciation) on investments.

See Notes to Financial Statements.

60

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Global Opportunities Equity Trust (BOE)

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Forward foreign currency exchange contracts: Average USD amounts purchased	\$ 3,229,040
Average USD amounts sold	\$ 3,197,145
Options:	
Average value of option contracts written	\$ 13,212,696
For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.	

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities		
Derivative Financial Instruments: Forward foreign currency exchange contracts Options	\$ 109,407	\$ 45,617 12,825,445		
Total derivative assets and liabilities in the Statements of Assets and Liabilities Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	\$ 109,407	\$ 12,871,062 (4,517,340)		
Total derivative assets and liabilities subject to an MNA	\$ 109,407	\$ 8,353,722		

The following table presents the Trust s derivative assets and liabilities by counterparty net of amounts available for offset under an Master Netting Agreement (MNA) and net of the related collateral pledged by the Trust:

	Derivative Assets Subject to an MNA by	Derivatives Available	Non-cash Collateral	Cash Collateral	Net Amount of
Counterparty Royal Bank of Scotland PLC	Counterparty \$109,407	for Offset	Received	Received	Derivative Assets ¹ \$109,407

	I	Derivative Liabilities t to an MNA by I	Derivatives Available	Non-cash Collateral	Cash Collateral	Net 2	Amount of
Counterparty	Co	unterparty	for Offset	Pledged ²	Pledged	Derivati	ive Liabilities ³
Bank of America N.A.	\$	444,427		\$ (372,102)		\$	72,325
Barclays Bank PLC		142,733					142,733
Citibank N.A.		608,492		(589,666)			18,826
Commonwealth Bank of Australia		45,617					45,617
Credit Suisse International		1,087,911		(1,081,914)			5,997
Deutsche Bank AG		1,157,775		(1,157,775)			
Goldman Sachs International		1,030,374		(1,030,374)			
HSBC Bank PLC		457,341					457,341
JPMorgan Chase Bank N.A.		173,643		(173,643)			
Morgan Stanley & Co. International PLC		1,513,237		(1,491,287)			21,950
UBS AG		1,652,519		(1,499,350)			153,169
Wells Fargo Bank, National Association		39,653					39,653
Total	\$	8,353,722		\$ (7,396,111)		\$	957,611

- ¹ Net amount represents the net amount receivable from the counterparty in the event of default.
- ² Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.
- ³ Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Global Opportunities Equity Trust (BOE)

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Australia		\$ 5,110,982		\$ 5,110,982
Belgium		32,105,266		32,105,266
Canada	\$ 12,607,290			12,607,290
China	10,575,899	7,527,011		18,102,910
France		10,086,525		10,086,525
Hong Kong		6,909,169		6,909,169
India		15,237,082		15,237,082
Indonesia		4,768,971		4,768,971
Ireland	7,235,805			7,235,805
Israel	4,515,677			4,515,677
Italy		20,281,649		20,281,649
Japan		49,359,944		49,359,944
Mexico	6,529,794			6,529,794
Netherlands	5,318,096	13,909,810		19,227,906
New Zealand		4,568,221		4,568,221
Norway		7,589,737		7,589,737
Portugal		9,352,002		9,352,002
South Africa		10,100,779		10,100,779
South Korea		3,448,368		3,448,368
Spain		12,249,314		12,249,314
Sweden		6,291,116		6,291,116
Switzerland		25,042,490		25,042,490
Taiwan		13,979,972		13,979,972
Thailand		3,620,726		3,620,726
United Kingdom	27,615,389	75,409,425		103,024,814
United States	481,908,664	4,520,998	\$ 3,290,175	489,719,837
Investment Companies		3,842,944		3,842,944
Preferred Stocks			25,672,885	25,672,885
Short-Term Securities	15,041,142	1,705,953		16,747,095
Total	\$ 571,347,756	\$ 347,018,454	\$ 28,963,060	\$ 947,329,270
Derivative Financial Instruments ¹				
Assets:				
Forward foreign currency exchange contracts		\$ 109,407		\$ 109,407
Liabilities:				
Equity contracts	\$ (4,196,990)	(8,628,455)		(12,825,445)
Foreign currency exchange contracts		(45,617)		(45,617)
Total	\$ (4,196,990)	\$ (8,564,665)		\$ (12,761,655)

¹ Derivative financial instruments are forward foreign currency exchange contracts and options written. Forward foreign currency exchange contracts are valued at the unrealized appreciation/depreciation on the instrument and options written are shown at value.

The Trust may hold assets and/or liabilities in which the fair value approximates the carrying amount for financial statement purposes. As of period end, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Ι	evel 1	Level 2	Level 3	Total
Assets: Foreign currency at value Liabilities:	\$	888,290			\$ 888,290
Collateral on securities loaned at value			\$ (1,705,953)		(1,705,953)
Total	\$	888,290	\$ (1,705,953)		\$ (817,663)

See Notes to Financial Statements.

62

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Global Opportunities Equity Trust (BOE)

Transfers between Level 1 and Level 2 were as follow:

	Transfers into Level 1 ¹	Transfers out of Level 1 ²	Transfers into Level 2 ²	Transfers out of Level 2 ¹
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks	\$ 8,123,988	\$ (45,571,349)	\$ 45,571,349	\$ (8,123,988)

¹ Systematic Fair Value Prices were not utilized at period end for these investments.

² External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks	Preferred Stocks	Total
Assets:			
Opening Balance, as of December 31, 2015	\$ 9,185,948	\$ 26,668,421	\$ 35,854,369
Transfers into Level 3			
Transfers out of Level 3	(5,237,738)		(5,237,738)
Accrued discounts/premiums			
Net realized gain (loss)			
Net change in unrealized appreciation/depreciation ^{1,2}	(658,035)	(995,536)	(1,653,571)
Purchases			
Sales			
Closing Balance, as of June 30, 2016	\$ 3,290,175	\$ 25,672,885	\$ 28,963,060
Net change in unrealized appreciation/depreciation on investments still held at June 30, 2016 ²	\$ (658,035)	\$ (995,536)	\$ (1,653,571)

¹ Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

² Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2016 is generally due to investments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation techniques used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) to determine the value of certain of the Trust s Level 3 investments as of period end.

			Unobservable	Range of Unobservable Inputs
	Value	Valuation Techniques	Inputs	Utilized
Assets:				
Common Stocks	\$ 3,290,175	Market Comparables		1.35x

Preferred Stocks	25,672,885	Market Comparables Probability-Weighted Expected Return Model	Tangible Book Value Multiple ¹ Priced to new financing round ¹ Revenue Multiple ¹ Revenue Growth Rate ¹ Discount Rate ² IPO Exit Probability ¹ Merger & Acquisition Probability ¹ Revenue Growth Rate ¹ Revenue Multiple ¹ Time to Exit ²	12.0x 84.00% 25.00% 70.00% 25.00% 80.00% 13.55x - 20.70x 1-2 years
Total	\$ 28,963,060			

- ¹ Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.
- ² Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Schedule of Investments June 30, 2016 (Unaudited)

BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets)

Common Stocks	Shares	Value
Biotechnology 18.2% AbbVie, Inc. (a)	32,686	\$ 2,023,589
Acceleron Pharma, Inc. (b)	29,400	\$ 2,023,389 999,012
Acerta Pharma BV, Series B (Acquired 2/01/16, cost \$986,402) (b)(c)	17,146,440	1,450,589
Actelion Ltd.	7,600	1,279,821
Agios Pharmaceuticals, Inc. (a)(b)	9,500	398,004
Alder Biopharmaceuticals, Inc. (a)(b)	10,100	252,197
Alexion Pharmaceuticals, Inc. (a)(b)	4,760	555,778
Alkermes PLC (a)(b)	16,800	726,096
Alnylam Pharmaceuticals, Inc. (a)(b)	12,600	699,174
Amgen, Inc. (a)	71,522	10,882,072
Aquinox Pharmaceuticals, Inc. (b)	15,900	105,258
Avexis, Inc. (b)	11,226	426,813
Axovant Sciences Ltd. (b)	12,100	155,364
Biogen, Inc. (a)(b)	23,948	5,791,105
BioMarin Pharmaceutical, Inc. (a)(b)	9,100	707,980
Celgene Corp. (a)(b)	41,786	4,121,353
Corvus Pharmaceuticals, Inc. (Acquired 3/23/16, cost \$297,937) (b)(c)	21,266	296,177
CytomX Therapeutics, Inc. (b)	28,059	286,623
Genomic Health, Inc. (a)(b)	19,300	499,774
Gilead Sciences, Inc. (a)	49,200	4,104,264
Global Blood Therapeutics, Inc. (b)	14,688	243,674
Incyte Corp. (a)(b)	13,800	1,103,724
Inotek Pharmaceuticals Corp. (b)	30,196	224,658
Intellia Therapeutics, Inc. (Acquired 5/6/16, Cost \$248,567) (b)(c)	30,613	630,894
Lion Biotechnologies, Inc. (Acquired 6/3/16, Cost \$123,281) (b)(c)	25,954	206,548
Medivation, Inc. (a)(b)	34,100	2,056,230
Neurocrine Biosciences, Inc. (a)(b)	41,762	1,898,083
Otonomy, Inc. (b)	8,400	133,392
Prothena Corp. PLC (a)(b)	4,344	151,866
PTC Therapeutics, Inc. (b)	30,300	212,706
Regeneron Pharmaceuticals, Inc. (a)(b)	7,358	2,569,634
REGENXBIO, Inc. (b)	35,850	286,800
Sage Therapeutics, Inc. (b)	9,342 4,400	281,474
Sarepta Therapeutics, Inc. (b)(d) Seattle Genetics, Inc. (a)(b)	14,867	83,908 600,775
Seres Therapeutics, Inc. (b)	2,210	64,202
Syndax Pharmaceuticals, Inc. (b)	13,956	137,467
Syndax Pharmaceuticals, Inc. (6) Syndax Pharmaceuticals, Inc. (Acquired 3/02/16, cost \$495,682) (b)(c)	35,428	343,053
Ultragenyx Pharmaceutical, Inc. (a)(b)	13,815	675,692
Vertex Pharmaceuticals, Inc. (a)(b)	36,705	3,157,364
	20,700	0,107,001
		50 922 197
Diversified Consumer Services 0.2%		50,823,187
Service Corp. International	20,600	557,024
Electronic Equipment, Instruments & Components 0.7%	20,000	557,024
FEI Co.	18,800	2,009,344
Health Care Equipment & Supplies 25.9%	10,000	2,007,544
Abbott Laboratories (a)	118,700	4,666,096
Baxter International, Inc. (a)	134,500	6,082,090
Becton Dickinson and Co. (a)	20,033	3,397,396
Boston Scientific Corp. (b)	518,400	12,115,008
CONMED Corp.	12,000	572,760
Cooper Cos., Inc. (a)	13,166	2,258,891
CR Bard, Inc. (a)	20,653	4,856,759
DENTSPLY SIRONA, Inc. (a)	22,500	1,395,900
Edwards Lifesciences Corp. (a)(b)	46,898	4,677,138
Common Stocks	Shares	Value
Health Care Equipment & Supplies (continued)		
Hologic, Inc. (a)(b)	36,600	\$ 1,266,360
Masimo Corp. (a)(b)	19,600	1,029,294

Medtronic PLC (a)	192,600	16,711,902
St. Jude Medical, Inc.	57,200	4,461,600
Stryker Corp. (a)	52,200	6,255,126
Zimmer Biomet Holdings, Inc. (a)	20,400	2,455,752
	,	_,,
		72 202 072
Health Care Providers & Services 22.3%		72,202,072
Aetna, Inc. (a)	44,311	5,411,701
Amedisys, Inc. (a)(b)	43,100	2,175,688
American Renal Associates Holdings, Inc. (b)	9,083	263,135
AmerisourceBergen Corp. (a)	14,400	1,142,208
Anthem, Inc. (a)	50,300	6,606,402
Cardinal Health, Inc. (a)	33,030	2,576,670
Centene Corp. (a)(b)	32,100	2,290,977
Cigna Corp. (a)	39,100	5,004,409
DaVita HealthCare Partners, Inc. (a)(b)	39,000	3,015,480
Express Scripts Holding Co. (a)(b)	11,076	839,561
HCA Holdings, Inc. (a)(b)	11,394	877,452
HealthEquity, Inc. (a)(b)	16,900	513,508
		4,676,880
Humana, Inc. (a) Laboratory Corp. of America Holdings (a)(b)	26,000	
	4,300 19,700	560,161
McKesson Corp. (a)	,	3,677,005
Quest Diagnostics, Inc. (a)	8,600	700,126
Teladoc, Inc. (b)(d)	18,800	301,176
UnitedHealth Group, Inc. (a)(e)	122,002	17,226,682
Universal Health Services, Inc., Class B (a)	28,100	3,768,210
WellCare Health Plans, Inc. (a)(b)	7,100	761,688
		62,389,119
Health Care Technology 0.8%		
Cerner Corp. (a)(b)	38,100	62,389,119 2,232,660
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1%		2,232,660
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a)	38,100 39,400	
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7%	39,400	2,232,660 5,821,744
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b)	39,400 38,625	2,232,660 5,821,744 8,925,851
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC	39,400 38,625 60,400	2,232,660 5,821,744 8,925,851 3,610,943
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a)	39,400 38,625 60,400 63,562	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd.	39,400 38,625 60,400 63,562 13,500	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b)	39,400 38,625 60,400 63,562 13,500 18,300	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a)	39,400 38,625 60,400 63,562 13,500 18,300 115,800	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a)	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b)	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500 54,481	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a)	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a)	$\begin{array}{c} 39,400\\ 38,625\\ 60,400\\ 63,562\\ 13,500\\ 18,300\\ 115,800\\ 116,000\\ 37,500\\ 54,481\\ 13,200\\ 66,470\end{array}$	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b)	$\begin{array}{c} 39,400\\ 38,625\\ 60,400\\ 63,562\\ 13,500\\ 18,300\\ 115,800\\ 116,000\\ 37,500\\ 54,481\\ 13,200\\ 66,470\\ 23,143\end{array}$	$\begin{array}{c} 2,232,660\\ 5,821,744\\ 8,925,851\\ 3,610,943\\ 4,674,985\\ 481,116\\ 535,275\\ 9,119,250\\ 2,491,113\\ 1,625,250\\ 2,114,952\\ 1,865,292\\ 8,062,811\\ 1,406,632\end{array}$
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a)	$\begin{array}{c} 39,400\\ 38,625\\ 60,400\\ 63,562\\ 13,500\\ 18,300\\ 115,800\\ 116,000\\ 37,500\\ 54,481\\ 13,200\\ 66,470\\ 23,143\\ 66,500 \end{array}$	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA	$\begin{array}{c} 39,400\\ 38,625\\ 60,400\\ 63,562\\ 13,500\\ 18,300\\ 115,800\\ 116,000\\ 37,500\\ 54,481\\ 13,200\\ 66,470\\ 23,143\\ 66,500\\ 17,900 \end{array}$	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA Mylan NV (a)(b)	$\begin{array}{c} 39,400\\ 38,625\\ 60,400\\ 63,562\\ 13,500\\ 18,300\\ 115,800\\ 116,000\\ 37,500\\ 54,481\\ 13,200\\ 66,470\\ 23,143\\ 66,500\\ 17,900\\ 54,600\\ \end{array}$	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418 2,360,904
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA Mylan NV (a)(b) Nektar Therapeutics (a)(b)	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500 54,481 13,200 66,470 23,143 66,500 17,900 54,600 23,800	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418 2,360,904 338,674
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA Mylan NV (a)(b) Nektar Therapeutics (a)(b) Pfizer, Inc. (a)	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500 54,481 13,200 66,470 23,143 66,500 17,900 54,600 23,800 205,098	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418 2,360,904 338,674 7,221,501
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA Mylan NV (a)(b) Nektar Therapeutics (a)(b) Pfizer, Inc. (a) Phibro Animal Health Corp., Class A	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500 54,481 13,200 66,470 23,143 66,500 17,900 54,600 23,800 205,098 23,300	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418 2,360,904 338,674 7,221,501 434,778
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA Mylan NV (a)(b) Nektar Therapeutics (a)(b) Pfizer, Inc. (a) Phibro Animal Health Corp., Class A Roche Holding AG	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500 54,481 13,200 66,470 23,143 66,500 17,900 54,600 23,800 205,098 23,300 10,900	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418 2,360,904 338,674 7,221,501 434,778 2,876,290
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA Mylan NV (a)(b) Nektar Therapeutics (a)(b) Pfizer, Inc. (a) Phibro Animal Health Corp., Class A Roche Holding AG Shire PLC ADR (a)	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500 54,481 13,200 66,470 23,143 66,500 17,900 54,600 23,800 205,098 23,300 10,900 25,929	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418 2,360,904 338,674 7,221,501 434,778 2,876,290 4,773,010
Cerner Corp. (a)(b) Life Sciences Tools & Services 2.1% Thermo Fisher Scientific, Inc. (a) Pharmaceuticals 26.7% Allergan PLC (a)(b) AstraZeneca PLC Bristol-Myers Squibb Co. (a) Chugai Pharmaceutical Co. Ltd. Dermira, Inc. (a)(b) Eli Lilly & Co. (a) GlaxoSmithKline PLC GlaxoSmithKline PLC ADR (a) Intra-Cellular Therapies, Inc. (b) Jazz Pharmaceuticals PLC (a)(b) Johnson & Johnson (a) Mallinckrodt PLC (a)(b) Merck & Co., Inc. (a) Merck KGaA Mylan NV (a)(b) Nektar Therapeutics (a)(b) Pfizer, Inc. (a) Phibro Animal Health Corp., Class A Roche Holding AG	39,400 38,625 60,400 63,562 13,500 18,300 115,800 116,000 37,500 54,481 13,200 66,470 23,143 66,500 17,900 54,600 23,800 205,098 23,300 10,900	2,232,660 5,821,744 8,925,851 3,610,943 4,674,985 481,116 535,275 9,119,250 2,491,113 1,625,250 2,114,952 1,865,292 8,062,811 1,406,632 3,831,065 1,819,418 2,360,904 338,674 7,221,501 434,778 2,876,290

See Notes to Financial Statements.

BlackRock Health Sciences Trust (BME)

Common Stocks	Shares	Value		
Pharmaceuticals (continued) Zoetis, Inc. (a)	45,300	\$ 2,149,938		
Total Common Stocks 96.9%		74,400,907 270,436,057		
Preferred Stocks Biotechnology 0.6% Afferent Pharmaceuticals, Inc., Series C (Acquired 6/30/15, cost \$466,519), 0.00% (b)(c)	190,160	941.292		
Lion Biotechnologies, Inc., Series B (Acquired 6/3/16, Cost \$144,728), 0.00% (b)(c) Ovid Therapeutics, Inc. (Acquired 8/7/15, cost \$503,166), 0.00% (b)(c) Total Preferred Stocks 0.6%	30,469 80,765	242,480 503,166 1,686,938		
Rights0.0%Biotechnology0.0%Dyax Corp.CVR (b)Total Long-Term Investments	61,727	68,517		
(Cost \$194,918,126) 97.5%		272,191,512		
Short-Term Securities BlackRock Liquidity Funds, TempFund, Institutional Class, 0.40% (f)(g)	Shares 9,585,944 Beneficial Interest	Value \$ 9,585,944		
BlackRock Liquidity Series, LLC Money Market Series, 0.59% (f)(g)(h) Total Short-Term Securities	(000) \$ 157	156,732		
(Cost \$9,742,676) 3.5% Total Investments Before Options Written		9,742,676		
(Cost \$204,660,802) 101.0%		281,934,188		
Options Written (Premiums Received \$2,147,026) (0.9)% Total Investments Net of Options Written 100.1% Liabilities in Excess of Other Assets (0.1)%		(2,593,549) 279,340,639 (312,707)		
Net Assets 100.0%		\$ 279,027,932		

Notes to Schedule of Investments

(a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) Non-income producing security.

(c) Restricted securities as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$4,614,199 and an original cost of \$3,266,282 which was 1.7% of its net assets.

(e) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(f) Current yield as of period end.

(g) During the six months ended June 30, 2016, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

			Shares/ Beneficial Interest Held at		
	Shares/ Beneficial Interest Held at December 31,	Net	June 30,	Value at June 30,	
Affiliates	2015	Activity	2016	2016	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	8,854,560	731,384	9,585,944	\$ 9,585,944	\$ 26,637
BlackRock Liquidity Series, LLC Money Market Series Total		\$ 156,732	\$ 156,732	\$ 156,732 \$ 9,742,676	\$ 1,512 ¹ \$ 28,149

Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(h) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series LLC, Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Health Sciences Trust (BME)

Derivative Financial Instruments Outstanding as of Period End Exchange-Traded Options Written

			St	trike		
	Put/	Expiration				
Description	Call	Date	Р	rice	Contracts	Value
Abbott Laboratories	Call	7/01/16	USD	39.00	176	\$ (6,511)
AbbVie, Inc.	Call	7/01/16	USD	60.50	13	(1,592)
Aetna, Inc.	Call	7/01/16	USD	115.00	18	(12,735)
Celgene Corp.	Call	7/01/16	USD	109.00	7	(350)
Express Scripts Holding Co.	Call	7/01/16	USD	72.50	13	(4,030)
Gilead Sciences, Inc.	Call	7/01/16	USD	85.50	35	(105)
GlaxoSmithKline PLC ADR	Call	7/01/16	USD	42.50	117	(9,945)
Mallinckrodt PLC	Call	7/01/16	USD	65.00	60	(3,000)
Medivation, Inc.	Call	7/01/16	USD	61.00	28	(1,148)
Medtronic PLC	Call	7/01/16	USD	81.50	92	(43,930)
Mylan NV	Call	7/01/16	USD	42.00	92 28	(11,408)
Shire PLC ADR	Call Call	7/01/16	USD	195.00	28	(840)
UnitedHealth Group, Inc.	Call	7/01/16	USD	134.00 92.00	170	(117,725)
Vertex Pharmaceuticals, Inc.	Call	7/01/16 7/07/16	USD USD		62 42	(10,540)
Bristol-Myers Squibb Co. Cerner Corp.	Call	7/07/16	USD	72.01 55.01	42 61	(7,849) (22,069)
AbbVie, Inc.	Call	7/08/16	USD	65.00	41	(22,009)
Aetna, Inc.	Call	7/08/16	USD	121.00	16	(3,504)
Allergan PLC	Call	7/08/16	USD	250.00	110	(1,650)
Amgen, Inc.	Call	7/08/16	USD	162.50	24	(1,050)
Anthem, Inc.	Call	7/08/16	USD	133.00	7	(550)
Bristol-Myers Squibb Co.	Call	7/08/16	USD	73.00	120	(12,840)
Celgene Corp.	Call	7/08/16	USD	111.00	4	(24)
Express Scripts Holding Co.	Call	7/08/16	USD	75.50	39	(3,744)
Medtronic PLC	Call	7/08/16	USD	83.00	130	(44,720)
Merck & Co., Inc.	Call	7/08/16	USD	57.00	55	(4,813)
Teva Pharmaceutical Industries Ltd. ADR	Call	7/08/16	USD	54.50	18	(234)
UnitedHealth Group, Inc.	Call	7/08/16	USD	138.00	25	(8,562)
UnitedHealth Group, Inc.	Call	7/08/16	USD	139.00	20	(5,330)
Stryker Corp.	Call	7/11/16	USD	110.12	50	(48,632)
Cardinal Health, Inc.	Call	7/12/16	USD	77.50	58	(7,179)
AbbVie, Inc.	Call	7/15/16	USD	62.50	41	(2,768)
Alder Biopharmaceuticals, Inc.	Call	7/15/16	USD	30.00	36	(5,040)
Alnylam Pharmaceuticals, Inc.	Call	7/15/16	USD	60.00	44	(5,280)
AmerisourceBergen Corp.	Call	7/15/16	USD	77.50	22	(4,785)
Baxter International, Inc.	Call	7/15/16	USD	45.00	52	(4,212)
BioMarin Pharmaceutical, Inc.	Call	7/15/16	USD	100.00	24	(1,620)
BioMarin Pharmaceutical, Inc.	Call	7/15/16	USD	90.00	24	(3,180)
Bristol-Myers Squibb Co.	Call	7/15/16	USD	72.50	177	(30,798)
Cardinal Health, Inc.	Call	7/15/16	USD	77.50	29	(3,915)
Celgene Corp.	Call	7/15/16	USD	110.00	4	(14)
Centene Corp.	Call	7/15/16	USD	70.00	36	(8,370)
Centene Corp.	Call	7/15/16	USD	72.50	20	(1,950)
Cerner Corp. Cigna Corp.	Call Call	7/15/16 7/15/16	USD USD	57.50 130.00	52 75	(8,840) (12,788)
Cooper Cos., Inc.	Call	7/15/16	USD	130.00	33	(12,788) (9,900)
CR Bard, Inc.	Call	7/15/16	USD	230.00	36	(21,960)
DaVita HealthCare Partners, Inc.	Call	7/15/16	USD	75.00	80	(21,000)
DENTSPLY SIRONA, Inc.	Call	7/15/16	USD	65.00	39	(1,170)
Dermira, Inc.	Call	7/15/16	USD	35.00	54	(25,920)
Eli Lilly & Co.	Call	7/15/16	USD	75.00	60	(23,700)
Gilead Sciences, Inc.	Call	7/15/16	USD	87.50	35	(23,700)
HealthEquity, Inc.	Call	7/15/16	USD	30.00	59	(5,605)
Incyte Corp.	Call	7/15/16	USD	85.00	50	(4,750)
						(.,)

Medtronic PLC	Call	7/15/16	USD	82.50	10	(4,325)
Merck & Co., Inc.	Call	7/15/16	USD	57.50	87	(6,438)
Neurocrine Biosciences, Inc.	Call	7/15/16	USD	50.00	73	(2,373)
Pfizer, Inc.	Call	7/15/16	USD	35.00	70	(3,640)
Prothena Corp. PLC	Call	7/15/16	USD	50.00	15	(412)
Regeneron Pharmaceuticals, Inc.	Call	7/15/16	USD	410.00	8	(220)

See Notes to Financial Statements.

66

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Health Sciences Trust (BME)

Seatt Genetics, Inc. Call 7/15/16 USD 40.00 55 5 (?, Shire PLC ADR Shire PLC ADR Call 7/15/16 USD 105000 15 (?) Stryker Corp. Call 7/15/16 USD 155.00 23 (14) Thermo Fisher Scientific, Inc. Call 7/15/16 USD 155.00 64 (0) Universal Health Services, Inc., Class B Call 7/15/16 USD 155.00 24 (8) Zoetis, Inc. Call 7/15/16 USD 155.00 24 (8) Actum, Inc. Call 7/15/16 USD 135.00 41 (7) Actin, Inc. Call 7/12/16 USD 122.00 16 (3) Actin, Inc. Call 7/22/16 USD 122.00 16 (3) Attern Increational, Inc. Call 7/22/16 USD 140.00 56 (2) Baxter International, Inc. Call 7/22/16 USD 140.00 <th></th> <th></th> <th></th> <th></th> <th>S</th> <th>trike</th> <th></th> <th></th>					S	trike		
Seatti Genetics, Inc. Call 7/15/16 USD 40,00 52 \$5,7 Shire PLC Call 7/15/16 USD 200,000 15 (14) Teva Pharmaceutical Industries Lul. ADR Call 7/15/16 USD 155,00 23 (14) Thermo Fisher Scientific, Inc. Call 7/15/16 USD 155,00 64 (0) Universal Health Services, Inc., Class B Call 7/15/16 USD 155,00 24 (8) Zoetis, Inc. Call 7/15/16 USD 155,00 24 (8) Zoetis, Inc. Call 7/15/16 USD 140,00 68 (3) Aetma, Inc. Call 7/22/16 USD 142,00 16 (3) Angen, Inc. Call 7/22/16 USD 162,00 92 (1) Baxter International, Inc. Call 7/22/16 USD 46,00 56 (2) Itally & Co. Human, Inc. Call 7/22/16 USD 160,00 21 (C) Johnson & Johnson Call			Put/	Expiration				
Shire PLCADRCall7/15/16USD15.003011.1Stryker Corp.Call7/15/16USD15.00250014.Teva Pharmaceutical Industries Ltd.ADRCall7/15/16USD55.002500Utragenyr, Marmaceutical, Inc.Call7/15/16USD15.0064000Utragenyr, Marmaceutical, Inc.Call7/15/16USD15.0064000<								Value
Stryker Corp.Call71/51/6USD51.0030(14)Teva Pharmaceutical Industries Ltd. ADRCall71/51/6USD55.0025(4)Utragenyx Pharmaceutical, Inc.Call71/51/6USD155.0064(6)Utriversal Health Services, Inc, Class BCall71/51/6USD155.0024(8)Zoetis, Inc.Call71/51/6USD150.0024(8)(8)(8)Zoetis, Inc.Call71/51/6USD115.0024(8)(7)(1)(1)(8)(8)(7)(7)(1)(8)(8)(7)(7)(8)(8)(8)(7)(7)(8)(8)(7)(7)(8)(8)(7)(7)(8)(8)(7)(7)(8)(8)(7)(7)(1)(1)(9)(8)(7)(7)(1)(1)(9)(8)(7)(7)(1)(1)(9)								\$ (7,020)
								(975)
Thermo Fisher Scientific, Inc.Call71/51/6USD155.0064(Ultragenyx Pharmaceutical, Inc.Call71/51/6USD65.0050(7)WellCare Health Plans, Inc.Call71/51/16USD105.0024(8)Zoetis, Inc.Call71/51/16USD105.0024(8)Actian, Inc.Call77/21/16USD122.0062(16)Alexion Pharmaceuticals, Inc.Call77/22/16USD122.0062(16)Baxter International, Inc.Call77/22/16USD162.5092(1)Baxter International, Inc.Call77/22/16USD45.50107(7)Baxter International, Inc.Call77/22/16USD45.0066(2)I Unitary & Co.Call77/22/16USD160.0021(4)Humana, Inc.Call77/22/16USD160.0021(1)Johnson & JohnsonCall77/22/16USD160.0021(1)Johnson & JohnsonCall77/22/16USD86.0071(1)Medtronic PLCCall77/22/16USD86.0071(1)Mylan NVCall77/22/16USD86.0071(1)Paramaceutical Industries Ltd.ADRCall77/22/16USD85.5017(1)Call 77/22/16USD93.0014(16,77/29/16USD93.0016								(14,700)
Ultragenyx Pharmaceutical, Inc.Call7/15/16USD65.005060Universal Health Services, Inc., Class BCall7/15/16USD135.0041(7,WellCare Health Plans, Inc.Call7/15/16USD145.0068(3,Actta, Inc.Call7/15/16USD44.0068(3,Actta, Inc.Call7/22/16USD122.0016(3,Amgen, Inc.Call7/22/16USD122.0016(3,Baxter International, Inc.Call7/22/16USD45.50107(7,Baxter International, Inc.Call7/22/16USD46.0056(2,Eli Lilly & Co.Call7/22/16USD197.50115(47,Humana, Inc.Call7/22/16USD197.5010(2,Jazz Pharmaceutical PLCCall7/22/16USD197.5010(2,Johnson & JohnsonCall7/22/16USD117.00144(70,Medtronic PLCCall7/22/16USD45.5010(0,Medtronic PLCCall7/22/16USD45.5010(2,Teva Pharmaceutical Industries Ltd. ADRCall7/22/16USD55.5076(2,Teva Pharmaceutical Industries Ltd. ADRCall7/22/16USD19.0041(16,Vertex Pharmaceutical Industries Ltd. ADRCall7/22/16USD19.0041(16,<		ADR						(112) (640)
Universal Health Services, Inc., Class BCall $7/15/16$ USD 135.00 41 $(7, WellCare Health Plans, Inc.WellCare Health Plans, Inc.Call7/15/16USD105.0024(8, Zattis, Inc.)Alexion Pharmaceuticals, Inc.Call7/12/16USD122.0062(16, Castis, Inc.)Alexion Pharmaceuticals, Inc.Call7/22/16USD122.0062(16, Castis, Inc.)Baxter International, Inc.Call7/22/16USD122.0062(16, Castis, Inc.)Baxter International, Inc.Call7/22/16USD162.5092(1, Inc.)Baxter International, Inc.Call7/22/16USD45.50107(7, Inc.)Baxter International, Inc.Call7/22/16USD150.00115(47, Inc.)Humana, Inc.Call7/22/16USD150.00115(47, Inc.)Jazz Pharmaceuticals PLCCall7/22/16USD150.0011(0, Inc.)Medivation, Inc.Call7/22/16USD61.5035(5, Inc.)Medivation, Inc.Call7/22/16USD45.50100(4, Inc.)Pitzer, Inc.Call7/22/16USD45.50100(4, Inc.)Vertex Pharmaceutical Industries Ltd.ADRCall7/22/16USD35.5076(2, Inc.)Teva Pharmaceuticals, Inc.Call7/22/16$								(640)
WellCare Health Plans, Inc. Call 7/15/16 USD 105:00 24 (8) Zoetis, Inc. Call 7/15/16 USD 48:00 68 (3) Actna, Inc. Call 7/15/16 USD 122:00 16 (3) Amgen, Inc. Call 7/22/16 USD 162:50 92 (1) Baxter International, Inc. Call 7/22/16 USD 45:50 107 (7) Baxter International, Inc. Call 7/22/16 USD 46:00 56 (2) Ibit Sily & Co. Call 7/22/16 USD 197:50 10 (2) Jazz Pharmaceuticals PLC Call 7/22/16 USD 197:50 10 (2) Johnson & Johnson Call 7/22/16 USD 161:50 35 (5) Medtronic PLC Call 7/22/16 USD 86:00 71 (10) Mylan NV Call 7/22/16 USD 56:50 17 (6) <td>•••</td> <td>3</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>(7,892)</td>	•••	3						(7,892)
Zoetis, Inc.Call $7/15/16$ USD 48.00 68 $(3.)$ Aetna, Inc.Call $7/22/16$ USD 122.00 62 $(16.)$ Alexion Pharmaceuticals, Inc.Call $7/22/16$ USD 122.00 16 $(3.)$ Baxter International, Inc.Call $7/22/16$ USD 45.20 92 $(1.)$ Baxter International, Inc.Call $7/22/16$ USD 46.00 56 $(2.)$ Eli Lilly & Co.Call $7/22/16$ USD 46.00 56 $(2.)$ Humana, Inc.Call $7/22/16$ USD 197.50 110 (4.7) Jazz Pharmaceuticals PLCCall $7/22/16$ USD 117.00 144 $(70.)$ Medivation, Inc.Call $7/22/16$ USD $61.0.00$ 21 $(0.)$ Mylan NVCall $7/22/16$ USD 86.00 71 $(10.)$ Mylan NVCall $7/22/16$ USD 86.00 71 $(10.)$ Iva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 86.00 71 $(10.)$ Iva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 86.00 71 $(10.)$ Iva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 86.00 71 $(10.)$ Iva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 94.00 43 $(4.)$ Masimo Corp.Call $7/22/16$ USD 94		-						(8,640)
Alexion Pharmaceuticals, Inc.Call $7/22/16$ USD 122.00 16(3, (3, (3, (3, 								(3,740)
Amgen, Inc.Call $7/22/16$ USD 162.50 92 $(1, Baxter International, Inc.Baxter International, Inc.Call7/22/16USD45.50107(7, Baxter International, Inc.Eli Lilly & Co.Call7/22/16USD45.0056(2, Eli Lilly & Co.Eli Lilly & Co.Call7/22/16USD45.0056(2, Eli Lilly & Co.Humana, Inc.Call7/22/16USD150.00115(47, Humana, Inc.)Jazz Pharmaceuticals PLCCall7/22/16USD160.0021(2, Jaxr)Medivation, Inc.Call7/22/16USD61.5035(5, Medironic PLC)Medivation, Inc.Call7/22/16USD86.0071(10, Mylan NV)Pfizer, Inc.Call7/22/16USD86.0071(10, Mylan NV)UnitedHealth Group, Inc.Call7/22/16USD55.5016(2, Prex Pharmaceutical Industries Ltd. ADR)Call7/22/16USD54.50100(4, Prex, Pharmaceutical, Inc.)UnitedHealth Group, Inc.Call7/22/16USD54.50100(4, Amgen, Inc.)Abbot LaboratoriesCall7/22/16USD54.50100(4, Amgen, Inc.)Actina, Inc.Call7/22/16USD53.0025(5, Amta, Inc.)Actina, Inc.Call7/29/16USD12.0043(4, Amgen, Inc.)$	tna, Inc.		Call	7/22/16	USD	122.00	62	(16,833)
Baxter International, Inc.Call $7/22/16$ USD 45.50 107 $(7, 32)$ Baxter International, Inc.Call $7/22/16$ USD 46.00 56 $(2, 32)$ Baxter International, Inc.Call $7/22/16$ USD 75.00 115 $(47, 42)$ Humana, Inc.Call $7/22/16$ USD 197.50 10 $(2, 32)$ Jazz Pharmaceuticals PLCCall $7/22/16$ USD 160.00 21 $(0, 32)$ Johnson &Call $7/22/16$ USD 61.50 35 $(5, 32)$ Medivation, Inc.Call $7/22/16$ USD 61.50 35 $(5, 32)$ Meditonic PLCCall $7/22/16$ USD 66.00 71 $(10, 42)$ Mylan NVCall $7/22/16$ USD 46.00 00 $(4, 97)$ Prizer, Inc.Call $7/22/16$ USD 56.50 17 $(0, 12)$ Inva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 10 $(1, 12)$ Inva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 94.00 43 $(4, 43)$ Vera Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 94.00 43 $(4, 43)$ Vera Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 93.00 41 $(16, 92)$ Vera Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 93.00 43 $(4, 93)$ <tr< td=""><td>exion Pharmaceuticals, Inc.</td><td></td><td>Call</td><td>7/22/16</td><td>USD</td><td>122.00</td><td>16</td><td>(3,480)</td></tr<>	exion Pharmaceuticals, Inc.		Call	7/22/16	USD	122.00	16	(3,480)
Baxter International, Inc.Call $7/22/16$ USD 46.00 56 $(2, Eli Lilly \& Co.$ Eli Lilly & Co.Call $7/22/16$ USD 75.00 115 $(47, 12)$ Humana, Inc.Call $7/22/16$ USD 197.50 100 $(2, 12)$ Jazz Pharmaceuticals PLCCall $7/22/16$ USD 160.00 21 $(0, 12)$ Johnson & JohnsonCall $7/22/16$ USD 117.00 144 $(70, 12)$ Medivation, Inc.Call $7/22/16$ USD 86.00 71 $(10, 12)$ Mylan NVCall $7/22/16$ USD 86.00 71 $(10, 12)$ Mylan NVCall $7/22/16$ USD 45.50 100 $(4, 12)$ Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 100 $(1, 12)$ Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 94.00 43 $(4, 12)$ Masimo Corp.Call $7/22/16$ USD 94.00 43 $(4, 12)$ Amamaceuticals, Inc.Call $7/22/16$ USD 93.50 150 $(1, 22)$ Aetna, Inc.Call $7/29/16$ USD 94.00 43 $(4, 42)$ Amagen, Inc.Call $7/29/16$ USD 93.50 150 $(1, 42)$ Aetna, Inc.Call $7/29/16$ USD 93.50 150 $(1, 42)$ Anthem, Inc.Call $7/29/16$ USD 132.00 88 $($			Call	7/22/16	USD	162.50		(1,886)
Eli Lilly & Co.Call $7/22/16$ USD 75.00 115 $(47, Humana, Inc.)$ Humana, Inc.Call $7/22/16$ USD 197.50 10 $(2, I)$ Jazz Pharmaceuticals PLCCall $7/22/16$ USD 197.50 10 $(2, I)$ Johnson & JohnsonCall $7/22/16$ USD 117.00 144 $(70, I)$ Medironic PLCCall $7/22/16$ USD 86.00 71 $(10, I)$ Mylan NVCall $7/22/16$ USD 86.00 71 $(10, I)$ Mylan NVCall $7/22/16$ USD 85.50 76 $(2, I)$ Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 10 Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 10 $(1, I)$ UnitedHealth Group, Inc.Call $7/22/16$ USD 54.50 17 $(1, I)$ Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43 $(4, I)$ Amagen, Inc.Call $7/29/16$ USD 53.01 36 $(5, Abbot Laboratories)$ $Call$ $7/29/16$ VSD 39.50 150 $(10, I)$ Anthem, Inc.Call $7/29/16$ USD 132.00 88 $(29, I)$ Biogen, Inc.Call $7/29/16$ USD 132.00 88 $(29, I)$ Biogen, Inc.Call $7/29/16$ USD 132.00 41 $(38, Celgene Corp.Call$								(7,116)
Humana, Inc.Call $7/22/16$ USD 197.50 10(2,Jazz Pharmaceuticals PLCCall $7/22/16$ USD 160.00 21(()Johnson &Call $7/22/16$ USD 117.00 1144 (70,Medivation, Inc.Call $7/22/16$ USD 61.50 35 (5,Medtronic PLCCall $7/22/16$ USD 86.00 71 (10,Mylan NVCall $7/22/16$ USD 46.00 100(4,Prizer, Inc.Call $7/22/16$ USD 54.50 10(()Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 10(()UnitedHealth Group, Inc.Call $7/22/16$ USD 54.50 10(()()Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43(4,Masimo Corp.Call $7/22/16$ USD 94.00 43(4,Adagen, Inc.Call $7/29/16$ USD 39.50 150(10,Aetna, Inc.Call $7/29/16$ USD 132.00 46(4,Amgen, Inc.Call $7/29/16$ USD 132.00 48(29,Biogen, Inc.Call $7/29/16$ USD 132.00 88(29,Biogen, Inc.Call $7/29/16$ USD 132.00 41(38,Celgene Corp.Call $7/29/16$ USD 132.00 88(29,Biogen, Inc.	·							(2,548)
Jazz Pharmaceuticals PLCCall $7/22/16$ USD 160.00 21 ()Johnson & JohnsonCall $7/22/16$ USD 117.00 144 (70,Medivation, Inc.Call $7/22/16$ USD 61.50 35 (5,Meditronic PLCCall $7/22/16$ USD 86.00 71(10,Mylan NVCall $7/22/16$ USD 86.00 71(10,Mylan NVCall $7/22/16$ USD 46.00 100(4,Prizer, Inc.Call $7/22/16$ USD 54.50 10(10,Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 56.50 17(10,UnitedHealth Group, Inc.Call $7/22/16$ USD 54.50 10(10,(11,Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43(4,Masimo Corp.Call $7/22/16$ USD 94.00 43(4,Anta, Inc.Call $7/29/16$ USD 94.00 43(15,Aetna, Inc.Call $7/29/16$ USD 132.00 88(29,Biogen, Inc.Call $7/29/16$ USD 132.00 88(29,Biogen, Inc.Call $7/29/16$ USD 132.00 88(29,Biogen, Inc.Call $7/29/16$ USD 132.00 88(29,Gelead Sciences, Inc.Call $7/29/16$ USD 180.00 97(12,Gl								(47,438)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $								(2,925)
Medivation, Inc.Call $7/22/16$ USD 61.50 35 $(5, Medtronic PLC)$ Medivation, PLCCall $7/22/16$ USD 86.00 71 $(10, Mylan NV)$ Mylan NVCall $7/22/16$ USD 46.00 100 $(4, Pfizer, Inc.)$ Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 10 $(0, Pfizer, Inc.)$ Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 56.50 17 $(0, Pfizer, Inc.)$ UnitedHealth Group, Inc.Call $7/22/16$ USD 56.50 17 $(16, Pfizer, Pharmaceuticals, Inc.)$ Call $7/22/16$ USD 94.00 43 $(4, Masimo Corp.)$ Atbott LaboratoriesCall $7/22/16$ USD 94.00 43 $(4, Amgen, Inc.)$ Call $7/29/16$ USD 39.50 150 $(10, Aetna, Inc.)$ Aetna, Inc.Call $7/29/16$ USD 121.00 43 $(4, Amgen, Inc.)$ $Call$ $7/29/16$ USD 123.00 16 $(4, Amgen, Inc.)$ Biogen, Inc.Call $7/29/16$ USD 132.00 88 $(29, Pficer, Pficer,$								(788)
Medtronic PLCCall $7/22/16$ USD 86.00 71 $(10, M)$ Mylan NVCall $7/22/16$ USD 46.00 100 $(4, P)$ Prizer, Inc.Call $7/22/16$ USD 35.50 76 $(2, C)$ Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 10 $(0, C)$ Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 56.50 17 $(0, C)$ UnitedHealth Group, Inc.Call $7/22/16$ USD 94.00 43 $(4, C)$ Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43 $(4, C)$ Masimo Corp.Call $7/22/16$ USD 93.50 150 $(10, C)$ Abott LaboratoriesCall $7/29/16$ USD 39.50 150 $(10, C)$ Actna, Inc.Call $7/29/16$ USD 123.00 16 $(4, C)$ Amgen, Inc.Call $7/29/16$ USD 132.00 88 $(29, C)$ Biogen, Inc.Call $7/29/16$ USD 132.00 88 $(29, C)$ Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 97 $(12, C)$ Gilead Science, Inc.Call $7/29/16$ USD 89.00 99 $(4, C)$ Humana, Inc.Call $7/29/16$ USD 89.00 99 $(4, C)$ Humana, Inc.Call $7/29/16$ USD 85.00 90 $(4, C)$ Metrick								(70,200) (5,985)
Mylan NVCall $7/22/16$ USD 46.00 100 $(4, Pfizer, Inc.)$ Teva Pharmaceutical Industries Ltd. ADRCall $7/22/16$ USD 55.50 76 $(2, Teva Pharmaceutical Industries Ltd. ADRCall7/22/16USD56.5010(1, Teva Pharmaceutical Industries Ltd. ADRCall7/22/16USD56.5017(1, Teva Pharmaceutical Industries Ltd. ADRCall7/22/16USD139.0041(16, Vertex Pharmaceuticals, Inc.)Call7/22/16USD94.0043(4, Masimo Corp.)Vertex Pharmaceuticals, Inc.Call7/22/16USD94.0043(4, Masimo Corp.)Abbott LaboratoriesCall7/22/16USD93.0136(5, Aetna, Inc.)Atema, Inc.Call7/29/16USD121.0043(16, A, Masimo L, C, Call)Anthem, Inc.Call7/29/16USD121.0043(15, Aetna, Inc.)Biogen, Inc.Call7/29/16USD132.0016(4, A, Call)Celgene Corp.Call7/29/16USD132.0088(29, Call)Gilead Sciences, Inc.Call7/29/16USD80.0097(12, Call)Humana, Inc.Call7/29/16USD80.0097(12, Call)Mallinekrodt PLCCall7/29/16USD85.5092(95, Mallinekrodt PLC)Metrok & Co., Inc.Call7/29/16<$								(10,828)
Pfizer, Inc.Call $7/22/16$ USD 35.50 76 (2) Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 10 (1) Teva Pharmaceutical Industries Ltd.ADRCall $7/22/16$ USD 54.50 17 (1) UnitedHealth Group, Inc.Call $7/22/16$ USD 139.00 41 $(16, 1)$ Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43 $(4, 1)$ Masimo Corp.Call $7/22/16$ USD 93.00 41 $(16, 1)$ Abbott LaboratoriesCall $7/29/16$ USD 39.50 150 $(10, 1)$ Aetna, Inc.Call $7/29/16$ USD 121.00 43 $(4, 2)$ Amgen, Inc.Call $7/29/16$ USD 157.50 3 $(2, 2)$ Anthem, Inc.Call $7/29/16$ USD 132.00 88 $(29, 2)$ Biogen, Inc.Call $7/29/16$ USD 132.00 88 $(29, 2)$ Biogen, Inc.Call $7/29/16$ USD 132.00 41 $(38, 2)$ Celgene Corp.Call $7/29/16$ USD 80.00 97 $(12, 3)$ Biogen, Inc.Call $7/29/16$ USD 80.00 97 $(12, 3)$ Gilead Sciences, Inc.Call $7/29/16$ USD 80.00 97 $(12, 3)$ HCA Holdings, Inc.Call $7/29/16$ USD 85.50 92 $95, 3$ Mallinckrodt PLC <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(4,750)</td></t<>								(4,750)
Teva Pharmaceutical Industries Ltd. ADRCall $7/22/16$ USD 54.50 10 (1) Teva Pharmaceutical Industries Ltd. ADRCall $7/22/16$ USD 56.50 17 (1) UnitedHealth Group, Inc.Call $7/22/16$ USD 139.00 41 (16) Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43 (4) Masimo Corp.Call $7/22/16$ USD 39.00 41 (16) Abbott LaboratoriesCall $7/22/16$ USD 39.50 150 (10) Aetna, Inc.Call $7/29/16$ USD 132.00 43 (15) Amgen, Inc.Call $7/29/16$ USD 123.00 16 (4) Amgen, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 130.00 41 (38) Celgene Corp.Call $7/29/16$ USD 107.00 150 (8) Eli Lilly & Co.Call $7/29/16$ USD 80.00 97 (12) Gilead Sciences, Inc.Call $7/29/16$ USD 182.50 92 95 Mallinckrodt PLCCall $7/29/16$ USD 182.50 92 95 Mallinckrodt PLCCall $7/29/16$ USD 85.50 141 (28) Merck & Co., Inc.Call $7/29/16$ USD								(2,660)
Teva Pharmaceutical Industries Ltd. ADRCall $7/22/16$ USD 56.50 17 (16) UnitedHealth Group, Inc.Call $7/22/16$ USD 139.00 41 (16) Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43 $(4,$ Masimo Corp.Call $7/22/16$ USD 53.01 36 $(5,$ Abbott LaboratoriesCall $7/29/16$ USD 39.50 150 $(10,$ Actna, Inc.Call $7/29/16$ USD 121.00 43 $(4,$ Amgen, Inc.Call $7/29/16$ USD 121.00 43 $(15,$ Actna, Inc.Call $7/29/16$ USD 121.00 43 $(15,$ Anthem, Inc.Call $7/29/16$ USD 123.00 16 $(4,$ Amgen, Inc.Call $7/29/16$ USD 132.00 88 $(29,$ Biogen, Inc.Call $7/29/16$ USD 132.00 88 $(29,$ Biogen, Inc.Call $7/29/16$ USD 107.00 150 $(8,$ Celgene Corp.Call $7/29/16$ USD 89.00 69 $(4,$ HCA Holdings, Inc.Call $7/29/16$ USD 89.00 69 $(4,$ Humana, Inc.Call $7/29/16$ USD 85.50 141 $(28,$ Malinckrodt PLCCall $7/29/16$ USD 85.50 141 $(28,$ Merck & Co, Inc.Call $7/29/16$ USD 85.00		ADR						(135)
UnitedHealth Group, Inc.Call $7/22/16$ USD 139.00 41 (16) Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43 (4) Masimo Corp.Call $7/22/16$ USD 94.00 43 (4) Abbott LaboratoriesCall $7/26/16$ USD 53.01 36 (5) Abtott LaboratoriesCall $7/29/16$ USD 39.50 150 (10) Aetna, Inc.Call $7/29/16$ USD 121.00 43 (15) Aetna, Inc.Call $7/29/16$ USD 123.00 16 (4) Amgen, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 107.00 150 (8) Celgene Corp.Call $7/29/16$ USD 80.00 97 (12) Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 69 (4) HCA Holdings, Inc.Call $7/29/16$ USD 182.50 92 (95) Mallinckrodt PLCCall $7/29/16$ USD 85.50 141 (28) Medtronic PLCCall $7/29/16$ USD 85.50 141 (28) Merck & Co., Inc.Call $7/29/16$ USD 55.00 90 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>(374)</td>								(374)
Vertex Pharmaceuticals, Inc.Call $7/22/16$ USD 94.00 43 $(4, Masimo Corp.)$ Masimo Corp.Call $7/26/16$ USD 53.01 36 $(5, Call T/29/16)$ USD 39.50 150 $(10, Call T/29/16)$ Abbott LaboratoriesCall $7/29/16$ USD 39.50 150 $(10, Call T/29/16)$ USD 121.00 43 $(15, Call T/29/16)$ Aetna, Inc.Call $7/29/16$ USD 123.00 16 $(4, Call T/29/16)$ USD 157.50 3 $(16, Call T/29/16)$ Amgen, Inc.Call $7/29/16$ USD 132.00 88 $(29, Call T/29/16)$ USD 132.00 88 $(29, Call T/29/16)$ Biogen, Inc.Call $7/29/16$ USD 132.00 41 $(38, Call Call T/29/16)$ USD 107.00 150 $(8, Call Call T/29/16)$ USD 80.00 97 $(12, Call Call T/29/16)$ USD 89.00 69 $(4, Call T/29/16)$ USD 82.50 92 $(95, Call T/29/16)$ USD 85.50 92 $(95, Call T/29/16)$ USD 85.50 92 $(95, Call T/29/16)$ USD 85.50 141 $(28, Call T/29/16)$ USD 85.50 141 $(28, Call T/29/16)$ USD 85.00 90 $(8, Call T/29/16)$ <td< td=""><td>itedHealth Group, Inc.</td><td></td><td></td><td></td><td></td><td></td><td></td><td>(16,708)</td></td<>	itedHealth Group, Inc.							(16,708)
Abbott LaboratoriesCall $7/29/16$ USD 39.50 150 (10) Aetna, Inc.Call $7/29/16$ USD 121.00 43 (15) Aetna, Inc.Call $7/29/16$ USD 123.00 16 (4) Amgen, Inc.Call $7/29/16$ USD 157.50 3 (16) Anthem, Inc.Call $7/29/16$ USD 157.50 3 (16) Biogen, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 107.00 150 (8) Celgene Corp.Call $7/29/16$ USD 80.00 97 (12) Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 69 (4) HCA Holdings, Inc.Call $7/29/16$ USD 89.00 69 (4) Humana, Inc.Call $7/29/16$ USD 182.50 92 (95) Mallinckrodt PLCCall $7/29/16$ USD 85.50 141 (28) Merck & Co., Inc.Call $7/29/16$ USD 58.00 90 (8) Pfizer, Inc.Call $7/29/16$ USD 55.00 295 (20)			Call	7/22/16	USD	94.00	43	(4,085)
Aetna, Inc.Call $7/29/16$ USD 121.00 43 (15,Aetna, Inc.Call $7/29/16$ USD 123.00 16(4,Amgen, Inc.Call $7/29/16$ USD 157.50 3(0)Anthem, Inc.Call $7/29/16$ USD 157.50 3(0)Biogen, Inc.Call $7/29/16$ USD 132.00 88(29,Biogen, Inc.Call $7/29/16$ USD 132.00 88(29,Biogen, Inc.Call $7/29/16$ USD 107.00 150(8,Celgene Corp.Call $7/29/16$ USD 80.00 97(12,Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 69(4,HCA Holdings, Inc.Call $7/29/16$ USD 79.50 39(4,Humana, Inc.Call $7/29/16$ USD 79.50 92(95,Mallinckrodt PLCCall $7/29/16$ USD 85.50 141(28,Merck & Co., Inc.Call $7/29/16$ USD 58.00 90(8,Pfizer, Inc.Call $7/29/16$ USD 58.00 90(8,	isimo Corp.		Call	7/26/16	USD	53.01	36	(5,358)
Aetna, Inc.Call $7/29/16$ USD 123.00 16 $(4, Amgen, Inc. CallAmgen, Inc.Call7/29/16USD157.503(1, 29, 10)Biogen, Inc.Call7/29/16USD132.0088(29, 29, 10)Biogen, Inc.Call7/29/16USD132.0088(29, 29, 10)Celgene Corp.Call7/29/16USD245.0041(38, 20, 10)Eli Lilly & Co.Call7/29/16USD107.00150(8, 20, 10)Gilead Sciences, Inc.Call7/29/16USD80.0097(12, 20)Humana, Inc.Call7/29/16USD89.0069(4, 10)Humana, Inc.Call7/29/16USD182.5092(95, 20)Mallinckrodt PLCCall7/29/16USD61.5021(5, 20)Metronic PLCCall7/29/16USD85.50141(28, 20)Merck & Co., Inc.Call7/29/16USD58.0090(8, 20)Pfizer, Inc.Call7/29/16USD35.00295(20, 20)$	bott Laboratories					39.50	150	(10,425)
Amgen, Inc.Call $7/29/16$ USD 157.50 3 ()Anthem, Inc.Call $7/29/16$ USD 132.00 88 $(29, 120)$ Biogen, Inc.Call $7/29/16$ USD 132.00 88 $(29, 120)$ Celgene Corp.Call $7/29/16$ USD 245.00 41 $(38, 120)$ Eli Lilly & Co.Call $7/29/16$ USD 107.00 150 $(8, 120)$ Gilead Sciences, Inc.Call $7/29/16$ USD 80.00 97 $(12, 120)$ HCA Holdings, Inc.Call $7/29/16$ USD 89.00 69 $(4, 120)$ Humana, Inc.Call $7/29/16$ USD 182.50 92 $(95, 120)$ Mallinckrodt PLCCall $7/29/16$ USD 61.50 21 $(5, 120)$ Metronic PLCCall $7/29/16$ USD 85.50 141 $(28, 120)$ Merck & Co., Inc.Call $7/29/16$ USD 58.00 90 $(8, 120)$ Pfizer, Inc.Call $7/29/16$ USD 35.00 295 $(20, 120)$								(15,801)
Anthem, Inc.Call $7/29/16$ USD 132.00 88 (29) Biogen, Inc.Call $7/29/16$ USD 245.00 41 (38) Celgene Corp.Call $7/29/16$ USD 107.00 150 (8) Eli Lilly & Co.Call $7/29/16$ USD 80.00 97 (12) Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 69 (4) HCA Holdings, Inc.Call $7/29/16$ USD 79.50 39 (4) Humana, Inc.Call $7/29/16$ USD 182.50 92 (95) Mallinckrodt PLCCall $7/29/16$ USD 61.50 21 (5) Metronic PLCCall $7/29/16$ USD 85.50 141 (28) Merck & Co., Inc.Call $7/29/16$ USD 58.00 90 (8) Pfizer, Inc.Call $7/29/16$ USD 35.00 295 (20)								(4,200)
Biogen, Inc.Call $7/29/16$ USD 245.00 41 $(38, Celgene Corp.)$ Celgene Corp.Call $7/29/16$ USD 107.00 150 $(8, Celgene Corp.)$ Eli Lilly & Co.Call $7/29/16$ USD 80.00 97 $(12, Celgene Corp.)$ Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 69 $(4, Celgene Corp.)$ HCA Holdings, Inc.Call $7/29/16$ USD 89.00 69 $(4, Celgene Corp.)$ Humana, Inc.Call $7/29/16$ USD 182.50 92 $(95, Celgene Corp.)$ Mallinckrodt PLCCall $7/29/16$ USD 61.50 21 $(5, Cellee Corp.)$ Metronic PLCCall $7/29/16$ USD 85.50 141 $(28, Cellee Corp.)$ Merck & Co., Inc.Call $7/29/16$ USD 58.00 90 $(8, Pfizer, Inc.)$ Call $7/29/16$ USD 35.00 295 $(20, Cellee Corp.)$	•							(478)
Celgene Corp.Call $7/29/16$ USD 107.00 150 $(8, 6)$ Eli Lilly & Co.Call $7/29/16$ USD 80.00 97 $(12, 6)$ Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 69 $(4, 6)$ HCA Holdings, Inc.Call $7/29/16$ USD 79.50 39 $(4, 6)$ Humana, Inc.Call $7/29/16$ USD 182.50 92 $(95, 6)$ Mallinckrodt PLCCall $7/29/16$ USD 61.50 21 $(5, 6)$ Metronic PLCCall $7/29/16$ USD 85.50 141 $(28, 6)$ Merck & Co., Inc.Call $7/29/16$ USD 58.00 90 $(8, 6)$ Pfizer, Inc.Call $7/29/16$ USD 35.00 295 $(20, 6)$								(29,480)
Eli Lilly & Co.Call $7/29/16$ USD 80.00 97 $(12, 32)$ Gilead Sciences, Inc.Call $7/29/16$ USD 89.00 69 $(4, 32)$ HCA Holdings, Inc.Call $7/29/16$ USD 79.50 39 $(4, 32)$ Humana, Inc.Call $7/29/16$ USD 182.50 92 $(95, 32)$ Mallinckrodt PLCCall $7/29/16$ USD 61.50 21 $(5, 32)$ Medtronic PLCCall $7/29/16$ USD 85.50 141 $(28, 32)$ Merck & Co., Inc.Call $7/29/16$ USD 58.00 90 $(8, 7/29/16)$ Pfizer, Inc.Call $7/29/16$ USD 35.00 295 $(20, 7/29/16)$								(38,745) (8,175)
Gilead Sciences, Inc.Call7/29/16USD89.0069(4,HCA Holdings, Inc.Call7/29/16USD79.5039(4,Humana, Inc.Call7/29/16USD182.5092(95,Mallinckrodt PLCCall7/29/16USD61.5021(5,Medtronic PLCCall7/29/16USD85.50141(28,Merck & Co., Inc.Call7/29/16USD58.0090(8,Pfizer, Inc.Call7/29/16USD35.00295(20,	•							(12,853)
HCA Holdings, Inc.Call7/29/16USD79.5039(4,Humana, Inc.Call7/29/16USD182.5092(95,Mallinckrodt PLCCall7/29/16USD61.5021(5,Medtronic PLCCall7/29/16USD85.50141(28,Merck & Co., Inc.Call7/29/16USD58.0090(8,Pfizer, Inc.Call7/29/16USD35.00295(20,	•							(4,347)
Humana, Inc.Call7/29/16USD182.5092(95,Mallinckrodt PLCCall7/29/16USD61.5021(5,Medtronic PLCCall7/29/16USD85.50141(28,Merck & Co., Inc.Call7/29/16USD58.0090(8,Pfizer, Inc.Call7/29/16USD35.00295(20,								(4,680)
Mallinckrodt PLCCall7/29/16USD61.5021(5,Medtronic PLCCall7/29/16USD85.50141(28,Merck & Co., Inc.Call7/29/16USD58.0090(8,Pfizer, Inc.Call7/29/16USD35.00295(20,	•							(95,220)
Merck & Co., Inc. Call 7/29/16 USD 58.00 90 (8, Pfizer, Inc. Call 7/29/16 USD 35.00 295 (20,								(5,828)
Pfizer, Inc. Call 7/29/16 USD 35.00 295 (20,	edtronic PLC		Call	7/29/16	USD	85.50	141	(28,764)
	erck & Co., Inc.		Call	7/29/16	USD	58.00	90	(8,235)
								(20,945)
								(3,311)
								(11,440)
		ADR						(1,458)
								(12,595)
	-							(33,264)
	·							(6,120) (34,425)
								(38,969)
								(44,220)
								(10,227)
								(4,836)
		ADR						(6,237)
	nmer Biomet Holdings, Inc.		Call			116.75	43	(22,317)
	iversal Health Services, Inc., Class B	3	Call	8/11/16			42	(20,117)
Pfizer, Inc. Call 8/12/16 USD 35.50 93 (5,	zer, Inc.		Call	8/12/16	USD	35.50	93	(5,115)
		ADR						(5,628)
								(12,000)
AbbVie, Inc. Call 8/19/16 USD 62.50 13 (2,	bVie, Inc.		Call	8/19/16	USD	62.50	13	(2,178)

Agios Pharmaceuticals, Inc.	Call	8/19/16	USD	60.00	30	(2,475)
Alkermes PLC	Call	8/19/16	USD	47.00	58	(8,844)
Amedisys, Inc.	Call	8/19/16	USD	55.00	135	(18,158)
AmerisourceBergen Corp.	Call	8/19/16	USD	80.00	28	(5,739)
Amgen, Inc.	Call	8/19/16	USD	155.00	126	(42,525)
e i						

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Health Sciences Trust (BME)

		Strike					
	Put/	Expiration					
Description	Call	Date	P	rice	Contracts		Value
Baxter International, Inc.	Call	8/19/16	USD	45.00	90	\$	(13,320)
Becton Dickinson and Co.	Call	8/19/16	USD	170.00	70		(30,100)
Biogen, Inc.	Call	8/19/16	USD	250.00	41		(39,975)
Cardinal Health, Inc.	Call	8/19/16	USD	80.00	29		(4,132)
Centene Corp.	Call	8/19/16	USD	72.50	56		(15,400)
Cigna Corp.	Call	8/19/16	USD	145.00	62		(9,486)
Cooper Cos., Inc.	Call	8/19/16	USD	165.00	13		(11,180)
CR Bard, Inc.	Call	8/19/16	USD	230.00	36		(32,940)
Edwards Lifesciences Corp.	Call	8/19/16	USD	100.00	166		(77,190)
Genomic Health, Inc.	Call	8/19/16	USD	30.00	67		(8,710)
Gilead Sciences, Inc.	Call	8/19/16	USD	92.50	33		(1,732)
Hologic, Inc.	Call	8/19/16	USD	36.00	97		(7,760)
Laboratory Corp. of America Holdings	Call	8/19/16	USD	130.00	20		(8,000)
McKesson Corp.	Call	8/19/16	USD	185.00	76		(55,100)
Medtronic PLC	Call	8/19/16	USD	82.50	130		(61,425)
Nektar Therapeutics	Call	8/19/16	USD	15.00	237		(18,960)
Pfizer, Inc.	Call	8/19/16	USD	35.00	13		(1,138)
Quest Diagnostics, Inc.	Call	8/19/16	USD	83.50	30		(3,150)
Shire PLC ADR	Call	8/19/16	USD	175.00	34		(47,770)
Stryker Corp.	Call	8/19/16	USD	120.00	102		(29,580)
Masimo Corp.	Call	8/26/16	USD	52.10	32		(8,794)
Total						\$ (1,996,332)

OTC Options Written

				St	rike		
	Put/		Expiration				
Description	Call	Counterparty	Date	P	rice	Contracts	Value
Zimmer Biomet Holdings, Inc.	Call	Citibank N.A.	7/07/16	USD	118.75	900	\$ (1,795)
Baxter International, Inc.		Morgan Stanley & Co. International					
	Call	PLC	7/08/16	USD	45.25	11,300	(5,505)
Boston Scientific Corp.	Call	Goldman Sachs International	7/08/16	USD	21.78	60,000	(96,646)
Acceleron Pharma, Inc.		Morgan Stanley & Co. International					
	Call	PLC	7/12/16	USD	34.17	10,200	(13,036)
Intra-Cellular Therapies, Inc.	Call	UBS AG	7/12/16	USD	35.64	19,000	(66,130)
AstraZeneca PLC	Call	Credit Suisse International	7/20/16	GBP	40.54	11,400	(68,132)
Zimmer Biomet Holdings, Inc.	Call	Citibank N.A.	7/21/16	USD	118.75	900	(2,351)
AstraZeneca PLC	Call	Credit Suisse International	7/26/16	GBP	40.50	5,000	(30,654)
DENTSPLY SIRONA, Inc.	Call	Barclays Bank PLC	7/28/16	USD	63.38	7,800	(5,147)
Roche Holding AG	Call	Goldman Sachs International	8/05/16	CHF	250.92	4,000	(40,917)
Boston Scientific Corp.	Call	Deutsche Bank AG	8/08/16	USD	23.02	66,100	(64,462)
GlaxoSmithKline PLC	Call	Bank of America N.A.	8/09/16	GBP	16.14	22,100	(9,951)
AstraZeneca PLC	Call	Citibank N.A.	8/10/16	GBP	41.35	5,000	(26,155)
Neurocrine Biosciences, Inc.	Call	Bank of America N.A.	8/15/16	USD	48.24	7,300	(16,644)
GlaxoSmithKline PLC	Call	Deutsche Bank AG	8/16/16	GBP	14.29	18,500	(45,362)
Actelion Ltd.	Call	Goldman Sachs International	8/23/16	CHF	158.30	2,600	(27,390)
Boston Scientific Corp.	Call	Deutsche Bank AG	8/29/16	USD	23.02	66,100	(76,940)
Total							\$ (597,217)

Transactions in Options Written for the Period Ended June 30, 2016

Puts

	Contracts	Premiums Received	Premiums Contracts Received
Outstanding options at beginning of period	287,378	\$ 2,456,919	
Options written	1,110,875	8,956,804	169 \$ 45,392
Options exercised	(240)	(43,827)	(90) (35,069)
Options expired	(539,256)	(3,987,643)	(79) (10,323)
Options closed	(531,656)	(5,235,227)	
Outstanding options at end of period	327,101	\$ 2,147,026	

As of period end, the value of portfolio securities subject to covered call options written was \$86,270,545.

See Notes to Financial Statements.

68

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Health Sciences Trust (BME)

.

Assets

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		Commodity Contracts	Credit Contracts	Equity Contracts	Foreign Currency Exchange Contracts	Interest Rate Contracts	Total
Liabilities Derivative Finar	ncial Instruments						
Options written	Options written, at value			\$ 2,593,549			\$ 2,593,549
For the six months ended June	30, 2016, the effect of derivative financial ins	struments in the S	Statements of	Operations wa	s as follows:		

Net Realized Gain (Loss) from: Options purchased ¹ Options written	Commodity Contracts	Credit Contracts	Equity Contracts \$ (478) 1,401,979	Foreign Currency Exchange Contracts	Interest Rate Contracts	Total \$ (478) 1,401,979	
Total			\$ 1,401,501			\$ 1,401,501	
Net Change in Unrealized Appreciation (Depreciation) on: Options written			\$ (291,746)			\$ (291,746)	

¹ Options purchased are included in net realized gain (loss) from investments.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:		
Average value of option contracts purchased ¹	\$	478
Average value of option contracts written	\$ 2,43	5,162

¹ Actual amounts for the period are shown due to limited outstanding derivative financial instruments as of each quarter. For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End The Trust s derivative assets and liabilities (by type) are as follows:

Liabilities

\$ 2,593,549

Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	(1	1,996,3	32)
Total derivative assets and liabilities subject to an MNA	\$	597,2	.17

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Health Sciences Trust (BME)

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under an Master Netting Agreement (MNA) and net of the related collateral pledged by the Trust:

Gross Amounts Not Offset in the Consolidated Statements of Assets and Liabilities

		and	Subject to an M	NA		
	Derivative Liabilities		Non-cash	Cash		
	Subject to an MNA blo	erivatives Available	Collateral	Collateral	Net A	Amount of
Counterparty	Counterparty	for Offset	Pledged ¹	Pledged	Derivati	ve Liabilities ²
Bank of America N.A.	\$ 26,595				\$	26,595
Barclays Bank PLC	5,147					5,147
Citibank N.A.	30,301					30,301
Credit Suisse International	98,786					98,786
Deutsche Bank AG	186,764					186,764
Goldman Sachs International	164,953					164,953
Morgan Stanley & Co. International PLC	18,541		\$ (18,541)			
UBS AG	66,130					66,130
Total	\$ 597,217		\$ (18,541)		\$	578,676

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

² Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Biotechnology	\$ 46,616,105	\$ 2,756,493	\$ 1,450,589 \$	50,823,187
Diversified Consumer Services	557,024			557,024
Electronic Equipment, Instruments & Components	2,009,344			2,009,344
Health Care Equipment & Supplies	72,202,072			72,202,072
Health Care Providers & Services	62,389,119			62,389,119
Health Care Technology	2,232,660			2,232,660
Life Sciences Tools & Services	5,821,744			5,821,744
Pharmaceuticals	63,122,027	11,278,880		74,400,907
Preferred Stocks ¹		242,480	1,444,458	1,686,938
Rights ¹			68,517	68,517
Short-Term Securities	9,585,944	156,732		9,742,676
Total	\$ 264,536,039	\$ 14,434,585	\$ 2,963,564 \$	281,934,188

Derivative Financial Instruments ²			
Liabilities:			
Equity contracts	\$ (1,838,272) \$	(755,277)	\$ (2,593,549)

¹ See above Schedule of Investments for values in each industry.

² Derivative financial instruments are options written, which are shown at value.

See Notes to Financial Statements.

70

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Health Sciences Trust (BME)

The Trust may hold assets and/or liabilities in which the fair value approximates the carrying amount for financial statement purposes. As of period end, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Le	vel 1	Level 2	Level 3	Total
Assets: Foreign currency at value Liabilities:	\$	1,088			\$ 1,088
Collateral on securities loaned at value			\$ (156,732)		(156,732)
Total	\$	1,088	\$ (156,732)		\$ (155,644)

During the six months ended June 30, 2016, there were no transfers between levels.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks	Preferred Stocks	Rights	Total
Assets:			-	
Opening Balance, as of December 31, 2015		\$ 5,907,930		\$ 5,907,930
Transfers into Level 3	\$ 986,402		\$ 25,848	1,012,250
Transfers out of Level 3		(2,497,481)		(2,497,481)
Accrued discounts/premiums				
Net realized gain		1,287,939		1,287,939
Net change in unrealized appreciation/depreciation ^{1,2}	464,187	(760,389)	42,669	(253,533)
Purchases				
Sales		(2,493,541)		(2,493,541)
Closing Balance, as of June 30, 2016	\$1,450,589	\$ 1,444,458	\$ 68,517	\$ 2,963,564
Net change in unrealized appreciation/depreciation on investments still held at June 30.				
2016 ²	\$ 464.187	\$ 474.772	\$ 42.669	\$ 981,628
	,	,		,

¹ Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

² Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2016 is generally due to investments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation techniques used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) to determine the value of certain of the Trust s Level 3 investments as of period end.

Assets:	Value	Valuation Techniques	Unobservable Inputs	Unobservable Inputs Utilized
Common Stocks	\$1,450,589	Discounted Cash Flow	Discount Rate ¹ Time to Exit ¹	1.23% 1-3 years
Preferred Stocks ⁴	1,444,458	Merger Terms	N/A	i o youro

Range of

Rights	68,517	Cost ² Acquisition Terms	N/A Intrinsic Value ³
Total	\$2,963,564		

- ¹ Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.
- ² The Trust fair values certain of its Level 3 investments using acquisition cost, although the transaction may not have occurred during the current reporting period. These investments are generally privately held investments. There may not be a secondary market, and/or there are a limited number of investors. The determination to fair value such investments at cost is based upon factors consistent with the principles of fair value measurement that are reasonably available to the Global Valuation Committee, or its delegate. Valuations are reviewed utilizing available market information to determine if the carrying value should be adjusted. Such market data may include, but is not limited to, observations of the trading multiples of public companies considered comparable to the private companies being valued, financial or operational information released by the company, and/or news or corporate events that affect the investment. Valuations may be adjusted to account for company-specific issues, the lack of liquidity inherent in a nonpublic investment and the fact that comparable public companies are not identical to the investments being fair valued by the Trust.
- ³ Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.
- ⁴ During the period ended June 30, 2016, the valuation technique for a certain investment classified as preferred stocks changed to merger terms. The investment was previously valued at acquisition cost. Merger Terms became a more relevant measure of fair value for this investment.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Schedule of Investments June 30, 2016 (Unaudited)

BlackRock International Growth and Income Trust (BGY) (Percentages shown are based on Net Assets)

Common Stocks	Shares	Value
Australia 1.1%	Shares	, unite
Newcrest Mining Ltd. (a)	440,365	\$ 7,632,349
Belgium 4.1%	157 646	20.846.625
Anheuser-Busch InBev SA Delhaize Group	157,646 72,400	20,846,635 7,647,960
Demaile Group	72,400	7,047,900
Canada 4.8%		28,494,595
Canadian Pacific Railway Ltd. (b)	30,900	3,978,170
Element Financial Corp. (b)	385,600	4,088,951
Fairfax Financial Holdings Ltd.	18,545	9,988,132
Gildan Activewear, Inc. (b)	285,900	8,373,742
Potash Corp. of Saskatchewan, Inc. (b)	256,232	4,164,923
PrairieSky Royalty Ltd.	145,900	2,769,045
China 3.5%		33,362,963
Alibaba Group Holding Ltd. ADR (a)(b)	80,774	6,423,956
China Construction Bank Corp., Class H	18,536,000	12,356,804
Tencent Holdings Ltd.	254,300	5,833,559
		24,614,319
Denmark 0.9% Novo Nordisk A/S, Class B	114,800	6,182,313
France 6.7% AXA SA	252,600	4,994,584
BNP Paribas SA	213,964	9,383,544
Dassault Aviation SA	4,363	4,323,326
Orange SA	723,500	11,764,528
Sanofi	45,000	3,738,739
Unibail-Rodamco SE REIT	48,200	12,469,107
Germany 2.4%		46,673,828
Continental AG	17,754	3,359,545
SAP SE	76,800	5,768,101
Wacker Chemie AG	86,678	7,590,699
		16,718,345
Hong Kong 1.5% AIA Group Ltd.	1,760,552	10,587,476
India 3.2%	1,700,002	10,007,170
Bharti Infratel Ltd.	1,031,359	5,284,749
HDFC Bank Ltd.	602,902	12,220,992
Tata Motors Ltd. ADR (a)(b)	146,525	5,080,022
		22,585,763
Indonesia 1.1% Matahari Department Store Tbk PT	4,950,580	7,545,222
Ireland 2.2%		
Green REIT PLC	4,017,426	6,192,659
Kingspan Group PLC	206,913	4,502,901
Ryanair Holdings PLC ADR (b)	66,236	4,606,051
Israel 0.5%		15,301,611
Teva Pharmaceutical Industries Ltd. ADR (b)	66,400	3,335,272
Italy 3.7% Atlantia SpA	187,200	4,677,202

Eni SpA Snam SpA Telecom Italia SpA (a)	543,200 1,033,200 7,398,400	8,749,454 6,176,940 6,076,401
		25,679,997
Japan 7.0% FANUC Corp. Nintendo Co. Ltd. Common Stocks Japan (continued)	46,300 40,600 Shares	7,531,772 5,834,188 Value
ORIX Corp. Panasonic Corp. Sony Corp. Sumitomo Mitsui Financial Group, Inc. Toyota Motor Corp.	385,800 359,000 261,500 483,100 118,300	\$ 4,992,432 3,088,671 7,704,307 13,949,541 5,832,017
		48,932,928
Mexico 1.1% Fomento Economico Mexicano SAB de CV ADR (b)	81,300	7,519,437
Netherlands 5.2% Aalberts Industries NV ASML Holding NV Koninklijke Philips NV Royal Dutch Shell PLC, B Shares	121,952 59,900 430,000 588,319	3,655,926 5,896,475 10,679,644 16,254,502
New Zealand 0.7%		36,486,547
Xero Ltd. (a)	359,605	4,693,586
Norway 1.5% Statoil ASA Philippines 0.3%	628,500	10,859,513
Cemex Holdings Philippines, Inc. (a)(c) Portugal 1.0%	10,538,000	2,407,854
Galp Energia SGPS SA South Africa 1.0%	528,600	7,351,975
Naspers Ltd., N Shares South Korea 2.0%	47,219	7,210,109
LG Chem Ltd. Samsung Electronics Co. Ltd.	30,400 5,600	6,942,409 6,973,967
Ser. 1.40/		13,916,376
Spain 1.4% Cellnex Telecom SAU (c)	604,240	9,482,109
Sweden 1.3% Nordea Bank AB Switzeeland 7.3%	1,107,236	9,393,399
Switzerland 7.3% Nestle SA Novartis AG Roche Holding AG UBS Group AG	246,200 59,200 66,523 723,800	19,075,166 4,886,282 17,554,078 9,391,735
Taiwan 2.2%		50,907,261
Hermes Microvision, Inc. Largan Precision Co. Ltd. Taiwan Semiconductor Manufacturing Co. Ltd.	99,437 57,000 1,248,000	4,123,074 5,271,545 6,289,542
Thailand 0.4%		15,684,161
True Corp Pcl United Kingdom 20.5%	13,637,300	2,799,638
AstraZeneca PLC	308,000	18,413,416
BAE Systems PLC Diageo PLC	1,995,400 349,000	13,968,993 9,749,595
GlaxoSmithKline PLC Imperial Brands PLC Liberty Global PLC LiLAC, Class A (a)	315,200 274,600 34,511	6,768,957 14,892,395 1,113,325

Liberty Global PLC, Class A (a) Lloyds Banking Group PLC Metro Bank PLC (a) Nomad Foods Ltd. (a) Reckitt Benckiser Group PLC 276,6008,037,99610,439,9007,561,558259,0266,234,527448,4933,578,97480,1008,031,800

See Notes to Financial Statements.

72

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock International Growth and Income Trust (BGY)

Common Stocks United Kingdom (continued)	Shares	Value
SABMiller PLC	191,200	\$ 11,150,672
Sophos Group PLC (c) Unilever PLC	1,222,500 291,600	3,431,928 13,972,129
Vodafone Group PLC	3,085,300	9,406,692
Worldpay Group PLC (a)(c)	1,959,500	7,132,025
United States 4.8%		143,444,982
Samsonite International SA	1,462,500	4,049,460
Shire PLC ADR (b)	48,700	8,964,696
WisdomTree Japan Hedged Equity Fund (b)	536,100	20,789,958
Total Common Stocks 93.4%		33,804,114 653,608,042
Investment Companies United Kingdom 0.9%		
Kennedy Wilson Europe Real Estate PLC	472,339	6,065,233
Preferred Stocks China 0.4%		
Xiaoju Kuaizhi, Inc., Series A-17 (Acquired 7/28/15, Cost \$2,106,332), 0.00% (a)(d) Preferred Stocks	76,800 Shares	2,936,064 Value
India 1.9%	398	\$ 9,784,137
Jasper Infotech Private Ltd., Series F (Acquired 5/7/14, cost \$2,825,580), 0.00% (a)(d) Jasper Infotech Private Ltd., Series G (Acquired 10/29/14, cost \$1,112,870), 0.00% (a)(d)	132	\$ 9,784,137 3,244,990
Total Preferred Stocks 2.3%		15,965,191
Total Long-Term Investments		
(Cost \$671,337,710) 96.6%		675,638,466
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.40% (e)(f) Total Short-Term Securities	21,785,695	21,785,695
(Cost \$21,785,695) 3.1% Total Investments Before Options Written		21,785,695
(Cost \$693,123,405) 99.7%		697,424,161
Options Written		(11 (10 500)
(Premiums Received \$8,059,417) (1.7)% Total Investments Net of Options Written 98.0%		(11,613,738) 685,810,423
Other Assets Less Liabilities 2.0%		14,101,773
Net Assets 100.0%		\$ 699,912,196

Notes to Schedule of Investments

(a) Non-income producing security.

(b) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(c) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933. This security may be resold in transactions exempt from registration to qualified institutional investors.

(d) Restricted security as to resale, excluding 144A securities. As of report date, the Trust held restricted securities with a current value of \$15,965,191 and an original cost of \$6,044,782 which was 2.3% of its net assets.

(e) During the six months ended June 30, 2016, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Shares/

Beneficial Interest

	Held at December 31,	Net	Shares Held at June 30,	June 30,	
Affiliates	2015	Activity	2016	2016	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	37,105,203	(15,319,508)	21,785,695	\$ 21,785,695	\$ 144,619
BlackRock Liquidity Series, LLC, Money Market Series	\$ 2,751,247	\$ (2,751,247)			\$ 15,998 ¹
Total				\$ 21,785,695	\$ 160,617

¹ Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(f) Current yield as of period end.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Value at

BlackRock International Growth and Income Trust (BGY)

Derivative Financial Instruments Outstanding as of Period End

Financial Futures Contracts

					Unrealized
Contracts Long	Issue	Expiration September	Notion	al Value	Appreciation
283 Total	Mini MSCI Emerging Markets Index Futures	2016	USD	11,811,005	\$279,332 \$279,332

Exchange-Traded Options Written

		Strike						
	Put/	Expiration						
Description	Call	Date	Pı	ice	Contracts	Value		
Alibaba Group Holding Ltd. ADR	Call	7/01/16	USD	82.00	132	\$ (264)		
Shire PLC ADR	Call	7/01/16	USD	195.00	127	(3,810)		
WisdomTree Japan Hedged Equity Fund	Call	7/01/16	USD	42.00	1,000	(25,000)		
Alibaba Group Holding Ltd. ADR	Call	7/08/16	USD	79.50	23	(2,543)		
Alibaba Group Holding Ltd. ADR	Call	7/08/16	USD	80.50	74	(4,773)		
Tata Motors Ltd. ADR	Call	7/08/16	USD	35.50	200	(5,500)		
Alibaba Group Holding Ltd. ADR	Call	7/15/16	USD	82.50	132	(5,610)		
Canadian Pacific Railway Ltd.	Call	7/15/16	CAD	175.00	77	(3,367)		
Element Financial Corp.	Call	7/15/16	CAD	15.00	465	(1,980)		
Element Financial Corp.	Call	7/15/16	CAD	16.00	595	(3,684)		
Fomento Economico Mexicano SAB de CV ADR	Call	7/15/16	USD	95.00	140	(68,600)		
Gildan Activewear, Inc.	Call	7/15/16	CAD	40.00	555	(3,866)		
Liberty Global PLC, Class A	Call	7/15/16	USD	37.50	581	(29,050)		
MSCI Emering Markets Index	Call	7/15/16	USD	810.00	50	(159,250)		
Potash Corp. of Saskatchewan, Inc.	Call	7/15/16	CAD	23.00	700	(13,276)		
Ryanair Holdings PLC ADR	Call	7/15/16	USD	80.00	80	(6,000)		
Ryanair Holdings PLC ADR	Call	7/15/16	USD	85.00	80	(6,000)		
Shire PLC ADR	Call	7/15/16	USD	200.00	70	(4,550)		
Tata Motors Ltd. ADR	Call	7/15/16	USD	33.00	200	(37,500)		
Teva Pharmaceutical Industries Ltd. ADR	Call	7/15/16	USD	55.00	200	(900)		
Alibaba Group Holding Ltd. ADR	Call	7/22/16	USD	80.00	22	(3,608)		
Tata Motors Ltd. ADR	Call	7/22/16	USD	35.50	200	(13,000)		
Alibaba Group Holding Ltd. ADR	Call	7/29/16	USD	81.50	31	(3,985)		
Tata Motors Ltd. ADR	Call	7/29/16	USD	36.50	200	(10,000)		
WisdomTree Japan Hedged Equity Fund	Call	7/29/16	USD	43.00	1,000	(11,500)		
WisdomTree Japan Hedged Equity Fund	Call	8/05/16	USD	43.50	500	(6,500)		
Teva Pharmaceutical Industries Ltd. ADR	Call	8/12/16	USD	52.00	165	(22,110)		
Canadian Pacific Railway Ltd.	Call	8/19/16	CAD	165.00	92	(55,722)		
Element Financial Corp.	Call	8/19/16	CAD	15.00	1,060	(18,460)		
Gildan Activewear, Inc.	Call	8/19/16	CAD	38.00	555	(53,913)		
MSCI Emering Markets Index	Call	8/19/16	USD	840.00	60	(144,900)		
WisdomTree Japan Hedged Equity Fund	Call	8/19/16	USD	44.00	500	(9,000)		
Total						\$ (738,221)		

OTC Options Written

			Strike					
	Put/		Expiration					
Description	Call	Counterparty	Date		Price	Contracts	Value	
Delhaize Group	Call	UBS AG	7/06/16	EUR	94.19	2,000	\$ (4,337)	
Eni SpA	Call	UBS AG	7/06/16	EUR	13.75	150,000	(133,309)	
Galp Energia SGPS SA	Call	UBS AG	7/06/16	EUR	12.10	67,000	(35,979)	
Nestle SA	Call	Bank of America N.A.	7/06/16	CHF	73.63	31,000	(69,158)	
Roche Holding AG	Call	UBS AG	7/06/16	CHF	247.75	19,500	(203,476)	
Samsonite International SA	Call	JPMorgan Chase Bank N.A.	7/06/16	HKD	23.20	300,000	(360)	
Sanofi	Call	Credit Suisse International	7/06/16	EUR	74.15	17,500	(26,859)	
Snam SpA	Call	Credit Suisse International	7/06/16	EUR	5.21	38,500	(8,262)	
Sony Corp.	Call	Morgan Stanley & Co. International PLC	7/06/16	JPY	2,961.08	44,000	(51,023)	
Taiwan Semiconductor								
Manufacturing Co. Ltd.	Call	Deutsche Bank AG	7/06/16	TWD	147.21	336,000	(159,590)	
UBS Group AG	Call	Bank of America N.A.	7/06/16	CHF	15.45	72,500	(24)	
Unibail-Rodamco SE REIT	Call	Bank of America N.A.	7/06/16	EUR	234.85	14,500	(22,372)	

See Notes to Financial Statements.

74

SEMI-ANNUAL REPORT

BlackRock International Growth and Income Trust (BGY)

					Strike		
	Put/		Expiration				
Description	Call	Counterparty	Date		Price	Contracts	Value
Aalberts Industries NV	Call	Morgan Stanley & Co. International PLC	7/07/16	EUR	31.18	25,000	\$ (3)
AIA Group Ltd.	Call	Bank of America N.A.	7/07/16	HKD	45.29	193,000	(37,519)
Fomento Economico							
Mexicano SAB de CV	C-11	Manage Stanlage & Ca. International DI C	7/07/16	UCD	07.56	14 100	(1, 207)
ADR GlaxoSmithKline PLC	Call Call	Morgan Stanley & Co. International PLC	7/07/16 7/07/16	USD GBP	97.56 14.59	14,100 23,400	(1,207)
Imperial Brands PLC	Call	Bank of America N.A. UBS AG	7/07/16	GBP	37.77	23,400 64,500	(48,059) (255,940)
Koninklijke Philips NV	Call	Morgan Stanley & Co. International PLC	7/07/16	EUR	23.79	66,000	(2,552)
Liberty Global PLC, Class	Call	Morgan Stanley & Co. International I LC	//0//10	LUK	23.19	00,000	(2,332)
A	Call	Bank of America N.A.	7/07/16	USD	37.41	36,000	
Lloyds Banking Group PLC	Call	Morgan Stanley & Co. International PLC	7/07/16	GBP	0.67	1,715,000	(68)
Nintendo Co. Ltd.	Call	Goldman Sachs International	7/07/16	JPY	15,620.25	15,000	(17,622)
Panasonic Corp.	Call	Bank of America N.A.	7/07/16	JPY	971.65	91,000	(983)
Royal Dutch Shell PLC, B							
Shares	Call	Credit Suisse International	7/07/16	GBP	16.86	62,000	(321,120)
Orange SA	Call	Credit Suisse International	7/08/16	EUR	15.40	132,000	(8,709)
ASML Holding NV	Call	Morgan Stanley & Co. International PLC	7/12/16	EUR	89.38	1,500	(2,489)
AstraZeneca PLC	Call	Citibank N.A.	7/12/16	GBP	39.44	35,000	(255,176)
Cellnex Telecom SAU	Call	Credit Suisse International	7/12/16	EUR	14.52	21,000	(3,504)
Kingspan Group PLC	Call	Goldman Sachs International	7/12/16	EUR	22.94	18,000	(924)
Koninklijke Philips NV	Call	Bank of America N.A.	7/12/16	EUR	23.09	171,000	(45,125)
Largan Precision Co. Ltd.	Call	JPMorgan Chase Bank N.A.	7/12/16	TWD	3,036.17	13,000	(21,315)
Naspers Ltd., N Shares	Call	UBS AG	7/12/16	ZAR	2,238.08	4,000	(15,874)
Statoil ASA	Call	Credit Suisse International	7/12/16	NOK	138.83	51,000	(45,980)
Unilever PLC	Call	UBS AG	7/12/16	GBP	31.51	50,500	(301,695)
Worldpay Group PLC	Call	Morgan Stanley & Co. International PLC	7/12/16	GBP	2.71	182,000	(18,484)
AIA Group Ltd.	Call	Morgan Stanley & Co. International PLC	7/13/16	HKD	44.64	354,000	(98,204)
BNP Paribas SA	Call	Morgan Stanley & Co. International PLC	7/13/16	EUR	49.59	61,500	(826)
Diageo PLC	Call	UBS AG	7/13/16	GBP	18.77	18,000	(53,502)
Eni SpA	Call	Goldman Sachs International	7/13/16	EUR	13.95	73,700	(56,594)
Nestle SA	Call	Morgan Stanley & Co. International PLC	7/13/16	CHF	74.18	22,500	(41,517)
Nordea Bank AB	Call	Credit Suisse International	7/13/16	SEK	81.46	105,000	(610)
Novartis AG	Call	Credit Suisse International	7/13/16	CHF	79.51	32,500	(61,235)
Novo Nordisk A/S, Class B	Call Call	Credit Suisse International Credit Suisse International	7/13/16 7/13/16	DKK EUR	380.12 15.49	31,500 144,000	(5,229) (15,015)
Orange SA PrairieSky Royalty Ltd.	Call	Citibank N.A.	7/13/16	CAD	25.94	36,500	(1,333)
Reckitt Benckiser Group	Call	Chibalk N.A.	//15/10	CAD	25.94	50,500	(1,555)
PLC	Call	Bank of America N.A.	7/13/16	GBP	69.09	20,500	(171,488)
Samsonite International SA	Call	UBS AG	7/13/16	HKD	23.56	316,500	(805)
SAP SE	Call	Credit Suisse International	7/13/16	EUR	73.25	22,000	(840)
Sony Corp.	Call	Bank of America N.A.	7/13/16	JPY	3,161.97	34,000	(18,459)
Telecom Italia SpA	Call	UBS AG	7/13/16	EUR	0.91	1,225,000	(553)
Wacker Chemie AG	Call	UBS AG	7/13/16	EUR	83.03	22,400	(24,312)
AXA SA	Call	Goldman Sachs International	7/14/16	EUR	22.44	69,000	(480)
BAE Systems PLC	Call	UBS AG	7/14/16	GBP	4.99	334,000	(129,274)
Delhaize Group	Call	Bank of America N.A.	7/14/16	EUR	98.01	2,000	(2,003)
Hermes Microvision, Inc.	Call	Citibank N.A.	7/14/16	TWD	938.40	50,000	(584,780)
ORIX Corp.	Call	JPMorgan Chase Bank N.A.	7/14/16	JPY	1,645.66	99,000	(66)
Telecom Italia SpA	Call	UBS AG	7/19/16	EUR	0.85	765,000	(8,144)
Unibail-Rodamco SE REIT	Call	UBS AG	7/19/16	EUR	243.39	12,000	(17,089)
Unilever PLC	Call	Goldman Sachs International	7/19/16	GBP	31.96	50,800	(274,845)
AstraZeneca PLC	Call	Credit Suisse International	7/20/16	GBP	40.54	39,000	(233,082)
BAE Systems PLC	Call	UBS AG	7/20/16	GBP	4.85	91,400	(52,519)
Cellnex Telecom SAU	Call	Morgan Stanley & Co. International PLC	7/20/16	EUR	14.33	22,000	(7,036)
Continental AG	Call	Credit Suisse International	7/20/16	EUR	193.79	5,200	(635)
Galp Energia SGPS SA	Call	Goldman Sachs International	7/20/16	EUR	12.00	107,000	(79,610)
Kingspan Group PLC	Call	Credit Suisse International	7/20/16	EUR	24.40	8,900	(453)
Kingspan Group PLC	Call	Morgan Stanley & Co. International PLC	7/20/16	EUR	25.60	10,000	(190)

Novo Nordisk A/S, Class B	Call	Credit Suisse International	7/20/16	DKK	380.12	31,500	(9,374)
Snam SpA	Call	Credit Suisse International	7/20/16	EUR	5.08	265,000	(98,009)
Xero Ltd.	Call	UBS AG	7/20/16	NZD	19.37	51,500	(10,960)
Tencent Holdings Ltd.	Call	Citibank N.A.	7/21/16	HKD	172.16	70,000	(67,120)
Fairfax Financial Holdings							
Ltd.	Call	Morgan Stanley & Co. International PLC	7/22/16	CAD	679.38	4,100	(80,445)
AstraZeneca PLC	Call	Credit Suisse International	7/26/16	GBP	40.50	42,000	(257,492)
China Construction Bank							
Corp., Class H	Call	Bank of America N.A.	7/26/16	HKD	5.28	6,250,000	(73,782)
Diageo PLC	Call	UBS AG	7/26/16	GBP	19.07	87,000	(229,283)
Imperial Brands PLC	Call	Citibank N.A.	7/26/16	GBP	38.90	20,000	(58,050)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock International Growth and Income Trust (BGY)

					Strike		
	Put/		Expiration				
Description	Call	Counterparty	Date		Price	Contracts	Value
Kingspan Group PLC	Call	Morgan Stanley & Co. International PLC	7/26/16	EUR	24.01	17,000	\$ (2,076)
Nordea Bank AB	Call	Bank of America N.A.	7/26/16	SEK	80.91	216,400	(7,508)
Potash Corp. of							
Saskatchewan, Inc.	Call	Deutsche Bank AG	7/26/16	CAD	22.56	35,000	(5,653)
Sophos Group PLC	Call	UBS AG	7/26/16	GBP	2.25	50,000	(2,267)
Statoil ASA	Call	UBS AG	7/26/16	NOK	137.51	47,000	(56,600)
Taiwan Semiconductor	a 11					14.000	(2.000)
Manufacturing Co. Ltd.	Call	JPMorgan Chase Bank N.A.	7/26/16	TWD	165.24	46,000	(3,009)
UBS Group AG	Call	Morgan Stanley & Co. International PLC	7/26/16	CHF	15.80	73,230	(551)
Worldpay Group PLC	Call	Morgan Stanley & Co. International PLC	7/26/16	GBP	2.84	162,800	(10,793)
Worldpay Group PLC	Call	Morgan Stanley & Co. International PLC	7/26/16	GBP	2.88	161,300	(8,101)
BAE Systems PLC	Call	Bank of America N.A.	7/27/16	GBP	5.21	243,000	(52,372)
Gildan Activewear, Inc.	Call	Deutsche Bank AG	7/29/16	CAD	38.57	46,200	(29,792)
Royal Dutch Shell PLC, B	Call	Credit Suisse International	8/01/16	GBP	18.26	00.000	(206 912)
Shares	Call	Deutsche Bank AG	8/01/16	USD	85.95	90,000 20,400	(306,813)
Ryanair Holdings PLC ADR Aalberts Industries NV	Call	Morgan Stanley & Co. International PLC	8/01/16	EUR	32.38	20,400 22,000	(1,651)
Anheuser-Busch InBev SA	Call	HSBC Bank PLC	8/02/16	EUR	116.71	40,000	(161) (221,470)
AstraZeneca PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	41.13	40,000	(221,470) (224,677)
Atlantia SpA	Call	Credit Suisse International	8/02/16	EUR	24.13	30,000	(5,210)
Atlantia SpA	Call	UBS AG	8/02/16	EUR	24.13	66,000	(39,647)
AXA SA	Call	UBS AG	8/02/16	EUR	18.47	70,000	(28,044)
BAE Systems PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	5.02	186,000	(74,453)
BNP Paribas SA	Call	Morgan Stanley & Co. International PLC	8/02/16	EUR	47.57	56,000	(11,022)
Cellnex Telecom SAU	Call	Credit Suisse International	8/02/16	EUR	14.43	65,000	(25,062)
Dassault Aviation SA	Call	Morgan Stanley & Co. International PLC	8/02/16	EUR	998.78	700	(1,042)
Delhaize Group	Call	Morgan Stanley & Co. International PLC	8/02/16	EUR	91.48	17,000	(96,890)
Diageo PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	19.09	87,000	(225,881)
Kingspan Group PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	EUR	25.70	7,500	(609)
LG Chem Ltd.	Call	Goldman Sachs International	8/02/16	KRW	278,932.50	7,500	(24,275)
Lloyds Banking Group PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	0.72	1,225,000	(2,092)
Metro Bank PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	21.15	35,600	(8,556)
Naspers Ltd., N Shares	Call	UBS AG	8/02/16	ZAR	2,364.97	16,500	(49,123)
Orange SA	Call	Goldman Sachs International	8/02/16	EUR	15.67	122,000	(26,907)
PrairieSky Royalty Ltd.	Call	Citibank N.A.	8/02/16	CAD	25.94	36,500	(5,170)
Reckitt Benckiser Group PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	71.26	6,000	(36,363)
SAP SE	Call	Morgan Stanley & Co. International PLC	8/02/16	EUR	73.47	38,100	(10,122)
Statoil ASA	Call	Credit Suisse International	8/02/16	NOK	142.08	17,000	(16,320)
UBS Group AG	Call	Morgan Stanley & Co. International PLC	8/02/16	CHF	14.99	252,000	(9,926)
Unilever PLC	Call	Credit Suisse International	8/02/16	GBP	34.01	59,000	(170,821)
Wacker Chemie AG	Call	Morgan Stanley & Co. International PLC	8/02/16	EUR	86.54	25,000	(25,182)
Worldpay Group PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	2.86	171,000	(12,338)
Galp Energia SGPS SA	Call	Goldman Sachs International	8/03/16	EUR	11.87	45,000	(42,530)
Kingspan Group PLC	Call	Credit Suisse International	8/03/16	EUR	24.40	8,900	(1,543)
Nintendo Co. Ltd.	Call	Goldman Sachs International	8/03/16	JPY	16,704.47	6,000	(8,950)
Sony Corp.	Call	Goldman Sachs International	8/03/16	JPY	3,192.58	35,000	(33,473)
Sony Corp.	Call	JPMorgan Chase Bank N.A.	8/03/16	JPY	3,103.03	25,300	(31,789)
Vodafone Group PLC	Call	Morgan Stanley & Co. International PLC	8/03/16	GBP	2.34	542,000	(36,273)
Xero Ltd.	Call	Morgan Stanley & Co. International PLC	8/03/16	NZD	19.75	17,289	(4,563)
Xero Ltd.	Call	UBS AG	8/03/16	NZD	19.04	28,600	(11,851)
ASML Holding NV	Call	Morgan Stanley & Co. International PLC	8/04/16	EUR	91.11	31,400	(72,031)
Panasonic Corp.	Call	Goldman Sachs International	8/04/16	JPY CDD	928.14	91,000	(24,256)
Worldpay Group PLC	Call	Morgan Stanley & Co. International PLC	8/04/16	GBP	2.89	109,000	(6,867)
Roche Holding AG	Call	Goldman Sachs International	8/05/16	CHF	250.92	17,000	(173,895)
Worldpay Group PLC Liberty Global PLC	Call	Morgan Stanley & Co. International PLC	8/05/16	GBP	2.73 39.33	169,000	(24,289)
Aalberts Industries NV	Call Call	Citibank N.A. Morgan Stanley & Co. International PLC	8/08/16 8/09/16	USD EUR	39.33	36,000 20,000	(946) (410)
Anheuser-Busch InBev SA	Call	Credit Suisse International	8/09/16	EUR	111.80	9,300	(91,561)
Ameuser Busen mbev SA	Can	Crout Suisse International	0/07/10	LUK	111.00	2,500	(71,501)

Atlantia SpA	Call	Morgan Stanley & Co. International PLC	8/09/16	EUR	22.61	7,000	(5,655)
Cellnex Telecom SAU	Call	Bank of America N.A.	8/09/16	EUR	14.40	40,400	(15,678)
China Construction Bank							
Corp., Class H	Call	UBS AG	8/09/16	HKD	5.23	3,900,000	(66,089)
Eni SpA	Call	Credit Suisse International	8/09/16	EUR	13.72	75,000	(86,311)
GlaxoSmithKline PLC	Call	Bank of America N.A.	8/09/16	GBP	16.14	75,000	(33,769)
Kingspan Group PLC	Call	Morgan Stanley & Co. International PLC	8/09/16	EUR	20.78	17,000	(6,114)

See Notes to Financial Statements.

76

SEMI-ANNUAL REPORT

BlackRock International Growth and Income Trust (BGY)

	Put/		Expiration		Strike		
Description	Call	Counterparty	Date		Price	Contracts	Value
Nordea Bank AB Reckitt Benckiser	Call	Credit Suisse International	8/09/16	SEK	75.80	71,500	\$ (11,077)
Group PLC Samsonite	Call	Deutsche Bank AG	8/09/16	GBP	67.57	17,500	(186,840)
International SA	Call	UBS AG	8/09/16	HKD	23.08	180,000	(5,780)
Sanofi	Call	Credit Suisse International	8/09/16	EUR	76.53	7,200	(13,314)
Snam SpA	Call	Credit Suisse International	8/09/16	EUR	5.01	264,500	(118,915)
Sony Corp.	Call	JPMorgan Chase Bank N.A.	8/09/16	JPY	3,043.94	5,500	(9,147)
Statoil ASA	Call	Credit Suisse International	8/09/16	NOK	146.36	111,000	(83,608)
Telecom Italia SpA Tencent Holdings	Call	UBS AG	8/09/16	EUR	0.88	750,000	(8,896)
Ltd. Tencent Holdings	Call	Citibank N.A.	8/09/16	HKD	172.51	30,800	(33,503)
Ltd. Worldpay Group	Call	Citibank N.A.	8/09/16	HKD	176.30	39,000	(32,182)
PLC	Call	Morgan Stanley & Co. International PLC	8/09/16	GBP	2.87	171,000	(13,659)
AstraZeneca PLC Kingspan Group	Call	Citibank N.A.	8/10/16	GBP	41.35	42,000	(219,706)
PLC Naspers Ltd., N	Call	Credit Suisse International	8/10/16	EUR	24.40	8,900	(2,165)
Shares Imperial Brands	Call	UBS AG	8/10/16	ZAR	2,256.73	5,400	(34,369)
PLC	Call	Citibank N.A.	8/11/16	GBP	38.20	20,000	(76,898)
AIA Group Ltd.	Call	UBS AG	8/12/16	HKD	46.25	422,000	(50,015)
Largan Precision	Cull	010/10	0/12/10	me	40.25	422,000	(50,015)
Co. Ltd.	Call	Morgan Stanley & Co. International PLC	8/12/16	TWD	3.156.95	18,000	(49,985)
Nestle SA	Call	UBS AG	8/12/16	CHF	71.57	82,000	(396,979)
ORIX Corp.	Call	Goldman Sachs International	8/12/16	JPY	1,430.89	113,000	(36,872)
Panasonic Corp.	Call	JPMorgan Chase Bank N.A.	8/12/16	JPY	909.95	7,700	(2,429)
Samsung		e e				.,	
Electronics Co. Ltd.	Call	UBS AG	8/12/16	KRW	1,458,315.00	2,300	(56,580)
Xero Ltd.	Call	Morgan Stanley & Co. International PLC	8/12/16	NZD	18.58	14,300	(8,407)
BAE Systems PLC Cellnex Telecom	Call	HSBC Bank PLC	8/16/16	GBP	4.83	243,000	(152,101)
SAU GlaxoSmithKline	Call	UBS AG	8/16/16	EUR	14.15	38,000	(23,514)
PLC	Call	Deutsche Bank AG	8/16/16	GBP	14.29	75,000	(183,901)
Statoil ASA	Call	Deutsche Bank AG	8/16/16	NOK	135.78	119,000	(173,232)
Anheuser-Busch InBev SA	Call	Goldman Sachs International	8/17/16	EUR	117.26	35,900	(165,936)
Imperial Brands PLC	Call	Morgan Stanley & Co. International PLC	8/17/16	GBP	40.45	11,000	(18,814)
Kingspan Group PLC	Call	Morgan Stanley & Co. International PLC	8/17/16	EUR	25.48	10,000	(2,070)
Lloyds Banking							
Group PLC Taiwan	Call	Goldman Sachs International	8/17/16	GBP	0.65	1,607,000	(20,658)
Semiconductor Manufacturing Co.	<i>a</i> 11		0.4 7 4.6		1 (0.00	204.000	(10.0.11)
Ltd.	Call	UBS AG	8/17/16	TWD	160.93	304,000	(49,841)
Xero Ltd.	Call	Morgan Stanley & Co. International PLC	8/17/16	NZD	17.64	43,000	(43,453)
Continental AG Cellnex Telecom	Call	Goldman Sachs International	8/18/16	EUR	184.40	4,500	(11,270)
SAU	Call	Morgan Stanley & Co. International PLC	8/23/16	EUR	14.46	50,000	(25,783)
Fairfax Financial Holdings Ltd.	Call	Deutsche Bank AG	8/23/16	CAD	659.32	6,000	(216,025)
Galp Energia SGPS	Ca11	Morgan Stanlay & Co. Internet DI C	0/12/11	FID	10.27	72 000	(52 047)
SA Liberty Global PLC	Call	Morgan Stanley & Co. International PLC Citibank N.A.	8/23/16	EUR	12.37	72,000	(52,047)
Liberty Global PLC Kingspan Group	Call	CHIDalik IN.A.	8/23/16	USD	36.12	22,000	(5,479)
PLC	Call	Credit Suisse International	8/24/16	EUR	24.18	7,500	(3,178)

I I I I I I I I I I I I I I I I I I I	Call	Bank of America N.A.	8/24/16	EUR	0.74	1,329,000	(81,714)
Royal Dutch Shell PLC, B Shares	Call	Credit Suisse International	8/26/16	GBP	17.56	89,000	(378,444)
Vodafone Group PLC	Call	Morgan Stanley & Co. International PLC	9/01/16	GBP	2.17	662.000	(147,490)
Nintendo Co. Ltd.	Call	Morgan Stanley & Co. International PLC	9/08/16	JPY	14,327.71	1,300	(15,039)
Vodafone Group PLC	Call	Morgan Stanley & Co. International PLC	9/15/16	GBP	2.22	492,500	(92,470)
Total							\$ (10,875,517)

Transactions in Options Written for the Period Ended June 30, 2016

	Cal	s	Puts		
	Contracts	Premiums Received	Premiums Contracts Received		
BGY					
Outstanding options at beginning of period	37,604,404	\$ 8,979,694			
Options written	113,913,553	29,836,338			
Options exercised	(11,900)	(75,089)			
Options expired	(65,524,091)	(18,337,234)			
Options closed	(54,070,381)	(12,344,292)			
Outstanding options at end of period	31,911,585	\$ 8,059,417			

As of period end, the value of portfolio securities subject to covered call options written was \$290,938,568.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock International Growth and Income Trust (BGY)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		Commodity Contracts	Credit Contracts	Equity Contracts	Foreign Currency Exchange Contracts	Interest Rate Contracts		Total
Assets Derivative Financial Instruments Futures contracts	Net unrealized appreciation ¹			\$ 279,332			\$	279,332
Liabilities Derivative Financial Instrumer Options written	nts Options written, at value			\$ 11,613,738			\$1	1,613,738

¹ Includes cumulative appreciation (depreciation) on futures contracts, if any, as reported in the Schedules of Investments. Only current day s variation margin is reported within the Statements of Assets and Liabilities.

For the six months ended June 30, 2016, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss) from: Futures Options purchased ¹ Options Written	Commodity Contracts	Credit Contracts	Equity Contracts \$ 6,314,451 (76,864) 12,722,468	Foreign Currency Exchange Contracts	Interest Rate Contracts	Total \$ 6,314,451 (76,864) 12,722,468
Total			\$ 18,960,055			\$ 18,960,055
Net Change in Unrealized Appreciation (Depreciation) on: Futures Options purchased ² Options Written			\$ 279,332 53,917 (6,070,479)			\$ 279,332 53,917 (6,070,479)
Total			\$ (5,737,230)			\$ (5,737,230)

¹ Options purchased are included in net realized gain (loss) from investments.

² Options purchased are included in net change in unrealized appreciation (depreciation) on investments.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Financial futures contracts: Average notional value of contracts - purchased Options:

Average value of option contracts written

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

\$ 10,331,542

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities
Derivative Financial Instruments: Futures contracts Options	\$ 127,350	\$ 11,613,738
Total derivative assets and liabilities in the Statements of Assets and Liabilities Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	\$ 127,350 (127,350)	\$ 11,613,738 (738,221)
Total derivative assets and liabilities subject to an MNA		\$ 10,875,517

See Notes to Financial Statements.

78

SEMI-ANNUAL REPORT

BlackRock International Growth and Income Trust (BGY)

The following table presents the Trust s derivative assets and liabilities by counterparty net of amounts available for offset under an Master Netting Agreement (MNA) and net of the related collateral pledged by the Trust:

Gross Amounts Not Offset in the Consolidated Statements of Assets and Liabilities and Subject to an MNA

Derivative Liabilities

	Subject to an MNA by	Derivatives Available	Non-cash Collateral	Cash Collateral	Net Amount of
Counterparty	Counterparty	for Offset ¹	Pledged	Pledged	Derivative Liabilities ²
Bank of America N.A.	\$ 680,013			\$ (152,000)	\$ 528,013
Citibank N.A.	1,340,343			(770,000)	570,343
Credit Suisse International	2,410,750			(1,340,000)	1,070,750
Deutsche Bank AG	956,684			(444,000)	512,684
Goldman Sachs International	999,097			(520,000)	479,097
HSBC Bank PLC	373,571				373,571
JPMorgan Chase Bank N.A.	68,115			(30,000)	38,115
Morgan Stanley & Co.					
International PLC	1,690,298			(946,619)	743,679
UBS AG	2,356,646			(960,000)	1,396,646
Total	\$10,875,517			(5,162,619)	\$5,712,898

¹ The amount of derivatives available for offset is limited to the amount of derivative assets and/or liabilities that are subject to an MNA.

² Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

,349
,595
,963
ŀ

China	6,423,956	18,190,363	24,614,319
Denmark	0,120,000	6,182,313	6,182,313
France		46,673,828	46,673,828
Germany		16,718,345	16,718,345
Hong Kong		10,587,476	10,587,476
India	5,080,022	17,505,741	22,585,763
Indonesia	3,000,022	7,545,222	7,545,222
Ireland	15,301,611	7,515,222	15,301,611
Israel	3,335,272		3,335,272
Italy	5,555,272	25,679,997	25,679,997
Japan		48,932,928	48,932,928
Mexico	7,519,437	40,752,720	7,519,437
Netherlands	7,519,457	36,486,547	36,486,547
New Zealand		4,693,586	4,693,586
Norway		10,859,513	10,859,513
Philippines	2,407,854	10,039,315	2,407,854
Portugal	2,407,034	7,351,975	7,351,975
South Africa		7,210,109	7,210,109
South Korea		13,916,376	13,916,376
Spain		9,482,109	9,482,109
Sweden		9,393,399	9,393,399
Sweden Switzerland		50,907,261	50,907,261
Taiwan		15,684,161	
			15,684,161
Thailand United Kingdom	19 064 922	2,799,638	2,799,638
United Kingdom	18,964,822	124,480,160	143,444,982
United States	29,754,654	4,049,460	33,804,114

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock International Growth and Income Trust (BGY)

Assets: (concluded)	Level 1	Level 2	Level 3	Total
Investments: (concluded) Long-Term Investments: (concluded) Investment Companies Preferred Stocks Short-Term Securities	\$ 21,785,695	\$ 6,065,233	\$ 15,965,191	\$ 6,065,233 15,965,191 21,785,695
Total	\$ 143,936,286	\$ 537,522,684	\$ 15,965,191	\$ 697,424,161
Derivative Financial Instruments ¹ Assets:	Level 1	Level 2	Level 3	Total
Equity contracts Liabilities:	\$ 279,332			\$ 279,332
Equity contracts	(738,221)	\$ (10,875,517)		(11,613,738)
Total	\$ (458,889)	\$ (10,875,517)		\$ (11,334,406)

¹ Derivative financial instruments are futures contracts and options written. Futures contracts are valued at the unrealized appreciation (depreciation) on the instrument and options written are shown at value.

The Trust may hold assets and/or liabilities in which the fair value approximates the carrying amount for financial statement purposes. As of period end, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

		Level 1	Level 2	Level 3		Total
Assets:						
Cash	\$	773,605			\$	773,605
Cash pledged:						
Collateral exchange traded options written		6,219,000				6,219,000
Collateral OTC derivatives		5,162,619				5,162,619
Futures Contracts		639,000				639,000
Foreign currency at value		1,035,172				1,035,172
Total	\$	13,829,396			\$	13,829,396
	Tr	ansfers into	Transfers out of	Transfers into	Tra	insfers out of

	I ransiers into	I ransiers out of	I ransiers into	I ransiers out of
	Level 1 ¹	Level 1 ²	Level 2 ²	Level 2 ¹
Assets: Long-Term Investments:				
Common Stocks	\$ 12,209,330	\$ (49,829,768)	\$ 49,829,768	\$ (12,209,330)

¹ Systematic Fair Value Prices were not utilized at period end for these investments.

 2 External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common Stocks	Preferred Stocks	Total
Assets:			
Opening Balance, as of December 31, 2015	\$ 4,465,011	\$ 15,504,609	\$ 19,969,620
Transfers into Level 3			
Transfers out of Level 3	(4,465,011)		(4,465,011)
Accrued discounts/premiums			
Net realized gain (loss)		206,788	206,788
Net change in unrealized appreciation/depreciation ^{1,2}		253,794	253,794
Purchases		2,618,793	2,618,793
Sales		(2,618,793)	(2,618,793)
Closing Balance, as of June 30, 2016		\$ 15,965,191	\$ 15,965,191
Net change in unrealized appreciation/depreciation on investments still held at June 30, 2016 ²		\$ 555,905	\$ 555,905

¹ Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

² Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2016 is generally due to investments no longer held or categorized as Level 3 at period end.

See Notes to Financial Statements.

80

SEMI-ANNUAL REPORT

BlackRock International Growth and Income Trust (BGY)

The following table summarizes the valuation techniques used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) to determine the value of certain of the Trust s Level 3 investments as of period end.

Range of

			Unobservable	Unobservable Inputs
Assets:	Value	Valuation Techniques	Inputs	Utilized
Preferred Stocks	\$ 15,965,191	Market Comparables	Revenue Multiple ¹	4.33x
		*	Revenue Growth Rate ¹	99.00%
		Probability-Weighted Expected Return Model	Discount Rate ²	25.00%
			IPO Exit Probability ¹	70.00%
			Merger and Acquisition Probability ¹	25.00%
			Revenue Growth Rate ¹	80.00%
			Revenue Multiple ¹	13.55x-20.70x
			Time to Exit ²	1-2 years

Total

\$ 15,965,191

¹ Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.

² Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Consolidated Schedule of Investments June 30, 2016

(Unaudited)

BlackRock Resources & Commodities Strategy Trust (BCX) (Percentages shown are based on Net Assets)

Common Stocks	Shares		Value
Chemicals 16.9% Albemarle Corp. (a)	196,188	\$	15,559,670
CF Industries Holdings, Inc. (a)	368,319	φ	8,876,488
Monsanto Co. (a)(b)	573,191		59,273,681
Mosaic Co. (a)	526,233		13,776,780
Potash Corp. of Saskatchewan, Inc. (a)	1,281,890		20,817,894
Syngenta AG	94,620		36,319,754
			154,624,267
Containers & Packaging 5.6%			
International Paper Co. (a)	559,075		23,693,600
Packaging Corp. of America (a) Smurfit Kappa Group PLC	244,348 511,889		16,354,212 11,271,007
Sinum Kappa Group Lee	511,007		11,271,007
Environment & Sources 200			51,318,819
Energy Equipment & Services 2.9% Baker Hughes, Inc. (a)	196,827		8,882,803
Schlumberger Ltd. (a)	223,252		17,654,768
			26,537,571
Food & Staples Retailing 1.8%			20,337,371
Fyffes PLC	10,547,711		16,153,414
Food Products 9.9%	422 822		11 017 422
AGT Food & Ingredients, Inc. Elders Ltd. (c)	433,833 997,356		11,917,432 2,773,566
First Resources Ltd.	8,361,900		9,756,787
Glanbia PLC	468,746		8,806,869
Golden Agri-Resources Ltd.	31,419,900		8,221,047
Kerry Group PLC, Class A	120,042		10,646,424
Leroy Seafood Group ASA	54,935		2,591,950
Mead Johnson Nutrition Co. (a) Select Harvests Ltd.	120,398 196,984		10,926,120 1,008,034
Tyson Foods, Inc., Class A (a)	260,690		1,008,034
Wilmar International Ltd.	2,594,400		6,315,557
			90,375,271
Independent Power and Renewable Electricity Producers 0.0%			90,373,271
Greenko Group PLC (c)	59,000		793
Metals & Mining 28.4%			
Alcoa, Inc. (a)	957,871		8,879,464
ArcelorMittal (c) Barrick Gold Corp. (a)	1,774,432 1,257,054		8,090,028 26,838,103
Boliden AB	527,583		10,311,133
Detour Gold Corp. (a)(c)	493,711		12,350,896
Eldorado Gold Corp.	3,572,003		16,063,576
First Quantum Minerals Ltd.	2,280,390		16,009,240
Glencore PLC	9,116,520		18,790,345
Grupo Mexico SAB de CV, Series B	4,503,263		10,552,127
Lundin Mining Corp. (c) MMC Norilsk Nickel PJSC ADR	4,193,910 907,245		14,153,371 12,151,036
Nevsun Resources Ltd.	2,662,497		7,810,568
Newcrest Mining Ltd. (c)	1,750,000		30,330,772
Rio Tinto PLC ADR (a)	763,366		23,893,356
Silver Wheaton Corp.	757,718		17,829,105
Tahoe Resources, Inc. (a)	1,086,180		16,268,109
Teck Resources Ltd., Class B	768,501		10,121,158

260,442,387

Anadarko Petroleum Corp. (a)	254,375	13,545,469
BP PLC ADR (a)	416,252	14,781,109
Cairn Energy PLC (c)	3,188,680	8,867,983
Chevron Corp. (a)(b)	156,552	16,411,346
Cimarex Energy Co. (a)	90,017	10,740,828
ConocoPhillips (a)	472,360	20,594,896
Enbridge, Inc. (a)	436,960	18,510,640
Common Stocks	Shares	Value
Oil, Gas & Consumable Fuels (continued)		
Eni SpA ADR	382,170	\$ 12,363,200
EOG Resources, Inc. (a)	198,118	16,527,004
Exxon Mobil Corp. (a)(b)	590,204	55,325,723
Hess Corp. (a)	181,772	10,924,497
Occidental Petroleum Corp. (a)	225,800	17,061,448
Royal Dutch Shell PLC, A Shares	215,918	5,930,253
Royal Dutch Shell PLC, A Shares ADR	1,036,474	57,234,094
		278,818,490
Paper & Forest Products 2.4%		_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Interfor Corp. (c)	585,385	5,015,838
Louisiana-Pacific Corp. (a)(c)	520,900	9,037,615
Precious Woods Holding AG (c)	20,000	112,647
TFS Corp. Ltd. (d)	7,903,565	8,348,434
		22,514,534
Real Estate Investment Trusts (REITs) 0.3%		
Weyerhaeuser Co. (a)	91,871	2,735,000
Total Common Stocks 98.6%		903,520,546
Rights		
Food Products 0.0%		
Elders Ltd. (Expires 6/22/16, Strike Price 3.40 AUD) (c)	249,339	59,507
Paper & Forest Products 0.0%		
Precious Woods Holding Chf (Expires 7/5/16, Strike Price 5.30 CHF) (c)	20,000	1,365
Total Rights 0.0%		60,872
Preferred Stocks		
Food Products 0.8%		
Tyson Foods, Inc. (c)	99,842	7,376,327
Total Long-Term Investments		
(Cost \$814,954,441) 99.4%		910,957,745
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.40% (e)(f)	15,411,219	15,411,219
	Beneficial	
	Interest	
	(000)	
BlackRock Liquidity Series, LLC Money Market Series, 0.59% (e)(f)(g)	\$ 1,338	1,337,693
Total Short-Term Securities		
(Cost \$16,748,912) 1.8%		16,748,912

See Notes to Financial Statements.

Consolidated Schedule of Investments (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

Options Purchased (Cost \$9,011) 0.0% Total Investments Before Options Written	Value \$ 9,011
(Cost \$831,712,364) 101.2%	927,715,668
Options Written (Premiums Received \$8,605,466) (1.2)% Total Investments Net of Options Written 100.0% Liabilities in Excess of Other Assets 0.0%	\$ Value (10,733,252) 916,982,416 (289,407)
Net Assets 100.0%	\$ 916,693,009

Notes to Schedule of Investments

(a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(c) Non-income producing security.

(d) Security, or a portion of security, is on loan.

(e) During the six months ended June 30, 2016, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares/		Shares/ Beneficial Interest		
	Beneficial Interest		Held at	Value at	
	Held at	Net	June 30,	June 30,	
	December 31,				
Affiliates	2015	Activity	2016	2016	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	6,170,241	9,240,978	15,411,219	\$15,411,219	\$31,123
BlackRock Liquidity Series, LLC Money Market Series	\$ 35,689	\$1,302,004	\$ 1,337,693	\$ 1,337,693	\$33,2771
Total				\$16,748,912	\$64,400

¹ Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(f) Current yield as of period end.

(g) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series LLC, Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

OTC Options Purchased

	Strike						
		Put/			Expiration		Market
Description	Counterparty	Call	Price		Price Date Contra		Value
Leroy Seafood Group ASA	Credit Suisse International	Call	NOK	421.16	7/12/16	10,600	\$ 1,912
Leroy Seafood Group ASA	Credit Suisse International	Call	NOK	421.16	7/19/16	10,600	3,762
Leroy Seafood Group ASA	Credit Suisse International	Call	NOK	434.72	8/02/16	8,700	3,337
Total							\$ 9,011

Exchange-Traded Options Written

	Strike					
	Put/	Expiration				
Description	Call	Date	Pr	ice	Contracts	Value
Alcoa, Inc.	Call	7/01/16	USD	9.50	1,250	\$ (1,875)
Baker Hughes, Inc.	Call	7/01/16	USD	49.00	57	(1,425)
Chevron Corp.	Call	7/01/16	USD	102.00	141	(40,044)
ConocoPhillips	Call	7/01/16	USD	46.00	300	(1,200)
International Paper Co.	Call	7/01/16	USD	42.00	230	(10,235)
International Paper Co.	Call	7/01/16	USD	43.50	314	(3,454)
Monsanto Co.	Call	7/01/16	USD	102.00	546	(98,280)
Schlumberger Ltd.	Call	7/01/16	USD	75.00	361	(146,205)
Anadarko Petroleum Corp.	Call	7/08/16	USD	53.50	104	(10,036)
Anadarko Petroleum Corp.	Call	7/08/16	USD	55.00	28	(1,190)
Baker Hughes, Inc.	Call	7/08/16	USD	48.00	365	(4,198)
ConocoPhillips	Call	7/08/16	USD	46.00	350	(3,500)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Consolidated Schedule of Investments (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

	Strike							
	Put/	Expiration						
Description	Call	Date		rice	Contracts	Value		
EOG Resources, Inc.	Call	7/08/16	USD	85.50	330	\$ (12,705)		
Exxon Mobil Corp.	Call	7/08/16	USD	89.50	255	(103,275)		
Hess Corp.	Call	7/08/16	USD	60.00	100	(12,300)		
International Paper Co. Occidental Petroleum Corp.	Call Call	7/08/16 7/08/16	USD USD	43.00 76.50	907 395	(17,687) (15,998)		
Schlumberger Ltd.	Call	7/08/16	USD	78.00	393 27	(4,455)		
Albemarle Corp.	Call	7/15/16	USD	80.00	190	(29,925)		
Alcoa, Inc.	Call	7/15/16	USD	10.50	1,000	(6,500)		
Anadarko Petroleum Corp.	Call	7/15/16	USD	55.00	209	(16,929)		
Barrick Gold Corp.	Call	7/15/16	USD	18.00	1,640	(553,500)		
BP PLC ADR	Call	7/15/16	USD	33.00	197	(52,698)		
Chevron Corp.	Call	7/15/16	USD	100.00	486	(251,505)		
Cimarex Energy Co.	Call	7/15/16	USD	115.00	185	(105,450)		
ConocoPhillips	Call	7/15/16	USD	46.00	378	(10,584)		
Detour Gold Corp.	Call	7/15/16	CAD	29.00	265	(73,329)		
Detour Gold Corp.	Call	7/15/16	CAD	30.00	510	(108,754)		
Enbridge, Inc.	Call	7/15/16	CAD	54.00	1,442	(132,821)		
EOG Resources, Inc.	Call	7/15/16	USD	82.50	210	(47,145)		
Exxon Mobil Corp.	Call	7/15/16	USD	90.00	255	(101,362)		
Hess Corp.	Call	7/15/16	USD	62.50	555	(46,898)		
International Paper Co.	Call	7/15/16	USD	43.00	240	(9,360)		
Louisiana-Pacific Corp.	Call	7/15/16	USD	19.00	300	(6,000)		
Lundin Mining Corp.	Call	7/15/16	CAD	4.50	3,500	(28,445)		
Mead Johnson Nutrition Co. Occidental Petroleum Corp.	Call Call	7/15/16 7/15/16	USD USD	85.00 77.50	210 395	(129,150) (18,565)		
Packaging Corp. of America	Call	7/15/16	USD	67.50	188	(18,800)		
Packaging Corp. of America	Call	7/15/16	USD	70.00	300	(18,800) (9,000)		
Rio Tinto PLC ADR	Call	7/15/16	USD	30.00	610	(109,800)		
Rio Tinto PLC ADR	Call	7/15/16	USD	32.50	512	(25,600)		
Schlumberger Ltd.	Call	7/15/16	USD	77.50	55	(13,145)		
Tahoe Resources, Inc.	Call	7/15/16	CAD	16.00	590	(154,127)		
Tahoe Resources, Inc.	Call	7/15/16	CAD	17.00	600	(113,085)		
Tyson Foods, Inc., Class A	Call	7/15/16	USD	65.00	102	(24,735)		
Anadarko Petroleum Corp.	Call	7/22/16	USD	54.50	67	(9,246)		
Anadarko Petroleum Corp.	Call	7/22/16	USD	56.00	51	(4,335)		
Barrick Gold Corp.	Call	7/22/16	USD	22.50	1,250	(75,000)		
BP PLC ADR	Call	7/22/16	USD	34.00	196	(37,240)		
CF Industries Holdings, Inc.	Call	7/22/16	USD	26.00	490	(22,540)		
ConocoPhillips	Call	7/22/16	USD	46.00	165	(8,085)		
Exxon Mobil Corp.	Call	7/22/16	USD	91.50	75 77	(21,750)		
Hess Corp. Mosaic Co.	Call Call	7/22/16 7/22/16	USD USD	62.50 27.50	526	(9,317) (34,979)		
Potash Corp. of Saskatchewan, Inc.	Call	7/22/16	USD	17.50	679	(35,987)		
Tyson Foods, Inc., Class A	Call	7/22/16	USD	64.00	200	(67,000)		
Weyerhaeuser Co.	Call	7/22/16	USD	32.50	109	(5,450)		
Alcoa, Inc.	Call	7/29/16	USD	10.50	1,600	(16,800)		
Anadarko Petroleum Corp.	Call	7/29/16	USD	55.50	103	(14,368)		
Baker Hughes, Inc.	Call	7/29/16	USD	48.50	365	(23,360)		
Barrick Gold Corp.	Call	7/29/16	USD	24.00	378	(15,498)		
BP PLC ADR	Call	7/29/16	USD	36.50	880	(52,360)		
CF Industries Holdings, Inc.	Call	7/29/16	USD	26.50	490	(24,990)		
ConocoPhillips	Call	7/29/16	USD	48.50	438	(11,607)		
EOG Resources, Inc.	Call	7/29/16	USD	83.00	210	(57,015)		
Exxon Mobil Corp.	Call	7/29/16	USD	90.50	75	(30,000)		
International Paper Co.	Call	7/29/16	USD	43.50	545	(35,425)		
Mosaic Co.	Call	7/29/16	USD	28.00	525	(37,538)		
Occidental Petroleum Corp. Potash Corp. of Saskatchewan, Inc.	Call Call	7/29/16 7/29/16	USD USD	78.50 16.50	113 1,600	(7,571) (126,400)		
Schlumberger Ltd.	Call	7/29/16	USD	79.50	1,600	(126,400) (5,481)		
Semuniberger Elu.	Call	1129/10	03D	19.50	21	(3,481)		

Tyson Foods, Inc., Class A	Call	7/29/16	USD	63.00	200	(86,000)
Anadarko Petroleum Corp.	Call	8/05/16	USD	56.00	69	(10,316)
BP PLC ADR	Call	8/05/16	USD	35.00	392	(55,272)
CF Industries Holdings, Inc.	Call	8/05/16	USD	27.50	490	(24,010)
ConocoPhillips	Call	8/05/16	USD	46.00	211	(18,674)
Exxon Mobil Corp.	Call	8/05/16	USD	90.50	573	(230,632)

See Notes to Financial Statements.

84

SEMI-ANNUAL REPORT

Consolidated Schedule of Investments (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

			Sti	rike			
	Put/	Expiration					
Description	Call	Date	Pr	rice	Contracts		Value
Monsanto Co.	Call	8/05/16	USD	110.00	415	\$	(135,912)
Mosaic Co.	Call	8/05/16	USD	28.50	524		(52,400)
Potash Corp. of Saskatchewan, Inc.	Call	8/05/16	USD	16.50	1,600		(171,200)
Potash Corp. of Saskatchewan, Inc.	Call	8/05/16	USD	17.50	620		(58,280)
Schlumberger Ltd.	Call	8/05/16	USD	80.00	61		(12,292)
Tyson Foods, Inc., Class A	Call	8/05/16	USD	67.00	400		(73,000)
Anadarko Petroleum Corp.	Call	8/12/16	USD	55.50	193		(36,188)
Exxon Mobil Corp.	Call	8/12/16	USD	93.50	624		(125,424)
Weyerhaeuser Co.	Call	8/12/16	USD	31.00	53		(2,915)
Packaging Corp. of America	Call	8/18/16	USD	69.65	189		(27,881)
Anadarko Petroleum Corp.	Call	8/19/16	USD	55.00	193		(43,811)
Barrick Gold Corp.	Call	8/19/16	USD	20.00	1,760		(418,880)
ConocoPhillips	Call	8/19/16	USD	44.00	47		(9,048)
Detour Gold Corp.	Call	8/19/16	CAD	32.00	670		(138,724)
Enbridge, Inc.	Call	8/19/16	CAD	56.00	305		(19,830)
EOG Resources, Inc.	Call	8/19/16	USD	85.00	42		(11,886)
Exxon Mobil Corp.	Call	8/19/16	USD	92.50	503		(139,331)
Louisiana-Pacific Corp.	Call	8/19/16	USD	18.00	430		(23,650)
Mead Johnson Nutrition Co.	Call	8/19/16	USD	90.00	271		(112,465)
Mosaic Co.	Call	8/19/16	USD	28.00	263		(28,010)
Mosaic Co.	Call	8/19/16	USD	29.00	262		(22,532)
Potash Corp. of Saskatchewan, Inc.	Call	8/19/16	USD	18.00	620		(32,240)
Rio Tinto PLC ADR	Call	8/19/16	USD	30.00	420		(106,050)
Rio Tinto PLC ADR	Call	8/19/16	USD	35.00	256		(12,800)
Schlumberger Ltd.	Call	8/19/16	USD	77.50	362		(135,750)
Tahoe Resources, Inc.	Call	8/19/16	CAD	18.00	590		(90,421)
Tyson Foods, Inc., Class A	Call	8/19/16	USD	67.50	140		(35,350)
Weyerhaeuser Co.	Call	8/19/16	USD	30.00	152		(14,440)
Total						\$ (5	5,990,230)

OTC Options Written

		Strike					
	Put/		Expiration				
Description	Call	Counterparty	Date	P	rice	Contracts	Value
Interfor Corp.	Call	Credit Suisse International	7/05/16	CAD	11.30	85,000	\$ (7,683)
Detour Gold Corp.	Call	Morgan Stanley & Co. International PLC	7/06/16	CAD	29.91	53,000	(103,841)
Glanbia PLC	Call	UBS AG	7/06/16	EUR	16.35	23,500	(16,825)
Newcrest Mining Ltd.	Call	Citibank N.A.	7/06/16	AUD	22.41	306,000	(263,415)
ArcelorMittal	Call	Deutsche Bank AG	7/07/16	EUR	4.96	355,000	(125)
Cimarex Energy Co.	Call	Morgan Stanley & Co. International PLC	7/07/16	USD	115.42	15,000	(68,685)
Glencore PLC	Call	Credit Suisse International	7/07/16	GBP	1.38	1,450,000	(335,337)
Syngenta AG	Call	Morgan Stanley & Co. International PLC	7/07/16	CHF	397.19	37,800	(70)
Glanbia PLC	Call	UBS AG	7/12/16	EUR	16.35	23,500	(18,973)
Glencore PLC	Call	Credit Suisse International	7/12/16	GBP	1.35	60,000	(16,532)
Grupo Mexico SAB de CV, Series B	Call	Citibank N.A.	7/12/16	MXN	41.97	500,000	(37,048)
Leroy Seafood Group ASA	Call	UBS AG	7/12/16	NOK	421.17	10,600	(1,793)
Lundin Mining Corp.	Call	Morgan Stanley & Co. International PLC	7/12/16	CAD	4.30	350,000	(48,455)
ArcelorMittal	Call	Deutsche Bank AG	7/13/16	EUR	4.96	355,000	(4,862)
First Quantum Minerals Ltd.	Call	Credit Suisse International	7/13/16	CAD	8.62	250,000	(148,409)
Interfor Corp.	Call	Citibank N.A.	7/13/16	CAD	13.89	65,000	(2,549)
Smurfit Kappa Group PLC	Call	Morgan Stanley & Co. International PLC	7/13/16	EUR	23.72	30,000	(5)
Teck Resources Ltd., Class B	Call	Credit Suisse International	7/13/16	USD	12.34	108,000	(126,454)
Kerry Group PLC, Class A	Call	Bank of America N.A.	7/19/16	EUR	81.73	30,000	(19,420)

Leroy Seafood Group ASA	Call	UBS AG	7/19/16	NOK	421.17	10,600	(3,363)
MMC Norilsk Nickel PJSC ADR	Call	Bank of America N.A.	7/19/16	USD	13.78	60,000	(18,011)
MMC Norilsk Nickel PJSC ADR	Call	UBS AG	7/19/16	USD	14.36	60,000	(8,068)
Glencore PLC	Call	Morgan Stanley & Co. International PLC	7/20/16	GBP	1.35	950,000	(280,909)
Newcrest Mining Ltd.	Call	Citibank N.A.	7/20/16	AUD	20.09	306,000	(764,419)
Smurfit Kappa Group PLC	Call	Goldman Sachs International	7/20/16	EUR	24.70	59,000	(913)
Boliden AB	Call	Citibank N.A.	7/26/16	SEK	151.41	80,000	(138,644)
MMC Norilsk Nickel PJSC ADR	Call	UBS AG	7/26/16	USD	13.56	70,000	(31,718)
Grupo Mexico SAB de CV, Series B	Call	UBS AG	7/28/16	MXN	42.82	500,000	(36,075)
Louisiana-Pacific Corp.	Call	Barclays Bank PLC	7/29/16	USD	18.06	43,000	(14,218)
Tahoe Resources, Inc.	Call	Credit Suisse International	7/29/16	CAD	17.01	59,000	(117,395)
Rio Tinto PLC ADR	Call	Deutsche Bank AG	8/01/16	USD	29.95	100,000	(221,005)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Consolidated Schedule of Investments (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

		Strike						
	Put/		Expiration					
Description	Call	Counterparty	Date	Pr	ice	Contracts		Value
Boliden AB	Call	UBS AG	8/02/16	SEK	160.86	28,500	\$	(28,889)
Interfor Corp.	Call	Citibank N.A.	8/02/16	CAD	12.51	75,000		(8,465)
Kerry Group PLC, Class A	Call	Morgan Stanley & Co. International PLC	8/02/16	EUR	82.43	18,000		(13,857)
Leroy Seafood Group ASA	Call	UBS AG	8/02/16	NOK	434.73	8,700		(2,933)
Lundin Mining Corp.	Call	Credit Suisse International	8/02/16	CAD	4.41	350,000		(60,329)
MMC Norilsk Nickel PJSC								
ADR	Call	UBS AG	8/02/16	USD	14.44	70,000		(13,921)
Teck Resources Ltd., Class B	Call	Morgan Stanley & Co. International PLC	8/03/16	USD	11.37	92,000		(206,494)
Rio Tinto PLC ADR	Call	Credit Suisse International	8/05/16	USD	32.66	25,500		(23,788)
First Quantum Minerals Ltd.	Call	Citibank N.A.	8/08/16	CAD	8.80	250,000		(183,328)
Boliden AB	Call	Credit Suisse International	8/09/16	SEK	148.86	52,500		(111,952)
Glanbia PLC	Call	Morgan Stanley & Co. International PLC	8/09/16	EUR	17.70	47,000		(19,927)
Tahoe Resources, Inc.	Call	Citibank N.A.	8/10/16	CAD	20.15	99,000		(58,668)
Boliden AB	Call	Credit Suisse International	8/11/16	SEK	158.52	50,000		(63,943)
Newcrest Mining Ltd.	Call	Citibank N.A.	8/11/16	AUD	24.02	88,000		(77,873)
Smurfit Kappa Group PLC	Call	Goldman Sachs International	8/11/16	EUR	22.20	57,000		(7,394)
Grupo Mexico SAB de CV,								
Series B	Call	Morgan Stanley & Co. International PLC	8/16/16	MXN	43.93	500,000		(32,211)
Interfor Corp.	Call	Citibank N.A.	8/16/16	CAD	11.90	80,000		(23,328)
MMC Norilsk Nickel PJSC								
ADR	Call	Bank of America N.A.	8/16/16	USD	13.47	103,000		(63,223)
Albemarle Corp.	Call	Goldman Sachs International	8/17/16	USD	83.01	59,400		(131,927)
Teck Resources Ltd., Class B	Call	Credit Suisse International	8/17/16	USD	13.00	108,000		(155,471)
Smurfit Kappa Group PLC	Call	UBS AG	8/25/16	EUR	23.25	57,000		(5,038)
First Quantum Minerals Ltd.	Call	Citibank N.A.	8/29/16	CAD	8.80	250,000		(217,923)
Tahoe Resources, Inc.	Call	Citibank N.A.	8/30/16	CAD	17.35	98,000		(196,929)
Packaging Corp. of America	Call	Goldman Sachs International	9/07/16	USD	68.50	30,000		(80,925)
Louisiana-Pacific Corp.	Call	JPMorgan Chase Bank N.A.	9/09/16	USD	17.25	92,000		(99,067)
Total							\$ (4,743,022)

Transactions in Options Written for the Period Ended June 30, 2016

	Cal	ls	Puts	
	Contracts	Premiums Received	Premiums Contracts Received	
Outstanding options at beginning of period	16,708,177	\$ 7,049,614		
Options written	56,012,288	34,494,102		
Options exercised	(15,831)	(62,902)		
Options expired	(27,665,060)	(10,530,693)		
Options closed	(35,899,656)	(22,344,655)		
Outstanding options at end of period	9,139,918	\$ 8,605,466		

As of period end, the value of portfolio securities subject to covered call options written was \$263,623,883.

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		Commodity Contracts	Equity Contracts	Foreign Currency Interest Exchange Rate Contracts Contracts	Total
Assets Derivative Financial Instrume Options purchased	Investments at value unaffiliated	1	\$ 9,011		\$ 9,011
Liabilities Derivative Financial Instr Options written	uments Options written, at value		\$ 10,733,252		\$ 10,733,252

¹ Includes options purchased at value as reported in the Schedule of Investments.

See Notes to Financial Statements.

86

SEMI-ANNUAL REPORT

Consolidated Schedule of Investments (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

For the six months ended June 30, 2016, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss) from: Options purchased ¹ Options written Total	Commodity Contracts	Credit Contracts	Equity Contracts \$ (4,715) (17,366,330) \$ (17,371,045)	Foreign Currency Exchange Contracts	Interest Rate Contracts	Total \$ (4,715) (17,366,330) \$ (17,371,045)
Net Change in Unrealized Appreciation (Depreciation) on: Options purchased ² Options written			\$ 2,849 (3,800,650)			\$ 2,849 (3,800,650)
Total			\$ (3,797,801)			\$ (3,797,801)

¹ Options purchased are included in net realized gain (loss) from investments.

² Options purchased are included in net change in unrealized appreciation (depreciation) on investments.

Average Quarterly Balances of Outstanding	Derivative Financial Instruments
---	---

Options:		
Average value of option contracts purchased	\$	9,011
Average value of option contracts written	\$11.	863,062
For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.		

Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities	
Derivative Financial Instruments: Options	\$ 9,0111	\$ 10,733,252	
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		\$ (5,990,230)	
Total derivative assets and liabilities subject to an MNA	\$ 9,011	\$ 4,743,022	

¹ Includes options purchased at value which is included in Investments at value - unaffiliated in the Consolidated Statements of Assets and Liabilities and reported in the Schedule of Investments.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Consolidated Schedule of Investments (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under an Master Netting Agreement (MNA) and net of the related collateral pledged by the Trust:

			Bross Amour and Subject to		the Statements of Assets and Liabili
			Non-cash		
	Derivative Assets			Cash	
	Subject to an MNA by	Derivatives Available C	ollateral	Collateral	Net Amount of
Counterparty Credit Suisse International	Counterparty \$ 9,011	for Offset \$(9,011)	Received	Received	Derivative Assets

Gross Amounts Not Offset in the Consolidated Statements of Assets and Liabilities

and Subject to an MNA

	Derivative Liabilities	Derivatives Available	Non-cash	Cash	
Counterparty Bank of America N.A.	Subject to an MNA by Counterparty \$ 100.654	for Offset	Collateral Pledged ¹ \$ (100,654)	Collateral Pledged	Net Amount of Derivative Liabilities ²
Barclays Bank PLC	14,218				\$ 14,218
Citibank N.A.	1,972,589		(1,972,589)		
Credit Suisse International	1,167,293	\$(9,011)	(1,158,282)		
Deutsche Bank AG	225,992		(225,992)		
Goldman Sachs International	221,159		(221,159)		
JPMorgan Chase Bank N.A.	99,067				99,067
Morgan Stanley & Co. International PLC	774,454		(774,454)		
UBS AG	167,596		(167,596)		
Total	\$4,743,022	\$(9,011)	\$ (4,620,726)		\$113,285

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

² Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

Level 1

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

Investments:								
Long-Term Investments:								
Common Stocks:								
Chemicals	\$	118,304,513	\$	36,319,754			\$	154,624,267
Containers & Packaging		40,047,812		11,271,007				51,318,819
Energy Equipment & Services		26,537,571						26,537,571
Food & Staples Retailing		16,153,414						16,153,414
Food Products		49,061,906		41,313,365				90,375,271
Independent Power and Renewable Electricity Producers					\$	793		793
Metals & Mining		180,769,073		79,673,314				260,442,387
Oil, Gas & Consumable Fuels		264,020,254		14,798,236				278,818,490
Paper & Forest Products		14,053,453		8,461,081				22,514,534
Real Estate Investment Trusts (REITs)		2,735,000						2,735,000
Rights				60,872				60,872
Preferred Stocks		7,376,327						7,376,327
Short-Term Securities		15,411,219		1,337,693				16,748,912
Options Purchased				9,011				9,011
Total	\$	734,470,542	\$	193,244,333	\$	793	\$	927,715,668
	Ŧ		Ŧ		Ŧ	,,,,,	4	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

	Level 1	Level 2	Level 3	Total
Derivative Financial Instruments ¹ Liabilities:				
Equity contracts	\$ (5,962,349) \$	(4,770,903)		\$ (10,733,252)

¹ Derivative financial instruments are options written, which are shown at value.

See Notes to Financial Statements.

88

SEMI-ANNUAL REPORT

Consolidated Schedule of Investments (concluded)

BlackRock Resources & Commodities Strategy Trust (BCX)

The Trust may hold liabilities in which the fair value approximates the carrying amount for financial statement purposes. As of period end, such liabilities are categorized within the disclosure hierarchy as follows:

	Level 1		Level 2	Level 3		Total	
Assets: Cash Foreign currency at value	\$	12,011 40,658			\$	12,011 40,658	
Liabilities: Collateral on securities loaned at value			\$ (1,337,693)			(1,337,693)	
Total	\$	40,658	\$ (1,337,693)		\$	(1,297,035)	

	Transfers into					
	Level 1	Tra	ansfers out of Level 1 ¹	Tr	ansfers into Level 2 ¹	Transfers out of Level 2
Assets:						
Long-Term Investments:						
Common Stocks		\$	(41,370,578)	\$	41,370,578	

¹ External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Schedule of Investments June 30, 2016 (Unaudited)

BlackRock Science and Technology Trust (BST) (Percentages shown are based on Net Assets)

Common Stocks Automobiles 0.5%	Shares	Value
Tesla Motors, Inc. (a)(b)(c) Communications Equipment 0.4%	9,200	\$ 1,952,976
Lumentum Holdings, Inc. (a) Diversified Financial Services 0.5%	67,800	1,640,760
Intercontinental Exchange, Inc. (b) Diversified Telecommunication Services 1.1%	8,700	2,226,852
Cogent Communications Holdings, Inc. (b) Zayo Group Holdings, Inc. (a)	72,300 69,000	2,896,338 1,927,170
	0,000	
Electronic Equipment, Instruments & Components 3.0%		4,823,508
CDW Corp.	56,500	2,264,520
Coherent, Inc. (a)(b)	23,800	2,184,364
Flextronics International Ltd. (a)(b) Largan Precision Co. Ltd.	176,100 33,000	2,077,980 3,051,947
Universal Display Corp. (a)	49,100	3,328,980
	.,,100	
Hotels, Restaurants & Leisure 1.0%		12,907,791
Six Flags Entertainment Corp. Household Durables 0.9%	69,800	4,044,910
Sony Corp. Internet & Catalog Retail 7.9%	133,400	3,930,228
Amazon.com, Inc. (a)(b)	29,200	20,896,104
Ctrip.com International Ltd. ADR (a)(b)	28,300	1,165,960
Ensogo Ltd. (a)	173,282	83,947
Expedia, Inc. (b)	20,600	2,189,780
Netflix, Inc. (a)(b)	39,320	3,596,994
Priceline Group, Inc. (a)(b)	2,400	2,996,184
TripAdvisor, Inc. (a)(b)	39,700	2,552,710
Internet Software & Services 21.4%		33,481,679
58.com, Inc. ADR (a)(b)	36,900	1,693,341
Alibaba Group Holding Ltd. ADR (a)(b)	109,100	8,676,723
Alphabet, Inc., Class A (a)(b)(d)	37,800	26,593,434
Auto Trader Group PLC (e)	573,100	2,709,219
comScore, Inc. (a)(b)	81,650	1,949,802
DeNA Co. Ltd.	80,400	1,880,838
Facebook, Inc., Class A (a)(b)	170,600	19,496,168
MercadoLibre, Inc. (b) New Relic, Inc. (a)(b)	26,500 44,300	3,727,755 1,301,534
Scout24 AG (a)(e)	92,122	3,424,248
Shopify, Inc., Class A (a)	65,900	2,027,084
Tencent Holdings Ltd.	680,700	15,615,036
Yahoo!, Inc. (a)(b)	33,900	1,273,284
IT Services 11.0%		90,368,466
Euronet Worldwide, Inc. (a)(b)	39,600	2,739,924
Fidelity National Information Services, Inc. (b)	59,100	4,354,488
Global Payments, Inc. (b)	60,100	4,289,938
InterXion Holding NV (a)(b)	73,400	2,706,992
Luxoft Holding, Inc. (a)	48,400	2,517,768
MasterCard, Inc., Class A (b)	99,300	8,744,358
PayPal Holdings, Inc. (a)(b)	79,700	2,909,847
Sabre Corp.	177,300	4,749,867
Visa, Inc., A Shares (b) WNS Holdings Ltd. ADR (a)	156,800 61,610	11,629,856 1,663,470
with notaings Lia. ADK (a)	01,010	1,005,470

Media 39% Concest Corp. Class A (b) 154,203 2,281,398 Evo. Iternational PLC (a)(b)(c) 154,423 2,201,321 Bayers 1(a), Names 164,653 2,103,277 Broor SE & Co. KGAA 46,800 2,152,772 Professional Services 1.3% 2,801,998 2,892,753 Treshnofon Holdings, Inc. 29,200 2,892,753 Treshnofon Holdings, Inc. 2,539,419 2,539,419 Convon Castle International Corp. (b) 84,600 8,880,978 Paintix, Inc. (b) 7,8100 8,880,978 Paintix, Inc. (b) 79,000 8,010,210 Paintix, Inc. (b) 72,010 8,880,773 Semiconductor & Semiconductor Equipment 14.5% 2,042,985 Accid Communications, Inc. (a)(b) 73,770 2,240,245 Applied Material, Inc. (b) 74,100 7,243,303 Eff Semiconductor Information V 84,400 8,353,86 Applied Material, Inc. (b) 7,370 2,400,453,854 Applied Material, Inc. (b) 7,2400 7,243,854 Applied Material, Inc. (b)	Common Stocks	Shares	46,306,508 Value
Evos International PLC (a)(b)(c) 154,305 2,510,542 REA Group Lid. 66,800 2,997,841 Strover SF & Co. KGa A 66,800 2,997,841 Professional Services L3% 2,620,725 7,810 2,610,720 Technologo Riddings, Inc. 92,900 2,892,755 7,8100 2,611,661 Real Patate Investment Trusts (REITs) 6.4% 5,644,419 5,644,419 2,611,661 Crown Carle International Corp. (b) 84,4000 8,810,978 9,7000 8,616,210 Semiconductors & Semiconductor Equipment 14,5% 7,9000 8,616,210 9,711,797 Accast Communications, Inc. (b) 11,8000 4,518,210 2,511 9,711,797 Accast Communications, Inc. (b) 14,55% 7,4100 7,243,404 2,858,86 Accast Communications, Inc. (a)(b) 18,800 4,249,403 4,404,933,414,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,403,933 4,249,493,9	Media 3.9%		
Napers 40,100 6,123,072 RAG Group Lud. 66,800 2,297,84 Stroer SF, & Co, KGA 46,800 2,152,772 Professional Services 1.3% 16,665,623 TransUnico (a) 72,000 2,802,755 TransUnico (a) 72,000 2,802,755 Real Eduite Investment Trusts (RETT) 6.4% 5,504,419 Crown Carde Incenzional Corp. (b) 84,600 8,809,78 Digital Realy Trust, Inc. (b) 2,694,2,985 4,600 8,809,78 Acciaia Communications, Inc. (h) 72,100 8,610,210 2,694,2,985 Acciaia Communications, Inc. (h) 17,8800 4,285,836 4,100 2,202,259 Broadom Lud, Cop. (b) 95,500 4,149,300 1,292,305 4,149,300 1,292,302 MCOM Teclinoup's Solutions Holdings, Inc. (a)(b) 17,800 4,282,836 4,149,300 1,292,302 1,293,305 Lam Research Cop. (b) 16,300 1,393,300 1,441,803 1,479,303 1,479,303 1,479,303 1,479,303 1,479,303 1,479,303 1,479,303 1,479,303	· · · · · · · · · · · · · · · · · · ·		\$
REA Comp Ltd. Stroker SL & Co. KGAA 96,800 2.957,811 Professional Services 1.3% 16,666,525 Professional Services 1.3% 2990,705 Teamblinion (a) 78,100 26,610,60 Read Estate Investment Trosts (RETTs) 6.4% 5,904,419 Crown Casele International Corp. (b) 39,000 8,580,735 Splint Real Trosts (RETTs) 6.4% 26,942,985 Semiconductors & Semiconductor Equipment 14.5% 26,942,985 Semiconductors & Semiconductor Equipment 14.5% 717 2,163,839 Applied Macri Trosts (RETTs) 5.4% 72,943,930 42,853,86 Semiconductors & Semiconductor Equipment 14.5% 717 2,163,839 Applied Macri Trosts (RETTs) 6.4% 9,750,00 8,7177 2,163,839 Be semiconductor Eduipment 14.5% 717 2,163,839 42,853,86 43,810 23,820,2359 50,800 42,853,86 Be semiconductor Industries NV 85,100 23,003 1,24,80,30 1,24,83,30 1,34,830 Marce Semiconductor Row (a) 73,700 2,430,62 9,44,00 2,330,03 1,64,84,00 2,330,03 </td <td></td> <td></td> <td></td>			
Streer SF & Co. KGaA 46,800 2,152,772 Professional Services 1.3% 16,665,625 TechnolPo Holdings, Inc. 92,900 2,892,755 Transition (a) 78,100 2,611,664 Real Estatic Investment Trasts (REITs) 6.4% 5,504,419 Coson Castle International Corp. (b) 79,000 8,500,798 Brightal Realty Trusts (m. cb) 79,000 8,600,210 Equints, Inc. (b) 79,000 8,500,798 Acceast Communications, Inc. (a)(b) 74,100 7,243,308 Applied Materian Industries NV 85,100 2,235,258 Broakcon Lu (b) 74,100 7,243,408 MACCOM Technology Solutions Holdings, Inc. (a)(b) 77,00 2,330,050 Maccon Technology, Inc. (a)(b) 77,00 2,230,650 Maccon Technology, Inc. (a)(b) 77,00 2,230,650 Maccon Technology, Inc. (a)(b) 77,00 2,330,050 Maccon Technology, Inc. (a)(b) 77,00 2,330,050 Maccon Technology, Inc. (a)(b) 77,00 7,21,511 Maccon Technology, Inc. (a)(b) 77,00 7,21,511 <td></td> <td></td> <td></td>			
Professional Services 1.3% 16.666.52 Technolym Rolings, Inc. 92.00 2.802.755 TransUnion (a) 78.100 2.611.664 Real Extits Investment Trusts (RETT) 6.4% 5.504.119 Crown Casile International Corp. (b) 84.600 85.809.788 Jeguinis, Inc. (b) 24.151 9.751.707 Semiconductor & Semiconductor Equipment 14.5% 7.216.3829 Acacia Communications, Inc. (a)(b) 74.110 7.943.40 Applied Materials, Inc. (b) 74.101 7.943.40 BE Semiconductor Routines NV 85.100 2.302.559 Prodeom Lu, (b) 64.196 9.976.088 Lam Research Corp. (b) 55.500 4.749.300 Macro Technology, Solutions Holdings, Inc. (a)(b) 73.700 2.303.127.004 Macro Technology, Corp. (a)(b) 73.700 2.313.10 Macro Technology, Solutions Holdings, Inc. (a)(b) 73.700 2.313.10 Macro Technology, Corp. (a)(b) 73.700 2.310.10 Macro Technology, Corp. (a)(b) 73.200 1.633.170 Macro Technology, Corp. ADR (b) 73.700 2.330.170	1		· · ·
Protessional Services 1.3% Services 1.3% Services 1.3% Technoly Politolings, Inc. 78,100 2.611.664 Convo Costle International Corp. (b) 84,600 85,800,978 Digital Reality Trust, Inc. (b) 25,1151 97,000 Semiconductors & Semiconductor Equipment 14.5% 26,942,985 Acacia Communications, Inc. (a)(b) 54,177 2.163,829 Applied Materials, Inc. (b) 74,100 7.294,304 BE Semiconductor Requipment 14.5% 85,000 4,285,830 Applied Materials, Inc. (a)(b) 54,177 2.163,829 Applied Materials, Inc. (a)(b) 74,100 7.294,304 BE Semiconductor Industries NV 85,100 2.302,300 BE Semiconductor Industries NV 85,100 2.302,300 MaCCOM Technology, Inc. (a)(b) 73,00 2.430,626 Microssent Corp. (b) 92,300 1.47,403 Morallitic Power Systems, Inc. (b) 82,300 1.47,403 Microssent Corp. (a)(b) 92,300 1.27,044 Microssent Corp. (b) 82,300 1.37,607 Microssent Corp. (a)(b) <t< td=""><td></td><td>40,000</td><td>2,132,772</td></t<>		40,000	2,132,772
Technolop Holdings, Inc. 92,900 2,802,75 TransUnion (a) 78,100 2,611,664 Real Estate Investment Trasts (REITs) 6.4% 5,004,419 Crown Castle International Corp. (b) 79,000 8,610,210 Eptial Realty Trast, Inc. (b) 79,000 8,610,210 Equinix, Inc. (b) 79,000 8,610,210 Equinix, Inc. (b) 78,100 2,51,51 9,751,707 Semiconductors & Semiconductor Equipment 14,5% 6,694,285 6,694,285 Acacia Communications, Inc. (a)(b) 74,100 7,294,304 7,4103 7,294,304 Associator Inductors & Semiconductor Equipment 14,5% 6,694,285,36 6,494,493 7,4100 7,294,304 7,4103 7,294,304 7,300 2,430,255 Broadcour Inductors Inductors Intus			16,665,625
TransUnion (a) 78,100 2,611,664 Real Estate Investment Trusts (RETr.) 6.4% 5,504,419 Crown Caste International Corp. (b) 84,600 8,580,978 Equinits, Iac. (b) 25,151 9,731,797 Cascia Communications, Inc. (a)(b) 74,100 7,294,304 Acacia Communications, Inc. (a)(b) 74,100 7,294,304 Portice Materials, Inc. (b) 64,100 2,312,373 Acacia Communications, Inc. (a)(b) 73,000 2,430,626 MACOM Technology Solution Biologias, Inc. (a)(b) 73,000 2,430,626 Microseni Corp. (b) 50,000 1,433,000 1,431,000 MACOM Technology Solution Biolings, Inc. (a)(b) 73,000 1,434,000 7,317,317 NUDDA Corp. (b) 50,300 1,643,804 1,434,000 7,317,317 NUDA Corp. (b) 50,300 1,643,804 1,997,100 7,343,045 Microseni Corp. (b) 50,300 1,643,804 1,997,200 1,843,000 1,313,316 Morealitic Power Systems, Inc. (b) 1,344,300 7,327,200 1,844,000 3,317,100 <td></td> <td></td> <td></td>			
Section 1 5,504,419 Crown Castle International Corp. (b) 79,000 8,580,978 Digital Really Trust, Inc. (b) 79,000 8,610,210 Equinix, Inc. (b) 79,000 8,610,210 Equinix, Inc. (b) 79,000 8,610,210 Equinix, Inc. (b) 71,731,797 26,942,985 Semiconductors & Semiconductor Equipment 14.5% 26,942,985 Assaic Communications, Inc. (a)(b) 74,100 7,294,300 Assaic Communications, Inc. (a)(b) 74,100 7,294,300 B Semiconductor Industries NV 85,110 2,320,59 Broadcown Ld. (b) 92,300 1,270,448 Micros Technology, Solutions Holdings, Inc. (a)(b) 92,300 1,270,448 Micros Technology, Solutions Holdings, Inc. (a)(b) 92,300 1,270,448 Monolithic Power Systems, Inc. (b) 92,300 1,270,448 NVEJ A Corp. (b) 47,400 37,133.16 Qerox, Inc. (a)(b) 14,54,000 7,327,00 Sillengy Corp. 90,000 2,347,429 Sillengy Corp. 90,000 2,347,429			
Rel Estate Investment Trusts (RETT) 6.4% State International Corp. (b) State International Corp. (c) State International Corp. (c)	TransUnion (a)	/8,100	2,611,664
Rel Estate Investment Trusts (RETT) 6.4% State International Corp. (b) State International Corp. (c) State International Corp. (c)			5,504,419
Digital Realty Trust, Inc. (b) 90,000 8.610.210 Equin, Inc. (b) 25,151 9,751,797 Semiconductors & Semiconductor Equipment 14.5% 26,942,985 Acacia Communications, Inc. (a)(b) 54,177 2,163,829 Applied Materials, Inc. (b) 74,100 7,294,304 Applied Materials, Inc. (b) 74,100 7,294,304 BE Semiconductor Industries NV 85,100 2,302,559 Broadcorn Ld, (b) 64,196 9,976,058 Lan Research Corp. (a)(b) 73,700 2,430,026 Macro Technology Solutions Holdings, Inc. (a)(b) 73,700 2,430,026 Microsterni Corp. (a)(b) 92,300 1,643,804 Monolitic Power Systems, Inc. (b) 87,200 409,927 NY DIA Corp. (b) 87,200 409,927 NY DIA Corp. (b) 47,400 3,713,716 Silicon Moinor Technology Corp. ADR (b) 49,900 2,385,200 Yian Semiconductors Corp. 190,000 2,247,429 Win Semiconductors Corp. 100,000 2,247,429 Vian Semiconductors Corp. 100,000			
Equinix, Inc. (b) 25,151 9,751,797 Semiconductors & Semiconductor Equipment 14.5% 26,942,985 Acacia Communications, Inc. (a)(b) 54,177 2,163,829 Applied Materials, Inc. (b) 178,800 4,285,836 ASML Holding, NV 85,100 2,302,559 Be Semiconductor Industries NV 85,100 2,302,559 Broadcom Lid, (b) 66,500 4,749,300 MACOM Technology Stutions Holdings, Inc. (a)(b) 73,700 2,430,626 Micron Technology (Inc. (a)(b) 50,300 1,643,804 Monolithic Power Systems, Inc. (b) 87,200 4,099,272 NVDIA Corp. (b) 87,200 4,099,272 NVDP Semiconductors NV (a)(b) 29,500 1,630,170 VAP Semiconductor Margeturing Co. Lid. 14,454,000 7,337,720 Vary Semiconductor Corp. 849,000 1,737,607 Taiwan Semiconductor Margeturing Co. Lid. 14,454,000 7,337,720 Vary Semiconductor Margeturing Co. Lid. 14,454,000 7,337,720 Vary Semiconductor Margeturing Co. Lid. 12,04,308 13,800	•	<i>,</i>	
Semiconductors & Semiconductor Equipment 14.5% Acacia Communications, Inc. (a)(b) 54,177 2.163,829 Applied Materias, Inc. (b) 74,100 7.294,304 Applied Materias, Inc. (b) 74,100 7.294,304 BE Semiconductor Industries NV 85,100 2.302,559 Broadcorn Lid. (b) 64,196 9.976,058 Lum Research Corp. (b) 56,500 4.749,390 MACOM Technology Solutions Holdings, Inc. (a)(b) 73,700 2.430,626 Microseni (Corp. (a)(b) 92,300 1.270,048 Monolithic Power Systems, Inc. (b) 92,300 1.643,804 Monolithic Power Systems, Inc. (b) 87,200 4.099,272 NXP Semiconductors NV (a)(b) 24,7400 3.713,310 Oervo, Inc. (a)(b) 47,400 3.713,310 Silicon Motion Technology Corp. ADR (b) 14,94,000 2.237,272 NYE Semiconductor Manufacturing Co. Ld. 14,94,000 7.327,720 Win Semiconductor Corp. 89,000 1.737,607 Marking Hitzard, Inc. (b) 19,700 7,121,511 Advision Blizzard, Inc. (b)			
Semiconductors & Semiconductor Equipment 14.5% Secaral Communications, Inc. (a)(b) 54.17 2.163.829 Acasia Communications, Inc. (a)(b) 178,800 4.285.836 ASML Holding NV 74.100 7.234.304 ASML Holding NV 85.100 2.302.559 Broadcorn Ld. (b) 64.196 9.976.058 Lam Research Corp. (b) 73.700 2.430.626 Micro Technology, Inc. (a)(b) 73.700 2.430.626 Micro Stern Loop, (b) 87.200 1.947.120 NUIDIA Corp. (b) 87.200 1.947.120 NUIDIA Corp. (b) 87.200 4.099.272 NXP Semiconductors NV (a)(b) 37.300 2.247.429 Oravo, Inc. (a)(b) 29.500 1.630.170 Silicon Motion Technology Corp. ADR (b) 49.900 2.352.20 Taiwan Semiconductor Manufacturing Co. Ld. 1.454.000 7.37.607 Vition Technology Corp. ADR (b) 30.300 1.845.000 7.37.607 Activision Bilizzard, Inc. (b) 70.00 1.245.100 1.37.1607 Activision Bilizzard, Inc. (b) 30.300 1.829.322	Equinix, Inc. (b)	25,151	9,751,797
Acacia Communications, Inc. (a)(b) 17 2.163,829 Applied Materials, Inc. (b) 178,800 4.285,836 ASML Holding NV 85,100 2.302,559 Broadcom Lid. (b) 64,196 9.976,055 Lam Research Corp. (b) 56,500 4.749,390 MACOM Technology Solutions Holdings, Inc. (a)(b) 73,700 2.430,626 Microsemi Corp. (a)(b) 50,300 1.643,804 Monolithic Power Systems, Inc. (b) 28,500 1.947,120 NVIDIA Corp. (a)(b) 47,400 3.713,316 Qervo, Inc. (a)(b) 47,400 3.713,316 Qirey, Corp. 190,000 2.247,429 Silter Orp. 190,000 2.247,429 Silter Mather Manufacturing Co. Ltd. 49,900 2.385,220 Taiwan Semiconductors Manufacturing Co. Ltd. 190,000 2.247,429 Software 17.2% 849,000 1.737,607 7.121,511 Activision Bitzard, Inc. (b) 66,100 66,331,719 7.121,511 Activision Bitzard, Inc. (b) 33,800 1.839,932 1.899,932 Blachbaaul, Inc	Somiconductors & Somiconductor Equipment 14.5%		26,942,985
Applied Materials, Inc. (b) 178,800 4,285,836 ASML: Holding NV 74,100 7,294,304 BE Semiconductor Industries NV 85,100 2,302,559 Broadcom Ld. (b) 64,196 9,976,058 Lam Research Corp. (b) 73,700 2,430,256 MACOM Technology, Inc. (a)(b) 92,300 1,270,048 Micros Technology, Inc. (a)(b) 92,300 1,270,048 Monolitic Power Systems, Inc. (b) 85,000 1,947,120 NVD JA Corp. (b) 87,200 4,099,272 NXP Semiconductors NV (a)(b) 29,500 1,630,170 Overvo, Inc. (a)(b) 29,500 1,630,170 Silicon Motion Technology Corp. ADR (b) 19,000 2,247,429 Silicon Motion Technology Corp. ADR (b) 49,090 2,352,20 Taiwan Semiconductors Corp. 449,000 1,737,007 Vin Semiconductor Manufacturing Co. Ld. 1,454,000 7,377,20 Advision Blizzard, Inc. (b) 66,100 63,317,195 Advision Blizzard, Inc. (b) 320,500 1,557,495 Altassian Corp. PLC, Class A (a)(b) 72,00		54 177	2,163,829
ASML Holding NV 74,100 7,243,04 BE Semiconductor Industries NV 85,100 2,302,579 Braadcom Ld. (b) 64,196 9,976,058 Lam Research Corp. (b) 73,700 2,430,625 MaCOM Technology Solutions Holdings, Inc. (a)(b) 73,700 2,430,625 Microsemi Corp. (a)(b) 50,300 1,643,804 Monolithic Power Systems, Inc. (b) 28,500 1,947,120 NVIDIA Corp. (b) 87,200 4,099,272 NAPS emiconductors NV (a)(b) 47,400 3,713,316 Qervo, Inc. (a)(b) 49,000 2,247,429 Siltergy Corp. 190,000 2,247,429 Siltergy Corp. 190,000 2,247,429 Vin Semiconductors NU (a)(b) 44,400 7,327,200 Vin Semiconductors Corp. 14,54,000 7,327,200 Vin Semiconductors Corp. 849,000 1,737,607 Software 17.2% 179,700 7,121,511 Activision Blizzard, Inc. (b) 66,100 6,331,719 Atlassian Corp. PLC, Class A (a)(b) 73,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,899,392 <td< td=""><td></td><td></td><td></td></td<>			
Broadcom Ld. (b) 64.196 9.976.058 Lam Research Corp. (b) 56.500 4.749.390 MACOM Technology Solutions Holdings, Inc. (a)(b) 92,300 1.270.048 Microsemi Corp. (a)(b) 50.300 1.643.804 Monolithic Power Systems, Inc. (b) 28,500 1.947,120 NVIDIA Corp. (b) 87,200 4.099.272 NVIDIA Corp. (b) 87,200 4.099.272 NVIDIA Corp. (b) 99,000 2.247.429 Silicon Motion Technology Corp. ADR (b) 19,0000 2.247.429 Silicon Motion Technology Corp. 49,000 2.385.220 Taiwan Semiconductors Corp. 49,000 2.385.200 Taiwan Semiconductors Corp. 49,000 2.377.00 Vin Semiconductors Corp. 49,000 1.737.607 Activision Bitzzard, Inc. (b) 179,700 7.121.511 Adobe Systems, Inc. (a)(b) 320,500 1.557.495 Attaisian Corp. PLC, Class A (a)(b) 320,500 1.557.495 Attaisian Corp. PLC, Class A (a)(b) 33,800 1.824.900 Eateronic Arts, Inc. (a)(b) 33,800			
Lam Research Corp. (b) 56,500 4,749,300 MACOM Technology Solutions Holdings, Inc. (a)(b) 73,700 2,430,626 Micron Technology, Inc. (a)(b) 50,300 1,643,804 Monolithic Power Systems, Inc. (b) 82,500 1,947,120 NVDIA Corp. (b) 87,200 4,099,272 NXP Semiconductors NV (a)(b) 47,400 3,713,316 Qurvo, Inc. (a)(b) 190,000 2,247,429 Silicon Motion Technology Corp. ADR (b) 14,9400 7,327,200 Taiwan Semiconductor Manufacturing Co. Ltd. 1,454,000 7,327,720 Win Semiconductors Corp. 61,204,308 61,204,308 Activision Blizzard, Inc. (b) 179,700 7,121,511 Adobe Systems, Inc. (a)(b) 33,800 1,829,323 Altassian Corp. PLC, Class A (a)(b) 33,800 1,829,332 Altassian Corp. Inc. (a)(b) 104,000 2,077,920 Calidius Software, Inc. (a)(b) 104,000 2,077,920 Calidius Software, Inc. (a)(b) 104,000 2,077,920 Calidius Software, Inc. (a)(b) 104,000 2,077,920 Cali	BE Semiconductor Industries NV	85,100	2,302,559
MACOM Technology Solutions Holdings, Inc. (a)(b) 73,700 2,430,625 Micron Technology Inc. (a)(b) 92,300 1,270,048 Microsemi Corp. (a)(b) 28,500 1,947,120 Monolithic Power Systems, Inc. (b) 28,500 1,947,120 NVIDIA Corp. (b) 47,400 3,713,316 Qorvo, Inc. (a)(b) 47,400 3,713,316 Qorvo, Inc. (a)(b) 49,900 2,235,220 Silergy Corp. 190,000 2,247,429 Silicon Motion Technology Corp. ADR (b) 49,900 2,335,220 Taiwan Semiconductors Corp. 49,900 2,335,220 Vin Semiconductors Corp. 49,000 1,374,000 Activision Blizzard, Inc. (b) 1,454,000 7,377,00 Activision Blizzard, Inc. (b) 10,07,00 7,121,511 Altium Ld. 120,500 1,557,495 Attaissin Corp. PLC, Class A (a)(b) 33,800 1,829,932 Blackband, Inc. 23,300 1,889,470 Callidus Software, Inc. (a)(b) 33,800 3,249,972 Blackband, Inc. 104,000 2,077,920	Broadcom Ltd. (b)	64,196	
Micron Technology, Inc. (a)(b) 92,300 1,270,48 Microsemi Corp. (a)(b) 50,300 1,643,804 Monolithir Power Systems, Inc. (b) 28,500 1,947,120 NVD DA Corp. (b) 87,200 4,099,272 NXP Semiconductors NV (a)(b) 29,500 1,630,170 Qorvo, Inc. (a)(b) 29,500 1,630,170 Silicon Motion Technology Corp. 190,000 2,247,429 Silicon Motion Technology Corp. 14,9900 2,385,220 Taiwan Semiconductor Manufacturing Co. Ltd. 1,454,000 7,327,720 Win Semiconductors Corp. 61,204,308 61,204,308 Software 17.2% 66,100 6,331,719 Activision Bitzard, Inc. (b) 179,700 7,121,511 Adobe Systems, Inc. (a)(b) 72,000 1,864,800 Autosian Corp. PLC, Class A (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,877,495 Autosian Corp. (b) 104,400 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,568,300 Microsoft Corp. (b) 104,400 2,040,922 Blackbaud, Inc. 30,800 3,204,972 Software, Inc. (a)(b) 37,200 2,470,080 Microsoft Corp. (b) 114,400 5,949,147 <tr< td=""><td>1</td><td></td><td></td></tr<>	1		
Microsemi Corp. (a) (b) 50.300 1.643.804 Monolithic Power Systems, Inc. (b) 28.500 1.947,120 NVIDIA Corp. (b) 47.400 3.713.316 Qorvo, Inc. (a) (b) 29.500 1.630.170 Silergy Corp. 190.000 2.247,429 Silicon Motion Technology Corp. ADR (b) 190.000 2.247,429 Taiwan Semiconductor Manfacturing Co. Ltd. 49.900 2.385.220 Taiwan Semiconductor Manfacturing Co. Ltd. 1.737,607 61.204.308 Software 17.2% Activision Bitzard, Inc. (b) 179,700 7,121,511 Adobe Systems, Inc. (a)(b) 320,500 1.557,495 Atlassian Corp. PLC, Class A (a)(b) 72,000 1.864,800 Autodesk, Inc. 29,300 1,589,470 Callidus Software, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 104,000 2,047,221 Electronic Arts, Inc. (a)(b) 50,800 3,204,972 Salesforce.com, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,400 5,949,147 Profopoint, Inc. (a)(b) 37,200			
Monolithic Power Systems, Inc. (b) 28,500 1,947,120 NVIDIA Corp. (b) 87,200 4,099,272 NNP Semiconductors NV (a)(b) 29,500 1,630,170 Soliteny Corp. 190,000 2,247,429 Silicon Motion Technology Corp. ADR (b) 49,900 2,385,220 Taiwan Semiconductors Manufacturing Co. Ltd. 1,454,000 7,327,720 Win Semiconductors Corp. 61,204,308 66,100 6,331,719 Activision Blizzard, Inc. (b) 320,500 1,557,495 1,57,495 Atlassin Corp. PLC, Class A (a)(b) 72,000 1,864,800 1,357,495 Autodesk, Inc. (a)(b) 72,000 1,864,800 1,99,700 2,989,403 Callidus Software, Inc. (a)(b) 72,000 1,864,800 1,99,700 1,21,511 Adobes Systems, Inc. (a)(b) 72,000 1,864,800 1,829,932 1,829,932 Callidus Software, Inc. (a)(b) 72,000 1,864,800 1,41,300 21,046,221 Nintendo Corp. (b) 11,300 21,046,221 1,1300 21,046,221 Nintendo Co. Ltd. 41,400			
NVIDIA Corp. (b) 87,200 4,099,272 NXP Semiconductors NV (a)(b) 47,400 3,713,316 Qorvo, Inc. (a)(b) 29,500 16,30,170 Silergy Corp. 190,000 2,247,429 Silicon Motion Technology Corp. ADR (b) 49,900 2,385,220 Taiwan Semiconductor Manufacturing Co. Ltd. 41,454,000 7,327,720 Win Semiconductors Corp. 849,000 1,737,607 61,204,308 Software 17.2% 61,204,308 Advision Blizzard, Inc. (b) 71,97,00 7,215,511 Adobe Systems, Inc. (a)(b) 66,100 6,331,719 Altium Ltd. 320,500 1,557,495 Altassian Corp. PLC, Class A (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,889,470 Calidus Software, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,6221 Niterosoft Corp. (b) 411,300 21,046,221 Niterosoft Corp. (b) 41,400 5,949,417 Salesforec.com, Inc. (a)(
NXP Semiconductors NV (a)(b) 47,400 3,713,316 Qorvo, Inc. (a)(b) 29,500 1,630,170 Sillergy Corp. 190,000 2,247,429 Sillcon Motion Technology Corp. ADR (b) 49,900 2,385,220 Taiwan Semiconductors Corp. 1,454,000 7,327,720 Win Semiconductors Corp. 61,204,308 Software 17.2% 179,700 7,121,511 Adobe Systems, Inc. (a)(b) 66,100 6,331,719 Atlussian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 320,500 1,857,495 Atlassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 104,000 2,077,920 Elackbaud, Inc. 29,300 1,882,932 Microsoft Corp. (b) 111,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proopoint, Inc. (a)(b) 37,200 2,470,080 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Stefware Inc. (a)(b) 33,300 3,158,736 Karow Linc. (a)(b) <td< td=""><td></td><td></td><td></td></td<>			
Qorvo, Inc. (a)(b) 29,500 1,630,170 Silicon Motion Technology Corp. ADR (b) 190,000 2,247,429 Silicon Motion Technology Corp. ADR (b) 14,99,000 2,385,220 Taiwan Semiconductor Manufacturing Co. Ltd. 1,454,000 7,327,720 Win Semiconductors Corp. 61,204,308 61,204,308 Software 17.2% 61,204,308 66,100 6,31,719 Activision Blizzard, Inc. (b) 66,100 6,31,719 7,121,511 Adobe Systems, Inc. (a)(b) 66,100 6,31,719 7,4100 1,864,800 Autoidesk, Inc. (a)(b) 320,500 1,557,495 7,200 1,864,800 1,864,800 1,864,800 1,864,800 1,989,470 2,300 1,989,470 2,31,00 2,864,800 2,9320 1,989,470 2,31,00 2,864,800 2,040,00 2,077,920 2,466,221 Niterosoft Corp. (b) 11,300 21,046,221 11,300 21,046,221 11,140 5,949,147 Proofpoint, Inc. (a)(b) 33,000 3,200,92 33,300 3,158,736 33,300 3,158,736			
Silergy Corp. 190,000 2.247,429 Silicon Motion Technology Corp. ADR (b) 49,900 2.385,220 Taiwan Semiconductor Manufacturing Co. Ltd. 1,454,000 7,327,720 Win Semiconductors Corp. 61,204,308 Software 17.2%			
Taiwan Semiconductor Manufacturing Co. Ltd. 1,454,000 7,327,720 Win Semiconductors Corp. 849,000 1,737,607 61,204,308 Software 17.2% Activision Blizzard, Inc. (b) 16,100 6,31,719 Aldobe Systems, Inc. (a)(b) 66,100 6,331,719 Altium Ltd. 320,500 1,557,495 Atlassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 104,000 2,077,920 Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 411,300 21,046,221 Nintendo Co. Itd. 411,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforee.com, Inc. (a)(b) 33,300 3,158,736 ServiceNow, Inc. (a)(b) 33,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 33,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305			
Win Semiconductors Corp. 849,000 1,737,607 Software 17.2% 61,204,308 Activision Blizzard, Inc. (b) 79,700 7,121,511 Adobe Systems, Inc. (a)(b) 66,100 6,331,719 Attimu Ltd. 320,500 1,557,495 Attassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofopint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 57,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Zendesk, Inc. (a)(b) 93,000 2,453,340 Take-Two Interactive Software, Inc. (a)(b) 2,453,340 3,453,345 Zendesk, Inc. (a)(b) 33,000 2,453,340	Silicon Motion Technology Corp. ADR (b)	49,900	2,385,220
Software 17.2% 61,204,308 Activision Blizzard, Inc. (b) 179,700 7,121,511 Adobe Systems, Inc. (a)(b) 66,100 6,331,719 Altium Ltd. 320,500 1,557,495 Atlassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,688,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofopint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 33,300 3,158,736 ServiceNow, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340	Taiwan Semiconductor Manufacturing Co. Ltd.		
Software 17.2% Activision Blizzard, Inc. (b) 179,700 7,121,511 Adobe Systems, Inc. (a)(b) 66,100 6,331,719 Altium Ltd. 320,500 1,557,495 Atlassian Corp, PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 9,989,470 Callidus Software, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 Salesforce.com, Inc. (a)(b) 50,800 3,204,972 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 33,300 3,158,736 Zendesk, Inc. (a)(b) 93,000 2,453,340	Win Semiconductors Corp.	849,000	1,737,607
Activision Blizzard, Inc. (b) 179,700 7,121,511 Adobe Systems, Inc. (a)(b) 66,100 6,331,719 Altium Ltd. 320,500 1,557,495 Atassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 37,200 2,470,080 Yero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2453,340	Software 17.20		61,204,308
Adobe Systems, Inc. (a)(b) 66,100 6,331,719 Altium Ltd. 320,500 1,557,495 Atlassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 37,200 2,470,080 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340		179 700	7 121 511
Altium Ltd. 320,500 1,557,495 Atlassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 33,300 3,158,736 Zendesk, Inc. (a)(b) 93,000 2,453,340			
Atlassian Corp. PLC, Class A (a)(b) 72,000 1,864,800 Autodesk, Inc. (a)(b) 33,800 1,829,932 Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 50,800 3,204,972 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340	• • • • • • • • • • • • • • • • • • • •		
Blackbaud, Inc. 29,300 1,989,470 Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 60,100 4,772,541 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340	Atlassian Corp. PLC, Class A (a)(b)		
Callidus Software, Inc. (a)(b) 104,000 2,077,920 Electronic Arts, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 60,100 4,772,541 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340	Autodesk, Inc. (a)(b)		1,829,932
Electronic Arts, Inc. (a)(b) 73,500 5,568,360 Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 60,100 4,772,541 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340			
Microsoft Corp. (b) 411,300 21,046,221 Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 60,100 4,772,541 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340			
Nintendo Co. Ltd. 41,400 5,949,147 Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 60,100 4,772,541 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340			
Proofpoint, Inc. (a)(b) 50,800 3,204,972 salesforce.com, Inc. (a)(b) 60,100 4,772,541 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340			
salesforce.com, Inc. (a)(b) 60,100 4,772,541 ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340			
ServiceNow, Inc. (a)(b) 37,200 2,470,080 Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340			
Take-Two Interactive Software, Inc. (a)(b) 83,300 3,158,736 Xero Ltd. (a) 111,500 1,455,305 Zendesk, Inc. (a)(b) 93,000 2,453,340			
Zendesk, Inc. (a)(b) 93,000 2,453,340 Technology Hardware, Storage & Peripherals 5.4%	Take-Two Interactive Software, Inc. (a)(b)	83,300	
Technology Hardware, Storage & Peripherals 5.4%			
Technology Hardware, Storage & Peripherals 5.4%	Zendesk, Inc. (a)(b)	93,000	2,453,340
Technology Hardware, Storage & Peripherals 5.4%			72,851.549
Apple, Inc. (b) 195,500 18,689,801	Technology Hardware, Storage & Peripherals 5.4%		,
	Apple, Inc. (b)	195,500	18,689,801

SEMI-ANNUAL REPORT

BlackRock Science and Technology Trust (BST)

Common Stocks Technology Hardware, Storage & Peripherals (continued)	Shares	Value	
Samsung Electronics Co. Ltd.	3,400	\$ 4,234,194	
Total Common Stocks 96.4%		22,923,995 407,776,559	
Preferred Stocks Internet & Catalog Retail 0.6%	1.054	2 577 030	
Jasper Infotech Private Ltd., Series I (Acquired 8/18/15, Cost 1,998,435) (a)(f) Internet Software & Services 2.8%	1,054	2,577,030	
Uber Technologies, Inc., Series E (Acquired 12/4/14, Cost \$3,000,048), 0.00% (a)(f)	90,044	4,391,644	
Xiaoju Kuaizhi, Inc., Series A-17 (Acquired 7/28/15, Cost \$3,016,964) (a)(f)	110,003	4,205,414	
Zuora, Inc. (Acquired 1/16/15, Cost \$3,894,522), 0.00% (a)(f)	1,025,063	3,148,994	
Software 0.3%		11,746,052	
Illumio, Inc., Series C (Acquired 3/11/15, Cost \$1,500,001), 0.00% (a)(f)	466,730	1,201,830	
Total Preferred Stocks 3.7%		15,524,912	
Total Long-Term Investments			
(Cost \$355,837,192) 100.1%		423,301,471	
Short-Term Securities BlackRock Liquidity Funds, TempFund, Institutional Class, 0.40% (g)(h)	Shares 1,959,043 Beneficial Interest	Value \$ 1,959,043	
BlackRock Liquidity Series, LLC Money Market Series, 0.59% (g)(h)(i) Total Short-Term Securities	(000) \$ 1,764	1,763,760	
(Cost \$3,722,803) 0.9% Total Investments Before Options Written		3,722,803	
(Cost \$359,559,995) 101.0%		427,024,274	
Options Written (Premiums Received \$4,290,822) (1.0)% Total Investments Net of Options Written 100.0% Other Assets Less Liabilities 0.0%		(4,379,867) 422,644,407 97,582	
Net Assets 100.0%		\$ 422,741,989	

Notes to Schedule of Investments

(a) Non-income producing security.

(b) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(d) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

- (e) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933. This security may be resold in transactions exempt from registration to qualified institutional investors.
- (f) Restricted security as to resale, excluding 144A securities. As of report date, the Trust held restricted securities with a current value of \$15,524,912 and an original cost of \$13,409,970 which was 3.7% of its net assets.

(g) Current yield as of period end.

(h) During the six months ended June 30, 2016, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

			Shares/ Beneficial Interest Held at		
	Shares/ Beneficial Interest Held at December 31,	Net	June 30,	Value at June 30,	
Affiliates	2015	Activity	2016	2016	Income
BlackRock Liquidity Funds, TempFund, Institutional Class	604,146	1,354,897	1,959,043	\$1,959,043	\$ 4,807
BlackRock Liquidity Series, LLC, Money Market Series	\$119,000	\$1,644,760	\$1,763,760	\$1,763,760	\$18,2141
Total				\$3,722,803	\$23,021

- Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
- (i) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series LLC, Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Science and Technology Trust (BST)

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

			Sti	ike		
	Put/	Expiration				
Description	Call	Date	Pr	ice	Contracts	Value
Activision Blizzard, Inc.	Call	7/01/16	USD	37.50	366	\$ (79,422)
Alibaba Group Holding Ltd. ADR	Call	7/01/16	USD	82.00	195	(390)
Alphabet, Inc., Class A	Call	7/01/16	USD	750.00	20	(100)
Electronic Arts, Inc.	Call	7/01/16	USD	77.00	107	(2,889)
Expedia, Inc.	Call	7/01/16	USD	111.00	21	(105)
Facebook, Inc., Class A	Call	7/01/16	USD	119.00	127	(190)
Netflix, Inc.	Call	7/01/16	USD	103.00	11	(33)
TripAdvisor, Inc.	Call	7/01/16	USD	67.00	70	(2,800)
Visa, Inc., A Shares	Call	7/01/16	USD	79.50	86	(344)
Yahoo!, Inc.	Call	7/01/16	USD	39.00	51	(51)
Alibaba Group Holding Ltd. ADR	Call	7/08/16	USD	79.50	39	(4,310)
Alibaba Group Holding Ltd. ADR	Call	7/08/16	USD	80.50	132	(8,514)
Alphabet, Inc., Class A	Call	7/08/16	USD	750.00	10	(250)
Applied Materials, Inc.	Call	7/08/16	USD	25.00	362	(3,077)
Ctrip.com International Ltd. ADR	Call	7/08/16	USD	48.00	55	(550)
Expedia, Inc.	Call	7/08/16	USD	116.00	31	(310)
Facebook, Inc., Class A	Call	7/08/16	USD	121.00	194	(679)
MasterCard, Inc., Class A	Call	7/08/16	USD	97.50	13	(156)
Microsoft Corp.	Call	7/08/16	USD	53.50	381	(952)
Netflix, Inc.	Call	7/08/16	USD	99.00	126	(1,260)
NXP Semiconductors NV	Call	7/08/16	USD	95.00	17	(170)
PayPal Holdings, Inc.	Call	7/08/16	USD	38.50	31	(1,550)
salesforce.com, Inc.	Call	7/08/16	USD	85.00	60	(390)
Visa, Inc., A Shares	Call	7/08/16	USD	81.00	248	(1,364)
Global Payments, Inc.	Call	7/12/16	USD	75.01	87	(2,492)
58.com, Inc. ADR	Call	7/15/16	USD	55.00	65	(975)
Acacia Communications, Inc.	Call	7/15/16	USD	40.00	95	(17,812)
Adobe Systems, Inc.	Call	7/15/16	USD	100.00	43	(989)
Alibaba Group Holding Ltd. ADR	Call	7/15/16	USD	82.50	195	(8,288)
Amazon.com, Inc.	Call	7/15/16	USD	727.50	8	(5,920)
Apple, Inc.	Call	7/15/16	USD	100.00	134	(1,474)
Applied Materials, Inc.	Call	7/15/16	USD	23.00	213	(23,856)
Atlassian Corp. PLC, Class A	Call	7/15/16	USD	25.00	108	(13,500)
Autodesk, Inc.	Call	7/15/16	USD	60.00	120	(720)
Broadcom Ltd.	Call	7/15/16	USD	150.00	100	(69,000)
Callidus Software, Inc.	Call	7/15/16	USD	20.00	183	(10,980)
Cogent Communications Holdings, Inc.	Call	7/15/16	USD	40.00	216	(17,820)
comScore, Inc.	Call	7/15/16	USD	35.00	220	(1,650)
Crown Castle International Corp.	Call	7/15/16	USD	90.00	114	(129,390)
Digital Realty Trust, Inc.	Call	7/15/16	USD	105.00	114	(48,450)
Equinix, Inc.	Call	7/15/16	USD	380.00	90	(100,350)
Eros International PLC	Call	7/15/16	USD	15.00	845	(139,425)
Fidelity National Information Services, Inc.	Call	7/15/16	USD	75.00	86	(3,354)
Flextronics International Ltd.	Call	7/15/16	USD	13.00	230	(575)
Intercontinental Exchange, Inc.	Call	7/15/16	USD	270.00	17	(510)
InterXion Holding NV	Call	7/15/16	USD	35.00	215	(36,550)
Lam Research Corp.	Call	7/15/16	USD	85.00	84	(8,610)
MACOM Technology Solutions Holdings, Inc.	Call	7/15/16	USD	35.00	70	(2,975)
MasterCard, Inc., Class A	Call	7/15/16	USD	97.50	13	(39)
MercadoLibre, Inc.	Call	7/15/16	USD	140.00	20	(7,800)
Monolithic Power Systems, Inc.	Call	7/15/16	USD	70.00	90	(5,625)
•						

NVIDIA Corp.	Call	7/15/16	USD	45.00	159	(39,591)
NXP Semiconductors NV	Call	7/15/16	USD	95.00	64	(640)
Qorvo, Inc.	Call	7/15/16	USD	55.00	52	(8,580)
salesforce.com, Inc.	Call	7/15/16	USD	82.50	90	(4,950)
Take-Two Interactive Software, Inc.	Call	7/15/16	USD	40.00	250	(6,250)
Tesla Motors, Inc.	Call	7/15/16	USD	230.00	32	(3,728)
Visa, Inc., A Shares	Call	7/15/16	USD	80.00	107	(696)
Zendesk, Inc.	Call	7/15/16	USD	25.00	170	(28,900)
Proofpoint, Inc.	Call	7/19/16	USD	63.50	120	(24,250)

See Notes to Financial Statements.

92

SEMI-ANNUAL REPORT

BlackRock Science and Technology Trust (BST)

			St	trike		
	Put/	Expiration				
Description	Call	Date		rice	Contracts	Value
Alibaba Group Holding Ltd. ADR	Call	7/22/16	USD	80.00	39	\$ (6,396)
Alphabet, Inc., Class A	Call	7/22/16	USD	730.00	21	(5,932)
Amazon.com, Inc.	Call Call	7/22/16	USD USD	720.00 77.00	85 40	(143,650)
Electronic Arts, Inc. Facebook, Inc., Class A	Call	7/22/16 7/22/16	USD	122.00	40 37	(4,700) (722)
MasterCard, Inc., Class A	Call	7/22/16	USD	98.00	71	(722)
MaserCard, Inc., Class A Microsoft Corp.	Call	7/22/16	USD	53.00	450	(30,375)
PayPal Holdings, Inc.	Call	7/22/16	USD	40.00	85	(4,250)
New Relic, Inc.	Call	7/25/16	USD	26.40	155	(50,012)
MercadoLibre, Inc.	Call	7/27/16	USD	135.00	72	(59,716)
Activision Blizzard, Inc.	Call	7/29/16	USD	38.50	10	(1,955)
Alphabet, Inc., Class A	Call	7/29/16	USD	745.00	48	(30,480)
Amazon.com, Inc.	Call	7/29/16	USD	745.00	8	(16,260)
Apple, Inc.	Call	7/29/16	USD	99.00	43	(4,966)
Applied Materials, Inc.	Call	7/29/16	USD	24.50	195	(7,995)
Broadcom Ltd.	Call	7/29/16	USD	160.00	125	(34,062)
Facebook, Inc., Class A	Call	7/29/16	USD	118.00	119	(24,038)
MasterCard, Inc., Class A	Call Call	7/29/16	USD USD	98.00 52.50	72 401	(1,152)
Microsoft Corp. NVIDIA Corp.	Call	7/29/16 7/29/16	USD	52.50 47.50	401	(38,696) (21,010)
PayPal Holdings, Inc.	Call	7/29/16	USD	38.50	70	(3,850)
Priceline Group, Inc.	Call	7/29/16	USD	1,340.00	7	(5,775)
salesforce.com, Inc.	Call	7/29/16	USD	82.50	60	(6,060)
Visa, Inc., A Shares	Call	7/29/16	USD	79.50	107	(4,976)
Apple, Inc.	Call	8/05/16	USD	100.00	43	(4,257)
Apple, Inc.	Call	8/05/16	USD	97.50	88	(15,928)
Applied Materials, Inc.	Call	8/05/16	USD	24.00	213	(15,975)
Comcast Corp., Class A	Call	8/05/16	USD	63.00	7	(2,030)
Comcast Corp., Class A	Call	8/05/16	USD	65.50	133	(16,426)
Ctrip.com International Ltd. ADR	Call	8/05/16	USD	41.00	44	(8,910)
Electronic Arts, Inc. MasterCard, Inc., Class A	Call Call	8/05/16 8/05/16	USD USD	74.00 93.50	110 153	(46,750) (11,169)
PayPal Holdings, Inc.	Call	8/05/16	USD	37.00	62	(11,109) (7,750)
TripAdvisor, Inc.	Call	8/05/16	USD	66.00	68	(22,610)
58.com, Inc. ADR	Call	8/09/16	USD	47.00	65	(14,361)
Activision Blizzard, Inc.	Call	8/12/16	USD	40.00	250	(42,125)
Apple, Inc.	Call	8/12/16	USD	97.50	2	(390)
Comcast Corp., Class A	Call	8/12/16	USD	65.50	103	(13,802)
Universal Display Corp.	Call	8/16/16	USD	68.80	190	(65,734)
Acacia Communications, Inc.	Call	8/19/16	USD	45.00	95	(19,000)
Apple, Inc. Callidus Software, Inc.	Call Call	8/19/16 8/19/16	USD USD	105.00 22.50	81 182	(2,997) (10,010)
Coherent, Inc.	Call	8/19/16	USD	95.00	83	(26,352)
comScore, Inc.	Call	8/19/16	USD	30.00	230	(20,125)
Euronet Worldwide, Inc.	Call	8/19/16	USD	70.00	69	(20,528)
Euronet Worldwide, Inc.	Call	8/19/16	USD	75.00	69	(8,452)
Facebook, Inc., Class A	Call	8/19/16	USD	120.00	117	(28,958)
Flextronics International Ltd.	Call	8/19/16	USD	13.00	130	(1,625)
Global Payments, Inc.	Call	8/19/16	USD	70.00	123	(50,430)
MACOM Technology Solutions Holdings, Inc.	Call	8/19/16	USD	40.00	123	(6,150)
MasterCard, Inc., Class A	Call	8/19/16	USD	95.00	25	(1,675)
Micron Technology, Inc.	Call	8/19/16	USD	14.15	320	(26,239)
Microsoft Corp. NVIDIA Corp.	Call Call	8/19/16 8/19/16	USD USD	52.50 48.00	91 159	(10,647) (36,172)
NVIDIA Corp. NXP Semiconductors NV	Call	8/19/16 8/19/16	USD	48.00 87.50	84	(30,172) (10,500)
Proofpoint, Inc.	Call	8/19/16	USD	65.00	60	(10,300) (20,400)
Qorvo, Inc.	Call	8/19/16	USD	55.00	51	(19,635)
ServiceNow, Inc.	Call	8/19/16	USD	75.00	120	(17,100)
Silicon Motion Technology Corp. ADR	Call	8/19/16	USD	50.00	84	(14,280)
Yahoo!, Inc.	Call	8/19/16	USD	39.00	51	(6,222)

Microsemi Corp.	Call	9/16/16	USD	35.00	96	(9,840)
Alphabet, Inc., Class A	Put	7/01/16	USD	687.50	11	(248)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Science and Technology Trust (BST)

		Strike							
	Put/	Expiration							
Description	Call	Date	Price		Contracts		Value		
Amazon.com, Inc.	Put	7/15/16	USD	690.00	6	\$	(2,790)		
Apple, Inc.	Put	7/15/16	USD	95.00	84		(8,316)		
Total						\$ (2	2,061,216)		

OTC Options Written

					Strike		
	Put/		Expiration				
Description	Call	Counterparty	Date		Price	Contracts	Value
CDW Corp.	Call	UBS AG	7/05/16	USD	43.44	12,300	\$ (9)
Flextronics International Ltd.	Call	Goldman Sachs International	7/05/16	USD	12.56	12,600	(26)
Sabre Corp.	Call	Morgan Stanley & Co. International PLC	7/06/16	USD	28.51	23,000	(50)
Sony Corp.	Call	Morgan Stanley & Co. International PLC	7/06/16	JPY	2,961.08	24,400	(28,295)
Stroeer SE & Co. KGaA	Call	Deutsche Bank AG	7/06/16	EUR	49.72	9,400	(20,290)
TechnoPro Holdings, Inc.	Call	JPMorgan Chase Bank N.A.	7/06/16	JPY	3.422.10	30,000	(2.122)
TechnoPro Holdings, Inc.	Call	UBS AG	7/06/16	JPY	3,362.00	8,200	(1,122)
Cogent Communications Holdings, Inc.	Call	Citibank N.A.	7/07/16	USD	41.31	1,900	(271)
Nintendo Co. Ltd.	Call	Goldman Sachs International	7/07/16	JPY	15,620.25	9,000	(10,573)
Sabre Corp.	Call	Barclays Bank PLC	7/07/16	USD	29.20	23,000	(10,575)
Six Flags Entertainment Corp.	Call	Morgan Stanley & Co. International PLC	7/07/16	USD	58.50	25,300	(10,544)
Win Semiconductors Corp.	Call	Citibank N.A.	7/07/16	TWD	61.67	150,000	(18,051)
Zayo Group Holdings, Inc.	Call	UBS AG	7/08/16	USD	28.28	24,100	(6,696)
CDW Corp.	Call	Citibank N.A.	7/11/16	USD	41.61	9,000	(1,462)
Digital Realty Trust, Inc.	Call	Morgan Stanley & Co. International PLC	7/11/16	USD	92.20	15,000	(252,054)
Lam Research Corp.	Call	Deutsche Bank AG	7/11/16	USD	75.01	11,300	(102,381)
Lumentum Holdings, Inc.	Call	Barclays Bank PLC	7/11/16	USD	24.98	28,000	(102,381) (9,940)
TransUnion	Call	Citibank N.A.	7/11/16	USD	32.04	9,000	(14,076)
ASML Holding NV	Call	Morgan Stanley & Co. International PLC	7/12/16	EUR	89.38	1.700	(2,821)
Largan Precision Co. Ltd.	Call	JPMorgan Chase Bank N.A.	7/12/16	TWD	2,363.85	4,000	(72,193)
Largan Precision Co. Ltd.	Call	JPMorgan Chase Bank N.A.	7/12/16	TWD	3,036.17	7,000	(12,193) (11,477)
Naspers Ltd., N Shares	Call	UBS AG	7/12/16	ZAR	2,238.08	2,800	(11,477) (11,112)
Win Semiconductors Corp.	Call	UBS AG	7/12/16	TWD	2,238.00 66.01	150.000	(7.022)
REA Group Ltd.	Call	UBS AG	7/13/16	AUD	56.36	6,800	(19,721)
Scout24 AG	Call	Morgan Stanley & Co. International PLC	7/13/16	EUR	35.84	2,800	(19,721) (645)
Taiwan Semiconductor Manufacturing	Call	Worgan Stanley & Co. International I EC	//15/10	LUK	55.64	2,800	(045)
Co. Ltd.	Call	Morgan Stanley & Co. International PLC	7/13/16	TWD	154.75	291.000	(72,325)
Auto Trader Group PLC	Call	Morgan Stanley & Co. International PLC	7/14/16	GBP	4.05	65,000	(72,323)
Flextronics International Ltd.	Call	Morgan Stanley & Co. International PLC	7/14/16	USD	12.43	13,000	(565)
Silicon Motion Technology Corp. ADR	Call	Morgan Stanley & Co. International PLC	7/14/16	USD	41.30	9,000	(58,349)
Crown Castle International Corp.	Call	Citibank N.A.	7/19/16	USD	91.57	18,100	(178,448)
Luxoft Holding, Inc.	Call	Deutsche Bank AG	7/19/16	USD	60.00	16,000	(178,448) (2,146)
TransUnion	Call	UBS AG	7/19/16	USD	33.02	7.800	(8,338)
Scout24 AG	Call	Morgan Stanley & Co. International PLC	7/20/16	EUR	35.84	2,900	(1,841)
TechnoPro Holdings, Inc.	Call	JPMorgan Chase Bank N.A.	7/20/16	JPY	3,533.29	12,800	(2,050)
Win Semiconductors Corp.	Call	Morgan Stanley & Co. International PLC	7/20/16	TWD	67.31	170,000	(8,065)
Xero Ltd.	Call	UBS AG	7/20/16	NZD	19.37	170,000	(2,767)
Intercontinental Exchange, Inc.	Call	Deutsche Bank AG	7/21/16	USD	261.50	300	(620)
Tencent Holdings Ltd.	Call	Citibank N.A.	7/21/16	HKD	172.16	183,000	(175,471)
Silergy Corp.	Call	Morgan Stanley & Co. International PLC	7/22/16	TWD	370.67	30,000	(173,471) (18,493)
Microsemi Corp.	Call	6 .	7/25/16	USD	33.63	,	,
TransUnion	Call	Goldman Sachs International Société Générale	7/25/16	USD	33.38	8,000 10,500	(6,213) (10,392)
ASML Holding NV	Call	Morgan Stanley & Co. International PLC	7/26/16	EUR	90.28	10,300	(10,392) (21,034)
ASML Holding NV	Call	Morgan Stanley & Co. International PLC Morgan Stanley & Co. International PLC	7/26/16	EUR	90.28 92.14	2,300	(21,034) (2,992)
•	Call	UBS AG	7/26/16	AUD	92.14 54.15	2,300	,
REA Group Ltd. Shopify, Inc., Class A	Call		7/26/16	USD	29.98	27,000	(122,798) (42,414)
Shopity, Inc., Class A	Call	Morgan Stanley & Co. International PLC JPMorgan Chase Bank N.A.	7/26/16	TWD	29.98 165.24	122,000	(42,414) (7,980)
	Call	JI WOIgan Chase Dalik IV.A.	//20/10	IWD	105.24	122,000	(7,900)

Taiwan Semiconductor Manufacturing							
Co. Ltd.							
CDW Corp.	Call	Morgan Stanley & Co. International PLC	7/27/16	USD	43.45	12,800	(1,683)
Scout24 AG	Call	Morgan Stanley & Co. International PLC	7/27/16	EUR	35.60	6,500	(6,541)
Adobe Systems, Inc.	Call	UBS AG	7/29/16	USD	98.47	19,000	(19,805)
Atlassian Corp. PLC, Class A	Call	Deutsche Bank AG	7/29/16	USD	26.00	14,400	(13,676)
Cogent Communications Holdings, Inc.	Call	Citibank N.A.	7/29/16	USD	41.79	13,000	(6,365)

See Notes to Financial Statements.

94

SEMI-ANNUAL REPORT

BlackRock Science and Technology Trust (BST)

			Strike					
	Put/		Expiration					
Description	Call	Counterparty	Date]	Price	Contracts		Value
Intercontinental Exchange,		x <i>v</i>						
Inc.	Call	Goldman Sachs International	7/29/16	USD	268.65	2,700	\$	(5,403)
Auto Trader Group PLC	Call	Morgan Stanley & Co. International PLC	8/02/16	GBP	4.15	62,000		(2,418)
BE Semiconductor Industries								
NV	Call	Credit Suisse International	8/02/16	EUR	25.77	30,000		(18,947)
Crown Castle International								
Corp.	Call	Bank of America N.A.	8/02/16	USD	101.37	17,000		(26,445)
Digital Realty Trust, Inc.	Call	Morgan Stanley & Co. International PLC	8/02/16	USD	93.75	17,000		(259,848)
Naspers Ltd., N Shares	Call	UBS AG	8/02/16	ZAR	2,364.97	8,500		(25,306)
Altium Ltd.	Call	Deutsche Bank AG	8/03/16	AUD	6.23	56,000		(16,890)
Altium Ltd.	Call	Deutsche Bank AG	8/03/16	AUD	6.29	56,000		(15,254)
Cogent Communications								
Holdings, Inc.	Call	Citibank N.A.	8/03/16	USD	40.57	3,200		(3,702)
DeNA Co. Ltd.	Call	JPMorgan Chase Bank N.A.	8/03/16	JPY	2,343.90	28,000		(45,384)
Nintendo Co. Ltd.	Call	Goldman Sachs International	8/03/16	JPY	16,704.47	1,700		(2,536)
Xero Ltd.	Call	Morgan Stanley & Co. International PLC	8/03/16	NZD	19.75	4,356		(1,150)
Xero Ltd.	Call	UBS AG	8/03/16	NZD	19.04	7,200		(2,984)
ASML Holding NV	Call	Morgan Stanley & Co. International PLC	8/04/16	EUR	91.11	11,100		(25,463)
Atlassian Corp. PLC, Class A	Call	Bank of America N.A.	8/05/16	USD	26.05	14,400		(17,064)
Stroeer SE & Co. KGaA	Call	Goldman Sachs International	8/05/16	EUR	47.78	10,000		(8,382)
Sabre Corp.	Call	Morgan Stanley & Co. International PLC	8/08/16	USD	27.82	16,000		(10,549)
Blackbaud, Inc.	Call	Morgan Stanley & Co. International PLC	8/09/16	USD	67.88	10,000		(27,493)
Fidelity National Information								
Services, Inc.	Call	Citibank N.A.	8/09/16	USD	75.45	12,000		(16,159)
Scout24 AG	Call	Credit Suisse International	8/09/16	EUR	34.67	5,000		(6,254)
Six Flags Entertainment Corp.	Call	Morgan Stanley & Co. International PLC	8/09/16	USD	57.64	13,000		(28,176)
Sony Corp.	Call	JPMorgan Chase Bank N.A.	8/09/16	JPY	3,043.94	40,500		(67,358)
Tencent Holdings Ltd.	Call	Citibank N.A.	8/09/16	HKD	172.51	55,000		(59,827)
Naspers Ltd., N Shares	Call	UBS AG	8/10/16	ZAR	2,256.73	2,700		(17,184)
Xero Ltd.	Call	Morgan Stanley & Co. International PLC	8/12/16	NZD	18.58	3,600		(2,116)
InterXion Holding NV	Call	Barclays Bank PLC	8/15/16	USD	37.25	4,200		(4,756)
Zendesk, Inc.	Call	Deutsche Bank AG	8/16/16	USD	27.30	15,500		(26,994)
Taiwan Semiconductor	C 11		04746		1(0.02	06.000		(15 520)
Manufacturing Co. Ltd.	Call	UBS AG	8/17/16	TWD	160.93	96,000		(15,739)
Auto Trader Group PLC	Call	Morgan Stanley & Co. International PLC	8/23/16	GBP	4.31	65,000		(3,547)
Silergy Corp.	Call	Morgan Stanley & Co. International PLC	8/23/16	TWD	369.20	32,000		(29,357)
Nintendo Co. Ltd.	Call	Morgan Stanley & Co. International PLC	9/08/16	JPY	14,327.71	3,300		(38,176)
Universal Display Corp.	Call	Citibank N.A.	9/13/16	USD	65.55	8,000		(54,380)
Flextronics International Ltd.	Put	Morgan Stanley & Co. International PLC	7/14/16	USD	11.75 84.99	34,300		(6,670)
ASML Holding NV	Put Put	Morgan Stanley & Co. International PLC Citibank N.A.	7/26/16 7/26/16	EUR GBP	84.99 3.76	6,400 100,000		(8,993) (42,918)
Auto Trader Group PLC	Put	CIUDANK IN.A.	//20/10	UBP	3.70	109,000	¢ /	
Total							\$ (.	2,318,651)

Transactions in Options Written for the Period Ended June 30, 2016

	Calls			its
	Contracts	Premiums Received	Contracts	Premiums Received
Outstanding options at beginning of period	5,291,725	\$ 4,168,452		
Options written	18,196,277	18,641,764	193,681	\$ 347,375
Options exercised	(90)	(6,568)	(7,285)	(95,000)
Options expired	(9,591,202)	(6,603,458)	(36,441)	(140,936)

Options closed	(11,470,727)	(11,958,746)	(154)	(62,061)
Outstanding options at end of period	2,425,983	\$ 4,241,444	149,801	\$ 49,378

As of period end, the value of portfolio securities subject to covered call options written was \$146,543,851.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Science and Technology Trust (BST)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

					Foreign		
					Currency	Interest	
		Commodity	Credit	Equity	Exchange	Rate	
Liabilities Derivative Financial Instru	monts	Contracts	Contracts	Contracts	Contracts	Contracts	Total
Options written	Options written, at value			\$4,379,867			\$ 4,379,867

For the six months ended June 30, 2016, the effect of derivative financial instruments in the Statements of Operations was as follows:

				Foreign		
				Currency	Interest	
	Commodity	Credit	Equity	Exchange	Rate	
Net Realized Gain (Loss) from: Options purchased ¹ Options written Total	Contracts	Contracts	Contracts \$ (5,993) 2,488,920 \$ 2,482,927	Contracts	Contracts	Total \$ (5,993) 2,488,920 \$ 2,482,927
Net Change in Unrealized Appreciation (Depreciation) on: Options written			\$ (1,558,348)			\$ (1,558,348)

¹ Options purchased are included in net realized gain (loss) from investments.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:	
Average value of option contracts purchased ²	\$ 5,993
Average value of option contracts written	\$ 5,018,401

² Actual amounts for the period are shown due to limited outstanding derivative financial instruments as of each quarter.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities
Derivative Financial Instruments: Options		\$ 4,379,867
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(2,061,216)
Total derivative assets and liabilities subject to an MNA		\$ 2,318,651

See Notes to Financial Statements.

96

SEMI-ANNUAL REPORT

BlackRock Science and Technology Trust (BST)

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under an Master Netting Agreement (MNA) and net of the related collateral pledged by the Trust:

Gross Amounts Not Offset in the Consolidated Statements of Assets and Liabilities

	Derivative Liabilities	nd Subject to a Non-cash	n MNA Cash			
	Subject to an MNA D	erivatives Available	Collateral	Collateral	Net A	mount of
Counterparty	Counterparty	for Offset	Pledged ¹	Pledged ¹	Derivativ	e Liabilities ²
Bank of America N.A.	\$ 43,509		0	0	\$	43,509
Barclays Bank PLC	14,701					14,701
Citibank N.A.	571,130					571,130
Credit Suisse International	25,201					25,201
Deutsche Bank AG	178,027			\$ (10,000)		168,027
Goldman Sachs International	33,133		\$ (33,133)			
JPMorgan Chase Bank N.A.	208,564					208,564
Morgan Stanley & Co. International PLC	973,384			(930,000)		43,384
Société Générale	10,392					10,392
UBS AG	260,610			(260,610)		
Total	\$ 2,318,651		\$ (33,133)	\$ (1,200,610)	\$	1,084,908

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

² Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Automobiles	\$ 1,952,976			\$ 1,952,976
Communications Equipment	1,640,760			1,640,760
Diversified Financial Services	2,226,852			2,226,852
Diversified Telecommunication Services	4,823,508			4,823,508
Electronic Equipment, Instruments &				
Components	9,855,844	\$ 3,051,947		12,907,791
Hotels, Restaurants & Leisure	4,044,910			4,044,910
Household Durables		3,930,228		3,930,228
Internet & Catalog Retail	33,397,732	83,947		33,481,679
Internet Software & Services	66,739,125	23,629,341		90,368,466
IT Services	46,306,508			46,306,508

Media Professional Services Real Estate Investment Trusts (REITs) Semiconductors & Semiconductor Equipment Software Technology Hardware, Storage & Peripherals Preferred Stocks Short-Term Securities	5,391,940 2,611,664 26,942,985 40,294,689 63,889,602 18,689,801 1,959,043	11,273,685 2,892,755 20,909,619 8,961,947 4,234,194 1,763,760	\$ 15,524,912	$\begin{array}{c} 16,665,625\\ 5,504,419\\ 26,942,985\\ 61,204,308\\ 72,851,549\\ 22,923,995\\ 15,524,912\\ 3,722,803 \end{array}$
Total	\$ 330,767,939	\$ 80,731,423	\$ 15,524,912	\$ 427,024,274
Derivative Financial Instruments ¹ Liabilities:	Level 1	Level 2	Level 3	Total
Equity contracts	\$ (1,818,412)	\$ (2,561,455)		\$ (4,379,867)

¹ Derivative financial instruments are options written, which are shown at value.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Science and Technology Trust (BST)

The Trust may hold assets and/or liabilities in which the fair value approximates the carrying amount for financial statement purposes. As of period end, such assets and/or liabilities are categorized within the disclosure hierarchy as follows:

	Level 1	Level 2	Level 3		Total
Assets: Foreign currency at value Cash pledged as collateral for exchange-traded options	\$ 54,490			\$	54,490
written Cash pledged as collateral for OTC derivatives	2,066,662 1,550,000				2,066,662 1,550,000
Liabilities: Collateral on securities loaned at value		\$ (1,763,760)			(1,763,760)
Total	\$ 3,671,152	\$ (1,763,760)		\$	1,907,392
	Transfers into	Transfers out of	Transfers into	Tra	unsfers out of
Assets:	Level 1	Level 1 ¹	Level 2 ¹		Level 2
Long-Term Investments: Common Stocks		\$ (24,886,725)	\$ 24,886,725		

¹ External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments and derivative financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the year in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Preferred
	Stocks
Assets:	
Opening Balance, as of December 31, 2015	\$15,696,540
Transfers into Level 3	
Transfers out of Level 3	
Accrued discounts/premiums	
Net realized gain (loss)	
Net change in unrealized appreciation/depreciation ^{1,2}	(171,628)
Purchases	
Sales	
Closing Balance, as of June 30, 2016	\$15,524,912
Net change in unrealized appreciation/depreciation on investments still held at June 30, 2016 ²	\$ (171,628)

¹ Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

² Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2016 is generally due to investments no longer held or categorized as Level 3 at period end.

See Notes to Financial Statements.

98

SEMI-ANNUAL REPORT

BlackRock Science and Technology Trust (BST)

The following table summarizes the valuation techniques used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) to determine the value of certain of the Trust s Level 3 investments as of period end.

				Range of	
			Unobservable	Unobservable Inputs	Weighted Average of
Assets:	Value	Valuation Techniques	Inputs	Utilized	Unobservable Inputs
Assets. Preferred Stocks	\$15,524,912	Market Comparables	Priced to new financing round ¹		
			Revenue Multiple ¹ Revenue Growth Rate ¹	4.33x 99.00%	
		Probability-Weighted Expected Return Model	Discount Rate ²	25.00%	
			IPO Exit Probability ¹ Merger and Acquisition	70.00% - 80.00%	71.73%
			Probability ¹	15.00% - 25.00%	23.27%
			Revenue Growth Rate ¹	28.00% - 80.00%	51.40%
			Revenue Growth Rate1	253.00%	
			Revenue Multiple ¹	5.00x - 20.70x	11.28x
			Revenue Multiple ¹	10.50x - 62.50x	
			Time to Exit ²	1-3 years	

Total

\$15,524,912

¹ Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.

² Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Schedule of Investments June 30, 2016 (Unaudited)

BlackRock Utility and Infrastructure Trust (BUI) (Percentages shown are based on Net Assets)

Common Stocks	Shares	Value
Construction & Engineering 3.2% Ferrovial SA Vinci SA	432,700 41,100	\$ 8,471,423 2,900,311
		11,371,734
Diversified Telecommunication Services 1.9% SBA Communications Corp., Class A (a)(b)	22,500	2,428,650
Verizon Communications, Inc. (c)	79,500	4,439,280
Electric Utilities 24.7%		6,867,930
American Electric Power Co., Inc.	96,800 177,168	6,784,712
Duke Energy Corp. (c) Edison International (c)	109,400	15,199,243 8,497,098
El Paso Electric Co.	36,900	1,744,263
Enel SpA	923,947	4,101,834
Eversource Energy (c)	80,900 306,600	4,845,910
Exelon Corp. (c) Iberdrola SA	198,600	11,147,976 1,354,769
NextEra Energy, Inc. (b)	168,900	22,024,560
Pinnacle West Capital Corp. (c)	47,000	3,809,820
PPL Corp.	115,400	4,356,350
Xcel Energy, Inc.	91,700	4,106,326
Gas Utilities 2.4%		87,972,861
New Jersey Resources Corp.	57,000	2,197,350
Snam SpA	743,800	4,446,775
Spire, Inc. (c)	27,400	1,941,016
Independent Power and Renewable Electricity Producers 4.0%		8,585,141
EDP Renovaveis SA	342,100	2,574,984
NextEra Energy Partners LP	130,100	3,952,438
NRG Yield, Inc., Class A NRG Yield, Inc., Class C	173,400 173,400	2,639,148 2,703,306
Pattern Energy Group, Inc. (c)	103,500	2,377,395
		14,247,271
Multi-Utilities 22.0% CMS Energy Corp. (b)(c)	446,300	20,467,318
Dominion Resources, Inc. (c)	215,100	16,762,741
DTE Energy Co. (c)	44,214	4,382,492
National Grid PLC	184,900	2,719,029
NiSource, Inc. (c) NorthWestern Corp. (c)	133,900 45,792	3,551,028
Public Service Enterprise Group, Inc. (c)	241,056	2,888,101 11,235,620
Sempra Energy (c)	83,800	9,554,876
Veolia Environnement SA	101,800	2,198,342
WEC Energy Group, Inc. (c)	70,600	4,610,180
Oil, Gas & Consumable Fuels 18.9%		78,369,727
Antero Midstream Partners LP	78,200	2,179,434
Columbia Pipeline Group, Inc. (a)	123,900	3,158,211
Columbia Pipeline Partners LP (c) Delek Logistics Partners LP (c)	76,300 29,700	1,144,500 793,287
Dominion Midstream Partners LP	29,700	8,154,887
Enbridge, Inc. (c)	96,200	4,075,032
Energy Transfer Partners LP (c)	42,296	1,610,209

Enterprise Products Partners LP (c)	177,354	5,189,378
EQT Midstream Partners LP (c)	28,600	2,296,580
GasLog Partners LP	5,100	96,798
Genesis Energy LP	114,869	4,407,524
Magellan Midstream Partners LP (c)	59,300	4,506,800
		, ,
MPLX LP (c)	108,119	3,636,042
ONEOK Partners LP (c)	62,545	2,505,553
Common Stocks	Shares	Value
Oil, Gas & Consumable Fuels (continued)		
ONEOK, Inc.	8,300	\$ 393,835
Phillips 66 Partners LP	42,300	2,363,301
Plains All American Pipeline LP (c)	87,570	2,407,299
Rose Rock Midstream LP	20,800	548,912
Shell Midstream Partners LP (c)	270,810	9,150,670
Sunoco Logistics Partners LP (c)	78,800	2,265,500
Targa Resources Corp. (c)	15,800	665,812
Tesoro Logistics LP (c)	33,658	1,667,081
Valero Energy Partners LP (c)	36,300	1,706,463
	18,814	
Western Gas Partners LP (c)		948,226
Williams Partners LP (c)	39,815	1,379,192
		67,250,526
Real Estate Investment Trusts (REITs) 3.1%		
American Tower Corp. (b)(c)	53,300	6,055,413
Crown Castle International Corp. (c)	51,100	5,183,073
crown Cashe international Corp. (c)	51,100	5,165,075
		11,238,486
Road & Rail 0.3%		
East Japan Railway Co.	9,900	917,466
Transportation Infrastructure 15.2%		
Abertis Infraestructuras SA	401,400	5,931,750
Aeroports de Paris	38,400	4,207,529
Atlantia SpA	489,884	12,239,778
China Merchants Holdings International Co. Ltd.	250,000	669,250
•		
Flughafen Zuerich AG	32,500	5,751,557
Fraport AG Frankfurt Airport Services Worldwide	29,100	1,558,047
Groupe Eurotunnel SE	358,200	3,783,575
Japan Airport Terminal Co. Ltd. (d)	63,500	2,303,860
Sydney Airport (e)	1,491,766	7,789,486
Transurban Group (e)	1,119,600	10,083,992
		51 210 021
		54,318,824
Water Utilities 3.8%		
American Water Works Co., Inc. (c)	158,900	13,428,639
Total Long-Term Investments		
(Cost \$271,981,923) 99.5%		354,568,605
Short-Term Securities		
BlackRock Liquidity Funds, TempFund, Institutional Class, 0.40% (f)(g)	5,911,111	5,911,111
BlackKock Elquidity Funds, TempFund, Institutional Class, 0.4076 (1)(g)		5,911,111
	Beneficial	
	Interest	
	(000)	
BlackRock Liquidity Series, LLC Money Market Series, 0.59% (f)(g)(h)	\$ 887	887,226
Total Short-Term Securities		
(Cost \$6,798,337) 1.9%		6,798,337
Total Investments Before Options Written		
(Cost \$278,780,260) 101.4%		361,366,942
Options Written		
•		(5.026.675)
(Premiums Received \$2,623,021) (1.4)% Total Investments Not of Options Written 100.0%		(5,036,675)
Total Investments Net of Options Written 100.0%		356,330,267
Liabilities in Excess of Other Assets 0.0%		(129,143)
Net Assets 100.0%		\$ 356,201,124

See Notes to Financial Statements.

100

SEMI-ANNUAL REPORT

BlackRock Utility and Infrastructure Trust (BUI)

Notes to Schedule of Investments

(a) Non-income producing security.

(b) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(c) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(d) Security, or a portion of security, is on loan.

(e) A security contractually bound to one or more other securities to form a single saleable unit which cannot be sold separately.

(f) During the six months ended June 30, 2016, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

	Shares/							
	Shares		Beneficial Interest					
	Held at		Held at	Value at				
	December 31,	Net	June 30,	June 30,				
Affiliates BlackRock Liquidity Funds, TempFund, Institutional Class BlackRock Liquidity Series, LLC Money Market Series Total	2015 8,391,615	Activity (2,480,504)	2016 5,911,111 \$ 887,226	2016 \$5,911,111 \$ 887,226 \$6,798,337	Income \$17,285 \$ 9,759 ¹ \$27,044			

Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(g) Current yield as of period end.

(h) Security was purchased with the cash collateral from loaned securities. The Trust may withdraw up to 25% of its investment daily, although the manager of the BlackRock Liquidity Series LLC, Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine industry sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

		Expiration	St	rike		
	Put/					
Description	Call	Date	Р	rice	Contracts	Value
American Tower Corp.	Call	7/01/16	USD	107.00	56	\$ (34,720)
Enterprise Products Partners LP	Call	7/01/16	USD	28.50	54	(4,050)
Eversource Energy	Call	7/01/16	USD	57.60	142	(32,672)
Verizon Communications, Inc.	Call	7/01/16	USD	50.50	33	(17,242)
Delek Logistics Partners LP	Call	7/06/16	USD	27.01	51	(3,131)
American Tower Corp.	Call	7/08/16	USD	107.00	56	(33,320)
Enterprise Products Partners LP	Call	7/08/16	USD	28.00	94	(12,455)
Enterprise Products Partners LP	Call	7/08/16	USD	28.50	162	(14,985)
Verizon Communications, Inc.	Call	7/08/16	USD	50.50	32	(16,720)
Crown Castle International Corp.	Call	7/15/16	USD	95.00	38	(24,320)
Dominion Resources, Inc.	Call	7/15/16	USD	72.50	282	(152,280)
DTE Energy Co.	Call	7/15/16	USD	95.00	100	(43,500)
Duke Energy Corp.	Call	7/15/16	USD	80.00	311	(181,935)
Enbridge, Inc.	Call	7/15/16	USD	42.50	168	(11,340)
Energy Transfer Partners LP	Call	7/15/16	USD	39.00	66	(4,785)
Enterprise Products Partners LP	Call	7/15/16	USD	28.00	94	(13,395)
EQT Midstream Partners LP	Call	7/15/16	USD	75.00	50	(28,000)
Exelon Corp.	Call	7/15/16	USD	35.00	268	(38,860)
Magellan Midstream Partners LP	Call	7/15/16	USD	72.50	103	(40,685)
MPLX LP	Call	7/15/16	USD	35.00	126	(5,040)
NiSource, Inc.	Call	7/15/16	USD	25.00	233	(34,950)
ONEOK Partners LP	Call	7/15/16	USD	40.00	146	(14,600)
Pinnacle West Capital Corp.	Call	7/15/16	USD	72.90	164	(134,067)
Plains All American Pipeline LP	Call	7/15/16	USD	27.00	77	(7,892)
Sempra Energy	Call	7/15/16	USD	110.00	117	(47,970)
Shell Midstream Partners LP	Call	7/15/16	USD	35.00	423	(14,805)
Targa Resources Corp.	Call	7/15/16	USD	44.00	55	(3,850)
Tesoro Logistics LP	Call	7/15/16	USD	50.00	59	(5,458)
Valero Energy Partners LP	Call	7/15/16	USD	45.00	64	(15,520)
Williams Partners LP	Call	7/15/16	USD	32.50	70	(18,375)
American Tower Corp.	Call	7/22/16	USD	109.00	74	(36,630)
American Water Works Co., Inc.	Call	7/22/16	USD	74.00	145	(152,725)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Utility and Infrastructure Trust (BUI)

		Expiration	Str	ike		
	Put/					
Description	Call	Date	Pr	ice	Contracts	Value
Enterprise Products Partners LP	Call	7/22/16	USD	28.00	108	\$ (15,390)
Verizon Communications, Inc.	Call	7/22/16	USD	51.00	33	(14,932)
Dominion Resources, Inc.	Call	7/27/16	USD	71.10	283	(194,510)
Edison International	Call	7/29/16	USD	74.00	187	(73,906)
Enterprise Products Partners LP	Call	7/29/16	USD	28.50	108	(13,500)
Verizon Communications, Inc.	Call	7/29/16	USD	52.00	147	(54,390)
Exelon Corp.	Call	8/01/16	USD	35.50	150	(9,150)
Sempra Energy	Call	8/01/16	USD	112.01	116	(39,381)
NorthWestern Corp.	Call	8/02/16	USD	63.76	80	(4,240)
Verizon Communications, Inc.	Call	8/05/16	USD	55.00	33	(4,191)
Eversource Energy	Call	8/08/16	USD	55.50	141	(67,818)
Exelon Corp.	Call	8/08/16	USD	35.00	299	(49,984)
NorthWestern Corp.	Call	8/10/16	USD	63.76	80	(5,200)
American Water Works Co., Inc.	Call	8/12/16	USD	78.02	148	(96,052)
CMS Energy Corp.	Call	8/12/16	USD	43.75	693	(148,544)
Delek Logistics Partners LP	Call	8/15/16	USD	27.00	52	(8,658)
Duke Energy Corp.	Call	8/17/16	USD	82.60	309	(99,483)
Columbia Pipeline Partners LP	Call	8/19/16	USD	15.00	90	(8,100)
DTE Energy Co.	Call	8/19/16	USD	100.00	64	(11,200)
Edison International	Call	8/19/16	USD	77.50	195	(41,925)
Enbridge, Inc.	Call	8/19/16	USD	42.50	168	(23,100)
EQT Midstream Partners LP	Call	8/19/16	USD	80.00	50	(16,500)
MPLX LP	Call	8/19/16	USD	35.00	252	(27,090)
Pattern Energy Group, Inc.	Call	8/19/16	USD	22.50	226	(32,205)
Plains All American Pipeline LP	Call	8/19/16	USD	27.50	76	(10,450)
Public Service Enterprise Group, Inc.	Call	8/19/16	USD	45.00	161	(36,225)
Sunoco Logistics Partners LP	Call	8/19/16	USD	29.00	75	(9,562)
WEC Energy Group, Inc.	Call	8/19/16	USD	65.00	275	(41,250)
Western Gas Partners LP	Call	8/19/16	USD	55.00	65	(5,525)
Public Service Enterprise Group, Inc.	Call	9/16/16	USD	45.00	100	(23,500)
Spire, Inc.	Call	9/16/16	USD	70.00	95	(13,300)
Total						\$ (2,399,538)

OTC Options Written

	Put/		Expiration		Strike		
Description	Call	Counterparty	Date		Price	Contracts	Value
El Paso Electric Co.	Call	Goldman Sachs International	7/05/16	USD	45.48	12,900	\$ (23,269)
East Japan Railway Co.		Morgan Stanley & Co.					
	Call	International PLC	7/06/16	JPY	10,079.97	3,500	(729)
EDP Renovaveis SA	Call	UBS AG	7/06/16	EUR	6.72	13,200	(1,657)
NextEra Energy Partners LP	Call	Goldman Sachs International	7/06/16	USD	28.40	22,500	(44,676)
Public Service Enterprise Group, Inc.	Call	Goldman Sachs International	7/06/16	USD	44.69	9,900	(19,063)
Snam SpA	Call	Credit Suisse International	7/06/16	EUR	5.21	140,000	(30,043)
Sydney Airport	Call	UBS AG	7/06/16	AUD	6.67	303,000	(79,103)
Ferrovial SA	Call	Bank of America N.A.	7/07/16	EUR	19.31	75,900	(68)
New Jersey Resources Corp.	Call	Citibank N.A.	7/07/16	USD	36.15	10,000	(24,067)
NiSource, Inc.		Morgan Stanley & Co.					
	Call	International PLC	7/07/16	USD	24.27	23,500	(52,868)
Xcel Energy, Inc.	Call	Barclays Bank PLC	7/07/16	USD	40.44	16,000	(69,538)
ONEOK Partners LP	Call	UBS AG	7/11/16	USD	36.47	7,200	(26,958)
CMS Energy Corp.	Call	Bank of America N.A.	7/12/16	USD	41.00	32,400	(157,676)
EDP Renovaveis SA	Call	Bank of America N.A.	7/12/16	EUR	6.69	23,500	(4,127)
Snam SpA	Call	Goldman Sachs International	7/12/16	EUR	5.21	60,300	(13,565)
Transurban Group	Call	Bank of America N.A.	7/12/16	AUD	12.16	95,000	(10,958)

(191,675)
(1)1,015)
(6,052)
(3,285)
(1,089)
(2,286)
(16,862)
(274)
(936)

See Notes to Financial Statements.

102

SEMI-ANNUAL REPORT

BlackRock Utility and Infrastructure Trust (BUI)

Value

(78,093)

(39,436)

(4,666)

(20, 834)(28,867)

(13,854)

(22,191)

(5,079)

(16,062)

(108,686)

(8,517)

(56,723)

(7,515)

(962) (28,988)

(35,951)

(30,876)

(1,790)

(43,820)

(33,656)

(46,657)

(45,055)

(3,077)

(26,705)(125,775)

(8,075)

(21, 908)

(7,410)

(695)

(8,684) (42,771)

(15,556)

(21,893)

(822)

(4,412)

(4,286)

(28,123)

(42,063)

(40,393)

(3,498)

(15,443)

(5,178)

(25,690)

(44,762)

(17,598)

(5,381)

(35,732)

(17,409)

(115,812)

	Put/		Expiration	Expiration Strike				
Description	Call	Counterparty	Date	Pr	ice	Contracts		
National Grid PLC	Call	UBS AG	7/14/16	GBP	10.15	64,800	\$	
Crown Castle International Corp.	Call	Citibank N.A.	7/19/16	USD	91.57	4,000		
EDP Renovaveis SA	Call	Bank of America N.A.	7/19/16	EUR	6.69	23,500		
Phillips 66 Partners LP	Call	Bank of America N.A.	7/19/16	USD	53.98	7,400		
American Electric Power Co., Inc.	Call	Barclays Bank PLC	7/20/16	USD	67.53	11,000		
New Jersey Resources Corp.	Call	Citibank N.A.	7/20/16	USD	37.50	10,000		
Snam SpA	Call	Credit Suisse International	7/20/16	EUR	5.08	60,000		
Sydney Airport	Call	UBS AG	7/20/16	AUD	7.25	109,700		
Transurban Group	Call	UBS AG	7/20/16	AUD	12.12	95,000		
Dominion Resources, Inc.	Call	Goldman Sachs International	7/21/16	USD	72.16	18,700		
PPL Corp.	Cull	Morgan Stanley & Co.	//21/10	COD	72.10	10,700	,	
TTE corp.	Call	International PLC	7/21/16	USD	38.75	40,400		
SBA Communications Corp., Class A	Call	Barclays Bank PLC	7/21/16	USD	101.23	8,000		
Vinci SA	Call	UBS AG	7/21/16	EUR	64.58	6,500		
	Call	UBS AU	//21/10	LUK	04.38	0,500		
China Merchants Holdings	Call	IDMorgon Chase Depts N.A.	7/22/16	HKD	22.15	44,000		
International Co. Ltd.		JPMorgan Chase Bank N.A.	7/25/16		22.15	,		
Genesis Energy LP	Call	Bank of America N.A.		USD	38.00	20,000		
Sunoco Logistics Partners LP	Call	UBS AG	7/25/16	USD	27.45	20,000		
Antero Midstream Partners LP	Call	UBS AG	7/26/16	USD	26.47	13,600		
EDP Renovaveis SA		Morgan Stanley & Co.			6.02	10.000		
	Call	International PLC	7/26/16	EUR	6.93	18,000		
Exelon Corp.		Morgan Stanley & Co.						
	Call	International PLC	7/26/16	USD	35.44	35,600		
NextEra Energy Partners LP	Call	UBS AG	7/26/16	USD	29.17	23,000		
NextEra Energy, Inc.	Call	Citibank N.A.	7/26/16	USD	129.50	18,500		
Public Service Enterprise Group, Inc.	Call	Deutsche Bank AG	7/26/16	USD	45.44	32,100		
Veolia Environnement SA		Morgan Stanley & Co.						
	Call	International PLC	7/26/16	EUR	20.84	25,700		
CMS Energy Corp.	Call	Deutsche Bank AG	7/27/16	USD	45.14	21,500		
American Electric Power Co., Inc.	Call	Deutsche Bank AG	7/28/16	USD	64.64	22,800	(
Dominion Midstream Partners LP	Call	Bank of America N.A.	7/28/16	USD	30.10	16,900		
Pattern Energy Group, Inc.	Call	Deutsche Bank AG	7/29/16	USD	21.68	13,600		
Abertis Infraestructuras SA		Morgan Stanley & Co.						
	Call	International PLC	8/02/16	EUR	13.86	34,000		
Aeroports de Paris		Morgan Stanley & Co.						
-	Call	International PLC	8/02/16	EUR	109.35	3,700		
Atlantia SpA	Call	Credit Suisse International	8/02/16	EUR	24.13	50,000		
Atlantia SpA	Call	UBS AG	8/02/16	EUR	22.22	71,200		
Crown Castle International Corp.	Call	Bank of America N.A.	8/02/16	USD	101.37	10,000		
Dominion Midstream Partners LP	Call	Deutsche Bank AG	8/02/16	USD	27.51	15,000		
EDP Renovaveis SA	Call	Credit Suisse International	8/02/16	EUR	7.12	13,300		
Enel SpA	Call	Credit Suisse International	8/02/16	EUR	4.25	91,600		
NextEra Energy, Inc.	Call	Deutsche Bank AG	8/03/16	USD	124.50	19,000	(
Sydney Airport	Call	JPMorgan Chase Bank N.A.	8/03/16	AUD	7.39	109,700		
Public Service Enterprise Group, Inc.	Call	UBS AG	8/05/16	USD	45.49	16,200		
Xcel Energy, Inc.	Call	Citibank N.A.	8/08/16	USD	42.35	16,000		
Atlantia SpA	cuii	Morgan Stanley & Co.	0/00/10	0.02	12100	10,000		
Addition op 1	Call	International PLC	8/09/16	EUR	22.61	50,000		
EDP Renovaveis SA	Can	Morgan Stanley & Co.	0/07/10	LUK	22.01	50,000		
	Call	International PLC	8/09/16	EUR	6.72	14,100		
Enel SpA	Call	Credit Suisse International	8/09/16	EUR	3.95	78,700		
Iberdrola SA	Call	Credit Suisse International	8/09/16	EUR	6.11	33,000		
Transurban Group	Call	UBS AG	8/09/16	AUD	12.14	106,100		
NextEra Energy, Inc.	Call	Morgan Stanley & Co.	0/09/10	AUD	12.14	100,100		
mentera energy, nic.	$C_{c^{11}}$	e ,	Q/10/16	UCD	120.01	21 600		
Dominion Midatao I.D.	Call	International PLC	8/10/16	USD	130.01	21,600		
Dominion Midstream Partners LP	Call	Bank of America N.A.	8/11/16	USD	30.18	19,500		
Enel SpA	Call	Goldman Sachs International	8/11/16	EUR	4.03	40,000		
Magellan Midstream Partners LP	C ¹¹	Morgan Stanley & Co.	0.11.1.1	1.0-	53 6 6			
	Call	International PLC	8/11/16	USD	73.80	10,400		
Williams Partners LP	Call	Bank of America N.A.	8/12/16	USD	33.50	6,900		

EDP Renovaveis SA	Call	Credit Suisse International	8/16/16	EUR	6.79	14,000	(3,135)
Energy Transfer Partners LP	Call	Citibank N.A.	8/16/16	USD	38.50	8,200	(11,676)
Sempra Energy	Call	Bank of America N.A.	8/16/16	USD	109.40	6,000	(30,153)
Tesoro Logistics LP	Call	Deutsche Bank AG	8/16/16	USD	48.00	5,800	(16,559)
Antero Midstream Partners LP	Call	Bank of America N.A.	8/17/16	USD	26.70	13,700	(31,399)
Iberdrola SA	Call	Deutsche Bank AG	8/17/16	EUR	5.89	36,500	(13,762)
Shell Midstream Partners LP	Call	Citibank N.A.	8/18/16	USD	34.35	10,700	(16,521)
Phillips 66 Partners LP	Call	Credit Suisse International	8/22/16	USD	55.34	7,400	(13,225)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Utility and Infrastructure Trust (BUI)

	Put/		Expiration	Stı	ike			
Description China Merchants Holdings	Call	Counterparty	Date	Pr	ice	Contracts		Value
International Co. Ltd. Flughafen Zuerich AG	Call	JPMorgan Chase Bank N.A. Morgan Stanley & Co.	8/23/16	HKD	21.17	44,000	\$	(4,447)
-	Call	International PLC	8/23/16	CHF	174.42	6,000		(26,910)
Vinci SA	Call	Goldman Sachs International	8/23/16	EUR	66.03	7,800		(10,754)
Transurban Group	Call	Citibank N.A.	8/24/16	AUD	12.03	95,700		(31,344)
Dominion Midstream Partners LP	Call	Bank of America N.A.	8/25/16	USD	29.50	15,000		(20,419)
Genesis Energy LP	Call	UBS AG	8/25/16	USD	37.70	20,000		(39,585)
Veolia Environnement SA		Morgan Stanley & Co.						
	Call	International PLC	8/25/16	EUR	19.80	10,000		(7,023)
CMS Energy Corp.	Call	Deutsche Bank AG	8/29/16	USD	43.82	33,000		(74,406)
Dominion Midstream Partners LP	Call	Bank of America N.A.	9/08/16	USD	29.60	20,900		(32,725)
Shell Midstream Partners LP Total	Call	Deutsche Bank AG	9/12/16	USD	33.26	41,700	\$ ((102,161) 2,637,137)

Transactions in Options Written for the Period Ended June 30, 2016

	C	alls Premiums	Puts Premiums
	Contracts	Received	Contracts Received
Outstanding options at beginning of year	3,321,328	\$ 2,174,098	
Options written	12,544,469	9,965,123	
Options exercised	(133)	(13,502)	
Options expired	(5,273,624)	(2,886,552)	
Options closed	(7,309,868)	(6,616,146)	
Outstanding options at end of year	3,282,172	\$ 2,623,021	

As of period end, the value of portfolio securities subject to covered call options written was \$117,540,814.

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

					Foreign		
					Currency	Interest	
		Commodity	Credit	Equity	Exchange	Rate	
		Contracts	Contracts	Contracts	Contracts	Contracts	Total
Liabilities Derivative Finance Options written	ial Instruments Options written, at value			\$ 5,036,675			\$ 5,036,675

For the six months ended June 30, 2016, the effect of derivative financial instruments in the Statements of Operations was as follows:

				Foreign					
				Currency	Interest				
	Commodity	Credit	Equity	Exchange	Rate				
Net Realized Gain (Loss) from: Options written	Contracts	Contracts	Contracts \$ (3,154,907)	Contracts	Contracts	Total \$ (3,154,907)			
Net Change in Unrealized Appreciation (Depreciation) on: Options written			\$ (1,695,678)			\$ (1,695,678)			
Average Quarterly Balances of Outstanding Derivative Financial Instruments									
Options: Average value of option contracts written For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.									

See Notes to Financial Statements.

104

SEMI-ANNUAL REPORT

BlackRock Utility and Infrastructure Trust (BUI)

Deriva	ative Financial Instruments	Offsetting as of Period End
The Trust	s derivative assets and liabilit	ies (by type) are as follows:

Derivative Financial Instruments:		Liabilities
Options		\$ 5,036,675
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(2,399,538)
Total derivative assets and liabilities subject to an MNA		\$ 2,637,137

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under an Master Netting Agreement (MNA) and net of the related collateral pledged by the Trust:

Gross Amounts Not Offset in the Consolidated Statements of Assets and Liabilities

	and Subject to an MNA					
	Derivative Liabilities		Non-cash	Cash		
	Subject to an MNA D	erivatives Available	Collateral	Collateral	Net A	mount of
Counterparty	Counterparty	for Offset	Pledged ¹	Pledged	Derivativ	e Liabilities ²
Bank of America N.A.	\$ 403,331				\$	403,331
Barclays Bank PLC	155,128					155,128
Citibank N.A.	225,618		\$ (225,618)			
Credit Suisse International	109,459		(109,459)			
Deutsche Bank AG	564,036		(342,784)			221,252
Goldman Sachs International	225,394		(225,394)			
JPMorgan Chase Bank N.A.	9,695					9,695
Morgan Stanley & Co. International PLC	279,510		(279,510)			
UBS AG	664,966		(563,846)			101,120
Total	\$ 2,637,137		\$ (1,746,611)		\$	890,526

¹ Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

² Net amount represents the net amount payable due to the counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

			Level 3	
	Level 1	Level 2		Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks:				
Construction & Engineering		\$ 11,371,734	\$	11,371,734
Diversified Telecommunication Services	\$ 6,867,930			6,867,930
Electric Utilities	82,516,258	5,456,603		87,972,861
Gas Utilities	4,138,366	4,446,775		8,585,141
Independent Power and Renewable Electricity				
Producers	11,672,287	2,574,984		14,247,271
Multi-Utilities	73,452,356	4,917,371		78,369,727
Oil, Gas & Consumable Fuels	67,250,526			67,250,526
Real Estate Investment Trusts (REITs)	11,238,486			11,238,486
Road & Rail		917,466		917,466
Transportation Infrastructure		54,318,824		54,318,824
Water Utilities	13,428,639	- //-		13,428,639
Short-Term Securities	5,911,111	887,226		6,798,337
	<i>y- y</i>			,
Total	\$ 276,475,959	\$ 84,890,983	\$	361,366,942

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Utility and Infrastructure Trust (BUI)

Derivative Financial Instruments ¹	Level 1	Level 2	Level 3	Total
Liabilities: Equity contracts	\$ (1,280,017)	\$ (3,756,658)		\$ (5,036,675)

¹ Derivative financial instruments are options written, which are shown at value.

The Trust may hold assets and/ or liabilities in which the fair value approximates the carrying amount for financial statements purposes. As of period end, such assets and/ or liabilities are categorized within the disclosure hierarchy as follows:

	I	Level 1	Level 2	Level 3	Total
Assets: Cash Foreign currency at value	\$	35,532 11,895			\$ 35,532 11,895
Liabilities: Collateral on securities loaned at value			\$ (887,226)		(887,226)
Total	\$	47,427	\$ (887,226)		\$ (839,799)

During the six months ended June 30, 2016, there were no transfers between levels.

See Notes to Financial Statements.

106

SEMI-ANNUAL REPORT

Statements of Assets and Liabilities

		BlackRock			
			BlackRock	BlackRock	
	BlackRock	Enhanced	Enhanced	Global	BlackRock
	Energy and	Capital and	Equity	Opportunities	Health
	Resources	Income	Dividend	Equity	Sciences
June 30, 2016 (Unaudited)	Trust (BGR)	Fund, Inc. (CII)	Trust (BDJ)	Trust (BOE)	Trust (BME)
Assets					
Investments at value unaffiliated ² Investments at value affiliated Cash pledged as collateral for OTC	\$ 445,417,891 21,613,354	\$ 616,496,525 9,391,637	\$ 1,652,094,925 11,882,407	\$ 930,582,175 16,747,095	\$ 272,191,512 9,742,676
derivatives Foreign currency at value ⁴ Receivables:	9,619	420,000 1,881	98,000 1,695	888,290	1,088
Investments sold Options written Dividends unaffiliated Dividends affiliated Securities lending income affiliated	301,697 485,287 3,142	12,729,293 475,769 509,668 4,877	11,020,356 1,282,420 2,976,605 1,867	2,444,017 777,830 2,093,397 4,146 4,316	2,191,011 210,161 287,199 4,718 142
Unrealized appreciation on forward foreign currency exchange contracts				109,407	
Prepaid offering costs Other assets	15,668	23,385	52,201	48,040	32,130 13,272
Total assets	467,846,658	640,053,035	1,679,410,476	953,698,713	284,673,909
Liabilities					
Bank overdraft	4,868		1,790		
Options written at value ⁵ Collateral on securities loaned at value Payables:	6,247,202	6,439,419	22,729,496	12,825,445 1,705,953	2,593,549 156,732
Investments purchased		3,806,474	4,192,076	10,489,821	2,357,618
Options written	529,957	385,543	2,338,085	548,759	192,702
Income dividends	204,118	311,510	323,759	241,022	
Investment advisory fees	426,194	437,965	1,036,552	725,262	226,734
Officer s and Trustees fees Unrealized depreciation on forward foreign currency exchange contracts	425,150	137,421	779,228	602,311 45,617	26,292
Other accrued expenses payable	164,066	240,046	325,554	245,891	92,350
Total liabilities	8,001,555	11,758,378	31,726,540	27,430,081	5,645,977
Net Assets	\$ 459,845,103	\$ 628,294,657	\$ 1,647,683,936	\$ 926,268,632	\$ 279,027,932
Net Assets Consist of					
Paid-in capital Distributions in excess of net investment	\$ 636,945,433	\$ 689,310,753	\$ 1,468,888,354	\$ 943,069,418	\$ 198,059,735
income	(11,948,206)	(23,863,063)	(37,650,903)	(40,931,857)	(10,361,612)
Accumulated net realized gain (loss) Net unrealized appreciation (depreciation)	(171,359,122) 6,206,998	(42,178,311) 5,025,278	(111,293,238) 327,739,723	(53,473,150) 77,604,221	14,508,331 76,821,478
Net Assets	\$ 459,845,103	\$ 628,294,657	\$ 1,647,683,936	\$ 926,268,632	\$ 279,027,932

Net asset value ^{6,7}	\$	15.42	\$	14.24	\$	8.72	\$	13.33	\$	33.84
 Investments at cost unaffiliated Securities loaned at value Investments at cost affiliated Foreign currency at cost Premiums received Shares outstanding, unlimited number of shares authorized, \$0.001 par value 	\$ \$ \$	437,147,378 21,613,354 9,623 4,182,881 29,825,326	\$ 6 \$ \$ \$	511,285,803 9,391,637 9,142 6,261,237	\$ 1 \$ \$ \$	1,317,068,048 11,882,407 1,756 15,445,785 188,978,322	\$ \$ \$	850,888,198 1,582,304 16,747,095 890,478 10,702,576 69,483,161	\$ 1 \$ \$ \$ \$	194,918,126 153,156 9,742,676 1,157 2,147,026 8,246,580
⁷ Shares outstanding, 200 million shares authorized, \$0.10 par value				44,121,400						

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Statements of Assets and Liabilities

June 30, 2016 (Linaudited) Trust (BGY) Trust (BCY) Trust (BCY) Trust (BCY) Nextent 575.638.466 910.066.756 5 423.301.471 \$ 355.638.466 Investments at value multiliated! 21.785.005 \$16.748.912 3,722.803 \$ 355.333 Cash pelogid: 773.605 \$16.748.912 3,722.803 \$ 355.333 Callateral exchange traded options written 6.219.000 2,066.662 \$ 1.858 Foreign currency at value ³ 1.035.172 40.658 \$ 1.4383 \$ 1.238.301 Investments at value ³ 1.035.172 40.658 \$ 9.870.07 \$ 33.628.455 9.870.07 \$ 33.628.455 9.870.07 \$ 33.628.455 9.870.07 \$ 33.629.990 \$			BlackRock International Growth and Income		BlackRock Resources & Commodities Strategy	:	BlackRock Science and Technology	BlackRock Utility and frastructure
Investments at value antiliated ¹⁵ Investments at value affiliated ¹⁵ (ash pleqei: Collateral OTC derivatives (Collareal) OTC	June 30, 2016 (Unaudited)	,	Trust (BGY)	1	Trust (BCX) ¹			
Investments at value affiliatedt 21,785,095 16,748,912 3,722,803 6,798,373 Cash Pedged: 773,605 12,011 2,066,662 35,532 Collateral exchange traded options written 6,219,000 2,066,662 11,885 Foreign currency at values ⁵ 6,219,000 2,066,662 11,885 Receivables: 10,851,772 40,658 54,490 11,885 Investments sold 2,066,770 33,662,865 1,943,344 1,281,301 Dividends unaffiliated 2,565,884 18,33,082 283,009 877,047 Variation margin on futures contracts 12,7150 528 5,026 1,612 Otier assets 39,192 46,462 14,459 12,013 Total assets 39,192 46,462 34,14956 556,511 Options written 2,510,0645 32,447,652 3,414,956 556,511 Options written 32,4027 377,70 106,821 14,359 Divestametis purchased 32,4027 377,70 106,821 14,359 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
Cash plagad: Cash plagad:<	Investments at value affiliated	\$	21,785,695	\$	16,748,912	\$		\$ 354,568,605 6,798,337
Collateral Collat			773,605		12,011			35,532
Futures contracts 639,000 $1,055,172$ $40,658$ $54,490$ $11,895$ Receivables: 1,055,172 $40,658$ $54,490$ $11,895$ Investments sold 2,065,470 $33,662,865$ $19,43,344$ $1.281,360$ Drividends unaffiliated 2,265,884 $18,330,082$ $223,099$ $877,047$ Variation margin on futures contracts $127,550$ 476 $2,163$ Securities lending income affiliated $10,251$ $5,450$ 476 $2,163$ Other assets $39,192$ $46,662$ $14,459$ $12,013$ Total assets $738,681,186$ $963,937,047$ $433,275,113$ $363,911,577$ Liabilities Options written at value ⁶ Options written at value ⁶ $11,613,738$ $10,733,252$ $4,379,867$ $503,66,75$ Collateral on securities loaned at value Payahles: $11,613,738$ $10,733,252$ $4,379,867$ $503,66,75$ Investiment advisory fees $523,573$ $739,502$ $277,832$ $364,220$ $378,302$ $266,494$	Collateral exchange traded options written						, ,	
Receivable: Investments sold 24,065,470 33,662,865 1-04,334 1,281,303 Dytions written 619,482 620,323 333,283 332,013 Dividends affiliated 2,655,884 1,833,082 283,009 877,407 Dividends affiliated 10,251 5,450 476 2,163 Variation marging on futures contracts 127,350 528 5,026 1,612 Other assets 39,192 46,462 14,459 12,013 Total assets 738,681,186 963,937,047 433,275,113 363,911,577 Libilities Options written at value ⁶ 11,613,738 10,733,252 4,379,867 5,086,675 Collateral on securities loaned at value Payahles: 133,4027 307,770 106,821 141,33,93 Investments parchased 253,673 739,902 227,832 24,47,32 Orticer s and Trustees fees 533,669 314,015 11,888 8,057 Ofter a supable							-,	
Options written 619.482 620.323 333.283 333.0283 370.047 233.0283 343.047 2.163 Variation margin on futures contracts 39.192 46.462 14.459 12.013 Total assets 738.681,186 963.937,047 433.275,113 363.911,577 Collaritien at value ⁶ 11.613,738 10.733.252 4.379,867 5.036.675 Collaritien to value ⁶ 12.613,738 10.733.252 4.379,867 5.036.675 Collaritien to value 25.100.645 32.447.632 3.414.956 556.211 Investments purchased	6 .		1,035,172		40,658		54,490	11,895
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Investments sold							1,281,360
	1		· · ·		,		,	,
Variation margin on futures contracts 127,350 Securities lending income affiliated 127,350 Securities lending income affiliated 39,192 46,462 14,459 12,013 Other assets 738,681,186 963,937,047 433,275,113 363,911,577 Liabilities 738,681,186 963,937,047 433,275,113 363,911,577 Liabilities 11,613,738 10,733,252 4,379,867 5,036,675 Options written at value ⁶ 11,613,738 10,733,252 3,414,956 556,511 Poyables: 1,337,693 1,763,760 887,222 378,302 664,941 Income dividends 324,027 307,770 106,821 143,593 Investment divisory fees 523,573 739,502 277,832 284,726 Ofter a crued expenses payable 222,215 309,954 199,698 128,724 Other accrued expenses payable 38,768,990 47,244,038 10,533,124 7,710,453 Net Assets S 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets S 699,912,196 \$ 916,693,009 \$ 422,741					, ,		,	
Securities lending income affiliated 528 5,025 1,612 Other assets 39,192 46,462 14,459 12,013 Total assets 738,681,186 963,937,047 433,275,113 363,911,577 Liabilities 738,681,186 963,937,047 433,275,113 363,911,577 Collar and securities loaned at value 11,613,738 10,733,252 4,379,867 5,036,675 Collateral on securities loaned at value 1,337,693 1,763,760 887,226 Payables: 1,337,693 1,763,760 887,226 Investment purchased 25,100,645 32,447,632 3,414,956 556,511 Options written 4451,133 994,220 378,302 6664,941 Income dividends 32,4027 307,770 106,821 143,593 Investment advisory fees 523,573 739,9502 277,832 284,724 Other accrued expenses payable 222,215 369,954 199,698 128,724 Total liabilities \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 </td <td></td> <td></td> <td>,</td> <td></td> <td>5,450</td> <td></td> <td>470</td> <td>2,105</td>			,		5,450		470	2,105
Other assets $39,192$ $46,462$ $14,459$ $12,013$ Total assets $738,681,186$ $963,937,047$ $433,275,113$ $363,911,577$ Liabilities Defines written at value ⁶ $11,613,738$ $10,733,252$ $4,379,867$ $5,036,675$ Collateral on securities loaned at value $1,337,693$ $1,763,760$ $887,225$ $34,14,956$ $556,511$ Payables: Investments purchased $25,100,645$ $32,447,632$ $3,414,956$ $556,511$ Options written $451,133$ $994,220$ $378,302$ $664,941$ Income dividends $324,027$ $307,770$ $106,821$ $143,593$ Income dividends $323,4027$ $304,015$ $11,888$ $8,057$ Ofticer s and Trustees fees $533,659$ $314,015$ $11,888$ $8,057$ Other accrued expenses payable $222,215$ $39,954$ $19,9688$ $128,724$ Total liabilities $86,99,912,196$ $916,693,009$ $8422,741,989$ $528,895,669$ Net Assets On tem cetrueized cost			127,550		528		5.026	1.612
Liabilities Options written at value ⁶ 11,613,738 10,733,252 4,379,867 5,036,675 Collateral on securities loaned at value 1,337,693 1,763,760 887,226 Payables: 1,337,693 1,763,760 887,226 Investments purchased 25,100,645 32,447,632 3,414,956 556,511 Options written 451,133 994,220 378,302 664,941 Incorm dividends 524,027 307,770 106,821 143,593 Investment advisory fees 523,573 739,502 277,832 284,726 Ofticer s and Trustees fees 533,659 314,015 11.888 8.057 Other accrued expenses payable 222,215 369,954 199,698 128,724 Total liabilities 38,768,990 47,244,038 10,533,124 7,710,453 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 <td></td> <td></td> <td>39,192</td> <td></td> <td>46,462</td> <td></td> <td>,</td> <td>12,013</td>			39,192		46,462		,	12,013
Options written at value ⁶ 11,613,738 10,733,252 4,379,867 5,036,675 Collateral on securities loaned at value 1,337,693 1,763,760 887,226 Payables: 1 1,337,693 1,763,760 887,226 Investments purchased 25,100,645 32,447,632 3,414,956 556,511 Options written 451,133 994,220 378,302 664,941 Income dividends 324,027 307,770 106,821 143,593 Investment advisory fees 533,659 314,015 11,888 8,057 Other accrued expenses payable 222,215 369,954 199,698 128,724 Total liabilities 38,768,990 47,244,038 10,533,124 7,710,453 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 256,201,124 Net Assets Consist of (30,589,796) (22,879,600) (13,145,322) (559,526 6 Accumulated net realized loss (561,065,110) (540,591,159) (31,876,447) (556,7651)	Total assets		738,681,186		963,937,047		433,275,113	363,911,577
Collateral on securities loaned at value 1,337,693 1,763,760 887,226 Payables: 1,337,693 1,763,760 887,226 Payables: 451,133 994,220 378,302 664,941 Income dividends 324,027 307,770 106,821 143,593 Investment advisory fees 523,573 739,502 277,832 284,726 Officer s and Trustees fees 533,659 314,015 11,888 8,057 Other accrued expenses payable 222,215 369,954 199,698 128,724 Total liabilities 38,768,990 47,244,038 10,533,124 7,710,453 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 288,195,604 Distributions in excess of net investment income (30,589,796) (22,879,6000) (13,145,322) (55,95,269 Accumulated net realized loss (561,065,110) (540,591,159) (31,876,447) (6,560,715 Net asset value ⁷ \$	Liabilities							
Payables:25,100,645 $32,447,632$ $3,414,956$ $556,511$ Investments purchased25,100,645 $32,447,632$ $3,414,956$ $556,511$ Options writen $451,133$ $994,220$ $378,302$ $664,941$ Income dividends $324,027$ $307,770$ $106,821$ $143,593$ Investment advisory fees $523,573$ $739,502$ $277,832$ $284,726$ Officer s and Trustees fees $533,659$ $314,015$ $11,888$ 8.057 Other accrued expenses payable $222,215$ $369,954$ $199,698$ $128,724$ Total liabilities $38,768,990$ $47,244,038$ $10,533,124$ $7,710,453$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$Accumulated net realized loss $(561,065,110)$ $(540,591,159)$ $(31,186,4247)$ $(6,560,715)$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net asset value?\$\$ 6.36 9.25 \$ 18.78 \$ 21.07 1Consolidated Statement of Assets and Liabilities. 2 $1.236,801$	Options written at value ⁶		11,613,738		10,733,252		4,379,867	5,036,675
Options written $451,133$ $994,220$ $378,302$ $664,941$ Income dividends $324,027$ $307,770$ $106,821$ $143,593$ Investment divisory fees $523,573$ $739,502$ $277,832$ $284,726$ Officer s and Trustees fees $533,659$ $314,015$ $11,888$ $8,057$ Other accrued expenses payable $222,215$ $369,954$ $199,698$ $128,724$ Total liabilities $38,768,990$ $47,244,038$ $10,533,124$ $7,710,453$ Net Assets \$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Distributions in excess of net investment income $(30,589,796)$ $(22,879,600)$ $(13,145,322)$ $(5,555,269)$ Accumulated net realized loss $(561,065,110)$ $(540,591,159)$ $(31,876,447)$ $(6,560,715)$ Net Assets \$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net asset value ⁷ \$ 636 \$ 9.25 \$ $18,78$ $21,07$ 1 Consolidated Statement of Assets and Liabilities. 2 <td>Payables:</td> <td></td> <td></td> <td></td> <td>1,337,693</td> <td></td> <td>1,763,760</td> <td>887,226</td>	Payables:				1,337,693		1,763,760	887,226
Income dividends $324,027$ $307,770$ $106,821$ $143,593$ Investment advisory fees $523,573$ $739,502$ $277,832$ $284,726$ Officer s and Trustees fees $533,659$ $314,015$ $11,888$ $8,057$ Other accrued expenses payable $222,215$ $369,954$ $199,698$ $128,724$ Total liabilities $38,768,990$ $47,244,038$ $10,533,124$ $7,710,453$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$Statistics\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets Consist ofPaid-in capital\$ $1,290,672,026$ \$ $1,386,290,465$ \$ $400,387,105$ \$ $288,195,604$ Distributions in excess of net investment income $(30,589,796)$ $(22,879,600)$ $(13,145,322)$ $(5,595,269)$ Accumulated net realized loss $(561,065,110)$ $(540,591,159)$ $(31,876,447)$ $(6,560,715)$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets\$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets\$, ,					556,511
Investment advisory fees $523,573$ $739,502$ $277,832$ $284,726$ Officer s and Trustees fees $533,659$ $314,015$ $11,888$ $8,057$ Other accrued expenses payable $222,215$ $369,954$ $199,698$ $128,724$ Total liabilities $38,768,990$ $47,244,038$ $10,533,124$ $7,710,453$ Net Assets \$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets \$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets \$ $699,912,196$ \$ $916,693,009$ \$ $422,741,989$ \$ $356,201,124$ Net Assets \$ $699,912,196$ \$ $1,386,290,465$ \$ $400,387,105$ \$ $288,195,604$ Distributions in excess of net investment income $(30,589,796)$ $(22,879,600)$ $(13,145,322)$ $(5,560,715)$ Net unrealized loss $(561,065,110)$ $(540,591,159)$ $(31,876,447)$ $(6,560,715)$ $80,161,504$ Net Assets \$ 6	1				· · ·		,	,
Officer s and Trustees fees 533,659 314,015 11,888 8,057 Other accrued expenses payable 222,215 369,954 199,698 128,724 Total liabilities 38,768,990 47,244,038 10,533,124 7,710,453 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets Consist of ************************************					· · ·			
Other accrued expenses payable 222,215 369,954 199,698 128,724 Total liabilities 38,768,990 47,244,038 10,533,124 7,710,453 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets Consist of Paid-in capital \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 Distributions in excess of net investment income \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 Accumulated net realized loss (561,065,110) (540,591,159) (31,876,447) (6,560,715 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value? \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value? \$ 6.36 \$ 9.25 \$ 18,78 \$ 21,07 1 Consolidated Statement of Assets and Liabilities. \$ 1,236,801 \$ 1,772,033 \$ 856,238 2 Investments at cost unaffiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 3								
Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 Distributions in excess of net investment income \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 Accumulated net realized loss \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 \$ 288,195,604 \$ 288,195,604 \$ 288,195,604 \$ 288,195,604 \$ 288,195,604 \$ 288,075 \$ 387,303 67,376,653 80,161,504 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value ⁷ \$,		<i>.</i>	128,724
Net Assets Consist of Paid-in capital \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 Distributions in excess of net investment income (30,589,796) (22,879,600) (13,145,322) (5,595,269 Accumulated net realized loss (561,065,110) (540,591,159) (31,876,447) (6,560,715 Net unrealized appreciation (depreciation) 895,076 93,873,303 67,376,653 80,161,504 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value ⁷ \$ 6.36 \$ 9.25 \$ 18.78 \$ 21.07 1 Consolidated Statement of Assets and Liabilities. 2 1 2 271,981,923 \$ 856,238 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Total liabilities		38,768,990		47,244,038		10,533,124	7,710,453
Paid-in capital \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 Distributions in excess of net investment income (30,589,796) (22,879,600) (13,145,322) (5,595,269 Accumulated net realized loss (561,065,110) (540,591,159) (31,876,447) (6,560,715 Net unrealized appreciation (depreciation) 895,076 93,873,303 67,376,653 80,161,504 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value ⁷ \$ 6.36 \$ 9.25 \$ 18.78 \$ 21.07 1 Consolidated Statement of Assets and Liabilities. \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Net Assets	\$	699,912,196	\$	916,693,009	\$	422,741,989	\$ 356,201,124
Paid-in capital \$ 1,290,672,026 \$ 1,386,290,465 \$ 400,387,105 \$ 288,195,604 Distributions in excess of net investment income (30,589,796) (22,879,600) (13,145,322) (5,595,269 Accumulated net realized loss (561,065,110) (540,591,159) (31,876,447) (6,560,715 Net unrealized appreciation (depreciation) 895,076 93,873,303 67,376,653 80,161,504 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value ⁷ \$ 6.36 \$ 9.25 \$ 18.78 \$ 21.07 1 Consolidated Statement of Assets and Liabilities. \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Net Assets Consist of							
Distributions in excess of net investment income (30,589,796) (22,879,600) (13,145,322) (5,595,269 Accumulated net realized loss (561,065,110) (540,591,159) (31,876,447) (6,560,715 Net unrealized appreciation (depreciation) 895,076 93,873,303 67,376,653 80,161,504 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value ⁷ \$ 6.36 \$ 9.25 \$ 18.78 \$ 21.07 1 Consolidated Statement of Assets and Liabilities. \$ 1,236,801 \$ 1,772,033 \$ 856,238 3 Securities loaned at value \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 4 Investments at cost affiliated \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Paid-in capital	\$	1,290,672,026	\$	1,386,290,465	\$	400,387,105	\$ 288,195,604
Net unrealized appreciation (depreciation) 895,076 93,873,303 67,376,653 80,161,504 Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value7 \$ 6.36 \$ 9.25 \$ 18.78 \$ 21.07 1 Consolidated Statement of Assets and Liabilities. 2 Investments at cost unaffiliated \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Distributions in excess of net investment income							(5,595,269)
Net Assets \$ 699,912,196 \$ 916,693,009 \$ 422,741,989 \$ 356,201,124 Net asset value ⁷ \$ 6.36 \$ 9.25 \$ 18.78 \$ 21.07 1 Consolidated Statement of Assets and Liabilities. \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 2 Investments at cost unaffiliated \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993					(540,591,159)			(6,560,715)
Net asset value7 \$ 6.36 \$ 9.25 \$ 18.78 \$ 21.07 1 Consolidated Statement of Assets and Liabilities. 2 Investments at cost unaffiliated \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 \$ 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Net unrealized appreciation (depreciation)		895,076		93,873,303		67,376,653	80,161,504
1 Consolidated Statement of Assets and Liabilities. 2 Investments at cost unaffiliated \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Net Assets	\$	699,912,196	\$	916,693,009	\$	422,741,989	\$ 356,201,124
2 Investments at cost unaffiliated \$ 671,337,710 \$ 814,963,452 \$ 355,837,192 \$ 271,981,923 3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	Net asset value ⁷	\$	6.36	\$	9.25	\$	18.78	\$ 21.07
3 Securities loaned at value \$ 1,236,801 \$ 1,772,033 \$ 856,238 4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993								
4 Investments at cost affiliated \$ 21,785,695 \$ 16,748,912 \$ 3,722,803 \$ 6,798,337 5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	investments at cost unarrinated	\$	671,337,710				· · ·	271,981,923
5 Foreign currency at cost \$ 1,034,873 \$ 43,325 \$ 54,479 \$ 11,993	becanties found at value	¢	21 785 (05					
ϕ $1,00,000$ ϕ $1,000$ ϕ $0,000$ ϕ $0,000$	investments at cost anniaced							
$\varphi = 0,000,100 \qquad \varphi = 1,20,022 \qquad \varphi = 2,020,021 \qquad \varphi = 1,20,022 \qquad \varphi = 2,020,021 \qquad \varphi = 1,000,000 \qquad \varphi = 1,200,022 \qquad \varphi = 2,020,021 \qquad \varphi = 1,000,000 \qquad \varphi = 1,000,000,000 \qquad \varphi = 1,000,000 \qquad \varphi = 1,000,000,000 \qquad \varphi = 1,000,000,000 \qquad \varphi = 1,000,000,000,000,000,000,000,000,000,0$	6 Premiums received	\$	8,059,417	\$	8,605,466	\$	4,290,822	\$ 2,623,021

⁷ Shares outstanding, unlimited number of shares authorized,				
\$0.001 par value	109,989,277	99,059,784	22,507,592	16,906,964

See Notes to Financial Statements.

108

SEMI-ANNUAL REPORT

Statements of Operations

Six Months Ended June 30, 2016 (Unaudited)	BlackRock Energy and Resources Trust (BGR)	BlackRock Enhanced Capital and Income Fund, Inc. (CII)	BlackRock Enhanced Equity Dividend Trust (BDJ)	BlackRock Global Opportunities Equity Trust (BOE)	BlackRock Health Sciences Trust (BME)
Investment Income					
Dividends unaffiliated	\$ 7,179,374	\$ 5,670,641	\$ 22,870,485	\$ 12,008,825	\$ 1,711,934
Foreign taxes withheld Dividends affiliated	(270,385)	(33,574) 36,416	(182,183)	(1,049,144)	(24,437)
Securities lending affiliated net	17,629 1,031	689	14,435 16	56,835 14,337	26,637 1,512
Securities ichaing arrinated net	1,051	009	10	14,557	1,512
Total income	6,927,649	5,674,172	22,702,753	11,030,853	1,715,646
Expenses					
Investment advisory	2,523,366	2,650,794	6,352,932	4,588,333	1,349,929
Transfer agent	56,806	44,552	112,980	72,803	25,065
Custodian	54,484	89,245	110,126	125,226	57,856
Offering costs					48,043
Professional	47,742	101,267	86,026	75,239	45,326
Officer and Trustees	46,875	37,891	124,712	85,418	15,172
Printing	11,108	14,241	30,892	20,326	8,759
Registration	5,620	8,281	35,580	13,041	5,444
Insurance	1,465	3,255	21,857	3,353	1,043
Miscellaneous	18,781	9,069	7,516	54,365	15,457
Total expenses Less fees waived by the Manager	2,766,247 (108,436)	2,958,595 (6,779)	6,882,621 (201,322)	5,038,104 (239,935)	1,572,094 (4,978)
Total expenses after fees waived	2,657,811	2,951,816	6,681,299	4,798,169	1,567,116
Net investment income	4,269,838	2,722,356	16,021,454	6,232,684	148,530
Realized and Unrealized Gain (Loss)					
Net realized gain (loss) from:					
Investments unaffiliated	(57,099,138)	(38,016,188)	31,686,546	(15,302,419)	10,692,572
Options written	(828,296)	5,303,228	(7,883,565)	10,629,203	1,401,979
Foreign currency transactions	(277,969)	1,021	(68,490)	(59,004)	7,173
	(58,205,403)	(32,711,939)	23,734,491	(4,732,220)	12,101,724
Net change in unrealized appreciation (depreciation) on:					
Investments unaffiliated	115,023,888	19,993,708	28,001,424	(19,293,624)	(21,451,770)
Options written	(4,407,470)	(1,728,400)	(10,630,720)	(5,915,951)	(291,746)
Foreign currency translations	2,105	(309)	926	98,955	(2,292)
	110,618,523	18,264,999	17,371,630	(25,110,620)	(21,745,808)
Net realized and unrealized gain (loss)	52,413,120	(14,446,940)	41,106,121	(29,842,840)	(9,644,084)
Net Increase (Decrease) in Net Assets Resulting from Operations	\$ 56,682,958	\$ (11,724,584)	\$ 57,127,575	\$ (23,610,156)	\$ (9,495,554)

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Statements of Operations

	BlackRock International Growth and Income	BlackRock Resources & Commodities Strategy	BlackRock Science and	BlackRock Utility and Infrastructure
Six Months Ended June 30, 2016 (Unaudited)	Trust (BGY)	Trust (BCX) ¹	Technology Trust (BST)	Trust (BUI)
Investment Income	ф 10.0×0 = ·-	¢ 10.000	b	
Dividends unaffiliated Foreign taxes withheld	\$ 12,369,763 (1,526,449)	\$ 13,299,521	\$ 2,277,146	\$ 6,812,591
Dividends affiliated	(1,520,449) 144,619	(681,852) 31,123	(90,939) 4,807	(227,666) 17,285
Securities lending affiliated net	15,998	33,277	18,214	9,759
Total income	11,003,931	12,682,069	2,209,228	6,611,969
Expenses Investment advisory	3,538,607	4,211,006	2,054,281	1,668,942
Custodian	110,112	4,211,000	73,593	63,096
Professional	66,443	73,775	56,026	48,299
Transfer agent	70,198	62,200	25,978	29,564
Officer and Trustees	78,286	57,361	20,001	15,278
Printing	16,874	17,582	5,128	9,072
Insurance	2,594	10,838	1,462	1,111
Registration	20,644	19,569	4,504	4,642
Miscellaneous	63,019	37,057	20,888	30,391
Total expenses	3,966,777	4,602,439	2,261,861	1,870,395
Less fees waived by the Manager	(380,651)	(5,825)	(411,718)	(3,216)
Total expenses after fees waived	3,586,126	4,596,614	1,850,143	1,867,179
Net investment income	7,417,805	8,085,455	359,085	4,744,790
Realized and Unrealized Gain (Loss)				
Net realized gain (loss) from:				
Investments unaffiliated	(34,846,316)	(115,077,280)	(7,407,373)	4,747,338
Options written	12,722,468	(17,366,330)	2,488,920	(3,154,907)
Financial futures contracts	6,314,451	24.220		(16.000)
Foreign currency transactions	(133,476)	34,230	(92,646)	(16,892)
	(15,942,873)	(132,409,380)	(5,011,099)	1,575,539
Net change in unrealized appreciation (depreciation) on:				
Investments unaffiliated	$(17,568,269)^2$	248,404,571	(1,019,198)	34,104,808
Options written Futures contracts	(6,070,479) 279,332	(3,800,650)	(1,558,348)	(1,695,678)
Foreign currency translations	(20,962)	22,216	(741)	(1,091)
	(23,380,378)	244,626,137	(2,578,287)	32,408,039
Net realized and unrealized gain (loss)	(39,323,251)	112,216,757	(7,589,386)	33,983,578
Net Increase (Decrease) in Net Assets Resulting from				

Consolidated Statement of Operations. Net of \$143,706 foreign capital gain tax. 1

See Notes to Financial Statements.

110

SEMI-ANNUAL REPORT

		Black	kRock		BlackRock								
	Six	Ener Resources 7 Months Ended	gy and Frust (Enhanced Capital and Income Fund, Inc. (CII) Six Months Ended								
Increase (Decrease) in Net Assets:		une 30, 2016 (Unaudited)		Year Ended ember 31, 2015		une 30, 2016 (Unaudited)		Year Ended ember 31, 2015					
Operations													
Net investment income Net realized gain (loss) Net change in unrealized appreciation/depreciation	\$	4,269,838 (58,205,403) 110,618,523	\$	8,686,290 (105,484,599) (70,456,190)	\$	2,722,356 (32,711,939) 18,264,999	\$	4,876,418 155,685,181 (132,503,358)					
Net increase (decrease) in net assets resulting from operations		56,682,958		(167,254,499)		(11,724,584)		28,058,241					
Distributions to Shareholders													
From net investment income		(15,819,353)1		$(8,567,540)^2$		(26,472,840)1		$(6,318,821)^2$ $(46,626,859)^2$					
From net realized gains From return of capital				(36,005,387) ²				(40,020,839)2					
Decrease in net assets resulting from distributions to													
shareholders		(15,819,353)		(44,572,927)		(26,472,840)		(52,945,680)					
Capital Share Transactions													
Reinvestment of dividends				1,205,970									
Net Assets													
Total increase (decrease) in net assets Beginning of period		40,863,605 418,981,498		(210,621,456) 629,602,954		(38,197,424) 666,492,081		(24,887,439) 691,379,520					
End of period	\$	459,845,103	\$	418,981,498	\$	628,294,657	\$	666,492,081					
Distributions in excess of net investment income, end of period	\$	(11,948,206)	\$	(398,691)	\$	(23,863,063)	\$	(112,579)					

¹ A portion of the distributions from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

² Distributions for annual periods determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

	Black Enhance Dividend T	d Equ	uity	BlackRock Global Opportunities Equity Trust (BOE)						
Increase (Decrease) in Net Assets:	Six Months Ended June 30, 2016 (Unaudited)		Year Ended cember 31, 2015	J	Months Ended une 30, 2016 Unaudited)		Year Ended cember 31, 2015			
Operations										
Net investment income Net realized gain (loss) Net change in unrealized appreciation/depreciation	\$ 16,021,454 23,734,491 17,371,630	\$	31,195,998 31,480,464 (60,335,311)	\$	6,232,684 (4,732,220) (25,110,620)	\$	7,638,770 29,095,008 (26,224,116)			
Net increase (decrease) in net assets resulting from operations	57,127,575		2,341,151		(23,610,156)		10,509,662			
Distributions to Shareholders										
From net investment income Distributions in excess of net investment income From return of capital	(52,951,726) ¹		$(31,248,083)^2$ $(74,655,369)^2$		(40,439,200) ¹		$(11,517,508)^2$ (7,284,361) ² (62,076,530) ²			
Decrease in net assets resulting from distributions to shareholders	(52,951,726)		(105,903,452)		(40,439,200)		(80,878,399)			
Net Assets										
Total increase (decrease) in net assets Beginning of period	4,175,849 1,643,508,087		(103,562,301) 1,747,070,388		(64,049,356) 990,317,988		(70,368,737) 1,060,686,725			
End of period	\$ 1,647,683,936	\$	1,643,508,087	\$	926,268,632	\$	990,317,988			
Distributions in excess of net investment income, end of period	\$ (37,650,903)	\$	(720,631)	\$	(40,931,857)	\$	(6,725,341)			

¹ A portion of the distributions from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

² Distributions for annual periods determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

112

SEMI-ANNUAL REPORT

Increase (Decrease) in Net Assets:	Healt	nckRock h Sciences st (BME) Year Ended December 31, 2015	Internatio	ckRock onal Growth e Trust (BGY) Year Ended December 31, 2015
On our finne				
Operations Net investment income (loss) Net realized gain (loss) Net change in unrealized appreciation/depreciation	\$ 148,530 12,101,724 (21,745,808)	\$ (443,773) 51,654,340 (17,934,847)	\$ 7,417,805 (15,942,873) (23,380,378)	\$
Net increase (decrease) in net assets resulting from operations	(9,495,554)	33,275,720	(31,905,446)	(7,723,570)
Distributions to Shareholders				
From net investment income From net realized gains	(9,878,346)1	$(5,039,768)^2$ $(48,696,568)^2$	(32,336,847)1	(12,357,754) ²
From return of capital				(52,315,941) ²
Decrease in net assets resulting from distributions to shareholders	(9,878,346)	(53,736,336)	(32,336,847)	(64,673,695)
Capital Share Transactions				
Net proceeds from the issuance of shares Reinvestment of distributions	871,872	10,367,053 4,520,259		
Net increase in net assets derived from shares transactions	871,872	14,887,312		
Net Assets				
Total decrease in net assets Beginning of period	(18,502,028) 297,529,960	(5,573,304) 303,103,264	(64,242,293) 764,154,489	(72,397,265) 836,551,754
End of period	\$ 279,027,932	\$ 297,529,960	\$ 699,912,196	\$ 764,154,489
Distributions in excess of net investment income, end of period	\$ (10,361,612)	\$ (631,796)	\$ (30,589,796)	\$ (5,670,754)

¹ A portion of the distributions from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

² Distributions for annual periods determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

		BlackRock	k Res	ources	BlackRock							
	Six	& Com Strategy Ti Months Ended			Six	Scien Technology Months Ended	ce and Trust					
Increase (Decrease) in Net Assets:	J	(Unaudited)	De	Year Ended cember 31, 2015	J	une 30, 2016 (Unaudited)		Year Ended ember 31, 2015				
Operations												
Net investment income Net realized loss Net change in unrealized appreciation/depreciation	\$	8,085,455 (132,409,380) 244,626,137	\$	24,601,192 (101,358,837) (172,541,820)	\$	359,085 (5,011,099) (2,578,287)	\$	676,774 (25,812,735) 58,241,453				
Net increase (decrease) in net assets resulting from operations		120,302,212		(249,299,465)		(7,230,301)		33,105,492				
Distributions to Shareholders												
From net investment income		$(30, 649, 097)^2$		(24,837,338) ³		$(13,504,555)^2$		$(603,909)^3$				
In excess of net investment income From return of capital				(55,321,839) ³				$(144,770)^3$ $(26,260,431)^3$				
Decrease in net assets resulting from distributions to												
shareholders		(30,649,097)		(80,159,177)		(13,504,555)		(27,009,110)				
Net Assets												
Total increase (decrease) in net assets Beginning of period		89,653,115 827,039,894		(329,458,642) 1,156,498,536		(20,734,856) 443,476,845		6,096,382 437,380,463				
End of period	\$	916,693,009	\$	827,039,894	\$	422,741,989	\$	443,476,845				
Undistributed (distributions in excess of) net investment income, end of period	\$	(22,879,600)	\$	(315,958)	\$	(13,145,322)	\$	148				

¹ Consolidated Statements of Changes in Net Assets.

² A portion of the distributions from net investment income maybe deemed a return of capital or net realized gain at fiscal year end.

³ Distributions for annual periods determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

114

SEMI-ANNUAL REPORT

Increase (Decrease) in Net Assets:	J	BlackRocl Infras Trus Months Ended (une 30, 2016 (Unaudited)	tructu t (BU]	ire
Operations				
Net investment income Net realized gain Net change in unrealized appreciation/depreciation	\$	4,744,790 1,575,539 32,408,039	\$	7,916,511 7,100,028 (40,550,712)
Net increase (decrease) in net assets resulting from operations		38,728,368		(25,534,173)
Distributions to Shareholders				
From net investment income From net realized gains From return of capital		(12,274,456) ¹		$(7,096,542)^2$ $(9,103,053)^2$ $(8,349,317)^2$
Decrease in net assets resulting from distributions to shareholders		(12,274,456)		(24,548,912)
Net Assets				
Total increase (decrease) in net assets Beginning of period		26,453,912 329,747,212		(50,083,085) 379,830,297
End of period	\$	356,201,124	\$	329,747,212
Undistributed (distributions in excess of) net investment income, end of period	\$	(5,595,269)	\$	1,934,397

¹ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

² Distributions for annual periods determined in accordance with federal income tax regulations.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Statements of Cash Flows

Six Months Ended June 30, 2016 (Unaudited)	BlackRock Energy and Resources Trust (BGR)	BlackRock Enhanced Capital and Income und, Inc. (CII)	BlackRock Enhanced Equity Dividend Trust (BDJ)
Cash Provided by Operating Activities			
Net increase (decrease) in net assets resulting from operations Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash provided by operating activities:	\$ 56,682,958	\$ (11,724,584)	\$ 57,127,575
Proceeds from sales of long-term investments	137,297,135	200,812,180	337,590,128
Purchases of long-term investments	(109,685,937)	(188,890,175)	(295,832,186)
Net (purchases) sales of short-term securities	(15,274,210)	6,410,833	1,888,537
Premiums paid on closing options written	(15,209,898)	(23,958,287)	(72,968,012)
Premiums received from options written	15,547,905	29,126,196	66,239,932
Net realized (gain) loss on investments and options written	57,927,434	32,712,960	(23,802,981)
Net unrealized gain on investments, options written and foreign currency translations	(110,615,978)	(18,265,616)	(17,370,641)
(Increase) decrease in assets: Receivables:	(,,,)	(,,)	(,,,)
Dividends receivable unaffiliated	95,954	234,710	116.671
Dividends receivable affiliated	(1,340)	(1,553)	2,495
Securities lending income receivable affiliated	6,204	195	2,495
Other assets	(3,976)	(5,543)	(11,384)
Increase (decrease) in liabilities:	(3,770)	(3,343)	(11,504)
Collateral on securities loaned at value	(944,554)		
Payables:	(944,554)		
Investment advisory fees	3,470	(44,664)	(46,412)
Officer s and Trustees fees	16,624	11,963	31,759
	22,957	56,781	50,508
Other accrued expenses	22,957	50,781	50,508
Net cash provided by operating activities	15,864,748	26,475,396	53,015,989
Cash Used for Financing Activities			
Cash dividends paid to shareholders	(15,908,879)	(26,476,012)	(53,017,857)
Increase in bank overdraft	4,868		1,790
Net cash used for financing activities	(15,904,011)	(26,476,012)	(53,016,067)
Cash Impact from Foreign Exchange Fluctuations			
Cash impact from foreign exchange fluctuations	(440)	308	(63)
Cash and Foreign Currency			
Net decrease in cash and foreign currency	(39,703)	(308)	(141)
Cash and foreign currency at beginning of period	49,322	2,189	1,836
Cash and foreign currency at end of period	\$ 9,619	\$ 1,881	\$ 1,695

See Notes to Financial Statements.

116 SEMI-AN

Statements of Cash Flows (continued)

Six Months Ended June 30, 2016 (Unaudited)	Oj	BlackRock Global oportunities Equity rust (BOE)		BlackRock Health Sciences 'rust (BME)	I	BlackRock nternational Growth and Income Frust (BGY)
Cash Provided by Operating Activities						
Net decrease in net assets resulting from operations	\$	(23,610,156)	\$	(9,495,554)	\$	(31,905,446)
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash						
provided by operating activities:						
Proceeds from sales of long-term investments		270,946,177		81,081,051		182,262,868
Purchases of long-term investments		(236,120,503)		(73,674,206)		(182,545,718)
Net (purchases) sales of short-term securities		(9,930,214)		(888,116)		18,070,755
Premiums paid on closing options written		(34,705,227)		(7,640,681)		(17,507,925)
Premiums received from options written		44,058,628		8,820,156		29,216,856
Net realized (gain) loss on investments, options written and financial futures contracts		4,673,216		(12,094,551)		22,123,848
Net unrealized loss on investments, options written and foreign currency translations		25,152,180		21,743,462		23,790,566
(Increase) decrease in assets:						
Cash Pledged:						(1.105.000)
Collateral exchange traded options written						(4,105,000)
Collateral OTC derivatives						(1,106,000)
Futures contracts						(639,000)
Receivables:		(750.010)		71 700		(1.022.228)
Dividends receivable unaffiliated Dividends receivable affiliated		(759,010) (2,757)		71,722 (478)		(1,033,338) (3,185)
Securities lending income receivable affiliated		(3,970)		(142)		(3,185) 6,690
Variation margin on futures contracts		(3,970)		(142)		(127,350)
Prepaid offering costs				48,042		(127,550)
Other assets		(8,909)		(1,948)		(16,731)
Increase (decrease) in liabilities:		(0,,,0))		(1,510)		(10,701)
Collateral on securities loaned at value		1,278,403		156,732		(2,751,247)
Payables:		, ,		,		
Investment advisory fees		(74,710)		(32,091)		(57,802)
Officer s and Trustees fees		25,957		1,289		32,122
Foreign taxes						(147,618)
Other accrued expenses		37,025		(23,247)		39,802
Net cash provided by operating activities		40,956,130		8,071,440		33,597,147
Cash Used for Financing Activities						
Cash dividends paid to shareholders		(40,463,844)		(9,007,390)		(32,347,088)
Net proceeds from issuance of shares		(10,100,011)		935,772		(02,017,000)
				,		
Net cash used for financing activities		(40,463,844)		(8,071,618)		(32,347,088)
Cash Impact from Foreign Exchange Fluctuations						
Cash impact from foreign exchange fluctuations		(6,395)		54		(8,112)
Cash and Foreign Currency		10-00				
Net increase (decrease) in cash and foreign currency		485,891		(124)		1,241,947
Cash and foreign currency at beginning of period		402,399		1,212		566,830
Cash and foreign currency at end of period	\$	888,290	\$	1,088	\$	1,808,777
Non-Cash Financing Activities			¢	051 051		
Capital shares issued in reinvestment of dividends paid to shareholders			\$	871,872		

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Statements of Cash Flows (concluded)

Six Months Ended June 30, 2016 (Unaudited)	1	BlackRock Resources & Commodities Strategy Frust (BCX) ¹	BlackRock Science and Technology Trust (BST)	Ir	BlackRock Utility and frastructure Frust (BUI)
Cash Provided by Operating Activities					
Net increase (decrease) in net assets resulting from operations	\$	120,302,212	\$ (7,230,301)	\$	38,728,368
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash					
provided by operating activities:					
Proceeds from sales of long-term investments		494,845,005	185,274,088		15,919,230
Purchases of long-term investments		(447,139,992)	(170,755,952)		(8,348,259)
Net (purchases) sales of short-term securities		(10,542,982)	(2,999,657)		1,593,278
Premiums paid on closing options written		(49,349,345)	(15,899,749)		(11,992,664)
Premiums received from options written		34,296,723	18,693,924		9,663,455
Net realized (gain) loss on investments and options written		132,443,610	4,918,453		(1,592,431)
Net unrealized (gain) loss on investments, options written and foreign currency translations		(244,603,951)	2,575,465		(32,409,187)
(Increase) decrease in assets:					
Cash Pledged:					
Collateral exchange traded options written			(2,066,662)		
Collateral OTC derivatives			(450,000)		
Receivables:					
Dividends receivable unaffiliated		(688,913)	(124,601)		(147,051)
Dividends receivable affiliated		(3,122)	(148)		948
Securities lending income receivable affiliated		(457)	(3,585)		(1,612)
Other assets		(5,668)	(2,917)		(3,131)
Increase (decrease) in liabilities:					
Collateral on securities loaned at value		1,302,004	1,644,760		887,226
Payables:					
Investment advisory fees		39,591	(24,102)		12,589
Officer s and Trustees fees		3,016	(1,575)		(1,677)
Other accrued expenses		16,453	(16,150)		(3,815)
Net cash provided by operating activities		30,914,184	13,531,291		12,305,267
Cash Used for Financing Activities					
Cash dividends paid to shareholders		(30,613,799)	(13,567,484)		(12,281,650)
Decrease in bank overdraft on foreign currency at value		(247,746)			
Net cash used for financing activities		(30,861,545)	(13,567,484)		(12,281,650)
Cash Impact from Foreign Exchange Fluctuations					
Cash impact from foreign exchange fluctuations		30	2,081		57
Cash and Foreign Currency					
Net increase (decrease) in cash and foreign currency		52,669	(34,112)		23,674
Cash and foreign currency at beginning of period			88,602		23,753
Cash and foreign currency at end of period	\$	52,669	\$ 54,490	\$	47,427

¹ Consolidated Statement of Cash Flows.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

118

BlackRock Energy and Resources Trust (BGR)

	Period Six Months									Year Ended October 31,								
		Ended			No	vember 1,					ocu	, , , , , , , , , , , , , , , , , , ,						
	Jun	June 30, 2016		June 30, 2016		ar Ended	ź	2014 to										
	(Ui	naudited)	December 31, 2015		December 31, 2014			2014	2013			2012		2011				
Per Share Operating Performance																		
Net asset value, beginning of period	\$	14.05	\$	21.15	\$	24.90	\$	30.12	\$	25.95	\$	28.33	\$	25.87				
Net investment income ¹		0.14		0.29		0.07		0.25		0.12		0.13		0.06				
Net realized and unrealized gain (loss)		1.76		(5.89)		(2.41)		(1.21)		5.67		(0.74)		4.02				
Net increase (decrease) from investment operations		1.90		(5.60)		(2.34)		(0.96)		5.79		(0.61)		4.08				
Distributions: ² From net investment income From net realized gain From return of capital		(0.53) ³		(0.29) (1.21)		(0.47) (0.94)		(0.44) (3.82)		(1.62)		(0.03) (1.44) (0.30)		(0.24) (1.38)				
Total distributions		(0.53)		(1.50)		(1.41)		(4.26)		(1.62)		(1.77)		(1.62)				
Net asset value, end of period	\$	15.42	\$	14.05	\$	21.15	\$	24.90	\$	30.12	\$	25.95	\$	28.33				
Market price, end of period	\$	14.20	\$	12.53	\$	19.95	\$	23.78	\$	26.82	\$	24.28	\$	26.54				
Total Return ⁴																		
Based on net asset value		14.30%5		(27.47)%		(9.06)% ⁵		(2.36)%		23.68%		(1.76)%		16.09%				
Based on market price		18.02% ⁵		(31.42)%		(10.18)% ⁵		4.73%		17.70%		(1.88)%		10.95%				
Ratios to Average Net																		
Assets Total expenses		1.32%6		1.29%		1.30%6		1.26%		1.26%		1.28%		1.26%				
Total expenses after fees waived and/or reimbursed		1.26%6		1.26%		1.26%6		1.26%		1.25%		1.22%		1.15%				
Net investment income		2.03%6		1.60%		1.82%6		0.89%		0.42%		0.50%		0.19%				
Supplemental Data																		
Net assets, end of period (000)	\$	459,845	\$	418,981	\$	629,603	\$	741,109	\$	896,635	\$	772,457	\$	843,328				
Portfolio turnover rate		26%		56%		4%		85%		132%		86%		111%				

¹ Based on average shares outstanding.

- ² Distributions for annual periods determined in accordance with federal income tax regulations.
- ³ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁴ Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.
- ⁵ Aggregate total return.
- ⁶ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

		a Months Ended	Ve	ar Ended	No	Period vember 1, 2014 to	Year Ended October 31,													
	Jun			June 30, 2016		June 30, 2016		June 30, 2016		ur Enucu										
	(Ui	naudited)		ecember 81, 2015	December 31, 2014		2014			2013		2012		2011						
Per Share Operating Performance																				
Net asset value, beginning of period	\$	15.11	\$	15.67	\$	15.47	\$	15.31	\$	14.11	\$	13.87	\$	14.53						
Net investment income ¹		0.06		0.11		0.04		0.55		0.31		0.33		0.35						
Net realized and unrealized gain (loss)		(0.33)		0.53		0.36		0.91		2.09		1.29		0.68						
Net increase (decrease) from investment operations		(0.27)		0.64		0.40		1.46		2.40		1.62		1.03						
Distributions: ² From net investment income In excess of net investment		$(0.60)^3$		(0.14)		(0.10)		(0.65)		(0.32)		(0.33) ⁴		(0.35) ⁴						
income ⁵ From net realized gain From return of capital				(1.06)		(0.10)		(0.65)		(0.88)		$(0.20)^4$ (0.13) (0.72)		$(0.23)^4$ (1.11)						
Total distributions		(0.60)		(1.20)		(0.20)		(1.30)		(1.20)		(1.38)		(1.69)						
Net asset value, end of period	\$	14.24	\$	15.11	\$	15.67	\$	15.47	\$	15.31	\$	14.11	\$	13.87						
Market price, end of period	\$	13.45	\$	14.14	\$	13.97	\$	14.89	\$	13.52	\$	12.99	\$	12.39						
Total Return ⁶																				
Based on net asset value		$(1.44)\%^7$		4.66%		2.69%7		10.49%		18.97%		12.94%		7.56%						
Based on market price		(0.52)%7		9.86%		(4.88)%7		20.43%		14.11%		16.39%		(7.11)%						
Ratios to Average Net Assets																				
Total expenses		0.95% ^{8,9}		0.94%		0.99%8		0.93%		0.93%		0.94%		0.94%						
Total expenses after fees waived and/or reimbursed		0.95%8		0.94%		0.95%8		0.93%		0.93%		0.94%		0.93%						
Net investment income		0.87%8		0.71%		1.42%8		3.56%		2.15%		2.34%		2.40%						
Supplemental Data																				
Supplemental Data Net assets, end of period (000)	\$	628,295	\$	666,492	\$	691,380	\$	682,485	\$	675,472	\$	622,657	\$	612,145						
Portfolio turnover rate		31%		133%		2%		80%		218%		205%		190%						

- ¹ Based on average shares outstanding.
- ² Distributions for annual periods determined in accordance with federal income tax regulations.
- ³ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁴ The amount of distributions to shareholders from net investment income reported in October 31, 2012 and October 31, 2011 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.53 and \$0.58, respectively.
- ⁵ Taxable distribution.
- ⁶ Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.
- ⁷ Aggregate total return.
- ⁸ Annualized.
- ⁹ Excludes expenses incurred indirectly as a result of investments in underlying funds of 0.01%.

See Notes to Financial Statements.

120

SEMI-ANNUAL REPORT

BlackRock Enhanced Equity Dividend Trust (BDJ)

	Si	x Months				Period		Year Ended October 31,								
		Ended			No	ovember 1,										
	Ju	ne 30, 2016	Y	ear Ended	ar Ended 2014 to											
	(U	naudited)		December 31, 2015		December 31, 2014		2014		2013		2012		2011		
Per Share Operating Performance Net asset value, beginning	¢	0.70	¢	0.24	¢	0.10	¢	0.00	¢	0.00	¢	0.02	¢	0.22		
of period	\$	8.70	\$	9.24	\$	9.19	\$	8.88	\$	8.30	\$	8.03	\$	8.32		
Net investment income ¹ Net realized and		0.08		0.17		0.04		0.16		0.18		0.18		0.16		
unrealized gain (loss)		0.22		(0.15)		0.10		0.76		0.96		0.77		0.38		
Net increase from investment operations		0.30		0.02		0.14		0.92		1.14		0.95		0.54		
Distributions: ² From net investment income In excess of net investment income ⁵ From net realized gain		(0.28) ³		(0.17)		(0.03)		(0.17)		(0.18) (0.20) (0.18)		$(0.18)^4$ $(0.22)^4$		$(0.16)^4$ $(0.35)^4$		
From return of capital				(0.39)		(0.06)		(0.44)		(0110)		(0.28)		(0.32)		
Total distributions		(0.28)		(0.56)		(0.09)		(0.61)		(0.56)		(0.68)		(0.83)		
Net asset value, end of period	\$	8.72	\$	8.70	\$	9.24	\$	9.19	\$	8.88	\$	8.30	\$	8.03		
Market price, end of period	\$	7.88	\$	7.61	\$	8.12	\$	8.35	\$	7.72	\$	7.41	\$	7.29		
Total Return ⁶		4.04.07.7		1.10%		1 (0) 7 7		11.100		15110		10.00%		6.000		
Based on net asset value		4.01%7		1.10%		1.69%7		11.40%		15.11%		13.22%		6.88%		
Based on market price		7.45%7		0.63%		(1.65)%7		16.42%		12.09%		11.34%		(10.20)%		
Ratios to Average																
Net Assets Total expenses		0.87% ⁸		0.86%		0.87%8		0.87% ⁹		0.87%		0.95%		1.15%		
Total expenses after fees waived and/or reimbursed		0.84%8		0.85%		$0.84\%^{8}$		0.86% ⁹		0.87%		0.95%		1.14%		
Net investment income		2.02%8		1.85%		2.30%8		1.81%		2.13%		2.16%		1.92%		
Supplemental Data																
Net assets, end of period (000)	\$	1,647,684	\$	1,643,508	\$	1,747,070	\$	1,648,683	\$	1,594,223	\$	1,490,096	\$	575,712		

Portfolio turnover rate	18%	26%	$0\%^{10}$	63%	180%	185%	231%

- ¹ Based on average shares outstanding.
- ² Distributions for annual periods determined in accordance with federal income tax regulations.
- ³ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁴ The amount of distributions to shareholders from net investment income reported in October 31, 2012 and October 31, 2011 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.40 and \$0.51, respectively.
- ⁵ Taxable distribution.
- ⁶ Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.
- ⁷ Aggregate total return.
- ⁸ Annualized.
- ⁹ Includes reorganization costs associated with the Trust s merger. Without these costs, total expenses and total expenses after fees waived would have been 0.86% and 0.86%, respectively
- ¹⁰ Amount is less than 0.5%.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Global Opportunities Equity Trust (BOE)

	Six Months Ended				Period November 1,					Year Ended October 31,								
		e 30, 2016	Ye	ar Ended		2014 to												
	(Un	audited)		ecember 81, 2015		December 31, 2014		2014		2013		2012		2011				
Per Share Operating Performance Net asset value, beginning																		
of period	\$	14.25	\$	15.27	\$	15.54	\$	16.68	\$	14.99	\$	16.03	\$	18.68				
Net investment income ¹ Net realized and		0.09		0.11		0.00^{2}		0.14		0.12		0.20		0.17				
unrealized gain (loss)		(0.43)		0.03		(0.07)		0.07		2.82		0.72		(0.54)				
Net increase (decrease) from investment operations		(0.34)		0.14		(0.07)		0.21		2.94		0.92		(0.37)				
Distributions: ³ From net investment income In excess of net		(0.58) ⁴		(0.17)				(0.17)		(0.17)		(0.22)		(0.17) ⁵				
investment income ⁶ From net realized gain				(0.10)				(0.28)		(0.91)				$(0.68)^5$ (0.61)				
From return of capital				(0.89)		(0.20)		(0.90)		(0.17)		(1.74)		(0.82)				
Total distributions		(0.58)		(1.16)		(0.20)		(1.35)		(1.25)		(1.96)		(2.28)				
Net asset value, end of period	\$	13.33	\$	14.25	\$	15.27	\$	15.54	\$	16.68	\$	14.99	\$	16.03				
Market price, end of period	\$	11.85	\$	12.76	\$	13.13	\$	14.00	\$	14.74	\$	13.24	\$	14.95				
Total Return ⁷ Based on net asset value		(1.70)%8		1.81%		$(0.27)\%^8$		2.10%		21.93%		7.36%		(2.55)%				
Based on market price		(2.41)% ⁸		6.03%		$(0.27)\%^{8}$ $(4.82)\%^{8}$		4.09%		21.93%		1.68%		(10.93)%				
based on market price		(2.41)%*		0.03%		(4.82)%*		4.09%		21.99%		1.08%		(10.93)%				
Ratios to Average Net Assets																		
Total expenses ⁹		$1.10\%^{10}$		1.08%		$1.10\%^{10}$		1.08%		1.08%		1.10%		1.10%				
Total expenses after fees waived and/or reimbursed ⁹		$1.05\%^{10}$		1.05%		$1.07\%^{10}$		1.08%		1.08%		1.10%		1.09%				
Net investment income9		1.36%10		0.73%		0.00%10,1	1	0.83%		0.77%		1.34%		0.96%				
Supplemental Data	\$	926,269	\$	990,318	\$	1,060,687	\$	1,079,862	\$	1,159,072	\$	1,041,210	\$	1,113,920				

Net assets, end of period (000)Portfolio turnover rate 27% 72% 16% 150% 279% 298% 253% 1 Based on average shares outstanding. 2 Amount is less than \$0.005 per share. 3 Distributions for annual periods determined in accordance with federal income tax regulations. 4 A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end. 5 The amount of distributions to shareholders from net investment income reported in October 31, 2011 and October 31, 2010 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.85 and \$1.44, respectively. 6 Taxable distribution. 7 Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.

- ⁸ Aggregate total return.
- ⁹ Excludes expenses incurred indirectly as a result of investments in underlying funds as follows:

			Period				
	Six Months				Year Ended	October 31,	
			November 1,				
	Ended						
		Year Ended	2014 to				
	June 30, 2016						
		December	December				
	(Unaudited)	31, 2015	31, 2015	2014	2013	2012	2011
Investments in							
underlying funds	0.01%	0.01%					

- ¹⁰ Annualized.
- ¹¹ Amount is less than 0.005%.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

122

BlackRock Health Sciences Trust (BME)

	Siz	x Months				Period			Y	ear Ended	Octo	ober 31,		
		Ended			No	vember 1,								
	Jun	ne 30, 2016	Ye	ar Ended	2	2014 to								
	(U	naudited)		ecember 61, 2015		ecember 31, 2014		2014		2013		2012		2011
Per Share Operating Performance														
Net asset value, beginning of period	\$	36.19	\$	38.61	\$	40.22	\$	34.92	\$	28.34	\$	26.65	\$	27.19
Net investment income (loss) ¹ Net realized and unrealized gain		0.02		(0.06)		(0.01)		$(0.00)^2$		0.12		0.08		(0.01)
(loss)		(1.17)		4.34		1.10		9.14		8.85		4.11		1.71
Net increase (decrease) from investment operations		(1.15)		4.28		1.09		9.14		8.97		4.19		1.70
Distributions: ³ From net investment income From net realized gain		(1.20) ⁴		(0.63) (6.07)		(0.01) (2.69)		(0.10) (3.74)		(0.06) (2.33)		(0.09) (2.41)		(2.24)
Total distributions		(1.20)		(6.70)		(2.70)		(3.84)		(2.39)		(2.50)		(2.24)
Net asset value, end of period	\$	33.84	\$	36.19	\$	38.61	\$	40.22	\$	34.92	\$	28.34	\$	26.65
Market price, end of period	\$	35.62	\$	39.35	\$	42.70	\$	41.37	\$	33.56	\$	27.86	\$	25.81
Total Return ⁵														
Based on net asset value		$(3.11)\%^{6}$		10.70%		2.38%6		28.00%		33.37%		16.42%		6.43%
Based on market price		(6.25)% ⁶		8.87%		10.07% ⁶		36.99%		30.38%		18.17%		3.26%
Ratios to Average Net Assets														
Total expenses		1.15%7,8,9		1.13%		1.16%7		1.11%		1.12%		1.13%		1.14%
Total expenses after fees waived and/or reimbursed and excluding amortization of offering costs		1.13%7		1.12%		1.11%7		1.11%		1.12%		1.13%		1.13%
Net investment income (loss)		0.11%7		(0.14)%		(0.10)%7		(0.01)%		0.38%		0.29%		(0.02)%
Supplemental Data Net assets, end of period (000)	\$	279,028	\$	297,530	\$	303,103	\$	313,933	\$	270,161	\$	218,377	\$	202,675
• · · ·	φ		φ		φ		φ		φ		φ		φ	
Portfolio turnover rate		29%		68%		6%		74%		155%		209%		226%

¹ Based on average shares outstanding.

- ² Amount is greater than (0.005) per share.
- ³ Distributions for annual periods determined in accordance with federal income tax regulations.
- ⁴ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁵ Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.
- ⁶ Aggregate total return.
- ⁷ Annualized.
- ⁸ Offering costs were not annualized in the calculation of the expense ratios. If these expenses were annualized, the total expenses would have been 1.16%.
- ⁹ Excludes expenses incurred indirectly as a result of investments in underlying funds of 0.01%.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock International Growth and Income Trust (BGY)

	Siv	x Months				Period		v	ear Ended	Octo	ober 31	
		Ended			No	vember 1,				oen	, joer 51,	
		ne 30, 2016	Ye	ar Ended	:	2014 to						
	(U	naudited)		ecember 31, 2015		ecember 31, 2014	2014		2013		2012	2011
Per Share Operating Performance												
Net asset value, beginning of period	\$	6.95	\$	7.61	\$	7.89	\$ 9.05	\$	8.28	\$	8.72	\$ 10.52
Net investment income (loss) ¹ Net realized and unrealized gain		0.07		0.08		$(0.00)^2$	0.10		0.13		0.16	0.14
(loss)		(0.37)		(0.15)		(0.17)	(0.53)		1.31		0.35	(0.58)
Net increase (decrease) from investment operations		(0.30)		(0.07)		(0.17)	(0.43)		1.44		0.51	(0.44)
Distributions: ³ From net investment income In excess of net investment		$(0.29)^4$		(0.11)			(0.13)		(0.17)		(0.18)	(0.14) ⁵
income ⁶ From return of capital				(0.48)		(0.11)	(0.08) (0.52)		(0.50)		(0.77)	$(0.53)^5$ (0.69)
Total distributions		(0.29)		(0.59)		(0.11)	(0.73)		(0.67)		(0.95)	(1.36)
Net asset value, end of period	\$	6.36	\$	6.95	\$	7.61	\$ 7.89	\$	9.05	\$	8.28	\$ 8.72
Market price, end of period	\$	5.75	\$	6.24	\$	6.74	\$ 7.26	\$	8.14	\$	7.41	\$ 7.88
Total Return ⁷												
Based on net asset value		(3.75)%8		(0.47)%		(2.10)%8	(4.49)%		19.25%		7.65%	(4.55)%
Based on market price		(3.08)% ⁸		0.90%		(5.77)% ⁸	(2.29)%		19.86%		6.61%	(14.07)%
Ratios to Average Net Assets												
Total expenses ⁹		1.12%10		1.09%		$1.12\%^{10}$	1.10%		1.09%		1.11%	1.10%
Total expenses after fees waived and/or reimbursed ⁹		1.01% ¹⁰		1.01%		$1.03\%^{10}$	1.05%		1.07%		1.11%	1.10%
Net investment income (loss) ⁹		2.10% ¹⁰		1.09%		(0.13)% ¹⁰	1.17%		1.49%		1.97%	1.37%
Supplemental Data Net assets, end of period (000)	\$	699,912	\$	763,986	\$	836,552	\$ 867,986	\$	995,736	\$	910,481	\$ 959,153
Portfolio turnover rate		32%		67%		14%	195%		266%		226%	217%

- ¹ Based on average shares outstanding.
- ² Amount is greater than (0.005) per share.
- ³ Distributions for annual periods determined in accordance with federal income tax regulations.
- ⁴ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁵ The amount of distributions to shareholders from net investment income reported in October 31, 2011 has been reclassified to allocate the amount between distributions from net investment income and distributions in excess of net investment income; both of which were included in the prior year net investment income in the amount of \$0.67.
- ⁶ Taxable distribution.
- ⁷ Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.
- ⁸ Aggregate total return.
- ⁹ Excludes expenses incurred indirectly as a result of investments in underlying funds as follows:

			Period				
	Six Months				Year Ended	October 31,	
			November 1,				
	Ended						
		Year Ended	2014 to				
	June 30, 2016						
		December	December				
	(Unaudited)	31, 2015	31, 2015	2014	2013	2012	2011
Investments in							
underlying funds	0.01%	0.01%					

¹⁰ Annualized.

See Notes to Financial Statements.

124

SEMI-ANNUAL REPORT

Consolidated Financial Highlights

BlackRock Resources & Commodities Strategy Trust (BCX)

							Year	· En	ded October 3	1			Period
												Μ	Iarch 30,
	Si	x Months				Period							2011 ¹
		Ended			No	ovember 1,						ť	through
			Ye	ar Ended		2014 to							
		ne 30, 2016		ecember		December						U	ctober 31,
	(U	naudited)	3	31, 2015		31, 2014	2014		2013		2012		2011
Per Share Operating Performance													
Net asset value, beginning of period	\$	8.35	\$	11.67	\$	12.50	\$ 13.54	\$	15.42	\$	16.83	\$	19.10 ²
Net investment income ³ Net realized and unrealized		0.08		0.25		0.04	0.23		0.25		0.18		0.03
gain (loss)		1.13		(2.76)		(0.72)	(0.27)		(0.97)		(0.19)		(1.57)
Net increase (decrease) from investment operations		1.21		(2.51)		(0.68)	(0.04)		(0.72)		(0.01)		(1.54)
Distributions: ⁴ From net investment income		(0.31) ⁵		(0.25)		(0.02)	(0.31)		(0.14)		(0.26)		
From net realized gain From return of capital				(0.56)		(0.13)	(0.69)		(1.02)		(0.01) (1.13)		(0.24) (0.46)
Total distributions		(0.31)		(0.81)		(0.15)	(1.00)		(1.16)		(1.40)		(0.70)
Capital charges with respect to the issuance of shares													(0.03)
Net asset value, end of period	\$	9.25	\$	8.35	\$	11.67	\$ 12.50	\$	13.54	\$	15.42	\$	16.83
Market price, end of period	\$	7.70	\$	7.11	\$	9.71	\$ 10.78	\$	11.68	\$	14.12	\$	14.95
Total Return ⁶													
Based on net asset value		15.67%7		(21.31)%		$(5.20)\%^7$	0.61%		(3.61)% ⁸		0.90%		$(7.80)\%^7$
Based on market price		13.08%7		(19.47)%		(8.53)% ⁷	0.58%		(9.19)%		4.02%		(21.79)% ⁷
Ratios to Average Net Assets													
Total expenses		1.09%9		1.07%		1.15%9	1.35%10		1.27%		1.25%		1.35%9
Total expenses after fees waived and/or reimbursed		1.09%9		1.07%		1.04%9	1.06% ¹⁰		1.07%		1.05%		1.13%9
Net investment income		1.92%9		2.43%		2.01%9	1.70%		1.76%		1.14%		0.27%9
Supplemental Data	\$	916,693	\$	827,040	\$	1,156,499	\$ 582,220	\$	630,617	\$	718,016	\$	783,792

Net	assets, end of period	c	, 3					
(00								
Por	tfolio turnover rate	56%	74%	2%	62%	156%	100%	27%
1	Commencement of investment of	operations. This in	formation include	s the initial investme	nt by BlackRock	HoldCo2, Inc.		
2	Net asset value, beginning of pe	eriod, reflects a dec	duction of \$0.8975	5 per share sales char	ge from initial of	fering price of \$20.0	00 per share.	
3	Based on average shares outstar	nding.						
4	Distributions for annual periods	determined in acc	cordance with fede	eral income tax regul	ations.			
5	A portion of the distributions from	om net investment	income may be d	eemed a return of ca	pital or net realize	ed gain at fiscal year	end.	
6	Total returns based on market p applicable, excludes the effects	rice, which can be of any sales charg	significantly grea es and assumes th	ter or less than the n e reinvestment of dis	et asset value, ma stributions.	y result in substanti	ally different retur	ns. Where
7	Aggregate total return.							
8	Includes a payment from an affi payment the Trust s total return			urities lending rever	ue which impacto	ed the Trust s total i	return. Not includi	ng this
9	Annualized.							

¹⁰ Includes reorganization costs associated with the Trust s merger. Without these costs, total expenses and total expenses after fees waived would have been 1.26% and 1.06%, respectively.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

BlackRock Science and Technology Trust (BST)

					Period	
	June	onths Ended e 30, 2016 naudited)	ar Ended ber 31, 2015	October 30, 2014 ¹ to December 31, 2014		
Per Share Operating Performance						
Net asset value, beginning of period	\$	19.70	\$ 19.43	\$	19.102	
Net investment income (loss) ³ Net realized and unrealized gain (loss)		0.02 (0.34)	0.03 1.44		(0.01) 0.48	
Net increase (decrease) from investment operations		(0.32)	1.47		0.47	
Distributions: ⁴ From net investment income In excess of net investment income From return of capital		(0.60) ⁵	(0.03) (0.01) (1.16)		$(0.00)^6$ (0.10)	
Total distributions		(0.60)	(1.20)		(0.10)	
Capital Charges with respect to the issuance of Shares					(0.04)	
Net asset value, end of period	\$	18.78	\$ 19.70	\$	19.43	
Market price, end of period	\$	16.50	\$ 17.31	\$	17.59	
Total Return ⁷						
Based on net asset value		(1.15)%8	8.61%		2.31%8	
Based on market price		(1.11)%8	5.36%		(11.55)%8	
Ratios to Average Net Assets						
Total expenses		1.10%9	1.12%		1.19%9	
Total expenses after fees waived and paid indirectly		0.90%9	0.92%		0.97% ⁹	
Net investment income (loss)		0.17%9	0.15%		(0.24)% ⁹	
Supplemental Data						
Net assets, end of period (000)	\$	422,742	\$ 443,477	\$	437,380	
Portfolio turnover rate		41%	91%		7%	

¹ Commencement of investment operations. This information includes the initial investment by BlackRock HoldCo2, Inc.

² Net asset value, beginning of period, reflects a deduction of \$0.8975 per share sales charge from the initial offering price of \$20.00 per share.

- ³ Based on average shares outstanding.
- ⁴ Distributions for annual periods determined in accordance with federal income tax regulations.
- ⁵ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁶ Amount is greater than (0.005) per share.
- ⁷ Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.
- ⁸ Aggregate total return.
- ⁹ Annualized.

See Notes to Financial Statements.

126

SEMI-ANNUAL REPORT

BlackRock Utility and Infrastructure Trust (BUI)

				Year Ended October 31,				Period November 25,				
	Siz	x Months				Period					INUV	2011 ¹
				ar Ended		vember 1,					1	hrough
	Jun			ember 31,	2014 to December							ctober 31,
	(Ui	naudited)		2015		31, 2014		2014		2013		2012
Per Share Operating Performance	¢	10.50	¢	22.47	¢	22.40	¢	20.79	¢	20.22	¢	10.102
Net asset value, beginning of period	\$	19.50	\$	22.47	\$	22.40	\$	20.78	\$	20.22	\$	19.10 ²
Net investment income ³ Net realized and unrealized gain (loss)		0.28 2.02		0.47 (1.99)		0.11 0.20		0.51 2.68		0.57 1.44		0.54 1.71
Net increase (decrease) from investment operations		2.30		(1.52)		0.31		3.19		2.01		2.25
Distributions: ⁴												
From net investment income		$(0.73)^5$		(0.42)		(0.10)		(0.51)		(0.52)		(0.49)
From net realized gain				(0.54)		· · /		(0.37)		(0.42)		(0.41)
From return of capital				(0.49)		(0.14)		(0.69)		(0.51)		(0.19)
Total distributions		(0.73)		(1.45)		(0.24)		(1.57)		(1.45)		(1.09)
Capital charges with respect to the issuance of shares												(0.04)
Net asset value, end of period	\$	21.07	\$	19.50	\$	22.47	\$	22.40	\$	20.78	\$	20.22
Market price, end of period	\$	20.37	\$	16.78	\$	20.74	\$	20.02	\$	18.36	\$	19.03
Total Return ⁶												
Based on net asset value		12.36%7		(6.09)%		1.50%7		16.94%		11.18%		12.05%7
Based on market price		26.23%7		(12.45)%		4.82%7		18.29%		4.37%		0.71%7
Ratios to Average Net Assets												0
Total expenses		1.12%8		1.11%		1.17%8		1.10%		1.11%		1.12%8
Total expenses after fees waived and/or reimbursed		1.12%8		1.11%		1.11%8		1.10%		1.10%		1.11%8
Total expenses after fees waived and/or reimbursed and excluding excise tax		1.12%8		1.11%		1.11%8		1.10%		1.10%		1.10%8
Net investment income		2.84%8		2.24%		2.83%8		2.36%		2.83%		2.94%8
Supplemental Data												
Net assets, end of period (000)	\$	356,201	\$	329,747	\$	379,830	\$	378,762	\$	351,325	\$	341,939

Portfolio turnover rate	3%	20%	2%	41%	133%	90%

- 1 Commencement of investment operations. This information includes the initial investment by BlackRock HoldCo2, Inc.
- ² Net asset value, beginning of period, reflects a deduction of \$0.8975 per share sales charge from initial offering price of \$20.00 per share.
- ³ Based on average shares outstanding.
- ⁴ Distributions for annual periods determined in accordance with federal income tax regulations.
- ⁵ A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- ⁶ Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions.
- ⁷ Aggregate total return.
- ⁸ Annualized.

See Notes to Financial Statements.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Notes to Financial Statements

1. Organization:

The following are registered under the Investment Company Act of 1940, as amended (the 1940 Act), as closed-end management investment companies and are referred to herein collectively as the Trusts or individually, as a Trust :

	Herein Referred		Diversification
Fund Name	To As	Organized	Classification
BlackRock Energy and Resources Trust	BGR	Delaware	Non-diversified
BlackRock Enhanced Capital and Income Fund, Inc.	CII	Maryland	Diversified
BlackRock Enhanced Equity Dividend Trust	BDJ	Delaware	Diversified
BlackRock Global Opportunities Equity Trust	BOE	Delaware	Diversified
BlackRock Health Sciences Trust	BME	Delaware	Non-diversified
BlackRock International Growth and Income Trust	BGY	Delaware	Non-diversified
BlackRock Resources & Commodities Strategy Trust	BCX	Delaware	Non-diversified
BlackRock Science and Technology Trust	BST	Delaware	Non-diversified
BlackRock Utility and Infrastructure Trust	BUI	Delaware	Non-diversified
		((I D I	CTT (1 D 1

The Boards of Directors/Boards of Trustees of the Trusts are collectively referred to throughout this report as the Board of Trustees or the Board, and the directors/trustees thereof are collectively referred to throughout this report as Trustees. The Trusts determine and make available for publication the NAVs of their shares on a daily basis.

The Trusts, together with certain other registered investment companies advised by BlackRock Advisors, LLC (the Manager) or its affiliates, are included in a complex of closed-end funds referred to as the Closed-End Complex.

Basis of Consolidation: The accompanying consolidated financial statements of BCX include the accounts of BlackRock Cayman Resources & Commodities Strategy Fund, Ltd. (the Subsidiary), which is a wholly owned subsidiary of BCX and primarily invests in commodity-related instruments. The Subsidiary enables BCX to hold these commodity-related instruments and satisfy regulated investment company tax requirements. BCX may invest up to 25% of its total assets in the Subsidiary. During the six months ended June 30, 2016, there were no transactions in the Subsidiary. Intercompany accounts and transactions, if any, have been eliminated. The Subsidiary is subject to the same investment policies and restrictions that apply to BCX, except that the Subsidiary may invest without limitation in commodity-related instruments.

2. Significant Accounting Policies:

The Trusts financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP), which may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates. Each Trust is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to investment companies. The following is a summary of significant accounting policies:

Foreign Currency: The Trusts books and records are maintained in U.S. dollars. Purchases and sales of investments are recorded at the rates of exchange prevailing on the respective dates of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the investments denominated in that currency will lose value; the opposite effect occurs if the U.S. dollar falls in relative value.

Each Trust does not isolate the portion of the results of operations arising as a result of changes in the exchange rates from the changes in the market prices of investments held or sold for financial reporting purposes. Accordingly, the effects of changes in exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those investments but are included as a component of net realized and unrealized gain (loss) from investments. Each Trust reports realized currency gains (losses) on foreign currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income for federal income tax purposes.

Segregation and Collateralization: In cases where a Trust enters into certain investments (e.g., futures contracts, options written and forward foreign currency exchange contracts), that would be treated as senior securities for 1940 Act purposes, such Trust may segregate or designate on

its books and records cash or liquid assets having a market value at least equal to the amount of its future obligations under such investments. Doing so allows the investment to be excluded from treatment as a senior security. Furthermore, if required by an exchange or counterparty agreement, a Trust may be required to deliver/deposit cash and/or securities to/with an exchange, or broker-dealer or custodian as collateral for certain investments or obligations.

SEMI-ANNUAL REPORT

128

Notes to Financial Statements (continued)

Investment Transactions and Investment Income: For financial reporting purposes, investment transactions are recorded on the dates the transactions are entered into (the trade dates). Realized gains and losses on investment transactions are determined on the identified cost basis. Dividend income is recorded on the ex-dividend dates. Dividends from foreign securities where the ex-dividend date may have passed are subsequently recorded when the Trust is informed of the ex-dividend date. Under the applicable foreign tax laws, a withholding tax at various rates may be imposed on capital gains, dividends and interest. Upon notification from issuers, some of the dividend income received from a real estate investment trust may be redesignated as a reduction of cost of the related investment and/or realized gain. Interest income, including amortization and accretion of premiums and discounts on debt securities, is recognized on the accrual basis.

Distributions: Distributions paid by the Trusts are recorded on the ex-dividend date. Subject to each Trust s level distribution plan, each Trust intends to make monthly cash distributions to shareholders, which may consist of net investment income, net options premium, net realized and unrealized gains on investments, and/or return of capital.

Portions of return of capital distributions under U.S. GAAP may be taxed at ordinary income rates.

The character of distributions is determined in accordance with federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds a Trust s current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital. Realized net capital gains can be offset by capital losses carried forward from prior years. However, certain Trusts have capital loss carryforwards from pre-2012 tax years that offset realized net capital gains but do not offset current earnings and profits. Consequently, if distributions in any tax year are less than a Trust s current earnings and profits but greater than net investment income and net realized capital gains (taxable income), distributions in excess of taxable income are not treated as non-taxable return of capital, but rather may be taxable to shareholders at ordinary income rates. Under certain circumstances, taxable excess distributions could be significant.

Net income and realized gains from investments held by the Subsidiary are treated as ordinary income for tax purposes. If a net loss is realized by the Subsidiary in any taxable year, the loss will generally not be available to offset the Trusts ordinary income and/or capital gains for that year.

Deferred Compensation Plan: Under the Deferred Compensation Plan (the Plan) approved by each Trust s Board, the independent Trustees (Independent Trustees) may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as though equivalent dollar amounts had been invested in common shares of certain other BlackRock Closed-End Funds selected by the Independent Trustees. This has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain other BlackRock Closed-End Funds.

The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust, if applicable. Deferred compensation liabilities are included in officer s and trustees fees payable in the Statements of Assets and Liabilities and will remain as a liability of the Trusts until such amounts are distributed in accordance with the Plan.

Indemnifications: In the normal course of business, the Trusts enter into contracts that contain a variety of representations that provide general indemnification. The Trusts maximum exposure under these arrangements is unknown because it involves future potential claims against the Trust, which cannot be predicted with any certainty.

Other: Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several Trusts are prorated among those Trusts on the basis of relative net assets or other appropriate methods.

The Trusts have an arrangement with custodian whereby fees may be reduced by credits earned on uninvested cash balances, which, if applicable, are shown as fees paid indirectly in the Statements of Operations. The custodian imposes fees on overdrawn cash balances, which can be offset by accumulated credits earned or may result in additional custody charges.

Correction of Previously Issued Financial Statements: For the year ended December 31, 2015, the Distributions in excess of net investment income was overstated by \$168,242 within the section Net Assets Consist of on the Statements of Assets and Liabilities for BGY. As a result, there was a corresponding understatement of Net Assets within this section. In addition, the Statements of Changes in Net Assets and the Financial Highlights reflected the immaterial error in the Distributions in excess of net investment income and Net Assets amounts, respectively. The affiliated income disclosed in the Notes to the Schedule of Investments was overstated by \$168,242 as well. Management elected to revise the financial statements to correct these errors. The corrections have no impact on the amounts previously reported for net investment income, performance or net asset value per share. In addition, there is no impact to reports previously filed for other interim or annual periods.

SEMI-ANNUAL REPORT

Notes to Financial Statements (continued)

3. Investment Valuation and Fair Value Measurements:

Investment Valuation Policies: The Trusts investments are valued at fair value (also referred to as market value within the financial statements) as of the close of trading on the New York Stock Exchange (NYSE) (generally 4:00 p.m., Eastern time). U.S. GAAP defines fair value as the price the Trusts would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date. The Trusts determine the fair values of its financial instruments using various independent dealers or pricing services under policies approved by the Board of Trustees of each Trust. The BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) is the committee formed by management to develop global pricing policies and procedures and to oversee of the pricing function for all financial instruments.

Fair Value Inputs and Methodologies: The following methods (or techniques) and inputs are used to establish the fair value of the each Trust s assets and liabilities:

Equity investments traded on a recognized securities exchange are valued at the official closing price each day, if available. For equity investments traded on more than one exchange, the official close price on the exchange where the stock is primarily traded is used. Equity investments traded on a recognized exchange for which there were no sales on that day may be valued at the last available bid (long positions) or ask (short positions) price. Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of business on the NYSE. Occasionally, events affecting the values of such instruments may occur between the foreign market close and the close of business on the NYSE that may not be reflected in the computation of the Trust s net assets. Each business day, the Trust s use a pricing service to assist with the valuation of certain foreign exchange-traded equity securities and foreign exchange-traded and over-the-counter (OTC) options (the Systematic Fair Value Price). Using current market factors, the Systematic Fair Value Price is designed to value such foreign securities and foreign options at fair value as of the close of business on the NYSE, which follows the close of the local markets.

Investments in open-end registered investment companies are valued at net asset value (NAV) each business day.

Each Trust values its investment in BlackRock Liquidity Series, LLC, Money Market Series (the Money Market Series) at fair value, which is ordinarily based upon its pro rata ownership in the underlying fund s net assets. The Money Market Series seeks current income consistent with maintaining liquidity and preserving capital. Although the Money Market Series is not registered under the 1940 Act, its investments will follow the parameters of investments by a money market fund that is subject to Rule 2a-7 under the 1940 Act. The Trusts may withdraw up to 25% of its investment daily, although the manager of the Money Market Series, in its sole discretion, may permit an investor to withdraw more than 25% on any one day.

Futures contracts traded on exchanges are valued at their last sale price.

Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates determined as of the close of business on the NYSE. Forward foreign currency exchange contracts are valued at the mean between the bid and ask prices and are determined as of the close of business on the NYSE. Interpolated values are derived when the settlement date of the contract is an interim date for which quotations are not available.

Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day s price will be used, unless it is determined that the prior day s price no longer reflects the fair value of the option. Over-the-counter (OTC) options and options on swaps (swaptions) are valued by an independent pricing service using a mathematical model, which incorporates a number of market data factors, such as the trades and prices of the underlying instruments. If events (e.g., a company announcement, market volatility or a natural disaster) occur that are expected to materially affect the value of such instruments, or in the event that the application of these methods of valuation results in a price for an investment that is deemed not to be

representative of the market value of such investment, or if a price is not available, the investment will be valued by the Global Valuation Committee, or its delegate, in accordance with a policy approved by the Board as reflecting fair value (Fair Valued Investments). When determining the price for Fair Valued Investments, the Global Valuation Committee, or its delegate, seeks to determine the price that each Trust might reasonably expect to receive or pay from the current sale or purchase of that asset or liability in an arm s-length transaction. Fair value determinations shall be based upon all available factors that the Global Valuation Committee, or its delegate, deems relevant consistent with the principles of fair value measurement, which include the market approach, income approach and/or in the case of recent investments, the cost approach, as appropriate. The market approach generally consists of using comparable market transactions. The income approach generally is used to discount future cash flows to present value and is adjusted for liquidity as appropriate. These factors include but are not limited to: (i) attributes specific to the investment or asset; (ii) the principal market for the investment or asset; (iii) the customary participants in the principal market for the investment or asset; (iv) data assumptions by market participants for the investment or asset, if reasonably available; (v) quoted prices for similar investments, credit risks, recovery rates, liquidation amounts and/or default rates. Due to the inherent uncertainty of valuations of such investments, the fair values may differ from the values that would have been used had an active market existed. The Global Valuation Committee, or its delegate, employs various methods for calibrating

130

SEMI-ANNUAL REPORT

valuation approaches for investments where an active market does not exist, including regular due diligence of each Trust s pricing vendors, regular reviews of key inputs and assumptions, transactional back-testing or disposition analysis to compare unrealized gains and losses to realized gains and losses, reviews of missing or stale prices and large movements in market values and reviews of any market related activity. The pricing of all Fair Valued Investments is subsequently reported to the Board or a committee thereof on a quarterly basis.

Fair Value Hierarchy: Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Trust has the ability to access

Level 2 other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market corroborated inputs)

Level 3 unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including each Trust s own assumptions used in determining the fair value of investments and derivative financial instruments) The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. The significant unobservable inputs used by the Global Valuation Committee in determining the price for Fair Valued Investments are typically categorized as Level 3. The fair value hierarchy for each Trust s investments and derivative financial instruments have been included in the Schedules of Investments.

Changes in valuation techniques may result in transfers into or out of an assigned level within the hierarchy. In accordance with each Trust s policy, transfers between different levels of the fair value hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investments and derivative financial instruments associated with investing in those securities.

4. Securities and Other Investments:

Preferred Stock: Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well) but is subordinated to the liabilities of the issuer in all respects. As a general rule, the market value of preferred stock with a fixed dividend rate and no conversion element varies inversely with interest rates and perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer s board of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.

Securities Lending: Certain Trusts may lend their securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges and maintains with the Trusts collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. Government. The initial collateral received by each Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value of at least 105% for all other securities. The collateral is maintained thereafter, at a value equal to at least 100% of the current market value of the securities on loan. The market value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust, or excess collateral returned by the Trust, on the next business day. During the term of the loan, the Trusts are entitled to all distributions made on or in respect of the loaned securities. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions.

The market value of any securities on loan, all of which were classified as common stocks in the Trusts Schedules of Investments, and the value of any related collateral are shown separately in the Statements of Assets and Liabilities as a component of investments at value unaffiliated, and collateral on securities loaned at value, respectively. As of period end, any securities on loan were collateralized by cash. The cash collateral invested by the securities lending agent, BlackRock Investment Management, LLC (BIM), if any, is disclosed in the Schedules of Investments.

Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each an MSLA) which provide the right, in the event of default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the

SEMI-ANNUAL REPORT

JUNE 30, 2016

defaulting party or request additional collateral. In the event that a borrower defaults, the Trusts as lender, would offset the market value of the collateral received against the market value of the securities loaned. When the value of the collateral is greater than that of the market value of the securities loaned, the lender is left with net amount payable to the defaulting party. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty s bankruptcy or insolvency. Under the MSLA, absent an event of default the borrower can resell or re-pledge the loaned securities, and the Trust can reinvest cash collateral received in connection with loaned securities. Upon an event of default, the parties, obligations to return the securities or collateral to the other party are extinguished, and the parties can resell or re-pledge the loaned securities or the collateral received in connection with the defaulting party s met payment obligation for all transactions under the MSLA. The defaulting party remains liable for any deficiency.

As of period end, the following table is a summary of the Trusts securities lending agreements by counterparty which are subject to offset under an MSLA:

BOE			
DUE	Securities Loaned	Cash Collateral	Net
Counterparty	at Value \$1,582,304	Received ¹	Amount
Goldman Sachs & Co.	\$1,382,304	\$(1,582,304)	
ВМЕ	Securities Loaned	Cash Collateral	Net
	Securities Ebaneu	Cash Conateral	Ince
Counterparty Citigroup Global Markets, Inc. Credit Suisse Securities (USA) LLC Total	at Value \$ 32,686 120,470 \$153,156	Received ¹ \$ (32,686) (120,470) \$(153,156)	Amount
BCX	Securities Loaned	Cash Collateral	Net
Counterparty Goldman Sachs & Co. Morgan Stanley & Co. LLC Total	at Value \$1,003,473 233,328 \$1,236,801	Received ¹ \$(1,003,473) (233,328) \$(1,236,801)	Amount
BST	Securities Loaned	Cash Collateral	Net
Counterparty Deutsche Bank Securities, Inc.	at Value \$ 30,913	Received ¹	Amount
JP Morgan Securities LLC Merrill Lynch, Pierce, Fenner & Smith, Inc. Total	781,190 959,930 \$1,772,033	\$ (30,400) (781,190) (944,000) \$(1,755,590)	\$ 513 15,930 \$16,443
BUI	Securities	Cash Collateral	Net
Counterparty JP Morgan Securities LLC	Loaned at Value \$370,069	Received1 \$(370,069)	Amount

Merrill Lynch, Pierce, Fenner & Smith, Inc.	486,169	(486,169)
Total	\$856,238	\$(856,238)

¹ Collateral with a value of \$1,705,953, \$156,732, \$1,337,693, \$1,763,760 and \$887,226 has been received in connection with securities lending agreements for BOE, BME, BCX, BST and BUI, respectively. Collateral received in excess of the value of securities loaned from the individual counterparty is not shown for financial reporting purposes in the table above.

The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM s indemnity allows for full replacement of the securities loaned if the collateral received does not cover the value on the securities loaned in the event of borrower default. The Trusts could suffer a loss if the value of an investment purchased with cash collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the original cash collateral received.

SEMI-ANNUAL REPORT

132

JUNE 30, 2016

5. Derivative Financial Instruments:

The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to manage their exposure to certain risks such as equity risk. Derivative financial instruments categorized by risk exposure are included in the Schedule of Investments. These contracts may be transacted on an exchange or OTC.

Futures Contracts: Certain Trusts invest in long and/or short positions in futures and options on futures contracts to gain exposure to, or manage exposure to, changes in the value of equity securities (equity risk).

Futures contracts are agreements between the Trusts and a counterparty to buy or sell a specific quantity of an underlying instrument at a specified price and on a specified date. Depending on the terms of a contract, it is settled either through physical delivery of the underlying instrument on the settlement date or by payment of a cash amount on the settlement date. Upon entering into a futures contract, the Trusts are required to deposit initial margin with the broker in the form of cash or securities in an amount that varies depending on a contract size and risk profile. The initial margin deposit must then be maintained at an established level over the life of the contract.

Securities deposited as initial margin are designated in the Schedules of Investments and cash deposited, if any, is shown as cash pledged for futures contracts in the Statements of Assets and Liabilities. Pursuant to the contract, the Trusts agree to receive from or pay to the broker an amount of cash equal to the daily fluctuation in market value of the contract (variation margin). Variation margin is recorded as unrealized appreciation (depreciation) and, if any, shown as variation margin receivable or payable on futures contracts in the Statements of Assets and Liabilities. When the contract is closed, a realized gain or loss is recorded in the Statements of Operations equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed. The use of futures contracts involves the risk of an imperfect correlation in the movements in the price of futures contracts and interest foreign currency exchange rates or underlying assets.

Forward Foreign Currency Exchange Contracts: Certain Trusts enter into forward foreign currency exchange contracts to gain or deduce exposure, to foreign currencies (foreign currency exchange rate risk).

A forward foreign currency exchange contract is an agreement between two parties to buy and sell a currency at a set exchange rate on a specified date. These contracts help to manage the overall exposure to the currencies in which some of the investments held by the Trusts are denominated and in some cases, may be used to obtain exposure to a particular market.

The contract is marked to market daily and the change in market value is recorded as unrealized appreciation (depreciation) in the Statements of Assets and Liabilities. When a contract is closed, a realized gain or loss is recorded in the Statements of Operations equal to the difference between the value at the time it was opened and the value at the time it was closed. Non-deliverable forward foreign currency exchange contracts are settled with the counterparty in cash without the delivery of foreign currency. The use of forward foreign currency exchange contracts involves the risk that the value of a forward foreign currency exchange contract changes unfavorably due to movements in the value of the referenced foreign currencies.

Options: Certain Trusts purchase and write call and put options to increase or decrease their exposure to underlying instruments (including equity risk and/or commodity price risk) and/or, in the case of options written, to generate gains from options premiums.

A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised), the underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the writer to buy the underlying instrument at the exercise or strike price at any time or at a specified time during the option period.

Premium paid on option purchased (and premium received on options written) as well as the daily fluctuation in market value, are included in investments at value unaffiliated and options written at value, respectively, in the Statements of Assets and Liabilities. When an instrument is purchased or sold through the exercise of an option, the premium is offset against the cost or proceeds of the underlying instrument. When an option expires a realize a gain or loss is recorded in the Statements of Operations to the extent of the premiums received or paid. When an option is closed or sold, a gain or loss is recorded in the Statements of Operations to the extent the cost of the closing transaction exceeds the premiums received or paid). When the Trusts write a call option, such option is typically covered, meaning that the they hold the underlying instrument subject to being called by the option counterparty. When the Trusts write a put option, such option is covered by cash in an amount sufficient to cover the obligation.

In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that the Trusts may not be able to enter into a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when it otherwise would not, or at a price different from the current market value.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Master Netting Arrangements: In order to define their contractual rights and to secure rights that will help them mitigate their counterparty risk, the Trusts may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (ISDA Master Agreement)) or similar agreement with their counterparties. An ISDA Master Agreement is a bilateral agreement between each Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting terms and netting provisions in the event of a default and/or termination event. Under an ISDA Master Agreement, each Trust may, under certain circumstances, offset with the counterparty certain derivative financial instruments payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the ISDA Master Agreement typically permit a single net payment in the event of default including the bankruptcy or insolvency laws of a particular jurisdiction may restrict or prohibit the right of offset in bankruptcy, insolvency or other events. In addition, certain ISDA Master Agreements allow counterparties to terminate derivative contracts prior to maturity in the event the Trusts net assets decline by a stated percentage or the Trusts fail to meet the terms of their ISDA Master Agreements. The result would cause the Trusts to accelerate payment of any net liability owed to the counterparty.

Collateral Requirements: For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by a Trust and the counterparty.

Cash collateral that has been pledged to cover obligations of the Trusts and cash collateral received from the counterparty, if any, is reported separately on the Statements of Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by the Trusts, if any, is noted in the Schedules of Investments. Generally, the amount of collateral due from or to a counterparty is subject to a certain minimum transfer amount threshold before a transfer is required, which is determined at the close of business of the Trusts. Any additional required collateral is delivered to/pledged by the Trusts on the next business day. Typically, a Trust s counterparty is not permitted to sell, re-pledge or use cash and non-cash collateral it receives A Trust generally agrees not to use non-cash collateral that it receives but may, absent default or certain other circumstances defined in the underlying ISDA Master Agreement, be permitted to use cash collateral received. In such cases, interest may be paid pursuant to the collateral arrangement with the counterparty. To the extent amounts due to the Trusts from their counterparties are not fully collateralized, they bear the risk of loss from counterparty non-performance. Likewise, to the extent the Trusts have delivered collateral to a counterparty and stand ready to perform under the terms of their agreement with such counterparty, they bear the risk of loss from a counterparty in the amount of the value of the collateral in the event the counterparty fails to return such collateral. Based on the terms of agreements, collateral may not be required for all derivative contracts.

For financial reporting purposes, the Trusts do not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets and Liabilities.

6. Investment Advisory Agreement and Other Transactions with Affiliates:

The PNC Financial Services Group, Inc. is the largest stockholder and an affiliate of BlackRock for 1940 Act purposes.

Investment Advisory

Each Trust entered into an Investment Advisory Agreement with BlackRock Advisors, LLC (the Manager), the Trusts investment adviser, an indirect, wholly owned subsidiary of BlackRock, to provide investment advisory and administration services. The Manager is responsible for the management of each Trust s portfolio and provides the necessary personnel, facilities, equipment and certain other services to the operations of each Trust. For such services, each Trust, except BCX and BST, pays the Manager a monthly fee at the following annual rates:

Average weekly value of each Trust s net assets:	
BGR 1.	.20%
BDJ 0.	.80%
BOE 1.	.00%
BME 1.	00%
Average daily value of each Trust s net assets:	
CII	
BGY	
BUI	

0.85% 1.00% 1.00%

BCX pays the Manager a monthly fee of 1.00% of the sum of the average daily value of the net assets of the Fund (excluding the value of the Fund s interest in its subsidiary) and the average daily value of the net assets of its subsidiary, which fee is allocated pro rata between the Fund and its subsidiary based on the average daily value of their respective net assets (excluding, in the case of the Fund, the value of the Fund s interest in its subsidiary).

SEMI-ANNUAL REPORT

134

JUNE 30, 2016

BST pays the Manager a monthly fee of 1.00% of its average daily managed assets. Managed Assets mean the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of the Trust s accrued liabilities (other than money borrowed for investment purposes).

Expense Limitations/Waivers/Reimbursements/Recoupments

The Manager has agreed to waive a portion of the investment advisory fees on BST as a percentage of its average daily managed assets as follows:

		Expiration Date
BST	0.20%	December 31, 2018
	0.15%	December 31, 2019
	0.10%	December 31, 2020
	0.05%	December 31, 2021
		C 11

The Manager has voluntarily agreed to waive a portion of its investment advisory fees on the following Trusts as a percentage of average weekly net assets as follows:

BGR BDJ	0.050% 0.025%
BOE	0.025%
The Manager has voluntarily agreed to waive 0.10% of BGY s investment advisory fees as a percentage of its average daily net assets.	

These voluntary waivers may be reduced or discontinued at any time without notice.

For the six months ended June 30, 2016, investment advisory fees waived which is included in fees waived by the Manager in the Statements of Operations were as follows:

BGR			\$ 105,139
BDJ			\$ 198,537
BOE			\$ 229,414
BGY			\$ 353,859
BST			\$ 410,856
		1	

The Manager provides investment management and other services to BCX s Subsidiary. The Manager does not receive separate compensation from the Subsidiary for providing investment management or administrative services. However, BCX pays the Manager based on the Trust s net assets which includes the assets of the Subsidiary.

The Manager voluntarily agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager indirectly through its investment in affiliated money market funds. These amounts are included in fees waived by the Manager in the Statements of Operations. However, the Manager does not waive its investment advisory fees by the amount of investment advisory fees paid in connection with each Trust s investment in other affiliated investment companies, if any. For the six months ended June 30, 2016, the amounts waived pursuant to this arrangement were as follows:

BGR	\$ 3,297
CII	\$ 6,779
BDJ	\$ 2,785
BOE BME	\$ 10,521
BME	\$ 4,978

BGY BCX BST BUI

\$ 26,792
\$ 5,825
\$ 862

\$ 3,216

The Manager entered into separate sub-advisory agreements with BlackRock International Limited (BIL), an affiliate of the Manager, to serve as sub-advisor for BGR and BCX. The Manager pays BIL for services it provides to each Trust, a monthly fee that is a percentage of the investment advisory fees paid by each Trust to the Manager.

BME has entered into a Distribution Agreement with BlackRock Investments, LLC (BRIL), an affiliate of the Manager, to provide for distribution of BME common shares on a reasonable best efforts basis through an equity shelf offering (a Shelf Offering) (the Distribution Agreement). Pursuant to the

SEMI-ANNUAL REPORT

JUNE 30, 2016

Distribution Agreement, BME compensates BRIL with respect to sales of common shares at a commission rate of 1.00% of the gross proceeds of the sale of BME s common shares and a portion of such commission is re-allowed to broker-dealers engaged by BRIL.

Securities Lending

The U.S. Securities and Exchange Commission (SEC) has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending. The Trusts are responsible for expenses in connection with the investment of cash collateral received for securities on loan (the collateral investment expenses). The cash collateral is invested in a private investment company managed by the Manager or its affiliates. However, BIM has agreed to cap the collateral investment expenses of the private investment company to an annual rate of 0.04%. The investment adviser to the private investment company will not charge any advisory fees with respect to shares purchased by the Trusts.

Securities lending income is equal to the total of income earned from the reinvestment of cash collateral, net of fees and other payments to and from borrowers of securities, and less the collateral investment expenses. Each Trust retains a portion of securities lending income and remits a remaining portion to BIM as compensation for its services as securities lending agent. Pursuant to a securities lending agreement effective January 1, 2015, BIM may lend securities only when the difference between the borrower rebate rate and the risk free rate exceeds a certain level (such securities, the specials only securities).

Pursuant to such agreement, each Trust retains 80% of securities lending income. In addition, commencing the business day following the date that the aggregate securities lending income earned across the Closed-End Complex in a calendar year exceeds the breakpoint dollar threshold applicable in the given year as set forth in the securities lending agreement, each Trust, pursuant to the securities lending agreement, will retain for the remainder of the calendar year securities lending income in an amount equal to 85% of securities lending income.

The share of securities lending income earned by each Trust is shown as securities lending affiliated net in the Statements of Operations. For the six months ended June 30, 2016, each Trust paid BIM the following amounts for securities lending agent services:

BGR	\$ 225
CII	\$ 172
BDJ	\$ 4
BOE	\$ 3,796
BME	\$ 387
BGY	\$ 3,956
BCX	\$ 8,323
BST	\$ 4,813
BUI	\$ 2,537
Officers and Trustees	

Certain officers and/or trustees of the Trusts are officers and/or trustees of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion of the compensation paid to the Trusts Chief Compliance Officer, which is included in Officer and Trustees in the Statements of Operations.

Other Transactions

The Trusts may purchase securities from, or sell securities to, an affiliated fund provided the affiliation is due solely to having a common investment adviser, common officers, or common trustees. For the six months ended June 30, 2016, the purchase and sale transactions which resulted in net realized gains (losses) with an affiliated fund in compliance with Rule 17a-7 under the 1940 Act were as follows:

	Purchases	Sales
BCX	\$435,002	
BGY	\$751,734	

SEMI-ANNUAL REPORT

136

7. Purchases and Sales:

For the six months ended June 30, 2016, purchases and sales of investments, excluding short-term securities, were as follows:

	Purchases	Sales
BGR	\$ 109,685,531	\$ 137,297,122
CII	\$ 192,696,649	\$ 213,538,909
BDJ	\$ 297,676,279	\$ 345,917,774
BOE	\$ 246,610,325	\$ 272,384,539
BME	\$ 75,619,580	\$ 82,363,759
BGY	\$ 207,646,362	\$ 206,327,971
BCX	\$ 479,578,427	\$ 528,496,996
BST	\$ 174,164,915	\$ 187,217,640
BUI	\$ 8,904,770	\$ 17,199,697

8. Income Tax Information:

It is the Trusts policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute substantially all of their taxable income to their shareholders. Therefore, no federal income tax provision is required.

The Trusts file U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on each Trust s U.S. federal tax returns generally remains open for the year ended December 31, 2015, the period ended December 31, 2014 and each of the three years ended October 31, 2014 with the exception of BST and BUI. The statutes of limitations on BUI s U.S. federal tax returns remains open for the year ended December 31, 2015, the period ended October 31, 2014 and the period ended October 31, 2015, the period ended December 31, 2014, the two years ended October 31, 2014 and the period ended October 31, 2012. The statutes of limitations on BST s U.S. federal tax returns remains open for the year ended December 31, 2014. The statute of limitations on each Trust s state and local tax returns may remain open for an additional year depending upon the jurisdiction.

Management has analyzed tax laws and regulations and their application to the Trusts as of June 30, 2016, inclusive of the open tax years and does not believe there are any uncertain tax positions that require recognition of a tax liability in the Trusts financial statements.

As of December 31, 2015, the Trusts had capital loss carryforwards available to offset future realized capital gains through the indicated expiration dates as follows:

Expires December 31,	BGR	CII	BDJ	BOE	BGY	BCX	BST
No expiration date ³ \$	5 90,148,351		\$ 10,263,758		\$ 13,249,726	\$ 351,265,582	\$ 17,183,438
2016		\$ 4,870,467	61,470,173	\$ 38,148,041	458,843,935	2,659,644	
2017		2,532,028	8,526,748		55,605,462	1,795,201	
Total \$	90,148,351	\$ 7,402,495	\$ 80,260,679	\$ 38,148,041	\$ 527,699,123	\$ 355,720,427	\$ 17,183,438

³ Must be utilized prior to losses subject to expiration.

As of period end, gross unrealized appreciation and gross unrealized depreciation based on cost for federal income tax purposes were as follows:

	BGR	CII	BDJ	BOE	BME
Tax cost	\$ 465,644,055	\$ 623,449,376	\$ 1,373,837,925	\$ 873,969,583	\$ 206,745,144

Gross unrealized appreciation	\$ 32,103,727	\$ 34,080,057	\$ 322,116,420	\$ 121,767,415	\$ 77,952,774
Gross unrealized depreciation	(30,716,537)	(31,641,271)	(31,977,013)	(48,407,728)	(2,763,730)
Net unrealized appreciation	\$ 1,387,190	\$ 2,438,786	\$ 290,139,407	\$ 73,359,687	\$ 75,189,044

Tax cost	BGY	BCX	BST	BUI
	\$ 697,394,190	\$ 872,694,219	\$ 360,627,995	\$ 272,308,247
Gross unrealized appreciation	\$ 49,812,541	\$ 82,934,549	\$ 75,890,072	\$ 98,493,576
Gross unrealized depreciation	(49,782,570)	(27,913,100)	(9,493,793)	(9,434,881)
Net unrealized appreciation	\$ 29,971	\$ 55,021,449	\$ 66,396,279	\$ 89,058,695

SEMI-ANNUAL REPORT

JUNE 30, 2016

9. Principal Risks:

In the normal course of business, the Trusts invest in securities and enter into transactions where risks exist due to fluctuations in the market (market risk) or failure of the issuer to meet all its obligations, including the ability to pay principal and interest when due (issuer credit risk). The value of securities held by the Trusts may decline in response to certain events, including those directly involving the issuers of securities owned by the Trusts. Changes arising from the general economy; the overall market and local, regional or global political or/and social or instability; as well as currency, interest rate and price fluctuations also affect the securities value.

Counterparty Credit Risk: Similar to issuer credit risk, the Trusts may be exposed to counterparty credit risk, or the risk that an entity may fail to or be unable to perform on its commitments related to unsettled or open transactions. The Trusts manage counterparty credit risk by entering into transactions only with counterparties that the Manager believes have the financial resources to honor their obligations and by monitoring the financial stability of those counterparties. Financial assets, which potentially expose the Trusts to market, issuer and counterparty credit risks, consist principally of financial instruments and receivables due from counterparties. The extent of the Trust s exposure to market, issuer and counterparty credit risks with respect to these financial assets is approximately their value recorded in the Statements of Assets and Liabilities, less any collateral held by the Trusts.

A derivative contract may suffer a mark-to-market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying instrument. Losses can also occur if the counterparty does not perform under the contract.

The Trust s risk of loss from counterparty credit risk on OTC derivatives is generally limited to the aggregate unrealized gain less the value of any collateral held by the Trust.

For OTC options purchased, each Trust bears the risk of loss in the amount of the premiums paid plus the positive change in market values net of any collateral held by the Trusts should the counterparty fail to perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally obligate the Trusts, and not the counterparty, to perform. The Trusts may be exposed to counterparty credit risk with respect to options written to the extent the Trusts deposit collateral with its counterparty to a written option.

With exchange-traded options purchased, there is less counterparty credit risk to the Trusts since the exchange or clearinghouse, as counterparty to such instruments, guarantees against a possible default. The clearinghouse stands between the buyer and the seller of the contract; therefore, credit risk is limited to failure of the clearinghouse. While offset rights may exist under applicable law, a Trust does not have a contractual right of offset against a clearing broker or clearinghouse in the event of a default (including the bankruptcy or insolvency). Additionally, credit risk exists in exchange-traded options with respect to initial and variation margin that is held in a clearing broker s customer accounts. While clearing brokers are required to segregate customer margin from their own assets, in the event that a clearing broker becomes insolvent or goes into bankruptcy and at that time there is a shortfall in the aggregate amount of margin held by the clearing broker for all its clients, typically the shortfall would be allocated on a pro rata basis across all the clearing broker s customers, potentially resulting in losses to the Trusts.

Concentration Risk: As of period end, the Trusts listed below invested a significant portion of their assets in securities in the following sectors:

Energy	BGR, BCX
Health Care	BME
Information Technology	BST
Utilities	BUI
Materials	BCX
Changes in economic conditions affecting these sectors would have a greater impact on these Trusts and could affect the value	, income and/or
liquidity of positions in such securities.	

BOE and BGY invest a substantial amount of their assets in issuers located in a single country or a limited number of countries. When a Trust concentrates its investments in this manner, it assumes the risk that economic, political and social conditions in those countries may have a significant impact on their investment performance. Foreign issuers may not be subject to the same uniform accounting, auditing and financial reporting standards and practices as used in the U.S. Foreign securities markets may also be less liquid, more volatile, and less subject to governmental supervision not typically associated with investing in United States securities. Investment percentages in specific countries are presented in the Schedule of Investments.

SEMI-ANNUAL REPORT

138

JUNE 30, 2016

BOE, BGY and BCX invests a significant portion of their assets in securities of issuers located in Europe or with significant exposure to European issuers or countries. The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Funds investments.

The United Kingdom has voted to withdraw from the European Union on June 23, 2016, which may introduce significant new uncertainties and instability in the financial markets across Europe.

As of period end, BOE s and BGY s investments had the following industry classifications:

Industry	BOE	BGY
Banks	7%	11%
Internet Software & Services	7%	2%
Oil, Gas & Consumable Fuels	7%	7%
Beverages	5%	7%
Pharmaceuticals Diversified Telecommunication Services	5% 5% 3%	10% 5%

* All other industries held were each less than 5%.

10. Capital Share Transactions:

There are an unlimited number of \$0.001 par value common shares of beneficial interest authorized for each Trust, with the exception of CII. CII is authorized to issue 200 million shares of \$0.10 par value shares, all of which were initially classified as Common Shares. The Board is authorized, however, to reclassify any unissued Common Shares to Preferred Shares without approval of Common Shareholders.

For the periods shown, shares issued and outstanding increased by the following amounts as a result of shares issued through the Shelf Offering:

	Six Months	
	Ended	Year Ended
	June 30,	December
	2016	31, 2015
BME		252,980
For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend rej	nvestments.	

For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend reinvestments:

	Six Months Ended June 30,	Year Ended December
	2016	31, 2015
BGR		59,109
BME	25,472	117,681
For the six months ended June 30, 2016, BGR, CII, BDJ, BOE, BGY, BCX, BST and BUI and for the year ended	December 31, 20	015, CII, BDJ,

BOE, BGY, BCX, BST and BUI, shares issued and outstanding remained constant.

On June 9, 2016, BME filed a final prospectus with the U.S. Securities and Exchange Commission (SEC) allowing it to issue an additional

2,500,000 Common Shares through a Shelf Offering. Under the Shelf Offering, BME, subject to market conditions, may raise additional equity capital from time to time in varying amounts and utilizing various offering methods at a net price at or above BME s net asset value (NAV) per Common Share (calculated within 48 hours of pricing). As of period end, 2,500,000 Common Shares remain available for issuance under the

Shelf Offering. From August 12, 2015 to June 9, 2016, BME was authorized to issue 453,000 Common Shares under a previous Shelf Offering. See Additional Information Shelf Offering Program for additional information about the Shelf Offering.

Costs incurred by BME in connection with the Shelf Offering are recorded as a deferred charge and amortized over 12 months.

SEMI-ANNUAL REPORT

JUNE 30, 2016

11. Subsequent Events:

Management s evaluation of the impact of all subsequent events on the Trusts financial statements was completed through the date the financial statements were issued and the following items were noted:

The Trusts paid a distribution on July 29, 2016 to shareholders of record on July 15, 2016 as follows:

Common Dividend

	Per Share
BGR	\$0.0776
CII	\$0.1000
BDJ	\$0.0467
BOE	\$0.0780
BME	\$0.2000
BGY	\$0.0380
BCX	\$0.0446
BST	\$0.1000
BUI	\$0.1210

Additionally, certain Trusts declared a distribution in the following amounts per share on August 31, 2016 payable to shareholders of record on August 15, 2016 as follows:

Common Dividend

	Per Share
BGR	\$0.0776
CII	\$0.1000
BDJ	\$0.0467
BOE	\$0.0780
BME	\$0.2000
BGY	\$0.0380
BCX	\$0.0446
BST	\$0.1000
BUI	\$0.1210

140

SEMI-ANNUAL REPORT

JUNE 30, 2016

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements

The Board of Directors or Trustees, as applicable (each, a Board, collectively, the Boards, and the members of which are referred to as Board Members), of BlackRock Energy and Resources Trust (BGR), BlackRock Enhanced Capital and Income Fund, Inc. (CII), BlackRock Enhanced Equity Dividend Trust (BDJ), BlackRock Global Opportunities Equity Trust (BOE), BlackRock Health Sciences Trust (BME), BlackRock International Growth and Income Trust (BGY), BlackRock Resources & Commodities Strategy Trust (BCX), BlackRock Utility and Infrastructure Trust (BUI) and BlackRock Science and Technology Trust (BST) and together with BGR, CII, BDJ, BOE, BME, BGY, BCX and BUI, each a Trust, and, collectively, the Trusts) met in person on April 28, 2016 (the April Meeting) and June 9-10, 2016 (the June Meeting) to consider the approval of each Trust s investment advisory agreement (the Advisory Agreement) with BlackRock Advisory, LLC (the Manager), each Trust s investment advisor. The Board of each of BGR and BCX also considered the approval of the sub-advisory agreement (the Sub-Advisor y Agreement) among the Manager, BlackRock International Limited (the Sub-Advisor), and the Trust. The Manager and the Sub-Advisor are referred to herein as BlackRock . The Advisory Agreements and the Sub-Advisory Agreements are referred to herein as the Agreements.

Activities and Composition of the Board

On the date of the June Meeting, the Board of each Trust consisted of eleven individuals, nine of whom were not interested persons of the Trust as defined in the Investment Company Act of 1940, as amended (the 1940 Act) (the Independent Board Members). The Board Members are responsible for the oversight of the operations of its Trust and perform the various duties imposed on the directors of investment companies by the 1940 Act. The Independent Board Members have retained independent legal counsel to assist them in connection with their duties. The Chair of each Board is an Independent Board Member. Each Board has established five standing committees: an Audit Committee, a Governance and Nominating Committee, a Compliance Committee, a Performance Oversight Committee, and an Executive Committee, each of which is chaired by an Independent Board Member and composed of Independent Board Members (except for the Executive Committee, which also has one interested Board Member).

The Agreements

Pursuant to the 1940 Act, each Board is required to consider the continuation of the Advisory Agreement for its Trust, and with respect to BGR and BCX, the Sub-Advisory Agreement, on an annual basis. Each Board has four quarterly meetings per year, each extending over two days, a fifth one-day meeting to consider specific information surrounding the consideration of renewing the Agreement(s) for its Trust and additional in-person and telephonic meetings as needed. In connection with this year-long deliberative process, each Board assessed, among other things, the nature, extent and quality of the services provided to its Trust by BlackRock, BlackRock s personnel and affiliates, including, as applicable; investment management, administrative, and shareholder services; the oversight of fund service providers; marketing; risk oversight; compliance; and ability to meet applicable legal and regulatory requirements.

Each Board, acting directly and through its committees, considers at each of its meetings, and from time to time as appropriate, factors that are relevant to its annual consideration of the renewal of the Agreement(s) for its Trust, including the services and support provided by BlackRock to the Trust and its shareholders. BlackRock also furnished additional information to each Board in response to specific questions from the Board. This additional information is discussed further below in the section titled Board Considerations in Approving the Agreements. Among the matters each Board considered were: (a) investment performance for one-year, three-year, five-year, ten-year, and/or since inception periods, as applicable, against peer funds, applicable benchmarks, and performance metrics, as applicable, as well as senior management s and portfolio managers analysis of the reasons for any over-performance or underperformance relative to its peers, benchmarks, and other performance metrics, as applicable; (b) fees, including advisory, administration, if applicable, paid to BlackRock and its affiliates by the Trust for services; (c) Trust operating expenses and how BlackRock allocates expenses to the Trust; (d) the resources devoted to, risk oversight of, and compliance reports relating to, implementation of the Trust s investment objective(s), policies and restrictions, and meeting regulatory requirements; (e) the Trust s compliance with its compliance policies and procedures; (f) the nature, cost and character of non-investment management services provided by BlackRock and its affiliates; (g) BlackRock s and other service providers internal controls and risk and compliance oversight mechanisms; (h) BlackRock s implementation of the proxy voting policies approved by the Board; (i) the use of brokerage commissions and execution quality of portfolio transactions; (j) BlackRock s implementation of the Trust s valuation and liquidity procedures; (k) an analysis of management fees for products with similar investment mandates across the open-end fund, closed-end fund and institutional account product channels, as applicable, and the similarities and differences between these products and the services provided as compared to the Trust; (1) BlackRock s compensation methodology for its investment professionals and the incentives and accountability it creates, along with investment professionals investments in the fund(s) they manage; and (m) periodic updates on BlackRock s business.

Board Considerations in Approving the Agreements

The Approval Process: Prior to the April Meeting, each Board requested and received materials specifically relating to the Agreement(s) for its Trust. Each Board is continuously engaged in a process with its independent legal counsel and BlackRock to review the nature and scope of the information provided to better assist its deliberations. The materials provided to the Board of each Trust in connection with the April Meeting included (a) information independently compiled and prepared by Broadridge Financial Solutions, Inc. (Broadridge) on Trust fees and expenses as compared with a peer group of funds as determined by Broadridge (Expense Peers) and the investment performance of the Trust as compared with a peer

SEMI-ANNUAL REPORT

JUNE 30, 2016

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

group of funds as determined by Broadridge,¹ as well as the performance of the Trust as compared with its custom benchmark; (b) information on the profits realized by BlackRock and its affiliates pursuant to the Trust s Agreement(s) and a discussion of fall-out benefits to BlackRock and its affiliates; (c) a general analysis provided by BlackRock concerning investment management fees charged to other clients, such as institutional clients, sub-advised mutual funds, and open-end funds, under similar investment mandates, as applicable; (d) review of non-management fees; (e) the existence, impact and sharing of potential economies of scale; and (f) a summary of aggregate amounts paid by the Trust to BlackRock.

At the April Meeting, each Board reviewed materials relating to its consideration of the Agreement(s) for its Trust. As a result of the discussions that occurred during the April Meeting, and as a culmination of each Board s year-long deliberative process, each Board presented BlackRock with questions and requests for additional information. BlackRock responded to these requests with additional written information in advance of the June Meeting.

At the June Meeting, each Board, including the Independent Board Members, unanimously approved the continuation of the Advisory Agreement between the Manager and its Trust for a one-year term ending June 30, 2017. The Board of each of BGR and BCX, including the Independent Board Members, also unanimously approved the continuation of the Sub-Advisory Agreement between the Manager and the Sub-Advisor, with respect to its Trust, for a one-year term ending June 30, 2017. In approving the continuation of the Agreement(s) for its Trust, each Board considered: (a) the nature, extent and quality of the services provided by BlackRock; (b) the investment performance of the Trust; (c) the advisory fee and the cost of the services and profits to be realized by BlackRock and its affiliates from their relationship with the Trust; (d) the Trust s costs to investors compared to the costs of Expense Peers and performance compared to the relevant performance metrics as previously discussed; (e) the sharing of potential economies of scale; (f) fall-out benefits to BlackRock and its affiliates as a result of its relationship with the Trust; and (g) other factors deemed relevant by the Board Members.

Each Board also considered other matters it deemed important to the approval process, such as other payments made to BlackRock or its affiliates relating to securities lending and cash management, services related to the valuation and pricing of Trust portfolio holdings, and advice from independent legal counsel with respect to the review process and materials submitted for the Board s review. Each Board noted the willingness of BlackRock personnel to engage in open, candid discussions with the Board. Each Board did not identify any particular information as determinative, and each Board Member may have attributed different weights to the various items considered.

A. Nature, Extent and Quality of the Services Provided by BlackRock: Each Board, including the Independent Board Members, reviewed the nature, extent and quality of services provided by BlackRock, including the investment advisory services and the resulting performance of its Trust. Throughout the year, each Board compared its Trust s performance to the performance of a comparable group of closed-end funds, relevant benchmark, and performance metrics, as applicable. Each Board met with BlackRock s senior management personnel responsible for investment activities, including the senior investment officers. Each Board also reviewed the materials provided by its Trust s portfolio management team discussing the Trust s performance and the Trust s investment objective(s), strategies and outlook.

Each Board considered, among other factors, with respect to BlackRock: the number, education and experience of investment personnel generally and its Trust s portfolio management team; BlackRock s research capabilities; investments by portfolio managers in the funds they manage; portfolio trading capabilities; use of technology; commitment to compliance; credit analysis capabilities; risk analysis and oversight capabilities; and the approach to training and retaining portfolio managers and other research, advisory and management personnel. Each Board engaged in a review of BlackRock s compensation structure with respect to the Trust s portfolio management team and BlackRock s ability to attract and retain high-quality talent and create performance incentives.

In addition to investment advisory services, each Board considered the quality of the administrative and other non-investment advisory services provided to its Trust. BlackRock and its affiliates provide each Trust with certain administrative, shareholder, and other services (in addition to any such services provided to the Trust by third parties) and officers and other personnel as are necessary for the operations of the Trust. In particular, BlackRock and its affiliates provide each Trust with administrative services including, among others: (i) preparing disclosure documents, such as the prospectus and the statement of additional information in connection with the initial public offering, and with respect to BME, registration statements in connection with BME s equity shelf program, and periodic shareholder reports; (ii) preparing communications with analysts to support secondary market trading of the Trust; (iii) preparing periodic filings with regulators; (iv) oversight of daily accounting and pricing; (v) preparing periodic filings with regulators and stock exchanges; (vi) overseeing and coordinating the activities of other service providers; (vii) organizing Board meetings and preparing the materials for such Board meetings; (viii) providing legal and compliance support; (ix) furnishing analytical and other support to assist the Board in its consideration of strategic issues such as the merger, consolidation or repurposing of certain closed-end funds; and (x) performing other administrative

¹ Funds are ranked by Broadridge in quartiles, ranging from first to fourth, where first is the most desirable quartile position and fourth is the least desirable.

142 SEMI-ANNUAL REPORT

JUNE 30, 2016

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

functions necessary for the operation of the Trust, such as tax reporting, fulfilling regulatory filing requirements and call center services. Each Board reviewed the structure and duties of BlackRock s fund administration, shareholder services, and legal & compliance departments and considered BlackRock s policies and procedures for assuring compliance with applicable laws and regulations.

B. The Investment Performance of the Trusts and BlackRock: Each Board, including the Independent Board Members, also reviewed and considered the performance history of its Trust. In preparation for the April Meeting, the Board of each Trust was provided with reports independently prepared by Broadridge, which included a comprehensive analysis of the Trust s performance. Each Board also reviewed a narrative and statistical analysis of the Broadridge data that was prepared by BlackRock. In connection with its review, the Board of each Trust received and reviewed information regarding the investment performance, based on net asset value (NAV), of the Trust as compared to other funds in its applicable Broadridge category and the performance of the Trust as compared with its custom benchmark. Each Board was provided with a description of the methodology used by Broadridge to select peer funds and periodically meets with Broadridge representatives to review its methodology. Each Board was provided with information on the composition of the Broadridge performance universes and expense universes. Each Board and its Performance Oversight Committee regularly review, and meet with Trust management to discuss, the performance of its Trust throughout the year.

In evaluating performance, each Board recognized that the performance data reflects a snapshot of a period as of a particular date and that selecting a different performance period could produce significantly different results. Further, each Board recognized that it is possible that long-term performance can be adversely affected by even one period of significant underperformance so that a single investment decision or theme has the ability to affect long-term performance disproportionately.

The Board of BST noted that for each of the one-year and since-inception periods reported, BST exceeded its customized benchmark. BlackRock believes that performance relative to the customized benchmark is an appropriate performance metric for BST.

The Board of each of BCX and BUI noted that for each of the one-year, three-year and since-inception periods reported, its Trust exceeded its customized benchmark. The since inception period for BCX and BUI is as of the customized benchmark creation date. BlackRock believes that performance relative to the customized benchmark is an appropriate performance metric for BCX and BUI.

The Board of BME noted that for the one-year, three-year and since-inception periods reported, BME exceeded, exceeded and underperformed its customized benchmark. The since inception period for BME is as of the customized benchmark creation date. BlackRock believes that performance relative to the customized benchmark is an appropriate performance metric for BME.

The Board of BGR noted that for each of the one-year, three-year and since-inception periods reported, BGR underperformed its customized benchmark. The since inception period for BGR is as of the customized benchmark creation date. BlackRock believes that performance relative to the customized benchmark is an appropriate performance metric for BGR. The Board and BlackRock reviewed and discussed the reasons for BGR s underperformance during these periods. The Board was informed that, among other things, poor sub-sector allocation decisions was a primary detractor, coupled with the portfolio management team s decision to increase BGR s oil price sensitivity.

The Board of CII noted that for the one-year, three-year and since-inception periods reported, CII exceeded, underperformed and underperformed, respectively, its customized benchmark. The since inception period for CII is as of the customized benchmark creation date. BlackRock believes that performance relative to the customized benchmark is an appropriate performance metric for CII. The Board also noted CII s improved performance during the one-year period. The Board and BlackRock reviewed and discussed the reasons for CII s underperformance during the three-year and since-inception periods. The Board was informed that, among other things, poor stock selection was the key driver of underperformance relative to the customized benchmark.

The Board of BDJ noted that for the one-year, three-year and since-inception periods reported, BDJ exceeded, underperformed and underperformed its customized benchmark. The since inception period for BDJ is as of the customized benchmark creation date. BlackRock believes that performance relative to the customized benchmark is an appropriate performance metric for BDJ. The Board also noted BDJ s improved performance during the one-year period. The Board and BlackRock reviewed and discussed the reasons for BDJ s underperformance during the three-year and since-inception periods. The Board was informed that, among other things, the largest detractor from relative performance was BDJ s underweight and stock selection in healthcare and information technology sectors.

The Board of BOE noted that for the one-year, three-year and since-inception periods reported, BOE exceeded, underperformed and underperformed its customized benchmark. The since inception period for BOE is as of the customized benchmark creation date. BlackRock

believes that performance relative to the customized benchmark is an appropriate performance metric for BOE. The Board also noted BOE s improved performance during the one-year period. The Board and BlackRock reviewed and discussed the reasons for BOE s underperformance during the three-year and since-inception

SEMI-ANNUAL REPORT

JUNE 30, 2016

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

periods. The Board was informed that, among other things, BOE s overweight positions in developed markets and volatility stocks coupled with underweight positions in emerging markets and value stocks hindered performance during the three-year and since-inception periods.

The Board of BGY noted that for the one-year, three-year and since-inception periods reported, BGY exceeded, underperformed, and underperformed its customized benchmark. The since inception period for BGY is as of the customized benchmark creation date. BlackRock believes that performance relative to the customized benchmark is an appropriate performance metric for BGY. The Board also noted BGY s improved performance during the one-year period. The Board and BlackRock reviewed and discussed the reasons for BGY s underperformance during the three-year and since-inception periods. The Board was informed that, among other things, BGY s overweight positions in developed markets and volatility stocks coupled with underweight positions in emerging markets and value stocks hindered performance during the three-year and since-inception periods.

The Board of each of BGR, CII, BDJ, BOE and BGY and BlackRock discussed BlackRock s strategy for improving its Trust s investment performance. Discussions covered topics such as: investment risks undertaken by the Trust; performance attribution; the Trust s investment personnel; and the resources appropriate to support the Trust s investment processes. Each such Board and BlackRock also discussed BlackRock s active equity platform, and it was noted that BlackRock has recruited a Head of Global Active Equity, and has appointed a Chief Performance Officer to provide analysis of investment performance to senior management and the Board.

BlackRock and the Board of each of CII and BDJ previously had concurred, given each Trust s poor historical performance, in making changes within the portfolio management team. Both BlackRock and the Board of each of CII and BDJ are hopeful that these changes will result in improved performance going forward, although there can be no assurance that will be the case. The Board of each of CII and BDJ will continue to monitor its Trust s performance.

C. Consideration of the Advisory/Management Fees and the Cost of the Services and Profits to be Realized by BlackRock and its Affiliates from their Relationship with the Trusts: Each Board, including the Independent Board Members, reviewed its Trust s contractual management fee rate compared with the other funds in its Broadridge category. The contractual management fee rate represents a combination of the advisory fee and any administrative fees, before taking into account any reimbursements or fee waivers. Each Board also compared its Trust s total expense ratio, as well as its actual management fee rate as a percentage of total assets, to those of other funds in its Broadridge category. The total expense ratio represents a fund s total net operating expenses, excluding any investment related expenses. The total expense ratio gives effect to any expense reimbursements or fee waivers that benefit a fund, and the actual management fee rate gives effect to any management fee reimbursements or waivers that benefit a fund. Each Board considered the services provided and the fees charged by BlackRock and its affiliates to other types of clients with similar investment mandates, as applicable, including institutional accounts and sub-advised mutual funds (including mutual funds sponsored by third parties).

Each Board received and reviewed statements relating to BlackRock s financial condition. Each Board reviewed BlackRock s profitability methodology and was also provided with a profitability analysis that detailed the revenues earned and the expenses incurred by BlackRock for services provided to its Trust. Each Board reviewed BlackRock s profitability with respect to its Trust and other funds the Board currently oversees for the year ended December 31, 2015 compared to available aggregate profitability data provided for the prior two years. Each Board reviewed BlackRock s profitability with respect to certain other U.S. fund complexes managed by the Manager and/or its affiliates. Each Board reviewed BlackRock s assumptions and methodology of allocating expenses in the profitability analysis, noting the inherent limitations in allocating costs among various advisory products. Each Board recognized that profitability may be affected by numerous factors including, among other things, fee waivers and expense reimbursements by the Manager, the types of funds managed, precision of expense allocations and business mix. As a result, calculating and comparing profitability at individual fund level is difficult.

Each Board noted that, in general, individual fund or product line profitability of other advisors is not publicly available. Each Board reviewed BlackRock s overall operating margin, in general, compared to that of certain other publicly-traded asset management firms. Each Board considered the differences between BlackRock and these other firms, including the contribution of technology at BlackRock, BlackRock s expense management, and the relative product mix.

In addition, each Board considered the cost of the services provided to its Trust by BlackRock, and BlackRock s and its affiliates profits relating to the management of its Trust and the other funds advised by BlackRock and its affiliates. As part of its analysis, each Board reviewed BlackRock s methodology in allocating its costs of managing its Trust, to the Trust. Each Board may receive and review information from independent third parties as part of its annual evaluation. Each Board considered whether BlackRock has the financial resources necessary to attract and retain high quality investment management personnel to perform its obligations under the Trust s Agreement(s) and to continue to provide the high quality of services that is expected by the Board. Each Board further considered factors including but not limited to BlackRock s

commitment of time, assumption of risk, and liability profile in servicing its Trust in contrast to what is required of BlackRock with respect to other products with similar investment mandates across the open-end fund, ETF, closed-end fund, sub-advised mutual fund and institutional account product channels, as applicable.

SEMI-ANNUAL REPORT

144

JUNE 30, 2016

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

The Board of each of CII and BUI noted that its Trust s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers.

The Board of BCX noted that BCX s contractual management fee rate ranked first out of four funds, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers.

The Board of each of BME and BST noted that its Trust s contractual management fee rate ranked second out of four funds, and that the actual management fee rate and total expense ratio ranked in the second and first quartiles, respectively, relative to the Expense Peers.

The Board of BGR noted that BGR s contractual management fee rate ranked in the third quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. In addition, the Board noted that BlackRock had voluntarily agreed to waive a portion of the advisory fee payable by BGR. This waiver was implemented on July 1, 2015. After discussions between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to an increase to the voluntary advisory fee waiver. This increase was implemented on July 1, 2016.

The Board of BDJ noted that BDJ s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. In addition, the Board noted that BlackRock had voluntarily agreed to waive a portion of the advisory fee payable by BDJ. This waiver was implemented on July 1, 2015. After discussions between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to remove the voluntary advisory fee waiver. This adjustment was implemented on July 1, 2016.

The Board of BOE noted that BOE s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio each ranked in the second quartile relative to the Expense Peers. In addition, the Board noted that BlackRock had voluntarily agreed to waive a portion of the advisory fee payable by BOE. This waiver was implemented on July 1, 2015. After discussions between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the voluntary advisory fee waiver.

The Board of BGY noted that BGY s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. The Board also noted that BlackRock had voluntarily agreed to waive a portion of the advisory fee payable by BGY. The Board further noted that BlackRock had agreed to an increase to the voluntary advisory fee waiver. This waiver increase was implemented on July 1, 2015. After discussions between the Board, including Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the voluntary advisory fee waiver.

D. Economies of Scale: Each Board, including the Independent Board Members, considered the extent to which economies of scale might be realized as the assets of its Trust increase. Each Board also considered the extent to which its Trust benefits from such economies in a variety of ways, and whether there should be changes in the advisory fee rate or breakpoint structure in order to enable the Trust to more fully participate in these economies of scale. Each Board considered its Trust s asset levels and whether the current fee was appropriate.

Based on each Board s review and consideration of the issue, each Board concluded that most closed-end funds do not have fund level breakpoints because closed-end funds generally do not experience substantial growth after the initial public offering. They are typically priced at scale at a fund s inception. The Board of BME noted that although BME may from time-to-time make additional share offerings pursuant to its equity shelf program, the growth of BME s assets will occur primarily through the appreciation of its investment portfolio.

E. Other Factors Deemed Relevant by the Board Members: Each Board, including the Independent Board Members, also took into account other ancillary or fall-out benefits that BlackRock or its affiliates may derive from their respective relationships with its Trust, both tangible and intangible, such as BlackRock s ability to leverage its investment professionals who manage other portfolios and risk management personnel, an increase in BlackRock s profile in the investment advisory community, and the engagement of BlackRock s affiliates as service providers to the Trust, including for administrative, securities lending and cash management services. Each Board also considered BlackRock s overall operations and its efforts to expand the scale of, and improve the quality of, its operations. Each Board also noted that BlackRock may use and benefit from third party research obtained by soft dollars generated by certain registered fund transactions to assist in managing all or a number of its other client accounts. Each Board further noted that it had considered the investment by BlackRock s funds in affiliated exchange traded funds (i.e., ETFs) without any offset against the management fees payable by the funds to BlackRock.

In connection with its consideration of the Agreement(s) for its Trust, each Board also received information regarding BlackRock s brokerage and soft dollar practices. Each Board received reports from BlackRock which included information on brokerage commissions and trade execution practices throughout the year.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (concluded)

Each Board noted the competitive nature of the closed-end fund marketplace, and that shareholders are able to sell their Trust shares in the secondary market if they believe that the Trust s fees and expenses are too high or if they are dissatisfied with the performance of the Trust.

Each Board also considered the various notable initiatives and projects BlackRock performed in connection with its closed-end fund product line. These initiatives included the redemption of AMPS for the BlackRock closed-end funds with AMPS outstanding; developing equity shelf programs; efforts to eliminate product overlap with fund mergers; ongoing services to manage leverage that has become increasingly complex; periodic evaluation of share repurchases and other support initiatives for certain BlackRock funds; and continued communications efforts with shareholders, fund analysts and financial advisers. With respect to the latter, the Independent Board Members noted BlackRock s continued communication program designed to raise investor and analyst awareness and understanding of closed-end funds. BlackRock s support services included, among other things: continuing communications concerning the redemption efforts related to AMPS; sponsoring and participating in conferences; communicating with closed-end fund analysts covering the BlackRock funds throughout the year; providing marketing and product updates for the closed-end funds; and maintaining and enhancing its closed-end fund website.

Conclusion

Each Board, including the Independent Board Members, unanimously approved the continuation of the Advisory Agreement between the Manager and its Trust for a one-year term ending June 30, 2017. The Board of each of BGR and BCX, including the Independent Board Members, also unanimously approved the continuation of the Sub-Advisory Agreement between the Manager and the Sub-Advisor, with respect to its Trust, for a one-year term ending June 30, 2017. Based upon its evaluation of all of the aforementioned factors in their totality, as well as other information, each Board, including the Independent Board Members, was satisfied that the terms of Agreement(s) for its Trust were fair and reasonable and in the best interest of the Trust and its shareholders. In arriving at its decision to approve the Agreement(s) for its Trust, each Board did not identify any single factor or group of factors as, all-important or controlling, but considered all factors together, and different Board Members may have attributed different weights to the various factors considered. The Independent Board Members were also assisted by the advice of independent legal counsel in making this determination. The contractual fee arrangements for each Trust reflect the results of several years of review by the Trust s Board Members and predecessor Board Members, and discussions between such Board Members (and predecessor Board Members) and BlackRock. As a result, the Board Members conclusions may be based in part on their consideration of these arrangements in prior years.

146

SEMI-ANNUAL REPORT

JUNE 30, 2016

Officers and Trustees

- Karen P. Robards, Vice Chairperson of the Board and Trustee
- Michael J. Castellano, Trustee
- Cynthia L. Egan, Trustee
- Frank J. Fabozzi, Trustee
- Jerrold B. Harris, Trustee
- R. Glenn Hubbard, Trustee
- Catherine A. Lynch, Trustee
- W. Carl Kester, Trustee
- Barbara Novick, Trustee
- John M. Perlowski, Trustee, President and Chief Executive Officer
- Jonathan Diorio, Vice President
- Neal Andrews, Chief Financial Officer
- Jay Fife, Treasurer
- Charles Park, Chief Compliance Officer
- Janey Ahn, Secretary

Effective March 1, 2016, Catherine A. Lynch was appointed to serve as a Trustee of the Trusts.

Effective March 31, 2016, Alastair Bishop became a portfolio manager of BCX. The other portfolio managers are Kyle McClements, Christopher Accettella, Thomas Holl and Skye Macpherson.

Effective April 1, 2016, Cynthia L. Egan was appointed to serve as a Trustee of the Trusts.

Investment Advisor	Sub-Advisors	Accounting Agent	Custodians
BlackRock Advisors, LLC	BlackRock International Ltd. ¹	The Bank of New York Mellon	The Bank of New York Mellon ²
Wilmington, DE 19809	Edinburgh, EH3 8BL	Wilmington, DE 19809	New York, NY 10286
	United Kingdom		

Brown Brothers Harriman & Co.3

Boston, MA 02109

Transfer Agent	Independent Registered Public	Legal Counsel	Address of the Funds
Computershare Trust Company, N.A.	Accounting Firm	Skadden, Arps, Slate, Meagher &	100 Bellevue Parkway
Canton, MA 02021	Deloitte & Touche LLP	Flom LLP	Wilmington, DE 19809
	Philadelphia, PA 19103	Boston, MA 02116	

¹ For BGR and BCX.

² For all Trusts except CII.

³ For CII.

SEMI-ANNUAL REPORT

JUNE 30, 2016

Additional Information

Trust Certification

All Trusts are listed for trading on the NYSE. All Trusts have filed with the relevant exchange their annual chief executive officer certification regarding compliance with such exchange s listing standards. The Trusts filed with the SEC the certification of its chief executive officer and chief financial officer required by section 302 of the Sarbanes-Oxley Act.

General Information

The Trusts do not make available copies of their Statements of Additional Information because the Trusts shares, except for BME, are not continuously offered, which means that the Statements of Additional Information of each Trust have not been updated after completion of the respective Trust s offerings and the information contained in each Trust s Statement of Additional Information may have become outdated.

The prospectus for BME includes additional information about the Trustees of the Trusts and is available, without charge, upon request, by calling 1-800-882-0052.

During the period, there were no material changes in the Trusts investment objectives or policies or to the Trusts charters or by-laws that would delay or prevent a change of control of the Trusts that were not approved by the shareholders or in the principal risk factors associated with investment in the Trusts. Other than as described on page 142, there have been no changes in the persons who are primarily responsible for the day-to-day management of the Trusts portfolios.

Quarterly performance, semi-annual and annual reports and other information regarding the Trusts may be found on BlackRock s website, which can be accessed at **http://www.blackrock.com**. This reference to BlackRock s website is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock s website in this report.

Electronic Delivery

Shareholders can sign up for e-mail notifications of quarterly statements, annual and semi-annual shareholder reports by enrolling in the electronic delivery program. Electronic copies of shareholder reports are available on BlackRock s website.

To enroll in electronic delivery:

Shareholders Who Hold Accounts with Investment Advisors, Banks or Brokerages:

Please contact your financial advisor. Please note that not all investment advisors, banks or brokerages may offer this service.

Householding

The Trusts will mail only one copy of shareholder documents, including annual and semi-annual reports and proxy statements, to shareholders with multiple accounts at the same address. This practice is commonly called householding and is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. Mailings of your shareholder documents may be householded indefinitely unless you instruct us otherwise. If you do not want the mailing of these documents to be combined with those for other members of your household, please call the Trusts at (800) 882-0052.

Availability of Quarterly Schedule of Investments

The Trusts file their complete schedule of portfolio holdings with the SEC for the first and third quarters of each fiscal year on Form N-Q. The Trusts Forms N-Q are available on the SEC s website at http://www.sec.gov. and may also be reviewed and copied at the SEC s Public Reference Room in Washington, DC. Information on how to access documents on the SEC s website without charge may be obtained by calling (800) SEC-0330. The Trusts Forms N-Q may also be obtained upon request and without charge by calling (800) 882-0052.

Availability of Proxy Voting Policies and Procedures

A description of the policies and procedures that the Trusts use to determine how to vote proxies relating to portfolio securities is available (1) without charge, upon request, by calling (800) 882-0052; (2) at http://www.blackrock.com; and (3) on the SEC at http://www.sec.gov.

Availability of Proxy Voting Record

Information about how the Trusts voted proxies relating to securities held in the Trusts portfolio during the most recent 12-month period ended June 30 is available upon request and without charge (1) at **http://www.blackrock.com** or by calling (800) 882-0052 and (2) on the SEC s website at http://www.sec.gov.

148

SEMI-ANNUAL REPORT

JUNE 30, 2016

Additional Information (concluded)

General Information (concluded) Availability of Trust Updates

BlackRock will update performance and certain other data for the Trusts on a monthly basis on its website in the Closed-end Funds section of **http://www.blackrock.com**. Investors and others are advised to periodically check the website for updated performance information and the release of other material information about the Trusts. This reference to BlackRock s website is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock s website in this report.

Shelf Offering Program

From time-to-time, each Trust may seek to raise additional equity capital through an equity shelf program (a Shelf Offering). In a Shelf Offering, a Trust may, subject to market conditions, raise additional equity capital by issuing new Common Shares from time to time in varying amounts at a net price at or above the Trust s net asset value (NAV) per Common Share (calculated within 48 hours of pricing). While any such Shelf Offering may allow a Trust to pursue additional investment opportunities without the need to sell existing portfolio investments, it could also entail risks including that the issuance of additional Common Shares may limit the extent to which the Common Shares are able to trade at a premium to NAV in the secondary market.

On August 12, 2015 and June 9, 2016, BME filed a final prospectus with the SEC in connection with its Shelf Offering. This report and the prospectus of BME are not offers to sell BME Common Shares or solicitations of an offer to buy BME Common Shares in any jurisdiction where such offers or sales are not permitted. The prospectus of BME contains important information about the Fund, including its investment objective, risks, charges and expenses. Investors are urged to read the prospectus of BME carefully and in its entirety before investing. Copies of the final prospectus for BME can be obtained from BlackRock at http://www.blackrock.com.

Dividend Policy

Each Trust s dividend policy is to distribute all or a portion of its net investment income to its shareholders on a monthly basis. In order to provide shareholders with a more stable level of dividend distributions, the dividends paid by the Trusts for any particular month may be more or less than the amount of net investment income earned by the Trusts during such month. The portion of dividend distributions that exceeds a Trust s current and accumulated earnings and profits, which are measured on a tax basis, will constitute a nontaxable return of capital. Dividend distributions in excess of a Trust s taxable income and net capital gains, but not in excess of a Trust s earnings and profits, will be taxable to shareholders as ordinary income and will not constitute a nontaxable return of capital. The Trusts current accumulated but undistributed net investment income, if any, is disclosed in the Statements of Assets and Liabilities, which comprises part of the financial information included in this report.

BlackRock Privacy Principles

BlackRock is committed to maintaining the privacy of its current and former fund investors and individual clients (collectively, Clients) and to safeguarding their non-public personal information. The following information is provided to help you understand what personal information BlackRock collects, how we protect that information and why in certain cases we share such information with select parties.

If you are located in a jurisdiction where specific laws, rules or regulations require BlackRock to provide you with additional or different privacy-related rights beyond what is set forth below, then BlackRock will comply with those specific laws, rules or regulations.

BlackRock obtains or verifies personal non-public information from and about you from different sources, including the following: (i) information we receive from you or, if applicable, your financial intermediary, on applications, forms or other documents; (ii) information about your transactions with us, our affiliates, or others; (iii) information we receive from a consumer reporting agency; and (iv) from visits to our websites.

BlackRock does not sell or disclose to non-affiliated third parties any non-public personal information about its Clients, except as permitted by law or as is necessary to respond to regulatory requests or to service Client accounts. These non-affiliated third parties are required to protect the confidentiality and security of this information and to use it only for its intended purpose.

We may share information with our affiliates to service your account or to provide you with information about other BlackRock products or services that may be of interest to you. In addition, BlackRock restricts access to non-public personal information about its Clients to those BlackRock employees with a legitimate business need for the information. BlackRock maintains physical, electronic and procedural safeguards that are designed to protect the non-public personal information of its Clients, including procedures relating to the proper storage and disposal of such information.

SEMI-ANNUAL REPORT

JUNE 30, 2016

This report is intended for existing current holders. It is not a prospectus. Past performance results shown in this report should not be considered a representation of future performance. Statements and other information herein are as dated and are subject to change.

CEF-BK9-6/16-SAR

- Item 2 Code of Ethics Not Applicable to this semi-annual report
- Item 3 Audit Committee Financial Expert Not Applicable to this semi-annual report
- Item 4 Principal Accountant Fees and Services Not Applicable to this semi-annual report
- Item 5 Audit Committee of Listed Registrants Not Applicable to this semi-annual report
- Item 6 Investments

 (a) The registrant s Schedule of Investments is included as part of the Report to Stockholders filed under Item 1 of this Form.
 (b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.
- Item 7 Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies Not Applicable to this semi-annual report
- Item 8 Portfolio Managers of Closed-End Management Investment Companies
 (a) Not Applicable to this semi-annual report
 (b) As of the date of this filing, there have been no changes in any of the portfolio managers identified in the

most recent annual report on Form N-CSR.

- Item 9 Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers Not Applicable
- Item 10 Submission of Matters to a Vote of Security Holders There have been no material changes to these procedures.
- Item 11 Controls and Procedures

(a) The registrant s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the 1940 Act)) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.

(b) There were no changes in the registrant s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the second fiscal quarter of the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant s internal control over financial reporting.

- Item 12 Exhibits attached hereto
 - (a)(1) Code of Ethics Not Applicable to this semi-annual report
 - (a)(2) Certifications Attached hereto
 - (a)(3) Not Applicable

(b) Certifications Attached hereto

(c) Notices to the registrant s common shareholders in accordance with the order under Section 6(c) of the 1940 Act granting an exemption from Section 19(b) of the 1940 Act and Rule 19b-1 under the 1940 Act, dated May 9, 2009¹

¹ The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund s common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period.

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Utility and Infrastructure Trust

By: <u>/s/ John M. Perlowski</u> John M. Perlowski Chief Executive Officer (principal executive officer) of BlackRock Utility and Infrastructure Trust

Date: September 2, 2016

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: <u>/s/ John M. Perlowski</u> John M. Perlowski Chief Executive Officer (principal executive officer) of BlackRock Utility and Infrastructure Trust

Date: September 2, 2016

By: <u>/s/ Neal J. Andrews</u> Neal J. Andrews Chief Financial Officer (principal financial officer) of BlackRock Utility and Infrastructure Trust

Date: September 2, 2016